<SEC-DOCUMENT>0001193125-13-437144.txt : 20131112
<SEC-HEADER>0001193125-13-437144.hdr.sgml : 20131111
<ACCEPTANCE-DATETIME>20131112084609
ACCESSION NUMBER:		0001193125-13-437144
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131112
DATE AS OF CHANGE:		20131112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		131207180

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d621569d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quarterly Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended September&nbsp;30, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Transition Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-33221 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>A.P. PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer Identification No.)</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>123 Saginaw Drive, Redwood City, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94063</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) 366-2626 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15 (d)&nbsp;of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer or a smaller reporting company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Small&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act.)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2013, 313,616,369 shares of the registrant&#146;s Common Stock, $0.01 par value per share, were outstanding. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc">
</A>INDEX</U></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PART&nbsp;I.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_1">FINANCIAL INFORMATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_2">Financial Statements (unaudited):</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_3">Condensed Balance Sheets as of September 30, 2013 and December 31, 2012</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_4">Condensed Statements of Operations for the three and nine months ended September 30, 2013 and 2012</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_5">Condensed Statements of Cash Flows for the nine months ended September 30, 2013 and 2012</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_6">Notes to Condensed Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_8">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_9">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PART&nbsp;II.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_10">OTHER INFORMATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_11">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_12">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_13">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_14">Defaults Upon Senior Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_15">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_17">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx621569_18">Signatures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_1"></A>PART I. Financial Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_2"></A>Item&nbsp;1. Financial Statements. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx621569_3"></A>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(Note 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable to related parties, net of discount</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(224,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(183,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx621569_4"></A>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,054</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from discontinued operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx621569_5"></A>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<br>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible note financing</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from warrant exercise</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercise</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of shares under the Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx621569_6"></A>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(1)&nbsp;BUSINESS AND
BASIS OF PRESENTATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.P. Pharma, Inc. (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148;) is a specialty pharmaceutical
company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that
must be injected once or twice per day to products that need to be injected only once every one or two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s lead product candidate,
APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing
moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of
delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&#146;s proprietary Biochonomer drug delivery system, which allows therapeutic drug
levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a
well-established record of safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S.
Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March&nbsp;28, 2013, we announced that the FDA had
issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the APF530 NDA in the
first quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to
commercialize APF530 in the U.S. on our own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we initiated a program to expand our pipeline of sustained release products, including a
new program targeting the relief of post-surgical pain.&nbsp;We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in patients receiving highly
emetogenic chemotherapy (HEC) agents.&nbsp;Currently there are no approved <FONT STYLE="white-space:nowrap">5-HT3</FONT> receptor antagonists for the treatment of delayed HEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics,
Inc. The name change is part of our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming
approval of APF530. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting
principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&nbsp;GAAP for complete financial
statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating
results for the three and nine months ended September&nbsp;30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2013 or for any other period. The condensed balance sheet as of
December&nbsp;31, 2012 has been derived from the audited financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto
should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, which was filed with the Securities and Exchange Commission (SEC) on
March&nbsp;1, 2013 (2012 10-K). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $224.8 million as of September&nbsp;30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us
capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0
million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8).
In June 2011, we entered into definitive agreements for a private placement of units, which were comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of
proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of September&nbsp;30, 2013, we had cash and cash equivalents of
$22.6 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our current working capital is sufficient to fund planned operations into 2014. However, we
will require additional capital to fund our development and operating activities. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could
differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no
recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September&nbsp;30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or
potential significance, to us. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(2) CASH EQUIVALENTS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our available-for-sale securities as of December&nbsp;31, 2012 consisted of money market funds primarily containing U.S. government-backed
securities, with original maturities of ninety days or less. The carrying value of our money market funds was included in cash equivalents and approximated their fair value. We have no available-for-sale securities as of September&nbsp;30, 2013. The
Company&#146;s bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 8). </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(3) FAIR VALUE MEASUREMENTS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The three-tier fair value hierarchy utilized prioritizes the inputs used in measuring fair value as follows: Level 1) observable inputs such
as quoted prices in active markets; Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3) unobservable inputs in which there is little or no market data, which require us to
develop our own assumptions. The hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. We measured our available-for-sale securities at fair value on a
recurring basis. We used quoted prices in active markets (Level l) to measure the fair value of our cash equivalents on our Condensed Balance Sheets as of December&nbsp;31, 2012. Cash equivalents consisted of highly rated money market funds with
maturities of ninety days or less. Due to the high ratings and short-term nature of these funds, we considered the inputs used to value all cash equivalents as Level 1 inputs. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(4)&nbsp;NET LOSS PER SHARE </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the
applicable period. Diluted net loss per share excludes the effect of outstanding potentially dilutive securities because they are anti-dilutive. The following table shows the outstanding potentially dilutive options, warrants and convertible notes
for the nine months ended September&nbsp;30, 2013 and 2012 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock underlying convertible notes outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(5) STOCK-BASED COMPENSATION </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock-based compensation expense for all awards (in thousands, except per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three&nbsp;Months&nbsp;Ended<BR>September 30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months&nbsp;Ended<BR>September 30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the three months ended September&nbsp;30, 2013, we recorded additional stock-based compensation expense as a result of
accelerated vesting of stock options in connection with the resignation of our former chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock
option activity for the nine months ended September&nbsp;30, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted an Employee Stock Purchase Plan (Purchase Plan) in 1997. Qualified employees may elect to have a certain percentage of their salary withheld to
purchase shares of our common stock under the Purchase Plan. In June&nbsp;2011, our stockholders authorized an increase in the number of shares reserved for issuance under the Purchase Plan by 500,000, for a total of 1,000,000 shares reserved at
September&nbsp;30, 2013. The purchase price per share is equal to 85% of the fair market value of the stock on specified dates. Sales under the Purchase Plan during the nine months ended September&nbsp;30, 2013 and 2012 consisted of 80,027 and
58,571 shares at an average price of $0.31 and $0.21, respectively. Shares available for future purchase under the Purchase Plan were 365,674 at September&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(6)&nbsp;COMPREHENSIVE LOSS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss for the periods reported was comprised solely of our net loss. The comprehensive loss for the three and nine months ended
September&nbsp;30, 2013 was $12.9 million and $41.2 million, respectively. The comprehensive loss for the three and nine months ended September&nbsp;30, 2012 was $6.1 million and $15.6 million, respectively. There were no changes in equity that were
excluded from our net loss for all reported periods. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(7)&nbsp;DISCONTINUED OPERATIONS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cosmeceutical and Toiletry Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2000, we completed the sale of certain technology rights for our cosmeceutical and toiletry business to RP&nbsp;Scherer Corporation (RP
Scherer), a subsidiary of Cardinal Health, Inc. Under the terms of the agreement, we guaranteed a minimum gross profit percentage on RP Scherer&#146;s combined sales of products to Ortho Dermatologics (Ortho) and Dermik Laboratories, Inc. (Dermik)
(Gross Profit Guaranty), both of which were acquired by Valeant Pharmaceuticals in July 2011. The Gross Profit Guaranty expense totaled $944,000 for the first seven guaranty years. Effective March 2007, in conjunction with a sale of assets by RP
Scherer&#146;s successor company to an Amcol International subsidiary (Amcol), a new agreement was signed between us and Amcol to provide continuity of product supply to Ortho and Dermik. We had previously recorded a liability of $1.1 million
related to the amount that Amcol asserted was due under the Gross Profit Guaranty. In February 2013, an arbitrator ruled that no additional amounts were owed. This event qualified as an adjusting event under ASC 855, <I>Subsequent Event</I>, and in
light of the arbitrator&#146;s decision in February 2013, which was final and binding, we reversed this accrual as of December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
cosmeceutical and toiletry business is reported as discontinued operations for all periods presented in our accompanying Condensed Statements of Operations. Income (loss) from discontinued operations primarily represents the income (loss)
attributable to changes in estimates of our cosmeceutical and toiletry business that was sold to RP Scherer on July&nbsp;25, 2000, as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three&nbsp;Months&nbsp;Ended<BR>September 30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months&nbsp;Ended<BR>September 30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Cosmeceutical and Toiletry Business</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in estimates for gross profit guarantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no material basic and diluted loss per common share resulting from discontinued operations for the three and nine
months ended September&nbsp;30, 2013 and 2012. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(8) CONVERTIBLE NOTES TO RELATED PARTIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, we entered into a Securities Purchase Agreement (Purchase Agreement) with certain institutional investors (Purchasers),
including a fund affiliated with Kevin C. Tang, who is the Chairman of our Board of Directors (Board), for a private placement of up to $4.5 million in Senior Secured Convertible Notes due 2021 (Notes). The Purchase Agreement provided for the
Purchasers to purchase $1.5 million aggregate principal amount of Notes at the initial closing. Pursuant to the Purchase Agreement, the Purchasers had the option to purchase an additional $3.0 million aggregate principal amount of Notes at any time
until May&nbsp;2, 2013 (Purchase Option). The Notes are convertible into shares of the Company&#146;s common stock at a rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes (Conversion Shares). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash received from the initial closing of the Note financing, which resulted in the issuance of $1.5
million aggregate principal amount of Notes, was approximately $1.3 million, net of issuance costs. In May 2012, the Purchasers exercised their Purchase Option in full, and we received $3.0 million of cash through the issuance of the remaining
$3.0&nbsp;million aggregate principal amount of Notes. As a result of the exercise of the Purchase Option, the Purchasers have purchased the full amount of Notes that the Company was obligated to sell under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes are secured by substantially all of the assets of the Company, including placing our bank accounts under a control agreement. The Notes initially
bore interest at 20%&nbsp;per annum, payable quarterly in cash or in additional principal amount of Notes at the election of the Purchasers. In June 2011, the Notes were amended to reduce the interest rate to 6%&nbsp;per annum effective July&nbsp;1,
2011. The Notes mature on May&nbsp;2, 2021; however, the holders of the Notes may require prepayment of the Notes at any time beginning on or after May&nbsp;2, 2012, at each holder&#146;s option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of the
Company&#146;s outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to the Company, which will not be effective until 61 days after delivery of the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, the Company was in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under
the Notes, the holders of the Notes have the right to require the Company to redeem all or a portion of their Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement,
the Company filed a registration statement on Form S-1, registering for resale 69.6&nbsp;million shares underlying the Notes. The registration statement was declared effective on July&nbsp;29, 2011. The Purchasers have agreed to waive their right to
require the Company to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes contain an embedded conversion feature that was in-the-money on both issuance dates. Based on an effective fixed conversion rate of 25,000 shares
for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the
issuance dates, and the Company began amortizing the resultant debt discount over the respective 10-year or remaining term of the Notes. During the three months ended September&nbsp;30, 2013, accrued interest of approximately $73,000 was
paid-in-kind and rolled into the principal balance of the Notes, which resulted in an additional full debt discount for the respective periods. For the three and nine months ended September&nbsp;30, 2013, interest expense relating to the stated rate
of the Notes was approximately $74,000 and $218,000, respectively. Interest expense relating to the amortization of debt discount for the three and nine months ended September&nbsp;30, 2013 was approximately $134,000 and $396,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, the carrying value of the Notes was approximately $888,000, which is comprised of the $4,958,000 principal amount of the Notes
outstanding, less debt discount of $4,070,000. If the $5.0 million principal amount of Notes is converted, the Company would issue 124.0&nbsp;million shares of its common stock. Accrued interest on the principal balance was $74,000 at
September&nbsp;30, 2013. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(9) STOCKHOLDERS&#146; EQUITY </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments to Articles of Incorporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2011, we amended our certificate of incorporation to increase the number of shares of authorized common stock to 1,500,000,000, par value $0.01 per
share. Prior to the amendment, the number of shares of authorized common stock was 100,000,000, par value $0.01 per share. The certificate of amendment was approved by a majority of our stockholders on June&nbsp;29, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2013, our stockholders approved a proposal to authorize our Board to effect a reverse stock split of all outstanding shares of our common stock
at any ratio at its discretion, from 1-for-10 to 1-for-20 and to grant the Board discretionary authority, within twelve months from September&nbsp;19, 2013, to determine whether to effect the split and the exact whole number ratio within the range
at which the split will be effected. The number of issued and outstanding shares of our common stock would be reduced in accordance with the ratio selected by the Board. The number of shares of common stock that are authorized for issuance under our
certificate of incorporation would also be reduced proportionately based on the exchange ratio of the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our annual meeting of stockholders in June 2011, our stockholders approved an amendment to our 2007 Equity Incentive Plan to increase the maximum number of
shares of common stock available for grant by 90,000,000 shares of common stock, resulting in an aggregate of 95,000,000 shares of common stock authorized for issuance pursuant to awards granted under our 2007 Equity Incentive Plan. The stockholders
also approved an amendment to our 1997 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance under the plan by 500,000, for a total of 1,000,000 shares reserved as of September&nbsp;30, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2011 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2011, we entered
into a Securities Purchase Agreement with certain purchasers (Securities Purchase Agreement), pursuant to which we agreed to sell 160,000,006 shares of our common stock (Shares) and warrants to purchase 80,000,005 shares of our common stock
(Warrants) with an exercise price of $0.18 per share (2011 Private Placement), for an aggregate price of $24.0 million. The 2011 Private Placement closed on July&nbsp;1, 2011. For each share purchased, the investors received one Warrant to purchase
0.5 shares of common stock (together with a Share, a Unit), at a purchase price of $0.15 per Unit. The Warrants were immediately exercisable and expire on the fifth anniversary of the closing date of July&nbsp;1, 2011. The Warrants may be exercised
for cash only or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the Warrants, by surrender of such Warrant, or a portion of such Warrant, by way of cashless
exercise. There is no right to exercise the Warrants to the extent that after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by
any particular purchaser. Each holder of the Warrants can amend or waive the foregoing limitation by written notice to the Company, with such waiver taking effect only upon the expiration of a 61-day notice period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Securities Purchase Agreement, on July&nbsp;29, 2011, the Company filed a registration statement with the SEC to register for resale
the Shares and the shares of common stock issuable upon the exercise of the Warrants (the Warrant Shares, and collectively with the Shares, the Registrable Securities). The registration statement was declared effective on August&nbsp;4, 2011. The
Company is obligated to maintain the effectiveness of the registration statement with respect to an investor&#146;s Registrable Securities until the investor is able to sell the Registrable Securities without limitation or restriction under Rule
144. There is currently only one investor who is an affiliate of the Company and is therefore not able to sell the Registrable Securities without limitation under Rule 144, and that investor has agreed to waive their right to require the Company to
maintain the effectiveness of the registration statement until they provide notice otherwise. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions) during the period the
Company is obligated to maintain the registration statement, the Company may be obligated to pay to the holders of the Registrable Securities liquidated damages in an amount equal to 1.0%&nbsp;per month of such holder&#146;s pro rata interest in the
total purchase price of the Private Placement, capped at a total penalty of 6.0%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received total proceeds of $22.8 million from the 2011
Private Placement, which was net of issuance costs of approximately $1.2 million. During the nine months ended September&nbsp;30, 2013, the Company received $0.6 million for an exercise of a Warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2012 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2012, the Company
entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell 102,000,000 shares of its common stock (2012 Shares) at a purchase price of $0.525 per share of common stock, for an aggregate price
of approximately $53.6 million (2012 Private Placement). The 2012 Private Placement closed on July&nbsp;30, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with entering into the
securities purchase agreement, the Company also entered into a registration rights agreement. On August&nbsp;24, 2012, the Company filed a registration statement with the SEC to register the 2012 Shares for resale. The registration statement was
declared effective on September&nbsp;6, 2012. If the Company fails to keep the registration statements continuously effective for a designated time (with limited exceptions), the Company may be obligated to pay to each holder of the 2012 Shares an
amount equal to 1.5%&nbsp;per month of the aggregate purchase price of the unregistered 2012 Shares held by such holder, capped at a total penalty of 9.0%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A.P. Pharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements &#150; (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received total proceeds of $50.5 million from the 2012 Private Placement, which was net of
issuance costs of approximately $3.1 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_7"></A>Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-looking Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Quarterly Report on Form 10-Q contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, including uncertainties associated with: the FDA&#146;s response to our NDA when resubmitted; the progress of our research, development and clinical programs; the timing of regulatory
approval and commercial introduction of APF530 and future product candidates; our ability to market, commercialize and achieve market acceptance for APF530 and other future product candidates; our ability to establish collaborations for our
technology, APF530 and other future product candidates; our estimates for future performance; our estimates regarding our capital requirements and our needs for and ability to obtain additional financing; our ability to protect or enforce our
intellectual property rights; volatility in the trading price of our common stock; and other risks and uncertainties identified in our filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect
our analysis only on their stated date. We do not undertake to update them except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty pharmaceutical company developing products using our proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery
platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, APF530, is being developed for the prevention of acute CINV for patients undergoing both moderately and highly emetogenic
chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment.
There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the
Company&#146;s proprietary Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron
was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2009, we filed
the original NDA seeking approval for APF530 with the FDA. The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March&nbsp;28, 2013, we
announced that the FDA had issued a Complete Response Letter which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to
resubmit the APF530 NDA in the first quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own the worldwide rights to APF530 and are in the early stages of building the commercial
infrastructure necessary to commercialize APF530 in the U.S. on our own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we initiated a program to expand our pipeline of sustained
release products, including a new program targeting the relief of post-surgical pain.&nbsp;We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in
patients receiving highly emetogenic chemotherapy (HEC) agents.&nbsp;Currently there are no approved <FONT STYLE="white-space:nowrap">5-HT3</FONT> receptor antagonists for the treatment of delayed HEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics,
Inc. The name change is part our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming
approval of APF530. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Policies and Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We prepare our condensed financial statements in accordance with U.S. generally accepted accounting principles, which require management to make estimates and
assumptions. Management bases these estimates and assumptions on historical results and known trends, as well as management forecasts. Actual results could differ from these estimates and assumptions. See our Annual Report on Form 10-K for the year
ended December&nbsp;31, 2012 (2012 10-K), Part&nbsp;II, Item&nbsp;7 &#151; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#150; Critical Accounting Policies and Estimates.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been
no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September&nbsp;30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or
potential significance, to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations for the Three and Nine Months Ended September&nbsp;30, 2013 and 2012 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development costs consist primarily of employee salaries and other personnel-related expenses, facility-related expenses, laboratory
consumables, development manufacturing, and clinical and pre-clinical related services performed by clinical research organizations, research institutions and other outside service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense for the three months ended September&nbsp;30, 2013 increased by $2.3 million to $5.9 million, from $3.6 million for the three
months ended September&nbsp;30, 2012. Research and development expense for the nine months ended September&nbsp;30, 2013 increased by $13.2 million to $23.2 million, from $10.0 million for the nine months ended September&nbsp;30, 2012. Compared to
the comparable periods in the prior year, headcount-related costs and project spending for APF530 were higher in the current year periods as we worked to validate our manufacturing processes and increase the scale of production. We expect research
and development expense for the year 2013 to be higher as compared to 2012 due to manufacturing-related expenses and additional efforts required to address issues raised in the Complete Response Letter we received in March 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related expenses, professional fees, directors&#146; fees, investor relations costs,
pre-commercialization costs, insurance expense and related overhead cost allocation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense for the three months ended
September&nbsp;30, 2013 increased by $4.4 million to $6.8 million, from $2.4 million for the three months ended September&nbsp;30, 2012. General and administrative expense for the nine months ended September&nbsp;30, 2013 increased by $12.2 million
to $17.4 million, from $5.2 million for the nine months ended September&nbsp;30, 2012. The increases in the current fiscal periods were primarily due to compensation expense incurred in the three months ended September&nbsp;30, 2013 related to the
resignation of our former chief executive officer, including stock compensation expense, higher headcount-related costs, market research, consulting costs and professional fees. We expect general and administrative expense for the year 2013 to be
higher as compared to 2012 due to increased support costs, including headcount-related costs, and a full year of pre-commercialization activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense, net was $0.2 million for the three months ended September&nbsp;30, 2013 and 2012, respectively. Interest expense, net was $0.6 million and
$0.4 million for the nine months ended September&nbsp;30, 2013 and 2012, respectively. Interest expense, net consists primarily of interest expense and amortization of debt discount related to the convertible note financing. Compared to the prior
year periods, the increases in the current fiscal periods in interest expense, net were due to a greater amount of convertible notes outstanding as a result of such convertible note holders purchasing more convertible notes pursuant to their
purchase option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income (loss) from discontinued operations represents the income (loss) attributable to the gross profit guaranty associated with the
sale of our cosmeceutical and toiletry business. The income (loss) from discontinued operations was $0.0 million and $0.1 million for the three months ended September&nbsp;30, 2013 and 2012, respectively. The income (loss) from discontinued
operations was $0.0 million for both the nine months ended September&nbsp;30, 2013 and 2012. See Note 7 of Notes to Condensed Financial Statements included in Item&nbsp;1 of this Quarterly Report on Form 10-Q for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Resources and Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had cash and
cash equivalents of $22.6 million at September&nbsp;30, 2013. Cash and cash equivalents decreased by $30.9 million from December&nbsp;31, 2012 to September&nbsp;30, 2013, primarily due to cash used in operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the nine months ended September&nbsp;30, 2013 was $31.1 million, compared to net cash used in operating activities
of $10.9 million for the nine months ended September&nbsp;30, 2012. The $20.2 million increase in net cash used was primarily due to the increase in operating loss which was partially offset by an increase in stock compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the nine months ended September&nbsp;30, 2013 was $1.5 million, compared to $0.5 million for the nine months ended
September&nbsp;30, 2012. The net cash used in both periods was for purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the
nine months ended September&nbsp;30, 2013 was $1.7 million, compared to $53.5 million for the nine months ended September&nbsp;30, 2012. The decrease of $51.8 million was primarily due to $50.5 million of net proceeds received from the sale of
common stock and $3.0 million of proceeds received from the issuance of convertible notes in the prior year period, which were partially offset by $1.1 million of proceeds from stock option exercises and $0.6 million of proceeds from a warrant
exercise in the current year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, we have financed our operations, including technology and product research and development,
primarily through sales of our common stock and other securities, royalties received on sales of Retin-A Micro and Carac, the sale of our rights to royalties on sales of Retin-A Micro and Carac, income from collaborative research and development
fees, proceeds received from the sales of our Analytical Standards division and our cosmeceutical and toiletry business, and interest earned on short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of
issuance costs, from the initial closing, whereby $1.5 million aggregate principal amount of convertible notes was issued. In May 2012, the purchasers exercised their rights to purchase the remaining $3.0 million aggregate principal amount of
convertible notes, and we received the additional $3.0 million of proceeds. In June 2011, we entered into definitive agreements for a private placement of units comprised of common stock and warrants, for which we received proceeds of $22.8 million,
net of issuance costs of approximately $1.2 million. In July 2012, we closed a common stock financing whereby the Company received approximately $50.5 million of proceeds, net of issuance costs of approximately $3.1 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our current cash resources are sufficient to fund planned operations into 2014. However, we will require additional capital to fund our
development and operating activities. Our capital requirements going forward will depend on numerous factors, including: our efforts to respond to the FDA&#146;s March 2013 Complete Response Letter; an approval decision by the FDA with respect to
APF530; the timing of and cost related to the manufacturing and the commercial launch of APF530, if approved; the technological and market developments from drugs that may compete with APF530; the degree of commercial success of APF530; the number
and characteristics of product development programs we pursue and the pace of each program; the scope, rate of progress, results and costs of preclinical testing and clinical trials; the time, cost and outcome involved in seeking other regulatory
approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development,
clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution capabilities for a specialty sales force if we commercialize other products independently; the cost of
establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not
be able to raise sufficient additional capital when we need it on favorable terms or at all. The sale of additional equity in the future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be
required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on unattractive terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
September 2013, our stockholders approved a proposal to authorize our Board to effect a reverse stock split of all outstanding shares of our common stock at any ratio at its discretion, from 1-for-10 to 1-for-20 and to grant the Board discretionary
authority, within twelve months from September&nbsp;19, 2013, to determine whether to effect the split and the exact whole number ratio within the range at which the split will be effected. The primary objective in effecting a reverse split is to
increase the per share trading price of our common stock. The Board believes that a reverse stock split would put the Company in a better position to have its shares listed on The NASDAQ Capital Market, facilitate higher levels of institutional
stock ownership (as investment policies generally prohibit investments in lower-priced securities) and better enable the Company to raise funds to finance development and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a summary of
fixed payments related to certain contractual obligations (in millions), consisting solely of our operating lease obligations. This table excludes amounts already recorded on our balance sheet as current liabilities as of September&nbsp;30, 2013.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Less&nbsp;than<BR>1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2&nbsp;to&nbsp;3<BR>years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">4&nbsp;to&nbsp;5<BR>years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">More&nbsp;than<BR>5 years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the convertible notes issued in May 2011 and May 2012 may require prepayment of such notes at any
time beginning on or after May&nbsp;2, 2012 at each holder&#146;s option. See Note 8 of Notes to Condensed Financial Statements included in Item&nbsp;1 of this Quarterly Report on Form 10-Q. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Off-Balance Sheet Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2013 we did not have any off-balance sheet arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_8"></A>Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our exposure to market risk is confined to our cash and cash equivalents. We did not hold any marketable securities at September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our debt obligations consist of our convertible debt, which carries a fixed interest rate and, as a result, we are not exposed to interest rate risk on our
convertible debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_9"></A>Item&nbsp;4. Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Evaluation of disclosure controls and procedures</U>:&nbsp;We carried out an evaluation, under the supervision and with the participation of our management,
including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15(d)-15(e) of the Securities and Exchange Act of 1934. Based upon that
evaluation, the Principal Executive Officer and Principal Financial Officer concluded that as of September&nbsp;30, 2013, the end of period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance
level. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Changes in internal control over financial reporting</U>:&nbsp;During the three months ended September&nbsp;30, 2013, there have been no
changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_10"></A>PART II. OTHER INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_11">
</A>Item&nbsp;1. Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no material changes to the legal proceedings described in the Company&#146;s Annual Report on Form
10-K for the period ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_12"></A>Item&nbsp;1A. Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to various risks, including those described below. You should consider carefully these risk factors and all of the other information
included in this Form 10-Q. Any of these risk factors could materially adversely affect our business, operating results and financial condition. These risks are not the only ones we face. Additional risks not presently known to us or that we
currently believe are immaterial may also significantly impair our business operations. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment in our securities. Before you decide
whether to purchase any of our common stock, you should carefully consider the risk factors set forth below as may be updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related To Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are
substantially dependent upon the success of our APF530 product candidate. Clinical trial results and the NDA resubmission for this product may not lead to regulatory approval. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of our most advanced product candidate, APF530, for which we are
initially seeking U.S. Food and Drug Administration (FDA) approval for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV
associated with moderately emetogenic chemotherapy (MEC). We currently also plan to conduct a Phase 3 study which, if successful, would allow us to expand our approved product label to include delayed CINV associated with highly emetogenic
chemotherapy (HEC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our near-term ability to generate revenues and our future success, in large part, depends on the approval and successful
commercialization of APF530. We will not be able to commercialize APF530 until we obtain regulatory approval in the United States or foreign countries. In order to satisfy FDA approval standards for the commercial sale of APF530, we must first
successfully resolve the issues identified in the Complete Response Letter received from the FDA in March 2013. This letter identified several issues that precluded the approval of APF530 NDA in its current form, including issues relating to:
manufacturing of APF530, the administration of APF530 and our analysis of efficacy data for APF530 under more recent guidelines classifying chemotherapy regimens. Although we are currently working to address these issues and currently expect to
resubmit the APF530 NDA in the first quarter 2014, there can be no assurance that these responses will be sufficient or that we will be able to resubmit within this time period. Further, the FDA&#146;s review of our resubmission may not produce
positive decisions as to whether: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">APF530 is safe and effective in its proposed use(s) and whether its benefits outweigh the risks; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed labeling for APF530 has our desired product indication regarding acute and delayed-onset CINV, as well as HEC and MEC regimens; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the methods used in manufacturing APF530 and the controls used to maintain its quality are adequate to preserve its identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deficiencies on any of the above, or other factors, could prevent or delay obtaining regulatory approval of APF530, which would negatively affect our
potential revenues, increase our costs and potentially impair our ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not obtain regulatory approval for
APF530 or any of our product candidates. Regulatory approval may also be delayed or cancelled or may entail limitations on the indicated uses of a proposed product. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process for obtaining approval of an NDA is time consuming, subject to unanticipated delays and costs, and requires the commitment of substantial
resources. The regulatory process, particularly for pharmaceutical product candidates like ours, is uncertain, can take many years and requires the expenditure of substantial resources. Any product that we or our collaborative partners develop must
receive all relevant regulatory agency approvals or clearances, if any, before it may be marketed in the United States or other countries. In particular, human pharmaceutical therapeutic products are subject to rigorous preclinical and clinical
testing and other requirements by the FDA in the United States and similar health authorities in foreign countries. We may not receive necessary regulatory approvals or clearances to market APF530 or any other product candidate. In September 2012,
we resubmitted the NDA seeking approval for APF530 with the FDA. In March 2013, we received a second Complete Response Letter, which identified several issues that precluded the approval of APF530 NDA in its current form. We are currently working to
address these issues and intend to resubmit the APF530 NDA in the first quarter 2014. Our NDA resubmission for APF530 may not be approved, or approval may be delayed, as a result of changes in FDA policies for drug approval prior to the FDA&#146;s
decision on our NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, although many products have been approved by the FDA in recent years under Section&nbsp;505(b)(2) under the Federal
Food, Drug, and Cosmetic Act, objections have been raised to the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If challenges to the FDA&#146;s interpretation of Section&nbsp;505(b)(2) are successful, the FDA may be required to change its
interpretation, which could delay or prevent the approval of our NDA for APF530. The review of our resubmitted NDA may also be delayed due to the FDA&#146;s internal resource constraints. Additionally, data obtained from preclinical and clinical
activities are susceptible to varying interpretations that could delay, limit or prevent regulatory agency approvals or clearances. For example, the FDA may require additional clinical data to support approval, such as confirmatory studies and other
data or studies to address questions or concerns that may arise during the FDA review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delays in obtaining regulatory approval for APF530, or the
issuance of a third Complete Response Letter, would, among other consequences, delay the launch of APF530 and adversely affect our ability to generate revenue from sales of this product and adversely affect our ability to raise additional capital
that would be necessary to sustain our operations. Given the additional delays that we would face prior to obtaining approval for APF530, if such approval is ever granted, we may need significant additional capital to fund our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if granted, regulatory approvals may include significant limitations on the uses for which products may be marketed. Failure to comply with applicable
regulatory requirements can, among other things, result in warning letters, imposition of civil penalties or other monetary payments, delay in approving or refusal to approve a product candidate, suspension or withdrawal of regulatory approval,
product recall or seizure, operating restrictions, interruption of clinical trials or manufacturing, injunctions and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
the marketing and manufacturing of drugs and biological products are subject to continuing FDA review, and later discovery of previously unknown problems with a product, its manufacture or its marketing may result in the FDA requiring further
clinical research or restrictions on the product or the manufacturer, including withdrawal of the product from the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If APF530 is approved, but
does not attain market acceptance by healthcare professionals and patients, our business prospects and results of operations will suffer. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if
APF530 receives regulatory approval for commercial sale, the revenue that we may receive from the sale of APF530 may be less than expected and will depend on many factors that are outside of our control. Factors that may affect revenue from APF530,
if approved, include; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of our approved product label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">perception of physicians and other members of the health care community of the safety and efficacy relative to that of competing products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient and physician satisfaction with the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to manufacture commercial product successfully and on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost and availability of raw materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market size for the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reimbursement policies of government and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable publicity concerning the product or similar drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the introduction, availability and acceptance of competing treatments, including those of our collaborators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse event information relating to the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product liability litigation alleging injuries relating to the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert language required by the FDA or regulatory authorities in other countries;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the regulatory developments related to the manufacture or continued use of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extent and effectiveness of sales and marketing and distribution support for the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our collaborators&#146; decisions as to the timing of product launches, pricing and discounting. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product
revenue will be adversely affected if, due to these or other factors, the products we or our collaborators are able to commercialize do not gain significant market acceptance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have a history of losses, we expect to generate losses in the near future, and we may never achieve or maintain profitability. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred recurring losses and had an accumulated deficit of $225 million through September&nbsp;30, 2013. Even if APF530 is approved, we expect to
continue to generate substantial losses over at least the next several years as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build a sales force and commence commercialization of APF530, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand drug product development and commercialization efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct preclinical development and clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue additional applications for our existing delivery technologies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To achieve and sustain profitability,
we must, alone or with others, successfully develop, obtain regulatory approval for, manufacture, market and sell our products. If APF530 is approved for commercialization, we must successfully launch and commercialize the product. If APF530 is not
approved, we will likely experience significant delays before we begin to recognize meaningful levels of revenue, if ever. We will incur substantial expenses in our efforts to develop and commercialize products and we may never generate sufficient
revenue to become profitable or to sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional capital may be needed to enable us to implement our business plan, and we may be
unable to raise capital, which would force us to limit or cease our operations and related product development programs. Raising such capital may have to be accomplished on unfavorable terms, likely causing dilution to our existing stockholders.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, the Company had cash and cash equivalents in the amount of $23 million. We believe that our current working capital
balance is sufficient to fund our operations into 2014. We are pursuing commercialization of APF530 without a partner for the U.S. market, which will likely require us to obtain additional funding and resources to sustain our operations until we can
achieve profitability. The need for and amount of additional funding that we may require depends on various factors, including the results of the on-going regulatory review by the FDA of our APF530 NDA resubmission, the time and costs related to
manufacturing of APF530, if approved, and technological and market developments of drugs that may compete with APF530. There can be no assurance that APF530 will be approved and, if approved, that we will be successful in obtaining the additional
necessary financial resources and expertise, with or without a partner, that will be required to launch APF530. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to raise sufficient
additional capital when we need it on favorable or any terms. If we are unable to obtain adequate funds, we may be required to curtail significantly or cease operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timing and degree of any future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product development programs we pursue and the pace of each program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress, results and costs of preclinical testing and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time, cost and outcome involved in seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific progress in our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the magnitude and scope of our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing and distribution capabilities for a specialty sales force if we commercialize any products independently; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we issue additional equity securities or securities convertible into equity
securities to raise funds, our stockholders will suffer dilution of their investment, and such issuance may adversely affect the market price of our common stock. Any debt financing we enter into may involve covenants that restrict our operations.
These restrictive covenants may include, among other things, limitations on borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem capital stock or make
investments. In the event that additional funds are obtained through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies, product candidates or products on terms that are not
favorable to us or require us to enter into a collaboration arrangement that we would otherwise seek to develop and commercialize ourselves. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or
more of our product development programs and reduce personnel-related and other costs, which will have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
general economic environment in which we operate is experiencing continued weakness and volatility. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to secure the additional capital that
may be necessary for implementation of our longer-term business plans may be diminished due to the continuing volatile business conditions and financial markets. For example, the difficulty in obtaining additional capital necessary to develop our
other product candidates has led us to temporarily suspend certain development programs in recent years. If the economic environment continues its weak recovery and financial markets continue to experience significant volatility, we may have
increasing difficulty in raising additional capital when needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may depend on collaborators as a source of capital and to help us complete the
process of developing and testing our products. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for the development, clinical testing and commercialization of our products may require
entering into collaborations with corporate partners, licensors, licensees and others. These collaborations may be critical to funding our operations and our success in bringing our products and product candidates to the market and promoting such
marketed products profitably. We could be dependent upon the subsequent success of these other parties in performing their respective responsibilities and the cooperation of our partners. Our collaborators may not cooperate with us or perform their
obligations under our agreements with them. We cannot control the amount and timing of our collaborators&#146; resources that will be devoted to our research activities related to our collaborative agreements with them. Our collaborators may choose
to pursue existing or alternative technologies in preference to those being developed in collaboration with us. We may prioritize other programs ahead of collaboration activities such that funding from these other parties could be reduced or
deferred. Failure to make or maintain these arrangements, or a delay in a collaborative partner&#146;s performance, or factors that may affect our partner&#146;s sales may materially adversely affect our business, results of operations and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under agreements with collaborators, we may rely significantly on them, among other activities, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fund research and development activities with us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay us fees upon the achievement of milestones; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market for or with us any commercial products that result from our collaborations. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical trials are expensive and may not result in commercially viable products. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials is a lengthy, time-consuming and expensive process. For example, we have incurred significant expenses in developing APF530 and,
even if approved, it may not result in a commercially viable product. We are planning a Phase 3 study of APF530 designed to demonstrate the utility of APF530 in the treatment of delayed-onset CINV in patients receiving HEC regimens.&nbsp;If
successful, we intend to submit the results of the study in a post-approval application to expand the label of APF530 to include delayed HEC.&nbsp;There can be no assurance that this study will be successful or that the FDA will grant any such label
expansion. Before obtaining regulatory approvals for the commercial sale of any products, we, or our partners, must demonstrate through preclinical testing and clinical trials that our product candidates are safe and effective for their intended
uses in humans. We have incurred and will continue to incur substantial expense and devote a significant amount of time to preclinical testing and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business, results of operations and financial condition may be materially adversely affected by any delays in, or termination of, our clinical trials.
Factors impacting our ability to generate commercially viable products through the conduct of clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient funds to conduct clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to find partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of clinical trials to demonstrate the safety and efficacy of our product candidates to the extent necessary to obtain regulatory approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or third-party investigators, contract research organizations, or other third parties involved in the research to adhere to regulatory requirements applicable to the conduct of clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of preclinical testing and early clinical trials to predict results of later clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay in completion of clinical trials, resulting in increased costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain regulatory approval of our product candidates following completion of clinical trials, or delays in obtaining such approvals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that if our clinical trials are successfully initiated and completed we will be able to obtain approval by the FDA in the United
States&nbsp;or similar regulatory authorities elsewhere in the world in a timely manner, if at all. If we fail to successfully develop and commercialize one or more of our product candidates, we may be unable to generate sufficient revenues to
attain profitability and our reputation in the industry and in the investment community would likely be damaged, each of which would cause our stock price to decrease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delays in clinical testing could increase our costs and delay our ability to obtain regulatory approval and commercialize our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we, or our collaborators, can receive regulatory approval for the commercial sale of our potential products, the FDA requires extensive preclinical
safety testing and clinical trials to demonstrate their safety and efficacy. Significant delays in preclinical and clinical testing could materially impact our product development costs and delay regulatory approval of our product candidates. For
example, enrollment in the Phase 3 clinical trial for APF530 was slower than we expected, resulting in delays in our development timeline and increased costs. Completing clinical trials in a timely manner depends on, among other factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining clinical materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable clinical study terms with prospective sites and clinical research organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining institutional review board approval to conduct a study at a prospective site; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruiting patients to participate in a study. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We rely on third parties to conduct our clinical trials,
and their failure to perform their obligations in a timely and competent manner may delay development and commercialization of our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We used clinical research organizations in the United States, Asia and Europe to oversee our clinical trials for APF530 and we expect to use the same or
similar organizations for our future clinical trials. There are numerous alternative sources to provide these services; however, we may face delays outside of our control if these parties do not perform their obligations in a timely or competent
fashion, or if we are forced to change service providers. Different cultural and operational issues in foreign countries could cause delays or unexpected problems with the patient enrollments or with the data obtained from those locations. If we
experience significant delays in the progress of our clinical trials or problems with the quality of data derived from clinical trials, the prospects for approval would decrease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have yet to demonstrate the full commercial viability of our delivery technology, and we cannot be certain
that attainment of such a goal can be accomplished. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bioerodible drug delivery technology is at an early stage of development. We may not be able
to substantiate the capability of our drug delivery technology for a variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selection of inappropriate therapeutic compound for delivery; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selection of inappropriate use or application for the particular product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to receive regulatory approval on a timely basis or at all; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties with manufacturing in commercial quantities at an acceptable cost. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful development of
delivery technologies requires significant preclinical and clinical testing prior to regulatory approval. Because of these scientific, regulatory and commercial hurdles, any program could be abandoned or otherwise fail, even after significant
resources have been expended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If our suppliers and contract manufacturers fail to complete pre-commercialization manufacturing development activities
for APF530 on a timely basis or fail to comply with stringent regulatory requirements, we will face delays in our ability to obtain regulatory approval for, and to commercialize, APF530, and our costs will increase. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not manufacture APF530 and do not currently plan to develop any capacity to do so. Instead, we have relied on third parties to manufacture and perform
important pre-commercialization manufacturing development activities for APF530. As part of the process for obtaining regulatory approval, we must demonstrate that the facilities, equipment and processes used to manufacture APF530 are capable of
consistently producing a product that meets all applicable quality criteria, and that is comparable to the product that was used in our clinical trials. We must also provide the FDA with information regarding the validation of the manufacturing
facilities, equipment and processes of our third-party suppliers and manufacturers, and data supporting the stability of APF530. If our third-party suppliers and manufacturers are not in compliance with current Good Manufacturing Practice (cGMP)
requirements, the approval of our marketing application may be delayed, existing product batches may be compromised, and we may experience delays in the availability of APF530 for commercial distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, our most recent Complete Response Letter from the FDA regarding our NDA resubmission for APF530 stated that the NDA could not be approved in its
present form due to, among other issues, deficiencies observed during an inspection of the facilities used by our third-party suppliers and manufacturers to produce APF530. If the FDA is not satisfied with our response and any corrective actions
taken by these third parties, we may be required to complete additional manufacturing development activities or provide other information to the FDA, which could cause substantial delays in obtaining regulatory approval for APF530, increase our
costs and have a material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We depend on contract manufacturers and collaborators for
manufacturing our products and provide them with technical expertise on the manufacturing process; we also perform quality control testing of the product; if we and our contract manufacturers do not perform as expected, our revenue and customer
relations will suffer. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of any product. Our
ability to develop and commercialize any products we may develop will depend in part on our ability to manufacture, or arrange for collaborators or other parties to manufacture, our products at a competitive cost, in accordance with regulatory
requirements, and in sufficient quantities for clinical testing and eventual commercialization. We do not intend to develop or acquire facilities to manufacture any of our product candidates for clinical trials or commercial purposes in the
foreseeable future. We rely on a small number of third-party manufacturers to produce our compounds and expect to continue to do so to meet the preclinical and clinical requirements of our potential products and for all of our commercial needs, some
of which are our sole source suppliers at present. We have no long-term agreements with any of these third parties. We may not be able to extend these agreements at satisfactory terms, or at all, and we may not be able to find a replacement contract
manufacturer at satisfactory terms or on a timely basis. Additionally, difficult economic conditions may cause operational and financial problems for our third-party suppliers, resulting in their failure and disruption to our operations. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we, along with our contract manufacturers and our collaborators, are required to comply with FDA
requirements related to product testing, quality assurance, manufacturing and documentation. Our contract manufacturers, or our collaborators, may not be able to comply with the applicable FDA regulatory requirements. They may be required to pass an
FDA pre-approval inspection for conformity with cGMPs before we can obtain approval to manufacture and will be subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP,
and other applicable government regulations and corresponding foreign standards. If we and our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with cGMP regulations, we may experience manufacturing
errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost
overruns or other problems that could seriously harm our business. Not complying with FDA requirements could result in a Warning Letter or an enforcement action such as product seizure, recall, or injunction, prevent commercialization of our product
candidates and impair our reputation and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of&nbsp;our contract manufacturers or by us could
delay clinical development or regulatory approval of product candidates or commercialization of our&nbsp;future products, depriving us of potential product revenue and resulting in additional losses. In addition,&nbsp;our dependence on a third party
for manufacturing may adversely affect&nbsp;our future profit margins and limit our ability to commercialize products on a timely and competitive basis. Our ability to replace an existing manufacturer may be difficult because the number of potential
manufacturers is limited, and the FDA must approve any replacement manufacturer before we can begin manufacturing&nbsp;APF530 or any of our other product candidates. Such approval would require new testing and compliance inspections. It may be
difficult or impossible for&nbsp;us to identify and engage a replacement manufacturer on acceptable terms in a timely manner, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APF530 or any of
our other product candidates may be in competition with other products for access to the facilities of third parties. Consequently, APF530 or any of our other product candidates may be subject to manufacturing delays if collaborators or outside
contractors give other companies&#146; products greater priority than our products. For this and other reasons, our collaborators or third-party service providers may not be able to manufacture APF530 or any of our other product candidates in a
cost-effective or timely manner. If not manufactured in a timely manner, the clinical development of any of our product candidates or their submission for regulatory approval could be delayed, and our ability to deliver products to market on a
timely basis could be impaired or precluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, APF530 has been manufactured in small quantities for preclinical studies and clinical trials. If in
the future APF530 or any of our product candidates are approved for commercial sale,&nbsp;we will need to manufacture our products in larger quantities. Significant scale-up of manufacturing may require additional process development and validation
studies, which the FDA must review and approve. The commercial success of our products, including APF530 in the near-term, will be dependent upon the ability of our contract manufacturers to produce a product in commercial quantities at competitive
costs of manufacture. The ability to do so cannot be presumed. Significant additional development work is required prior to any commercial launch of a product. In the case of APF530, the high viscosity of the product creates particularly challenging
factors relative to attainable production rates and cost of manufacture. If APF530 receives regulatory approval, we plan to scale-up manufacturing for APF530 in order to realize important economies of scale. These scale-up activities would take time
to implement, require additional capital investment, process development and validation studies, and FDA approval. We cannot guarantee that we will be successful in achieving competitive manufacturing costs through such scale-up activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any products we may develop,
we may be unable to generate product revenue. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have a sales organization for the sales, marketing and distribution of
pharmaceutical products. In order to commercialize any products, we must build our sales, marketing, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We have started to
establish internal sales and marketing capabilities for APF530, but may enter into agreements with third parties to sell and market other products we may develop. Although we have hired sales and marketing personnel with prior commercial experience,
our company has no direct experience in developing, training or managing a marketing and sales force. The establishment and development of a sales force to market APF530 will be expensive and time consuming and could delay product launch, and we
cannot be certain that we will be able to successfully develop this capacity. If we are unable to establish our sales and marketing capability or any other non-technical capabilities necessary to commercialize APF530, we will need to contract with
third parties to market and sell such products we may develop. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may
not become profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we fail to comply with continuing federal, state and foreign regulations, we could lose our approvals to
market drugs, and our business would be seriously harmed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following initial regulatory approval of any drugs we may develop, including APF530, we will
be subject to continuing regulatory review, including review of adverse drug experiences and clinical results that are reported after our drug products become commercially available. This would include results from any post-marketing tests or
continued actions required as a condition of approval. The manufacturer and manufacturing facilities we use to make any of our drug candidates will be subject to periodic review and inspection by the FDA. If a previously unknown problem or problems
with a product or a manufacturing and laboratory facility used by us is discovered, the FDA or foreign regulatory agency may impose restrictions on that product or on the manufacturing facility, including requiring us to withdraw the product from
the market. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our contract manufacturers will be subject to ongoing FDA
requirements for submission of safety and other post-market information. If we and our contract manufacturers fail to comply with applicable regulatory requirements, a regulatory agency may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose civil or criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw our regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or terminate any of our ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications filed by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">close the facilities of our contract manufacturers; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products or require a product recall. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, such regulatory review covers a
company&#146;s activities in the promotion of its drugs, with significant potential penalties and restrictions for promotion of drugs for an unapproved use. Sales and marketing programs are under scrutiny for compliance with various mandated
requirements, such as illegal promotions to healthcare professionals. We are establishing a sales force to market APF530, which may include contracting with third parties to market and sell such products we may develop, and may be unable to ensure
that our own employees as well as any third-party employees adhere to legal and regulatory requirements for product advertising and promotion. We are also required to submit information on our open and completed clinical trials to public registries
and databases; failure to comply with these requirements could expose us to negative publicity, fines and penalties that could harm our business. If APF530 is approved, we will also be required to comply with the requirements to submit to
governmental authorities information on payments to physicians and certain other third parties; failure to comply with these requirements could expose us to negative publicity, fines and penalties that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to recruit and retain skilled employees, we may not be able to achieve our objectives. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on a small number of key management and technical personnel. Retaining our current employees and recruiting qualified scientific personnel to perform
future research and development and commercialization work will be critical to our success. While recent pharmaceutical and biotechnology industry layoffs have somewhat mitigated a usual shortage of skilled personnel in our industry, competition is
always present for experienced scientists, and an inability to recruit or retain sufficient skilled personnel could result in delays to product development or approval, loss of sales and diversion of management resources. If we lose members of our
senior management team, we may not be able to find suitable replacements and our business may be harmed as a result </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face intense competition from
other companies. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APF530 is expected to face significant competition for the prevention of delayed CINV, principally from Eisai&#146;s Aloxi
(palonosetron). In addition to Aloxi, APF530 will compete with entrenched generic forms of granisetron (formerly marketed by Roche as Kytril) and ondansetron (formerly marketed by GlaxoSmithKline as Zofran). Generic versions of Aloxi may become
available after its scheduled patent expiration date, which was recently extended to 2024. There are ongoing challenges to the Aloxi patents which may shorten the effective patent term. We are also aware of several companies that have developed or
are developing both generic and new formulations of granisetron, including transdermal formulations such as ProStrakan&#146;s Sancuso<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(granisetron transdermal patch). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are several companies that are developing new formulations of existing drugs using novel drug delivery technologies. Many of these companies have
substantially greater financial, research and development, manufacturing, sales and marketing and distribution resources and experience than we do. The following are some of our major competitors among drug delivery system developers: Alkermes,
Inc., Durect Corporation, and Pacira Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Smaller or early stage companies and research institutions may also prove to be significant competitors,
particularly through collaborative arrangements with large and established pharmaceutical companies. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical
trial sites and patient registration for clinical trials, and acquiring and in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in obtaining approval
from the FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than ours, our commercial opportunity could be significantly reduced. Major technological changes can happen
quickly in the biotechnology and pharmaceutical industries, and the development of technologically improved or different products or drug delivery technologies may make our product candidates or platform technologies obsolete or noncompetitive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we cannot establish pricing of our product candidates acceptable to the United States or foreign governments, insurance companies, managed care
organizations and other payors, or arrange for favorable reimbursement policies, any product sales will be severely hindered. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The continuing efforts
of the United States and foreign governments, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect our ability to generate adequate revenues and gross
margins to make the products we develop commercially viable. Our ability to commercialize any product candidates successfully will depend in part on the extent to which governmental authorities, private health insurers and other organizations
establish appropriate reimbursement levels for the cost of such products and related treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain foreign markets, the pricing of prescription
pharmaceuticals is subject to government control. In the United States, given recent federal and state government initiatives directed at lowering the total cost of health care, the U.S. Congress and state legislatures will likely continue to focus
on health care reform, the cost of prescription pharmaceuticals and on the reform of the Medicare and Medicaid systems. The trend toward managed health care in the United States, which could significantly influence the purchase of health care
services and products, as well as legislative proposals to reform health care, control pharmaceutical prices or reduce government insurance programs, may result in lower prices for our product candidates. While we cannot predict whether any
legislative or regulatory proposals affecting our business will be adopted, the announcement or adoption of these proposals could have a material and adverse effect on our potential revenues and gross margins. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our business strategy includes the entry into additional collaborative agreements. We may not be able to enter into additional collaborative agreements or
may not be able to negotiate commercially acceptable terms for these agreements. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current business strategy includes the entry into additional
collaborative agreements for the development and commercialization of our delivery technologies. The negotiation and consummation of these types of agreements typically involve simultaneous discussions with multiple potential collaborators and
require significant time and resources from our officers, business development and research and development staff. In addition, in attracting the attention of pharmaceutical and biotechnology company collaborators, we compete with numerous other
third parties with product opportunities as well as the collaborators&#146; own internal product opportunities. We may not be able to consummate additional collaborative agreements, or we may not be able to negotiate commercially acceptable terms
for these agreements. If we do not consummate additional collaborative agreements, we may consume money more rapidly on our product development efforts, continue to defer certain development activities or forego the exploitation of certain
geographic territories, any of which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we or our collaborators cannot arrange for adequate third-party reimbursement for our products, our future
revenue will suffer. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both domestic and foreign markets, sales of our potential products, including APF530, will depend in substantial part on the
availability of adequate reimbursement from third-party payors such as government health administration authorities, private health insurers and other organizations. Third-party payors often challenge the price and cost-effectiveness of medical
products and services and such pressure may increase in the future. Significant uncertainty exists as to the adequate reimbursement status of newly approved health care products. Any products we are able to successfully develop may not be
reimbursable by third-party payors. In addition, our products may not be considered cost-effective and adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize a profit. Legislation and
regulations affecting the pricing of pharmaceuticals may change before our products are approved for marketing and any such changes could further limit reimbursement. Reimbursement policies utilized by our collaborators or ourselves may be
challenged by regulatory entities, with resultant fines, negative publicity and the need to implement changes that reduce the utilization of our products. If any products we develop do not receive adequate reimbursement, our revenue will be severely
limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our inability to obtain specialized materials could slow down our product development process. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the critical materials and components used in producing APF530 are sourced from a single supplier. An interruption in supply of a key material could
significantly delay our research and development process or increase our expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specialized materials must often be manufactured for the first time
for use in drug delivery technologies, or materials may be used in the technologies in a manner different from their customary commercial uses. The quality of materials can be critical to the performance of a drug delivery technology, so a reliable
source of a consistent supply of materials is important. Materials or components needed for our drug delivery technologies may be difficult to obtain on commercially reasonable terms, particularly when relatively small quantities are required or if
the materials traditionally have not been used in pharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to adequately protect or enforce our intellectual property
rights or secure rights to third-party patents, we may lose valuable assets, experience reduced market share or incur costly litigation to protect our rights or our third-party collaborators may choose to terminate their agreements with&nbsp;us.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our ability to obtain patents and maintain trade secret protection, as well as successfully defending these patents
against challenges, while operating without infringing the proprietary rights of others. We have filed a number of U.S. patent applications on inventions relating to the composition of a variety of polymers, specific products, product groups and
processing technology. In addition to obtaining patents in a number of foreign countries, we have also filed U.S. and foreign patent applications on our polymer technology under the Patent Cooperation Treaty and with the European Patent Office,
Australia, Canada, China, Hong Kong, Japan, South Korea, Singapore and Taiwan. At December&nbsp;31, 2012, we had a total of 22 issued U.S. patents and an additional 54 issued (or registered) foreign patents. The patents on the bioerodible
technologies expire between January 2016 and April 2026. In addition, APF530 is covered by multiple patents that will expire in 2024. Our existing patents may not cover future products, additional patents may not be issued, and current patents, or
patents issued in the future, may not provide meaningful protection or prove to be of commercial benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical
companies, including ours, are uncertain and involve complex legal and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued. Consequently, our patent applications, or
those that are licensed to us, may not issue into patents, and any issued patents may not provide sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against competitive technologies
or may be held invalid if challenged or circumvented. Patent applications in the United States are maintained in confidence for at least 18&nbsp;months after their filing. Consequently, we cannot be certain that the patent applications we are
pursuing will lead to the issuance of any patent or be free from infringement or other claims from other parties. Our competitors may also independently develop products similar to ours or design around or otherwise circumvent patents issued to us
or licensed by us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent as U.S. laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party
to collaborative agreements. These agreements subject us to obligations which must be fulfilled and require us to manage complex relationships with third parties. If we are unable to meet our obligations or manage our relationships with our
collaborators under these agreements or enter into additional collaboration agreements or if our existing collaborations are terminated or not extended on terms as beneficial as we anticipate, our revenue may decrease. The loss or diminution of our
intellectual property rights could result in a decision by our third-party collaborators to terminate their agreements with us. In addition, these agreements are generally complex and contain provisions that could give rise to legal disputes,
including potential disputes concerning ownership of intellectual property and data under collaborations. Such disputes can lead to lengthy, expensive litigation or arbitration, requiring us to divert management time and resources to such dispute.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also rely upon trade secrets, technical know-how and continuing technological innovation to develop and
maintain our competitive position. We require our employees, consultants, advisors and collaborators to execute appropriate confidentiality and assignment-of-inventions agreements with us. These agreements typically provide that all materials and
confidential information developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances, and that all
inventions arising out of the individual&#146;s relationship with us shall be our exclusive property. These agreements may be breached, and in some instances, we may not have an appropriate remedy available for breach of the agreements. Furthermore,
our competitors may independently develop substantially equivalent proprietary information and techniques, reverse engineer our information and techniques, or otherwise gain access to our proprietary technology. We may be unable to meaningfully
protect our rights in trade secrets, technical know-how and other non-patented technology. We may have to resort to litigation to protect our intellectual property rights, or to determine their scope, validity or enforceability. In addition,
interference proceedings declared by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications. Enforcing or defending our proprietary rights is expensive, could cause
diversion of our resources and may not prove successful. In addition, courts outside the United States may be less willing to protect trade secrets. Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope
of our proprietary rights. Any failure to enforce or protect our rights could cause us to lose the ability to exclude others from using our technology to develop or sell competing products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may infringe on the intellectual property rights of others, and any litigation could force us to stop developing or selling potential products and could
be costly, divert management attention and harm our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must be able to develop products without infringing the proprietary rights of other
parties. Because the markets in which we operate involve established competitors with significant patent portfolios, including patents relating to the composition of a variety of polymers, specific products, product groups and processing technology,
it could be difficult for us to use our technologies or develop products without infringing the proprietary rights of others. We may not be able to design around the patented technologies or inventions of others and we may not be able to obtain
licenses to use patented technologies on acceptable terms, or at all. If we cannot operate without infringing the proprietary rights of others, we will not be able to develop or commercialize some or all of our product candidates, and consequently
will not be able to earn product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are required to defend ourselves in a lawsuit, we could incur substantial costs and the lawsuit could
divert management attention, regardless of the lawsuit&#146;s merit or outcome. These legal actions could seek damages and seek to enjoin testing, manufacturing and marketing of the accused product or process. In addition to potential liability for
significant damages, we could be required to obtain a license to continue to manufacture or market the accused product or process and any license required under any such patent may not be made available to us on acceptable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodically, we review publicly available information regarding the development efforts of others in order to determine whether these efforts may violate our
proprietary rights. We may determine that litigation is necessary to enforce our proprietary rights against others. Such litigation could result in substantial expense, regardless of its outcome, and may not be resolved in our favor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are exposed to risks and increased expenses as a result of laws requiring filers to evaluate internal controls over financial reporting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (Section 404) requires management to evaluate the effectiveness of our internal controls over financial
reporting as of the end of each fiscal year and to include a management report assessing the effectiveness of our internal control over financing reporting in our annual report on Form&nbsp;10-K for each fiscal year. Starting with our annual report
for the year ended December&nbsp;31, 2012, our independent auditors are required to report on the effectiveness of our internal control over financial reporting. We and our independent registered public accounting firm may not be able to conclude on
an ongoing basis that we have effective internal controls over financial reporting in accordance with Section&nbsp;404. We have implemented an ongoing program to perform the system and process evaluation we believe to be necessary to comply with
these requirements. However, we cannot assure you that we will be successful in our efforts. We expect to incur increased expense and to devote additional management resources to Section&nbsp;404 compliance. Any failure to implement required new or
improved controls, or difficulties encountered in the implementation or operation of these controls, could harm our operating results and cause us to fail to meet our financial reporting obligations, which could adversely affect our business and
reduce our stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls
over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. We cannot assure
you that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future, which would require management and our independent registered public accounting firm to evaluate our
internal controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the price of our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legislative actions, potential new accounting pronouncements and higher insurance costs are likely to impact
our future financial position or results of operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future changes in financial accounting standards may cause adverse, unexpected fluctuations in
the timing of the recognition of revenue or expenses and may affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency and may occur in the future, and we
may make changes in our accounting policies in the future. Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses. Changing laws, regulations and standards relating to corporate governance
and public disclosure, including the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act, new Securities and Exchange Commission (SEC) regulations and the Public Company Accounting Oversight Board pronouncements, are creating uncertainty for companies
such as ours and insurance, accounting and auditing costs are increasing as a result of this uncertainty and other factors. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, we intend to
invest all reasonably necessary resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to
compliance activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We could be exposed to significant product liability claims that could be time consuming and costly to defend, divert
management attention and adversely impact our ability to obtain and maintain insurance coverage. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing, manufacture, marketing and sale of our
products involve an inherent risk that product liability claims will be asserted against us. Although we are insured against such risks up to an annual aggregate limit in connection with clinical trials and commercial sales of our products, our
present product liability insurance may be inadequate and may not fully cover the costs of any claim or any ultimate damages we might be required to pay. Product liability claims or other claims related to our products, regardless of their outcome,
could require us to spend significant time and money in litigation or to pay significant damages. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable or
reasonable terms. In addition, product liability coverage may cease to be available in sufficient amounts or at an acceptable cost. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential
product liability claims could prevent or inhibit the commercialization of our products. A product liability claim could also significantly harm our reputation and delay market acceptance of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our use of hazardous materials could subject us to liabilities, fines and sanctions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our laboratory and clinical testing sometimes involve use of hazardous, radioactive or otherwise toxic materials. We are subject to federal, state and local
laws and regulations governing how we use, manufacture, handle, store and dispose of these materials. Although we believe that our safety procedures for handling and disposing of such materials comply in all material respects with all federal, state
and local regulations and standards, there is always the risk of accidental contamination or injury from these materials. In the event of an accident, we could be held liable for any damages that result and such liability could exceed our financial
resources. If we fail to comply with these regulations and standards or with the conditions attached to our operating licenses, the licenses could be revoked, and we could be subjected to criminal sanctions and substantial financial liability or be
required to suspend or modify our operations. Compliance with environmental and other laws may be expensive and current or future regulations may impair our development or commercialization efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earthquake damage to our facilities could delay our research and development and quality control testing efforts and adversely affect our business.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our facility in Redwood City, California, is located in a seismic zone, and there is the possibility of an earthquake, which could be disruptive to
our operations and result in delays in our research and development efforts and supplies of APF530, if approved. In the event of an earthquake, if our facilities or the equipment in our facilities are significantly damaged or destroyed, we may not
be able to rebuild or relocate our facility or replace any damaged equipment in a timely manner and our business, financial condition and results of operations could be materially and adversely affected. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related To Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
stock is considered a penny stock and is subject to additional restrictions on trading. Although we are seeking to relist on Nasdaq, we may be unable or unwilling to take actions required by Nasdaq to successfully relist. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, our common stock was delisted from the Nasdaq Capital Market for non-compliance with Nasdaq&#146;s $1.00 per share minimum bid price continued
listing requirement and is now quoted on the OTC Bulletin Board, thereby causing trading in our common stock to be limited by &#147;penny stock&#148; restrictions and our ability to raise additional capital to potentially be compromised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the delisting of our common stock and our current trading price, it comes within the definition of
&#147;penny stock&#148; as defined in the Securities Exchange Act of 1934 and is covered by Rule 15g-9 of the Securities Exchange Act of 1934. That rule imposes additional sales practice requirements on broker-dealers who sell securities to persons
other than established customers and accredited investors. For transactions covered by Rule 15g-9, the broker-dealer must make a special suitability determination for the purchaser and receive the purchaser&#146;s written agreement to the
transaction prior to the sale. Consequently, Rule 15g-9 potentially affects the ability or willingness of broker-dealers to sell our securities and accordingly would also affect the ability of stockholders to sell their securities in the public
market. These additional procedures could also limit our ability to raise additional capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we have filed a listing application
to have our stock re-listed on the Nasdaq Capital Market, there can be no assurance that we will be successful in regaining our Nasdaq listing.&nbsp;For example, we currently do not satisfy the minimum bid price requirement and expect that we would
need to effect a reverse split of our common stock to qualify.&nbsp;Further, our current board of directors does not satisfy Nasdaq&#146;s listing standards and we will need to make changes to our board composition to satisfy governance-related
listing standards.&nbsp;However, we may be unable or unwilling to make the required changes in board composition, in which case we would not relist our common stock on Nasdaq and would expect to remain trading on the OTC Bulletin Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The price of our common stock has been and may continue to be volatile and our planned reverse stock split may further increase volatility or cause a
decline in value. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock markets, in general, and the markets for drug delivery and pharmaceutical stocks, in particular, have experienced extreme
volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, the limited trading volume of our stock may
contribute to its volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our stock price may be subject to additional volatility if we effect a reverse stock split in support of a listing
application on Nasdaq. Following reverse splits, the prices of the stocks often trade below the immediate post-split value, resulting in a net loss in value for stockholders. We currently intend to pursue a reverse split of our common stock and we
have stockholder authority to implement a split at a ratio of up to 1-for-20. Stockholders who purchase shares prior to our reverse split may lose value after the split is implemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a particular company&#146;s securities, litigation has often been brought against that
company. If litigation of this type is brought against us, it could be extremely expensive and divert management&#146;s attention and our company&#146;s resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our certificate of incorporation, our bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent
attempts by our stockholders to replace or remove our current management. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of Delaware law, our certificate of incorporation and our bylaws
may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any
attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include&nbsp;authorizing the issuance of &#147;blank check&#148;
preferred stock without any need for action by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of Delaware General Corporation Law may discourage, delay or
prevent a change in control of our company by prohibiting stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us, unless certain approvals are obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further concentration in stockholder ownership could influence strategic actions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, principal stockholders and affiliated entities currently beneficially own or control a majority of our outstanding
securities. Tang Capital Partners, LP and its affiliates&#146; beneficial ownership in our common stock, as determined in accordance with Rule 13d-3 of the Exchange Act, was approximately 23% as of May 2013, excluding potential further concentration
underlying outstanding warrants and our convertible note facility. Kevin&nbsp;C.&nbsp;Tang, the Managing Director of Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP, is also a member of our board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such a concentration of common stock ownership could significantly influence corporate actions on various strategic matters, including, for example,
receptivity to collaborations and merger or sale overtures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales of our common stock may cause our stock price to decline. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal stockholders and affiliated entities hold a substantial number of shares of our common stock that they are able to sell in the public market. In
addition, they currently own convertible notes and outstanding warrants for additional shares of our common stock. The exercise of these warrants, conversion of the notes or the sale by our current stockholders of a substantial number of shares, or
the expectation that such exercises or sales may occur, could significantly reduce the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future utilization of net
operating loss carry-forwards may be impaired due to recent changes in ownership. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our net operating losses and tax attributes may be
subject to limitation under Section&nbsp;382 of the Internal Revenue Code of 1986. As a result, our deferred tax assets, and related valuation allowance, have been reduced for the estimated impact of the net operating losses and credits that we
currently estimate may expire unused. Utilization of our remaining net operating loss and research and development credit carry-forwards may still be subject to substantial annual limitations due to ownership change limitations provided by the
Internal Revenue Code and similar state provisions for ownership changes after December&nbsp;31, 2012, including those that may come in conjunction with future equity financings or market trades by our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_13"></A>Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_14"></A>Item&nbsp;3. Defaults Upon
Senior Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_15"></A>Item&nbsp;4. Mine Safety Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_16"></A>Item&nbsp;5. Other
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx621569_17"></A>Item&nbsp;6. Exhibits </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;31.1&nbsp;&#150;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934 as amended.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;31.2&nbsp;&#150;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certification of Chief Operating Officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934 as amended.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;32.1&nbsp;&#150;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;32.2&nbsp;&#150;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certification of Chief Operating Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.INS</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.SCH</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.CAL</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.DEF</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Extension Definition</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.LAB</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;101.PRE</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx621569_18"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">A.P. PHARMA, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;12, 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d621569dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Barry D.
Quart, Chief Executive Officer, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of A.P. Pharma, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to
us by others, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;12, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d621569dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Stephen R.
Davis, Chief Operating Officer (Principal Financial Officer), certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of A.P. Pharma, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to
us by others, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;12, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen R. Davis</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stephen R. Davis</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Chief Operating Officer (Principal Financial Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d621569dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of A.P. Pharma, Inc. (the &#147;Company&#148;) on Form 10-Q for the period ending September&nbsp;30, 2013 as filed
with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Barry D. Quart, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the Report fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">November&nbsp;12, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d621569dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of A.P. Pharma, Inc. (the &#147;Company&#148;) on Form 10-Q for the period ending September&nbsp;30, 2013 as filed
with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Stephen R. Davis, Chief Operating Officer (Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the Report fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">November&nbsp;12, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen R. Davis</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Stephen R. Davis</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;Chief Operating Officer (Principal Financial Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>appa-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:appa="http://www.appharma.com/20130930" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:compsci="http://compsciresources.com" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="appa-20130930.xsd"/>
  <context id="c0_AsOf30Sep2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="c1_AsOf31Dec2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="c2_From1Jul2013To30Sep2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c3_From1Jul2012To30Sep2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2013To30Sep2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c5_From1Jan2012To30Sep2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c6_AsOf31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf30Sep2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="c8_AsOf31Oct2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="c9_AsOf30Apr2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c10_From1Apr2011To30Apr2011_NetOfIssuanceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="appa:DisclosureAxis">appa:NetOfIssuanceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c11_From1May2012To31May2012_PurchaseOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="appa:DisclosureAxis">appa:PurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-05-01</startDate>
      <endDate>2012-05-31</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2011To31Jul2011_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="appa:DisclosureAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jul2012To31Jul2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2013To30Sep2013_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2012To30Sep2012_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c16_From1Jan2013To30Sep2013_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c17_From1Jan2012To30Sep2012_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c18_From1Jan2013To30Sep2013_ConvertibleDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c19_From1Jan2012To30Sep2012_ConvertibleDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2011To30Jun2011_EmployeeStockPurchasePlan1997Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">appa:EmployeeStockPurchasePlan1997Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c21_AsOf30Sep2013_EmployeeStockPurchasePlan1997Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">appa:EmployeeStockPurchasePlan1997Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="c22_From1Jan2013To30Sep2013_EmployeeStockPurchasePlan1997Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">appa:EmployeeStockPurchasePlan1997Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c23_From1Jan2012To30Sep2012_EmployeeStockPurchasePlan1997Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">appa:EmployeeStockPurchasePlan1997Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c24_From1Jul2013To30Sep2013_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c25_From1Jul2012To30Sep2012_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c26_From1Jan2013To30Sep2013_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c27_From1Jan2012To30Sep2012_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c28_From1Jul2013To30Sep2013_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c29_From1Jul2012To30Sep2012_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2013To30Sep2013_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c31_From1Jan2012To30Sep2012_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="c32_From1Jan2012To31Dec2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="c33_From1Jul2000To30Jun2007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2000-07-01</startDate>
      <endDate>2007-06-30</endDate>
    </period>
  </context>
  <context id="c34_AsOf30Apr2011_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c35_AsOf30Apr2011_InitialClosingAmountMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">appa:InitialClosingAmountMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c36_AsOf30Apr2011_PurchaseOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">appa:PurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c37_From1Apr2011To30Apr2011_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c38_From1Apr2011To30Apr2011_PrincipalAmountMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">appa:PrincipalAmountMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c39_From1Apr2011To30Apr2011_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c40_From1May2012To31May2012_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-05-01</startDate>
      <endDate>2012-05-31</endDate>
    </period>
  </context>
  <context id="c41_AsOf1Jul2011_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-07-01</instant>
    </period>
  </context>
  <context id="c42_From1Jun2011To1Jul2011_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-07-01</endDate>
    </period>
  </context>
  <context id="c43_From28Jul2011To29Jul2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-07-28</startDate>
      <endDate>2011-07-29</endDate>
    </period>
  </context>
  <context id="c44_From1Jul2013To30Sep2013_PaymentInKindPIKNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c45_AsOf30Sep2013_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="c46_From1Jan2013To30Sep2013_SeniorNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c47_AsOf29Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-06-29</instant>
    </period>
  </context>
  <context id="c48_AsOf28Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-06-28</instant>
    </period>
  </context>
  <context id="c49_From1Sep2013To30Sep2013_CommonStockMember_ScenarioActualMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c50_From1Sep2013To30Sep2013_CommonStockMember_ScenarioProposedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">appa:ScenarioProposedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c51_From1Jun2011To30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c52_AsOf30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c53_AsOf30Jun2011_StockCompensationPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c54_AsOf30Sep2013_StockCompensationPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="c55_From1Jun2011To30Jun2011_CommonStockMember_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c56_AsOf30Jun2011_CommonStockMember_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c57_From1Jun2011To31Jul2011_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="c58_From1Jun2011To31Jul2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="c59_AsOf31Jul2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2011-07-31</instant>
    </period>
  </context>
  <context id="c60_From1Jun2011To30Sep2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c61_From1Jun2011To30Sep2013_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2012To30Jul2012_CommonStockMember_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-07-30</endDate>
    </period>
  </context>
  <context id="c63_AsOf30Jul2012_CommonStockMember_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-07-30</instant>
    </period>
  </context>
  <context id="c64_From1Jan2012To30Jul2012_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-07-30</endDate>
    </period>
  </context>
  <context id="c65_From1Jul2012To30Sep2013_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2012To30Jun2012_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">appa:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="usdPeritem">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>compsci:item</measure>
      </unitDenominator>
    </divide>
  </unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">22597000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">53506000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">763000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">584000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">23360000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">54090000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">2857000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">1752000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">153000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">26370000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">55972000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">2250000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">1912000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">2360000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">1750000</us-gaap:AccruedLiabilitiesCurrent>
  <appa:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">888000</appa:ConvertibleNotesPayableRelatedPartiesCurrent>
  <appa:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">492000</appa:ConvertibleNotesPayableRelatedPartiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">5498000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">4154000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">3110000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">3024000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">242589000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">232381000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">-224827000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">-183587000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">20872000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">51818000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="-3">26370000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2012" decimals="-3">55972000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">5885000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">3626000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">23188000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">10022000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">6779000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">2428000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">17438000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">5181000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">12664000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">6054000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">40626000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">15203000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">-12664000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">-6054000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-40626000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-15203000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">-209000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">-195000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-614000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-402000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperations unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">-12873000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">-6249000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-41240000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-15605000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">128000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-6000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">-12873000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">-6121000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-41240000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-15611000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c2_From1Jul2013To30Sep2013" decimals="2">-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c3_From1Jul2012To30Sep2012" decimals="2">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c5_From1Jan2012To30Sep2012" decimals="2">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c2_From1Jul2013To30Sep2013" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c3_From1Jul2012To30Sep2012" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c5_From1Jan2012To30Sep2012" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">307496000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">274488000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">306096000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">225063000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">237000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">147000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">8333000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">3773000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">396000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">262000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">202000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">89000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">514000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">980000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">826000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-352000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-31136000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-10884000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">1518000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">546000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-1518000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-546000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">50491000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">3000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">600000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">1120000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">25000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">13000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">1745000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">53504000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">-30909000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">42074000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c6_AsOf31Dec2011" decimals="-3">17974000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c7_AsOf30Sep2012" decimals="-3">60048000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <dei:EntityRegistrantName contextRef="c4_From1Jan2013To30Sep2013">AP PHARMA INC /DE/</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="c4_From1Jan2013To30Sep2013">10-Q</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c4_From1Jan2013To30Sep2013">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c8_AsOf31Oct2013" decimals="INF">313616369</dei:EntityCommonStockSharesOutstanding>
  <dei:AmendmentFlag contextRef="c4_From1Jan2013To30Sep2013">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey contextRef="c4_From1Jan2013To30Sep2013">0000818033</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c4_From1Jan2013To30Sep2013">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="c4_From1Jan2013To30Sep2013">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory contextRef="c4_From1Jan2013To30Sep2013">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c4_From1Jan2013To30Sep2013">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentFiscalYearFocus contextRef="c4_From1Jan2013To30Sep2013">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="c4_From1Jan2013To30Sep2013">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate contextRef="c4_From1Jan2013To30Sep2013">2013-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA793&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(1)&amp;#160;BUSINESS AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA795&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;A.P. Pharma, Inc. (the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; and &amp;#8220;our&amp;#8221;) is a specialty pharmaceutical company developing products using its proprietary Biochronomer&amp;#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA798&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&amp;#8217;s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed
      phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA800&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the APF530 NDA in the first quarter of 2014.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA802&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p id=&quot;PARA1249&quot; style=&quot;text-align: left; line-height: 1.25; margin: 0pt;&quot;&gt;
      &lt;font style=&quot;font-family: Times New Roman, Times, serif; font-size: 10pt;&quot;&gt;In November 2013, we initiated a program to expand our pipeline of sustained release products, including a new program targeting the relief of post-surgical pain.&amp;#160; We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents.&amp;#160; Currently there are no approved 5-HT3 receptor antagonists for the treatment of delayed HEC.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA803&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. The name change is part of our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming approval of APF530.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA805&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&amp;#160;GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2013 or for any other period. The condensed balance sheet as of December&amp;#160;31, 2012 has been derived from the audited
      financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March&amp;#160;1, 2013 (2012 10-K).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA807&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA809&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $224.8 million as of September 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were
      comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of September 30, 2013, we had cash and cash equivalents of $22.6 million.&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA811&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We believe that our current working capital is sufficient to fund planned operations into 2014. However, we will require additional capital to fund our development and operating activities. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA814&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Critical Accounting Policies and Estimates&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA815&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA817&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA819&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:NatureOfOperations contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA795&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;A.P. Pharma, Inc. (the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; and &amp;#8220;our&amp;#8221;) is a specialty pharmaceutical company developing products using its proprietary Biochronomer&amp;#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA798&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&amp;#8217;s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed
      phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA800&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the APF530 NDA in the first quarter of 2014.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA802&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p id=&quot;PARA1249&quot; style=&quot;text-align: left; line-height: 1.25; margin: 0pt;&quot;&gt;
      &lt;font style=&quot;font-family: Times New Roman, Times, serif; font-size: 10pt;&quot;&gt;In November 2013, we initiated a program to expand our pipeline of sustained release products, including a new program targeting the relief of post-surgical pain.&amp;#160; We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents.&amp;#160; Currently there are no approved 5-HT3 receptor antagonists for the treatment of delayed HEC.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA803&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. The name change is part of our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming approval of APF530.&lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA805&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&amp;#160;GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2013 or for any other period. The condensed balance sheet as of December&amp;#160;31, 2012 has been derived from the audited
      financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March&amp;#160;1, 2013 (2012 10-K).&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:LiquidityDisclosureTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA807&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA809&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $224.8 million as of September 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were
      comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of September 30, 2013, we had cash and cash equivalents of $22.6 million.&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA811&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We believe that our current working capital is sufficient to fund planned operations into 2014. However, we will require additional capital to fund our development and operating activities. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <appa:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1 unitRef="usd" contextRef="c9_AsOf30Apr2011" decimals="-5">4500000</appa:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c10_From1Apr2011To30Apr2011_NetOfIssuanceCostsMember" decimals="-5">1300000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c11_From1May2012To31May2012_PurchaseOptionMember" decimals="-5">3000000</us-gaap:ProceedsFromConvertibleDebt>
  <appa:ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet unitRef="usd" contextRef="c12_From1Jan2011To31Jul2011_PrivatePlacementMember" decimals="-5">22800000</appa:ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c13_From1Jul2012To31Jul2012" decimals="-5">50500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA814&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Critical Accounting Policies and Estimates&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA815&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA817&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA819&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA821&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(2) CASH EQUIVALENTS&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA823&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Our available-for-sale securities as of December&amp;#160;31, 2012 consisted of money market funds primarily containing U.S. government-backed securities, with original maturities of ninety days or less. The carrying value of our money market funds was included in cash equivalents and approximated their fair value. We have no available-for-sale securities as of September 30, 2013. The Company&apos;s bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 8).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA825&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(3) FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA827&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The three-tier fair value hierarchy utilized prioritizes the inputs used in measuring fair value as follows: Level 1) observable inputs such as quoted prices in active markets; Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3) unobservable inputs in which there is little or no market data, which require us to develop our own assumptions. The hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. We measured our available-for-sale securities at fair value on a recurring basis. We used quoted prices in active markets (Level l) to measure the fair value of our cash equivalents on our Condensed Balance Sheets as of December&amp;#160;31, 2012. Cash equivalents consisted of highly rated money market funds with maturities of ninety days or less. Due to
      the high ratings and short-term nature of these funds, we considered the inputs used to value all cash equivalents as Level 1 inputs.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA829&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(4)&amp;#160;NET LOSS PER SHARE&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA831&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the applicable period. Diluted net loss per share excludes the effect of outstanding potentially dilutive securities because they are anti-dilutive. The following table shows the outstanding potentially dilutive options, warrants and convertible notes for the nine months ended September 30, 2013 and 2012 (in thousands):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1175.finRow.1&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.1.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1163&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.1.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1164&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1165&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.3&quot;&gt;
        &lt;td style=&quot;WIDTH: 70%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1166&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Options outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.amt.2&quot;&gt;
          125,392
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.amt.3&quot;&gt;
          67,940
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1169&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Warrants outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.amt.2&quot;&gt;
          79,377
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.amt.3&quot;&gt;
          84,377
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1172&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Common stock underlying convertible notes outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.amt.2&quot;&gt;
          123,957
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.amt.3&quot;&gt;
          116,790
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1175.finRow.1&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.1.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1163&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.1.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1164&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1165&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1175.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.3&quot;&gt;
        &lt;td style=&quot;WIDTH: 70%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1175.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1166&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Options outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.amt.2&quot;&gt;
          125,392
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.amt.3&quot;&gt;
          67,940
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1169&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Warrants outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.amt.2&quot;&gt;
          79,377
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.amt.3&quot;&gt;
          84,377
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1175.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1172&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Common stock underlying convertible notes outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.amt.2&quot;&gt;
          123,957
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.amt.3&quot;&gt;
          116,790
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1175.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c14_From1Jan2013To30Sep2013_StockOptionMember" decimals="-3">125392000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c15_From1Jan2012To30Sep2012_StockOptionMember" decimals="-3">67940000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c16_From1Jan2013To30Sep2013_WarrantMember" decimals="-3">79377000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c17_From1Jan2012To30Sep2012_WarrantMember" decimals="-3">84377000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c18_From1Jan2013To30Sep2013_ConvertibleDebtSecuritiesMember" decimals="-3">123957000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c19_From1Jan2012To30Sep2012_ConvertibleDebtSecuritiesMember" decimals="-3">116790000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATcvbNwCXh+T4L4UHo3KxIZo=] CSR-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA836&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(5) STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA838&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The following table summarizes the stock-based compensation expense for all awards (in thousands, except per share amounts):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1205.finRow.2&quot;&gt;
        &lt;td style=&quot;WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.2.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1176&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Three Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1178&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.2.amt.D5&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1177&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1179&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1180&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1181&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1182&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D5&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1183&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.4&quot;&gt;
        &lt;td style=&quot;WIDTH: 52%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1184&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Operating expenses:&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1185&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Research and development&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.2&quot;&gt;
          544
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.3&quot;&gt;
          397
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.4&quot;&gt;
          1,088
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.5&quot;&gt;
          1,061
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.7&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1190&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;General and administrative&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.2&quot;&gt;
          3,551
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.3&quot;&gt;
          1,583
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.4&quot;&gt;
          7,245
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.5&quot;&gt;
          2,712
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1195&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Total stock-based compensation expense&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.2&quot;&gt;
          4,095
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.3&quot;&gt;
          1,980
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.4&quot;&gt;
          8,333
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.5&quot;&gt;
          3,773
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.9&quot;&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 52%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.10&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1200&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Impact on basic and diluted net loss per common share&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.2&quot;&gt;
          0.01
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.3&quot;&gt;
          0.01
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.4&quot;&gt;
          0.03
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.5&quot;&gt;
          0.02
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA841&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In the three months ended September 30, 2013, we recorded additional stock-based compensation expense as a result of accelerated vesting of stock options in connection with the resignation of our former chief executive officer.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA842&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The following table summarizes stock option activity for the nine months ended September 30, 2013:&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1230.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1206&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Shares (in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1209&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted- Average Exercise&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1211&quot;&gt;
            &lt;b&gt;Price&lt;/b&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1207&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1208&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1210&quot;&gt;
            &lt;b&gt;Remaining Contractual Term&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1212&quot;&gt;
            (Years)
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.5&quot;&gt;
        &lt;td&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1213&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Outstanding at January 1, 2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.2&quot;&gt;
          86,478
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.3&quot;&gt;
          0.42
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.4&quot;&gt;
          8.2
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.7&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1217&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.amt.2&quot;&gt;
          76,735
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.amt.3&quot;&gt;
          0.40
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1220&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.amt.2&quot;&gt;
          (4,323
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.amt.3&quot;&gt;
          0.26
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.9&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1223&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expired and forfeited&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.amt.2&quot;&gt;
          (33,498
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.amt.3&quot;&gt;
          0.47
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.10&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1226&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Outstanding at September 30, 2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.2&quot;&gt;
          125,392
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.3&quot;&gt;
          0.40
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.4&quot;&gt;
          8.0
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA847&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA848&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We adopted an Employee Stock Purchase Plan (Purchase Plan) in 1997. Qualified employees may elect to have a certain percentage of their salary withheld to purchase shares of our common stock under the Purchase Plan. In June&amp;#160;2011, our stockholders authorized an increase in the number of shares reserved for issuance under the Purchase Plan by 500,000, for a total of 1,000,000 shares reserved at September 30, 2013. The purchase price per share is equal to 85% of the fair market value of the stock on specified dates. Sales under the Purchase Plan during the nine months ended September 30, 2013 and 2012 consisted of 80,027 and 58,571 shares at an average price of $0.31 and $0.21, respectively. Shares available for future purchase under the Purchase Plan were 365,674 at September 30, 2013.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized unitRef="shares" contextRef="c20_From1Jan2011To30Jun2011_EmployeeStockPurchasePlan1997Member" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c21_AsOf30Sep2013_EmployeeStockPurchasePlan1997Member" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c22_From1Jan2013To30Sep2013_EmployeeStockPurchasePlan1997Member" decimals="2">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans unitRef="shares" contextRef="c22_From1Jan2013To30Sep2013_EmployeeStockPurchasePlan1997Member" decimals="INF">80027</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans unitRef="shares" contextRef="c23_From1Jan2012To30Sep2012_EmployeeStockPurchasePlan1997Member" decimals="INF">58571</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c22_From1Jan2013To30Sep2013_EmployeeStockPurchasePlan1997Member" decimals="2">0.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c23_From1Jan2012To30Sep2012_EmployeeStockPurchasePlan1997Member" decimals="2">0.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c21_AsOf30Sep2013_EmployeeStockPurchasePlan1997Member" decimals="INF">365674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1205.finRow.2&quot;&gt;
        &lt;td style=&quot;WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.2.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1176&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Three Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1178&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.2.amt.D5&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1177&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1179&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.2.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1180&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1181&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1182&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.3.amt.D5&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1183&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.3.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.4&quot;&gt;
        &lt;td style=&quot;WIDTH: 52%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1205.finRow.4.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1184&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Operating expenses:&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1205.finRow.5.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1185&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Research and development&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.2&quot;&gt;
          544
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.3&quot;&gt;
          397
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.4&quot;&gt;
          1,088
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.amt.5&quot;&gt;
          1,061
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.6.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.7&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1190&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;General and administrative&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.2&quot;&gt;
          3,551
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.3&quot;&gt;
          1,583
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.4&quot;&gt;
          7,245
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.symb.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.amt.5&quot;&gt;
          2,712
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.7.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1195&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Total stock-based compensation expense&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.2&quot;&gt;
          4,095
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.3&quot;&gt;
          1,980
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.4&quot;&gt;
          8,333
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.amt.5&quot;&gt;
          3,773
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.8.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.9&quot;&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 52%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.lead.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.symb.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.amt.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1205.finRow.9.trail.B5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1205.finRow.10&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1200&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Impact on basic and diluted net loss per common share&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.2&quot;&gt;
          0.01
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.3&quot;&gt;
          0.01
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.4&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.4&quot;&gt;
          0.03
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.symb.5&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.amt.5&quot;&gt;
          0.02
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1205.finRow.10.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c24_From1Jul2013To30Sep2013_ResearchAndDevelopmentExpenseMember" decimals="-3">544000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c25_From1Jul2012To30Sep2012_ResearchAndDevelopmentExpenseMember" decimals="-3">397000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c26_From1Jan2013To30Sep2013_ResearchAndDevelopmentExpenseMember" decimals="-3">1088000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c27_From1Jan2012To30Sep2012_ResearchAndDevelopmentExpenseMember" decimals="-3">1061000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c28_From1Jul2013To30Sep2013_GeneralAndAdministrativeExpenseMember" decimals="-3">3551000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c29_From1Jul2012To30Sep2012_GeneralAndAdministrativeExpenseMember" decimals="-3">1583000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c30_From1Jan2013To30Sep2013_GeneralAndAdministrativeExpenseMember" decimals="-3">7245000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c31_From1Jan2012To30Sep2012_GeneralAndAdministrativeExpenseMember" decimals="-3">2712000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">4095000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">1980000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">8333000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">3773000</us-gaap:AllocatedShareBasedCompensationExpense>
  <appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare unitRef="usdPershares" contextRef="c2_From1Jul2013To30Sep2013" decimals="2">0.01</appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare>
  <appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare unitRef="usdPershares" contextRef="c3_From1Jul2012To30Sep2012" decimals="2">0.01</appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare>
  <appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">0.03</appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare>
  <appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare unitRef="usdPershares" contextRef="c5_From1Jan2012To30Sep2012" decimals="2">0.02</appa:StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1230.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1206&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Shares (in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1209&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted- Average Exercise&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1211&quot;&gt;
            &lt;b&gt;Price&lt;/b&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.lead.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.4.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1207&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1208&quot;&gt;
            &lt;b&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1210&quot;&gt;
            &lt;b&gt;Remaining Contractual Term&lt;/b&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1212&quot;&gt;
            (Years)
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.4.trail.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.5&quot;&gt;
        &lt;td&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1230.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1213&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Outstanding at January 1, 2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.2&quot;&gt;
          86,478
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.3&quot;&gt;
          0.42
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.amt.4&quot;&gt;
          8.2
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.7&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1217&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.amt.2&quot;&gt;
          76,735
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.amt.3&quot;&gt;
          0.40
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.7.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.7.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1220&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.amt.2&quot;&gt;
          (4,323
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.amt.3&quot;&gt;
          0.26
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.8.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.9&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1223&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expired and forfeited&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.amt.2&quot;&gt;
          (33,498
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.amt.3&quot;&gt;
          0.47
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.9.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1230.finRow.9.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1230.finRow.10&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1226&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Outstanding at September 30, 2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.2&quot;&gt;
          125,392
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.3&quot;&gt;
          0.40
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.amt.4&quot;&gt;
          8.0
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1230.finRow.10.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c1_AsOf31Dec2012" decimals="-3">86478000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2012" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c32_From1Jan2012To31Dec2012">P8Y73D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">76735000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">4323000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c4_From1Jan2013To30Sep2013" decimals="-3">33498000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_From1Jan2013To30Sep2013" decimals="2">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c0_AsOf30Sep2013" decimals="-3">125392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_AsOf30Sep2013" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c4_From1Jan2013To30Sep2013">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA850&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(6)&amp;#160;COMPREHENSIVE LOSS&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA852&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Comprehensive loss for the periods reported was comprised solely of our net loss. The comprehensive loss for the three and nine months ended September 30, 2013 was $12.9 million and $41.2 million, respectively. The comprehensive loss for the three and nine months ended September 30, 2012 was $6.1 million and $15.6 million, respectively. There were no changes in equity that were excluded from our net loss for all reported periods.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-5">-12900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="-5">-41200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-5">-6100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-5">-15600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA854&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(7)&amp;#160;DISCONTINUED OPERATIONS&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA856&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Cosmeceutical and Toiletry Business&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA858&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;On July&amp;#160;25, 2000, we completed the sale of certain technology rights for our cosmeceutical and toiletry business to RP&amp;#160;Scherer Corporation (RP Scherer), a subsidiary of Cardinal Health, Inc. Under the terms of the agreement, we guaranteed a minimum gross profit percentage on RP Scherer&apos;s combined sales of products to Ortho Dermatologics (Ortho) and Dermik Laboratories, Inc. (Dermik) (Gross Profit Guaranty), both of which were acquired by Valeant Pharmaceuticals in July 2011. The Gross Profit Guaranty expense totaled $944,000 for the first seven guaranty years. Effective March 2007, in conjunction with a sale of assets by RP Scherer&amp;#8217;s successor company to an Amcol International subsidiary (Amcol), a new agreement was signed between us and Amcol to provide continuity of product supply to Ortho and Dermik. We had previously recorded a liability of $1.1 million related to the amount that Amcol
      asserted was due under the Gross Profit Guaranty. In February 2013, an arbitrator ruled that no additional amounts were owed. This event qualified as an adjusting event under ASC 855, &lt;i&gt;Subsequent Event&lt;/i&gt;, and in light of the arbitrator&amp;#8217;s decision in February 2013, which was final and binding, we reversed this accrual as of December 31, 2012.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA860&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The cosmeceutical and toiletry business is reported as discontinued operations for all periods presented in our accompanying Condensed Statements of Operations. Income (loss) from discontinued operations primarily represents the income (loss) attributable to changes in estimates of our cosmeceutical and toiletry business that was sold to RP Scherer on July&amp;#160;25, 2000, as follows (in thousands):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1246.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.2.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1232&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Three Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1234&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.2.amt.D5&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1233&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1235&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1236&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1237&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1238&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D5&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1239&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1240&quot;&gt;
            &lt;u&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Cosmeceutical and Toiletry Business&lt;/font&gt;&lt;/u&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.4-0&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1245&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Change in estimates for gross profit guarantees&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.2-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.2-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.2-0&quot;&gt;
          -
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.2-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.3-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.3-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.3-0&quot;&gt;
          128
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.3-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.4-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.4-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.4-0&quot;&gt;
          -
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.4-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.5-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.5-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.5-0&quot;&gt;
          (6
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.5-0&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA863&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;There was no material basic and diluted loss per common share resulting from discontinued operations for the three and nine months ended September 30, 2013 and 2012.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid unitRef="usd" contextRef="c33_From1Jul2000To30Jun2007" decimals="0">944000</us-gaap:LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities unitRef="usd" contextRef="c32_From1Jan2012To31Dec2012" decimals="-5">1100000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <appa:IncomeLossFromDiscontinuedOperationsTableTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1246.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.2.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1232&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Three Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1234&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.2.amt.D5&quot; colspan=&quot;6&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1233&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Nine Months Ended&lt;/font&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1235&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;September 30,&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.2.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1236&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1237&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1238&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2013&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.lead.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.3.amt.D5&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1239&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;2012&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1246.finRow.3.trail.D5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1240&quot;&gt;
            &lt;u&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Cosmeceutical and Toiletry Business&lt;/font&gt;&lt;/u&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.5&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.5&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1246.finRow.4-0&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt&quot; id=&quot;PARA1245&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Change in estimates for gross profit guarantees&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.2-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.2-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.2-0&quot;&gt;
          -
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.2-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.3-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.3-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.3-0&quot;&gt;
          128
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.3-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.4-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.4-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.4-0&quot;&gt;
          -
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.4-0&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.lead.5-0&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.symb.5-0&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.amt.5-0&quot;&gt;
          (6
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1246.finRow.4.trail.5-0&quot; nowrap=&quot;nowrap&quot;&gt;
          )
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</appa:IncomeLossFromDiscontinuedOperationsTableTextBlock>
  <appa:ChangeInEstimatesForGrossProfitGuarantees unitRef="usd" contextRef="c3_From1Jul2012To30Sep2012" decimals="-3">128000</appa:ChangeInEstimatesForGrossProfitGuarantees>
  <appa:ChangeInEstimatesForGrossProfitGuarantees unitRef="usd" contextRef="c5_From1Jan2012To30Sep2012" decimals="-3">-6000</appa:ChangeInEstimatesForGrossProfitGuarantees>
  <us-gaap:DebtDisclosureTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA865&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(8) CONVERTIBLE NOTES TO RELATED PARTIES&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA867&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In April 2011, we entered into a Securities Purchase Agreement (Purchase Agreement) with certain institutional investors (Purchasers), including a fund affiliated with Kevin C. Tang, who is the Chairman of our Board of Directors (Board), for a private placement of up to $4.5 million in Senior Secured Convertible Notes due 2021 (Notes). The Purchase Agreement provided for the Purchasers to purchase $1.5 million aggregate principal amount of Notes at the initial closing. Pursuant to the Purchase Agreement, the Purchasers had the option to purchase an additional $3.0 million aggregate principal amount of Notes at any time until May 2, 2013 (Purchase Option). The Notes are convertible into shares of the Company&amp;#8217;s common stock at a rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes (Conversion Shares).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA869&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The cash received from the initial closing of the Note financing, which resulted in the issuance of $1.5 million aggregate principal amount of Notes, was approximately $1.3 million, net of issuance costs. In May 2012, the Purchasers exercised their Purchase Option in full, and we received $3.0 million of cash through the issuance of the remaining $3.0&amp;#160;million aggregate principal amount of Notes. As a result of the exercise of the Purchase Option, the Purchasers have purchased the full amount of Notes that the Company was obligated to sell under the Purchase Agreement.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA871&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Notes are secured by substantially all of the assets of the Company, including placing our bank accounts under a control agreement. The Notes initially bore interest at 20%&amp;#160;per annum, payable quarterly in cash or in additional principal amount of Notes at the election of the Purchasers. In June 2011, the Notes were amended to reduce the interest rate to 6%&amp;#160;per annum effective July&amp;#160;1, 2011. The Notes mature on May 2, 2021; however, the holders of the Notes may require prepayment of the Notes at any time beginning on or after May&amp;#160;2, 2012, at each holder&apos;s option.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA873&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of the Company&apos;s outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to the Company, which will not be effective until 61 days after delivery of the notice.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA875&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;As of September 30, 2013, the Company was in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require the Company to redeem all or a portion of their Notes.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA877&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Pursuant to the Purchase Agreement, the Company filed a registration statement on Form S-1, registering for resale 69.6&amp;#160;million shares underlying the Notes. The registration statement was declared effective on July&amp;#160;29, 2011. The Purchasers have agreed to waive their right to require the Company to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA879&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Notes contain an embedded conversion feature that was in-the-money on both issuance dates. Based on an effective fixed conversion rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates, and the Company began amortizing the resultant debt discount over the respective 10-year or remaining term of the Notes. During the three months ended September 30, 2013, accrued interest of approximately $73,000 was paid-in-kind and rolled into the principal balance of the Notes, which resulted in an additional full debt discount for the respective periods. For the three and nine months ended September 30, 2013, interest expense relating to the stated rate of the Notes was approximately $74,000 and
      $218,000, respectively. Interest expense relating to the amortization of debt discount for the three and nine months ended September 30, 2013 was approximately $134,000 and $396,000, respectively.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA881&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;As of September 30, 2013, the carrying value of the Notes was approximately $888,000, which is comprised of the $4,958,000 principal amount of the Notes outstanding, less debt discount of $4,070,000. If the $5.0 million principal amount of Notes is converted, the Company would issue 124.0 million shares of its common stock. Accrued interest on the principal balance was $74,000 at September 30, 2013.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <appa:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1 unitRef="usd" contextRef="c34_AsOf30Apr2011_SeniorNotesMember" decimals="-5">4500000</appa:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1>
  <appa:NotesAuthorizedUnderPrivatePlacementInitialClosing unitRef="usd" contextRef="c35_AsOf30Apr2011_InitialClosingAmountMember" decimals="-5">1500000</appa:NotesAuthorizedUnderPrivatePlacementInitialClosing>
  <appa:PurchaseOptionUnderPrivatePlacement unitRef="usd" contextRef="c36_AsOf30Apr2011_PurchaseOptionMember" decimals="-5">3000000</appa:PurchaseOptionUnderPrivatePlacement>
  <appa:DebtInstrumentConversionRatioShares unitRef="shares" contextRef="c37_From1Apr2011To30Apr2011_CommonStockMember" decimals="INF">25000</appa:DebtInstrumentConversionRatioShares>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 unitRef="pure" contextRef="c38_From1Apr2011To30Apr2011_PrincipalAmountMember" decimals="0">1000</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <appa:NotesAuthorizedUnderPrivatePlacementInitialClosing unitRef="usd" contextRef="c9_AsOf30Apr2011" decimals="-5">1500000</appa:NotesAuthorizedUnderPrivatePlacementInitialClosing>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts unitRef="usd" contextRef="c39_From1Apr2011To30Apr2011_SeniorNotesMember" decimals="-5">1300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts unitRef="usd" contextRef="c40_From1May2012To31May2012_SeniorNotesMember" decimals="-5">3000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c34_AsOf30Apr2011_SeniorNotesMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c41_AsOf1Jul2011_SeniorNotesMember" decimals="2">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c42_From1Jun2011To1Jul2011_SeniorNotesMember">2021-05-02</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDateRangeStart1 contextRef="c42_From1Jun2011To1Jul2011_SeniorNotesMember">2012-05-02</us-gaap:DebtInstrumentMaturityDateRangeStart1>
  <appa:BeneficialOwnershipAfterConversion unitRef="pure" contextRef="c42_From1Jun2011To1Jul2011_SeniorNotesMember" decimals="4">0.0999</appa:BeneficialOwnershipAfterConversion>
  <appa:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes contextRef="c42_From1Jun2011To1Jul2011_SeniorNotesMember">P61D</appa:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes>
  <appa:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes unitRef="shares" contextRef="c43_From28Jul2011To29Jul2011" decimals="-5">69600000</appa:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes>
  <us-gaap:PaidInKindInterest unitRef="usd" contextRef="c44_From1Jul2013To30Sep2013_PaymentInKindPIKNoteMember" decimals="0">73000</us-gaap:PaidInKindInterest>
  <us-gaap:InterestExpenseDebtExcludingAmortization unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="0">74000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization unitRef="usd" contextRef="c4_From1Jan2013To30Sep2013" decimals="0">218000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c2_From1Jul2013To30Sep2013" decimals="-3">134000</us-gaap:AmortizationOfDebtDiscountPremium>
  <appa:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c45_AsOf30Sep2013_SeniorNotesMember" decimals="0">888000</appa:ConvertibleNotesPayableRelatedPartiesCurrent>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c45_AsOf30Sep2013_SeniorNotesMember" decimals="0">4958000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentUnamortizedDiscount unitRef="usd" contextRef="c45_AsOf30Sep2013_SeniorNotesMember" decimals="0">4070000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments unitRef="pure" contextRef="c46_From1Jan2013To30Sep2013_SeniorNotesMember" decimals="-5">124000000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:InterestPayableCurrent unitRef="usd" contextRef="c0_AsOf30Sep2013" decimals="0">74000</us-gaap:InterestPayableCurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c4_From1Jan2013To30Sep2013">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA883&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;(9) STOCKHOLDERS&apos; EQUITY&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA885&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Amendments to Articles of Incorporation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA887&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In June 2011, we amended our certificate of incorporation to increase the number of shares of authorized common stock to 1,500,000,000, par value $0.01 per share. Prior to the amendment, the number of shares of authorized common stock was 100,000,000, par value $0.01 per share. The certificate of amendment was approved by a majority of our stockholders on June&amp;#160;29, 2011.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA889&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In September 2013, our stockholders approved a proposal to authorize our Board to effect a reverse stock split of all outstanding shares of our common stock at any ratio at its discretion, from 1-for-10 to 1-for-20 and to grant the Board discretionary authority, within twelve months from September 19, 2013, to determine whether to effect the split and the exact whole number ratio within the range at which the split will be effected. The number of issued and outstanding shares of our common stock would be reduced in accordance with the ratio selected by the Board. The number of shares of common stock that are authorized for issuance under our certificate of incorporation would also be reduced proportionately based on the exchange ratio of the reverse stock split.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA891&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock Plans&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA893&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;At our annual meeting of stockholders in June 2011, our stockholders approved an amendment to our 2007 Equity Incentive Plan to increase the maximum number of shares of common stock available for grant by 90,000,000 shares of common stock, resulting in an aggregate of 95,000,000 shares of common stock authorized for issuance pursuant to awards granted under our 2007 Equity Incentive Plan. The stockholders also approved an amendment to our 1997 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance under the plan by 500,000, for a total of 1,000,000 shares reserved as of September 30, 2013.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA895&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;2011 Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA897&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In June 2011, we entered into a Securities Purchase Agreement with certain purchasers (Securities Purchase Agreement), pursuant to which we agreed to sell 160,000,006 shares of our common stock (Shares) and warrants to purchase 80,000,005 shares of our common stock (Warrants) with an exercise price of $0.18 per share (2011 Private Placement), for an aggregate price of $24.0 million. The 2011 Private Placement closed on July 1, 2011. For each share purchased, the investors received one Warrant to purchase 0.5 shares of common stock (together with a Share, a Unit), at a purchase price of $0.15 per Unit. The Warrants were immediately exercisable and expire on the fifth anniversary of the closing date of July 1, 2011. The Warrants may be exercised for cash only or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the
      Warrants, by surrender of such Warrant, or a portion of such Warrant, by way of cashless exercise. There is no right to exercise the Warrants to the extent that after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the Warrants can amend or waive the foregoing limitation by written notice to the Company, with such waiver taking effect only upon the expiration of a 61-day notice period.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA899&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Under the terms of the Securities Purchase Agreement, on July 29, 2011, the Company filed a registration statement with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants (the Warrant Shares, and collectively&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;with the Shares, the Registrable Securities). The registration statement was declared effective on August 4, 2011. The Company is obligated to maintain the effectiveness of the registration statement with respect to an investor&amp;#8217;s Registrable Securities until the investor is able to sell the Registrable Securities without limitation or restriction under Rule 144. There is currently only one investor who is an affiliate of the Company and is therefore not able to sell the
      Registrable Securities without limitation under Rule 144, and that investor has agreed to waive their right to require the Company to maintain the effectiveness of the registration statement until they provide notice otherwise. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions)&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;during the period the Company is obligated to maintain the registration statement, the Company may be obligated to pay to the holders of the Registrable Securities liquidated damages in an amount equal to 1.0% per month of such holder&apos;s pro rata interest in the total purchase price of the Private Placement, capped at a total penalty of 6.0%.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA901&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Company received total proceeds of $22.8 million from the 2011 Private Placement, which was net of issuance costs of approximately $1.2 million. During the nine months ended September 30, 2013, the Company received $0.6 million for an exercise of a Warrant.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA903&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;2012 Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA905&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In July 2012, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell 102,000,000 shares of its common stock (2012 Shares) at a purchase price of $0.525 per share of common stock, for an aggregate price of approximately $53.6 million (2012 Private Placement). The 2012 Private Placement closed on July 30, 2012.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA907&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In connection with entering into the securities purchase agreement, the Company also entered into a registration rights agreement. On August 24, 2012, the Company filed a registration statement with the SEC to register the 2012 Shares for resale. The registration statement was declared effective on September 6, 2012. If the Company fails to keep the registration statements continuously effective for a designated time (with limited exceptions), the Company may be obligated to pay to each holder of the 2012 Shares an amount equal to 1.5% per month of the aggregate purchase price of the unregistered 2012 Shares held by such holder, capped at a total penalty of 9.0%.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA909&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Company received total proceeds of $50.5 million from the 2012 Private Placement, which was net of issuance costs of approximately $3.1 million.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c47_AsOf29Jun2011" decimals="INF">1500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c47_AsOf29Jun2011" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c48_AsOf28Jun2011" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c48_AsOf28Jun2011" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 unitRef="pure" contextRef="c49_From1Sep2013To30Sep2013_CommonStockMember_ScenarioActualMember" decimals="0">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 unitRef="pure" contextRef="c50_From1Sep2013To30Sep2013_CommonStockMember_ScenarioProposedMember" decimals="0">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized unitRef="shares" contextRef="c51_From1Jun2011To30Jun2011" decimals="INF">90000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c52_AsOf30Jun2011" decimals="INF">95000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <appa:IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance unitRef="shares" contextRef="c53_AsOf30Jun2011_StockCompensationPlanMember" decimals="INF">500000</appa:IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance unitRef="shares" contextRef="c54_AsOf30Sep2013_StockCompensationPlanMember" decimals="INF">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c55_From1Jun2011To30Jun2011_CommonStockMember_PrivatePlacement2011Member" decimals="INF">160000006</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c56_AsOf30Jun2011_CommonStockMember_PrivatePlacement2011Member" decimals="INF">80000005</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights unitRef="usdPeritem" contextRef="c56_AsOf30Jun2011_CommonStockMember_PrivatePlacement2011Member" decimals="2">0.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c57_From1Jun2011To31Jul2011_PrivatePlacement2011Member" decimals="-5">24000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <appa:SharesAvailablePerWarrantExercisedCommonStock unitRef="shares" contextRef="c58_From1Jun2011To31Jul2011" decimals="INF">0.5</appa:SharesAvailablePerWarrantExercisedCommonStock>
  <appa:ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit unitRef="usdPeritem" contextRef="c59_AsOf31Jul2011" decimals="2">0.15</appa:ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit>
  <appa:LimitationOnExercisableWarrants unitRef="pure" contextRef="c60_From1Jun2011To30Sep2013" decimals="4">0.0999</appa:LimitationOnExercisableWarrants>
  <appa:EffectiveRateOfLiquidatedDamages unitRef="pure" contextRef="c61_From1Jun2011To30Sep2013_PrivatePlacement2011Member" decimals="3">0.010</appa:EffectiveRateOfLiquidatedDamages>
  <appa:PrivatePlacementCappedPenatly unitRef="pure" contextRef="c61_From1Jun2011To30Sep2013_PrivatePlacement2011Member" decimals="3">0.060</appa:PrivatePlacementCappedPenatly>
  <appa:ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet unitRef="usd" contextRef="c57_From1Jun2011To31Jul2011_PrivatePlacement2011Member" decimals="-5">22800000</appa:ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c57_From1Jun2011To31Jul2011_PrivatePlacement2011Member" decimals="-5">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c62_From1Jan2012To30Jul2012_CommonStockMember_PrivatePlacement2012Member" decimals="INF">102000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c63_AsOf30Jul2012_CommonStockMember_PrivatePlacement2012Member" decimals="3">0.525</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c64_From1Jan2012To30Jul2012_PrivatePlacement2012Member" decimals="-5">53600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <appa:EffectiveRateOfLiquidatedDamages unitRef="pure" contextRef="c65_From1Jul2012To30Sep2013_PrivatePlacement2012Member" decimals="3">0.015</appa:EffectiveRateOfLiquidatedDamages>
  <appa:PrivatePlacementCappedPenatly unitRef="pure" contextRef="c65_From1Jul2012To30Sep2013_PrivatePlacement2012Member" decimals="3">0.090</appa:PrivatePlacementCappedPenatly>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c66_From1Jan2012To30Jun2012_PrivatePlacement2012Member" decimals="-5">50500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c66_From1Jan2012To30Jun2012_PrivatePlacement2012Member" decimals="-5">3100000</us-gaap:PaymentsOfStockIssuanceCosts>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>appa-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<xs:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.appharma.com/20130930" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:appa="http://www.appharma.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" elementFormDefault="qualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="appa-20130930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="appa-20130930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="appa-20130930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="appa-20130930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.appharma.com/role/ConsolidatedBalanceSheet" id="appa_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/ConsolidatedIncomeStatement" id="appa_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/ConsolidatedCashFlow" id="appa_ConsolidatedCashFlow">
        <link:definition>003 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentation" id="appa_Note1BusinessandBasisofPresentation">
        <link:definition>004 - Disclosure - Note 1 - Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note2CashEquivalents" id="appa_Note2CashEquivalents">
        <link:definition>005 - Disclosure - Note 2 - Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note3FairValueMeasurements" id="appa_Note3FairValueMeasurements">
        <link:definition>006 - Disclosure - Note 3 - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note4NetLossPerShare" id="appa_Note4NetLossPerShare">
        <link:definition>007 - Disclosure - Note 4 - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note5StockBasedCompensation" id="appa_Note5StockBasedCompensation">
        <link:definition>008 - Disclosure - Note 5 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note6ComprehensiveLoss" id="appa_Note6ComprehensiveLoss">
        <link:definition>009 - Disclosure - Note 6 - Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note7DiscontinuedOperations" id="appa_Note7DiscontinuedOperations">
        <link:definition>010 - Disclosure - Note 7 - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties" id="appa_Note8ConvertibleNotestoRelatedParties">
        <link:definition>011 - Disclosure - Note 8 - Convertible Notes to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note9StockholdersEquity" id="appa_Note9StockholdersEquity">
        <link:definition>012 - Disclosure - Note 9 - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/AccountingPoliciesByPolicy" id="appa_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note4NetLossPerShareTables" id="appa_Note4NetLossPerShareTables">
        <link:definition>014 - Disclosure - Note 4 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note5StockBasedCompensationTables" id="appa_Note5StockBasedCompensationTables">
        <link:definition>015 - Disclosure - Note 5 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsTables" id="appa_Note7DiscontinuedOperationsTables">
        <link:definition>016 - Disclosure - Note 7 - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails" id="appa_Note1BusinessandBasisofPresentationDetails">
        <link:definition>017 - Disclosure - Note 1 - Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATa+YLEgiDxM8gUA78JEhOaVsP34qzv/1og==] CSR-->
      <link:roleType roleURI="http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable" id="appa_OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable">
        <link:definition>018 - Disclosure - Note 4 - Net Loss Per Share (Details) - Outstanding potentially dilutive options, warrants and convertible notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note5StockBasedCompensationDetails" id="appa_Note5StockBasedCompensationDetails">
        <link:definition>019 - Disclosure - Note 5 - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/StockbasedCompensationExpenseTable" id="appa_StockbasedCompensationExpenseTable">
        <link:definition>020 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/StockbasedOptionDetailsTable" id="appa_StockbasedOptionDetailsTable">
        <link:definition>021 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Stock-based Option Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note6ComprehensiveLossDetails" id="appa_Note6ComprehensiveLossDetails">
        <link:definition>022 - Disclosure - Note 6 - Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsDetails" id="appa_Note7DiscontinuedOperationsDetails">
        <link:definition>023 - Disclosure - Note 7 - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable" id="appa_IncomelossfromdiscontinuedoperationsTable">
        <link:definition>024 - Disclosure - Note 7 - Discontinued Operations (Details) - Income (loss) from discontinued operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails" id="appa_Note8ConvertibleNotestoRelatedPartiesDetails">
        <link:definition>025 - Disclosure - Note 8 - Convertible Notes to Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/Note9StockholdersEquityDetails" id="appa_Note9StockholdersEquityDetails">
        <link:definition>026 - Disclosure - Note 9 - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.appharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Disclosure - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="CurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CurrentAssetsAbstract"/>
  <xs:element name="CurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CurrentLiabilitiesAbstract"/>
  <xs:element name="ConvertibleNotesPayableRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
  <xs:element name="BasicAndDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_BasicAndDilutedNetLossPerShareAbstract"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="IncomeLossFromDiscontinuedOperationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock"/>
  <xs:element name="OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract"/>
  <xs:element name="StockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_StockBasedCompensationExpenseAbstract"/>
  <xs:element name="OperatingExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_OperatingExpensesAbstract0"/>
  <xs:element name="StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare"/>
  <xs:element name="StockBasedOptionDetailsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_StockBasedOptionDetailsAbstract"/>
  <xs:element name="IncomeLossFromDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_IncomeLossFromDiscontinuedOperationsAbstract"/>
  <xs:element name="CosmeceuticalAndToiletryBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CosmeceuticalAndToiletryBusinessAbstract"/>
  <xs:element name="ChangeInEstimatesForGrossProfitGuarantees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="appa_ChangeInEstimatesForGrossProfitGuarantees"/>
  <xs:element name="DisclosureDomain" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_DisclosureDomain"/>
  <xs:element name="Note1BusinessandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="appa_Note1BusinessandBasisofPresentationDetailsTable"/>
  <xs:element name="Note1BusinessandBasisofPresentationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_Note1BusinessandBasisofPresentationDetailsLineItems"/>
  <xs:element name="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
  <xs:element name="ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
  <xs:element name="Note5StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="appa_Note5StockBasedCompensationDetailsTable"/>
  <xs:element name="Note5StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_Note5StockBasedCompensationDetailsLineItems"/>
  <xs:element name="Note8ConvertibleNotestoRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable"/>
  <xs:element name="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
  <xs:element name="NotesAuthorizedUnderPrivatePlacementInitialClosing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
  <xs:element name="PurchaseOptionUnderPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="appa_PurchaseOptionUnderPrivatePlacement"/>
  <xs:element name="DebtInstrumentConversionRatioShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_DebtInstrumentConversionRatioShares"/>
  <xs:element name="BeneficialOwnershipAfterConversion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_BeneficialOwnershipAfterConversion"/>
  <xs:element name="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
  <xs:element name="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
  <xs:element name="Note9StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="appa_Note9StockholdersEquityDetailsTable"/>
  <xs:element name="Note9StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_Note9StockholdersEquityDetailsLineItems"/>
  <xs:element name="IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance"/>
  <xs:element name="SharesAvailablePerWarrantExercisedCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_SharesAvailablePerWarrantExercisedCommonStock"/>
  <xs:element name="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
  <xs:element name="LimitationOnExercisableWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_LimitationOnExercisableWarrants"/>
  <xs:element name="EffectiveRateOfLiquidatedDamages" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_EffectiveRateOfLiquidatedDamages"/>
  <xs:element name="PrivatePlacementCappedPenatly" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_PrivatePlacementCappedPenatly"/>
  <xs:element name="DisclosureAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="appa_DisclosureAxis"/>
  <xs:element name="InitialClosingAmountMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_InitialClosingAmountMember"/>
  <xs:element name="PrivatePlacement2012Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_PrivatePlacement2012Member"/>
  <xs:element name="PurchaseOptionMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_PurchaseOptionMember"/>
  <xs:element name="ScenarioProposedMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_ScenarioProposedMember"/>
  <xs:element name="EmployeeStockPurchasePlan1997Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_EmployeeStockPurchasePlan1997Member"/>
  <xs:element name="PrincipalAmountMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_PrincipalAmountMember"/>
  <xs:element name="PrivatePlacement2011Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_PrivatePlacement2011Member"/>
  <xs:element name="NetOfIssuanceCostsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_NetOfIssuanceCostsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="appa_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>appa-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedBalanceSheet" roleURI="http://www.appharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedIncomeStatement" roleURI="http://www.appharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedCashFlow" roleURI="http://www.appharma.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATcczADnzsaQgCMlPWbwwtpo6K5Lt8EwG4g==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>appa-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedBalanceSheet" roleURI="http://www.appharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedIncomeStatement" roleURI="http://www.appharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedCashFlow" roleURI="http://www.appharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentation" roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note2CashEquivalents" roleURI="http://www.appharma.com/role/Note2CashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note3FairValueMeasurements" roleURI="http://www.appharma.com/role/Note3FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note4NetLossPerShare" roleURI="http://www.appharma.com/role/Note4NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensation" roleURI="http://www.appharma.com/role/Note5StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note6ComprehensiveLoss" roleURI="http://www.appharma.com/role/Note6ComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperations" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperations"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedParties" roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquity" roleURI="http://www.appharma.com/role/Note9StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_AccountingPoliciesByPolicy" roleURI="http://www.appharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note4NetLossPerShareTables" roleURI="http://www.appharma.com/role/Note4NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationTables" roleURI="http://www.appharma.com/role/Note5StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperationsTables" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable" roleURI="http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_StockbasedCompensationExpenseTable" roleURI="http://www.appharma.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_StockbasedOptionDetailsTable" roleURI="http://www.appharma.com/role/StockbasedOptionDetailsTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_IncomelossfromdiscontinuedoperationsTable" roleURI="http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetails" roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetails" roleURI="http://www.appharma.com/role/Note5StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note6ComprehensiveLossDetails" roleURI="http://www.appharma.com/role/Note6ComprehensiveLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperationsDetails" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetails" roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetails" roleURI="http://www.appharma.com/role/Note9StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#DocumentAndEntityInformation" roleURI="http://www.appharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CurrentAssetsAbstract" xlink:href="appa-20130930.xsd#appa_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="appa_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CurrentLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="appa_CurrentLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_StockholdersEquityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_BasicAndDilutedNetLossPerShareAbstract" xlink:href="appa-20130930.xsd#appa_BasicAndDilutedNetLossPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_BasicAndDilutedNetLossPerShareAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_CashFlowsFromOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromInvestingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_CashFlowsFromInvestingActivitiesAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromFinancingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="appa_CashFlowsFromFinancingActivitiesAbstract" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note1BusinessandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note2CashEquivalents">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note3FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note4NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note6ComprehensiveLoss">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note9StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note4NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/StockbasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_OperatingExpensesAbstract0" xlink:href="appa-20130930.xsd#appa_OperatingExpensesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="appa_OperatingExpensesAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" xbrldt:closed="true"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATbTevlJOD/gb+/Lpz8L/lHA=] CSR-->
    <loc xlink:type="locator" xlink:label="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" xlink:href="appa-20130930.xsd#appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/StockbasedOptionDetailsTable">
    <loc xlink:type="locator" xlink:label="appa_StockBasedOptionDetailsAbstract" xlink:href="appa-20130930.xsd#appa_StockBasedOptionDetailsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable">
    <loc xlink:type="locator" xlink:label="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="appa_CosmeceuticalAndToiletryBusinessAbstract" xlink:href="appa-20130930.xsd#appa_CosmeceuticalAndToiletryBusinessAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="appa_CosmeceuticalAndToiletryBusinessAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ChangeInEstimatesForGrossProfitGuarantees" xlink:href="appa-20130930.xsd#appa_ChangeInEstimatesForGrossProfitGuarantees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="appa_ChangeInEstimatesForGrossProfitGuarantees" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="appa_Note1BusinessandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_DisclosureAxis" xlink:href="appa-20130930.xsd#appa_DisclosureAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsTable" xlink:to="appa_DisclosureAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_DisclosureDomain" xlink:href="appa-20130930.xsd#appa_DisclosureDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="appa_DisclosureAxis" xlink:to="appa_DisclosureDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_DisclosureDomain_0" xlink:href="appa-20130930.xsd#appa_DisclosureDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="appa_DisclosureAxis" xlink:to="appa_DisclosureDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_NetOfIssuanceCostsMember" xlink:href="appa-20130930.xsd#appa_NetOfIssuanceCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_DisclosureDomain" xlink:to="appa_NetOfIssuanceCostsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PurchaseOptionMember" xlink:href="appa-20130930.xsd#appa_PurchaseOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_DisclosureDomain" xlink:to="appa_PurchaseOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_DisclosureDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="appa-20130930.xsd#appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:href="appa-20130930.xsd#appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="appa_Note5StockBasedCompensationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="appa_Note5StockBasedCompensationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="appa_Note5StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note5StockBasedCompensationDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_EmployeeStockPurchasePlan1997Member" xlink:href="appa-20130930.xsd#appa_EmployeeStockPurchasePlan1997Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="appa_EmployeeStockPurchasePlan1997Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note6ComprehensiveLossDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtSecurityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_InitialClosingAmountMember" xlink:href="appa-20130930.xsd#appa_InitialClosingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="appa_InitialClosingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PurchaseOptionMember" xlink:href="appa-20130930.xsd#appa_PurchaseOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="appa_PurchaseOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_PaymentInKindPIKNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PrincipalAmountMember" xlink:href="appa-20130930.xsd#appa_PrincipalAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="appa_PrincipalAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="appa-20130930.xsd#appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:href="appa-20130930.xsd#appa_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PurchaseOptionUnderPrivatePlacement" xlink:href="appa-20130930.xsd#appa_PurchaseOptionUnderPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_PurchaseOptionUnderPrivatePlacement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_DebtInstrumentConversionRatioShares" xlink:href="appa-20130930.xsd#appa_DebtInstrumentConversionRatioShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_DebtInstrumentConversionRatioShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_BeneficialOwnershipAfterConversion" xlink:href="appa-20130930.xsd#appa_BeneficialOwnershipAfterConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_BeneficialOwnershipAfterConversion" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:href="appa-20130930.xsd#appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:href="appa-20130930.xsd#appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note9StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="appa_Note9StockholdersEquityDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="appa_Note9StockholdersEquityDetailsTable" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_Note9StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="appa_Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioActualMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioActualMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioActualMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ScenarioProposedMember" xlink:href="appa-20130930.xsd#appa_ScenarioProposedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="appa_ScenarioProposedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacement2011Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2011Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="appa_PrivatePlacement2011Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacement2012Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2012Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="appa_PrivatePlacement2012Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:href="appa-20130930.xsd#appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_SharesAvailablePerWarrantExercisedCommonStock" xlink:href="appa-20130930.xsd#appa_SharesAvailablePerWarrantExercisedCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_SharesAvailablePerWarrantExercisedCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:href="appa-20130930.xsd#appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_LimitationOnExercisableWarrants" xlink:href="appa-20130930.xsd#appa_LimitationOnExercisableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_LimitationOnExercisableWarrants" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_EffectiveRateOfLiquidatedDamages" xlink:href="appa-20130930.xsd#appa_EffectiveRateOfLiquidatedDamages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_EffectiveRateOfLiquidatedDamages" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacementCappedPenatly" xlink:href="appa-20130930.xsd#appa_PrivatePlacementCappedPenatly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_PrivatePlacementCappedPenatly" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:href="appa-20130930.xsd#appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.appharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>appa-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_CurrentAssetsAbstract" xlink:href="appa-20130930.xsd#appa_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CurrentAssetsAbstract" xlink:to="appa_CurrentAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CurrentAssetsAbstract" xlink:to="appa_CurrentAssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_CurrentLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CurrentLiabilitiesAbstract" xlink:to="appa_CurrentLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CurrentLiabilitiesAbstract" xlink:to="appa_CurrentLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl0" xml:lang="en-US">Convertible notes payable to related parties, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&apos; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; equity: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating expenses: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">Income (loss) from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_BasicAndDilutedNetLossPerShareAbstract" xlink:href="appa-20130930.xsd#appa_BasicAndDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_BasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Basic and diluted net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_BasicAndDilutedNetLossPerShareAbstract" xlink:to="appa_BasicAndDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_BasicAndDilutedNetLossPerShareAbstract_lbl0" xml:lang="en-US">Basic and diluted net loss per share: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_BasicAndDilutedNetLossPerShareAbstract" xlink:to="appa_BasicAndDilutedNetLossPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Loss from continuing operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Shares used to compute basic and diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromOperatingActivitiesAbstract" xlink:to="appa_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from operating activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromOperatingActivitiesAbstract" xlink:to="appa_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Changes in operating assets and liabilities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="appa_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromInvestingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromInvestingActivitiesAbstract" xlink:to="appa_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from investing activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromInvestingActivitiesAbstract" xlink:to="appa_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_CashFlowsFromFinancingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromFinancingActivitiesAbstract" xlink:to="appa_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from financing activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CashFlowsFromFinancingActivitiesAbstract" xlink:to="appa_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible note financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US">Proceeds from the issuance of shares under the Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock" xlink:to="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" xlink:href="appa-20130930.xsd#appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract_lbl" xml:lang="en-US">Outstanding potentially dilutive options, warrants and convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" xlink:to="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract_lbl0" xml:lang="en-US">Outstanding potentially dilutive options, warrants and convertible notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" xlink:to="appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_StockBasedCompensationExpenseAbstract" xlink:href="appa-20130930.xsd#appa_StockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_StockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Stock-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedCompensationExpenseAbstract" xlink:to="appa_StockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_StockBasedCompensationExpenseAbstract_lbl0" xml:lang="en-US">Stock-based Compensation Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedCompensationExpenseAbstract" xlink:to="appa_StockBasedCompensationExpenseAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_OperatingExpensesAbstract0" xlink:href="appa-20130930.xsd#appa_OperatingExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_OperatingExpensesAbstract0_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_OperatingExpensesAbstract0" xlink:to="appa_OperatingExpensesAbstract0_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_OperatingExpensesAbstract0_lbl0" xml:lang="en-US">Operating expenses: [Abstract]0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_OperatingExpensesAbstract0" xlink:to="appa_OperatingExpensesAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" xlink:href="appa-20130930.xsd#appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare_lbl" xml:lang="en-US">Stock-based compensation expense impact on basic and diluted net earnings per common share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" xlink:to="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare_lbl0" xml:lang="en-US">Impact on basic and diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" xlink:to="appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_StockBasedOptionDetailsAbstract" xlink:href="appa-20130930.xsd#appa_StockBasedOptionDetailsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_StockBasedOptionDetailsAbstract_lbl" xml:lang="en-US">Stock-based Option Details</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="appa_StockBasedOptionDetailsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_StockBasedOptionDetailsAbstract_lbl0" xml:lang="en-US">Stock-based Option Details [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_StockBasedOptionDetailsAbstract" xlink:to="appa_StockBasedOptionDetailsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Expired and forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired and forfeited (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_IncomeLossFromDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Income (loss) from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="appa_IncomeLossFromDiscontinuedOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_IncomeLossFromDiscontinuedOperationsAbstract_lbl0" xml:lang="en-US">Income (loss) from discontinued operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="appa_IncomeLossFromDiscontinuedOperationsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_CosmeceuticalAndToiletryBusinessAbstract" xlink:href="appa-20130930.xsd#appa_CosmeceuticalAndToiletryBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CosmeceuticalAndToiletryBusinessAbstract_lbl" xml:lang="en-US">Cosmeceutical and Toiletry Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CosmeceuticalAndToiletryBusinessAbstract" xlink:to="appa_CosmeceuticalAndToiletryBusinessAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CosmeceuticalAndToiletryBusinessAbstract_lbl0" xml:lang="en-US">Cosmeceutical and Toiletry Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CosmeceuticalAndToiletryBusinessAbstract" xlink:to="appa_CosmeceuticalAndToiletryBusinessAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_ChangeInEstimatesForGrossProfitGuarantees" xlink:href="appa-20130930.xsd#appa_ChangeInEstimatesForGrossProfitGuarantees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ChangeInEstimatesForGrossProfitGuarantees_lbl" xml:lang="en-US">Change in estimates for gross profit guarantees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ChangeInEstimatesForGrossProfitGuarantees" xlink:to="appa_ChangeInEstimatesForGrossProfitGuarantees_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_DisclosureDomain" xlink:href="appa-20130930.xsd#appa_DisclosureDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_DisclosureDomain_lbl" xml:lang="en-US">Disclosure [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DisclosureDomain" xlink:to="appa_DisclosureDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Note 1 - Business and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsTable" xlink:to="appa_Note1BusinessandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note1BusinessandBasisofPresentationDetailsLineItems_lbl" xml:lang="en-US">Note 1 - Business and Basis of Presentation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="appa_Note1BusinessandBasisofPresentationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="appa-20130930.xsd#appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl" xml:lang="en-US">Convertible Debt Issuable In Connection With Private Placement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:href="appa-20130930.xsd#appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds From Sale Of Units Of Common Stock And Warrants Net (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:to="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl0" xml:lang="en-US">Convertible debt issuable in connection with private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl0" xml:lang="en-US">Cash Inflow from sale of units of common stock and warrants net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:to="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note5StockBasedCompensationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note5StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Note 5 - Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note5StockBasedCompensationDetailsTable" xlink:to="appa_Note5StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note5StockBasedCompensationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note5StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Note 5 - Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note5StockBasedCompensationDetailsLineItems" xlink:to="appa_Note5StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid_lbl" xml:lang="en-US">Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" xlink:to="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain_lbl" xml:lang="en-US">Major Types of Debt Securities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Note 8 - Convertible Notes to Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Note 8 - Convertible Notes to Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:href="appa-20130930.xsd#appa_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl" xml:lang="en-US">Notes Authorized Under Private Placement Initial Closing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_PurchaseOptionUnderPrivatePlacement" xlink:href="appa-20130930.xsd#appa_PurchaseOptionUnderPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PurchaseOptionUnderPrivatePlacement_lbl" xml:lang="en-US">Purchase Option Under Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PurchaseOptionUnderPrivatePlacement" xlink:to="appa_PurchaseOptionUnderPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_DebtInstrumentConversionRatioShares" xlink:href="appa-20130930.xsd#appa_DebtInstrumentConversionRatioShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_DebtInstrumentConversionRatioShares_lbl" xml:lang="en-US">Debt Instrument Conversion Ratio, Shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DebtInstrumentConversionRatioShares" xlink:to="appa_DebtInstrumentConversionRatioShares_lbl"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATQouNJLbVqoMlNiAcupkpIlFXgSMP0k6uA==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_BeneficialOwnershipAfterConversion" xlink:href="appa-20130930.xsd#appa_BeneficialOwnershipAfterConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_BeneficialOwnershipAfterConversion_lbl" xml:lang="en-US">Beneficial Ownership After Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_BeneficialOwnershipAfterConversion" xlink:to="appa_BeneficialOwnershipAfterConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:href="appa-20130930.xsd#appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl" xml:lang="en-US">Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:href="appa-20130930.xsd#appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl" xml:lang="en-US">Common Shares Registered For Resale In Connection With Convertible Notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Paid-in-Kind Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl1" xml:lang="en-US">Carrying Value of Notes Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="appa_ConvertibleNotesPayableRelatedPartiesCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl0" xml:lang="en-US">Notes authorized under private placement initial closing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_PurchaseOptionUnderPrivatePlacement_lbl0" xml:lang="en-US">Purchase option under private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PurchaseOptionUnderPrivatePlacement" xlink:to="appa_PurchaseOptionUnderPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_DebtInstrumentConversionRatioShares_lbl0" xml:lang="en-US">Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DebtInstrumentConversionRatioShares" xlink:to="appa_DebtInstrumentConversionRatioShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_BeneficialOwnershipAfterConversion_lbl0" xml:lang="en-US">Percentage amount the holder would beneficially own of the company&apos;s outstanding common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_BeneficialOwnershipAfterConversion" xlink:to="appa_BeneficialOwnershipAfterConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl0" xml:lang="en-US">Notice period associated with beneficial ownership percentage limitation, convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl0" xml:lang="en-US">Common shares registered for resale in connection with convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note9StockholdersEquityDetailsTable" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note9StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Note 9 - Stockholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note9StockholdersEquityDetailsTable" xlink:to="appa_Note9StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_Note9StockholdersEquityDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_Note9StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Note 9 - Stockholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_Note9StockholdersEquityDetailsLineItems" xlink:to="appa_Note9StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:href="appa-20130930.xsd#appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl" xml:lang="en-US">Increase in the Number of Shares of Common Stock Reserved for Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:to="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_SharesAvailablePerWarrantExercisedCommonStock" xlink:href="appa-20130930.xsd#appa_SharesAvailablePerWarrantExercisedCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl" xml:lang="en-US">Shares Available Per Warrant ExercisedCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_SharesAvailablePerWarrantExercisedCommonStock" xlink:to="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:href="appa-20130930.xsd#appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl" xml:lang="en-US">Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Item)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_LimitationOnExercisableWarrants" xlink:href="appa-20130930.xsd#appa_LimitationOnExercisableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_LimitationOnExercisableWarrants_lbl" xml:lang="en-US">Limitation On Exercisable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_LimitationOnExercisableWarrants" xlink:to="appa_LimitationOnExercisableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_EffectiveRateOfLiquidatedDamages" xlink:href="appa-20130930.xsd#appa_EffectiveRateOfLiquidatedDamages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_EffectiveRateOfLiquidatedDamages_lbl" xml:lang="en-US">Effective Rate Of Liquidated Damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_EffectiveRateOfLiquidatedDamages" xlink:to="appa_EffectiveRateOfLiquidatedDamages_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacementCappedPenatly" xlink:href="appa-20130930.xsd#appa_PrivatePlacementCappedPenatly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PrivatePlacementCappedPenatly_lbl" xml:lang="en-US">Private Placement Capped Penatly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacementCappedPenatly" xlink:to="appa_PrivatePlacementCappedPenatly_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl0" xml:lang="en-US">Increase in the number of shares of common stock reserved for issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:to="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl0" xml:lang="en-US">The amount of shares available to be exercised per warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_SharesAvailablePerWarrantExercisedCommonStock" xlink:to="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl0" xml:lang="en-US">Purchase Price Unit (1 Warrant to Purchase 0.5 shares of Common Stock)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_LimitationOnExercisableWarrants_lbl0" xml:lang="en-US">There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company&apos;s outstanding shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_LimitationOnExercisableWarrants" xlink:to="appa_LimitationOnExercisableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_EffectiveRateOfLiquidatedDamages_lbl0" xml:lang="en-US">Failure to keep the registration statement continuously effective for a designated time will result in the rated penalty of liquidated damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_EffectiveRateOfLiquidatedDamages" xlink:to="appa_EffectiveRateOfLiquidatedDamages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_PrivatePlacementCappedPenatly_lbl0" xml:lang="en-US">Percentage of penalty that may not exceed stated percentage of original purchase price of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacementCappedPenatly" xlink:to="appa_PrivatePlacementCappedPenatly_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentInKindPIKNoteMember_lbl" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentInKindPIKNoteMember" xlink:to="us-gaap_PaymentInKindPIKNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecurityAxis_lbl" xml:lang="en-US">Debt Security [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_DebtSecurityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioActualMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioActualMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioActualMember_lbl" xml:lang="en-US">Scenario, Actual [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioActualMember" xlink:to="us-gaap_ScenarioActualMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotesMember_lbl" xml:lang="en-US">Senior Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US">Stock Compensation Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="appa_DisclosureAxis" xlink:href="appa-20130930.xsd#appa_DisclosureAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_DisclosureAxis_lbl" xml:lang="en-US">Disclosure [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DisclosureAxis" xlink:to="appa_DisclosureAxis_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_DisclosureAxis_lbl0" xml:lang="en-US">Disclosure [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DisclosureAxis" xlink:to="appa_DisclosureAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_InitialClosingAmountMember" xlink:href="appa-20130930.xsd#appa_InitialClosingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_InitialClosingAmountMember_lbl" xml:lang="en-US">Initial Closing Amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_InitialClosingAmountMember" xlink:to="appa_InitialClosingAmountMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_InitialClosingAmountMember_lbl0" xml:lang="en-US">Initial Closing Amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_InitialClosingAmountMember" xlink:to="appa_InitialClosingAmountMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacement2012Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2012Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PrivatePlacement2012Member_lbl" xml:lang="en-US">Private Placement 2012 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacement2012Member" xlink:to="appa_PrivatePlacement2012Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PrivatePlacement2012Member_lbl0" xml:lang="en-US">Private Placement 2012 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacement2012Member" xlink:to="appa_PrivatePlacement2012Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_PurchaseOptionMember" xlink:href="appa-20130930.xsd#appa_PurchaseOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PurchaseOptionMember_lbl" xml:lang="en-US">Purchase Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PurchaseOptionMember" xlink:to="appa_PurchaseOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PurchaseOptionMember_lbl0" xml:lang="en-US">Purchase Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PurchaseOptionMember" xlink:to="appa_PurchaseOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_ScenarioProposedMember" xlink:href="appa-20130930.xsd#appa_ScenarioProposedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ScenarioProposedMember_lbl" xml:lang="en-US">Scenario Proposed [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ScenarioProposedMember" xlink:to="appa_ScenarioProposedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_ScenarioProposedMember_lbl0" xml:lang="en-US">Scenario, Proposed [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ScenarioProposedMember" xlink:to="appa_ScenarioProposedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_EmployeeStockPurchasePlan1997Member" xlink:href="appa-20130930.xsd#appa_EmployeeStockPurchasePlan1997Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_EmployeeStockPurchasePlan1997Member_lbl" xml:lang="en-US">Employee Stock Purchase Plan 1997 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_EmployeeStockPurchasePlan1997Member" xlink:to="appa_EmployeeStockPurchasePlan1997Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_EmployeeStockPurchasePlan1997Member_lbl0" xml:lang="en-US">Employee Stock Purchase Plan 1997 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_EmployeeStockPurchasePlan1997Member" xlink:to="appa_EmployeeStockPurchasePlan1997Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_PrincipalAmountMember" xlink:href="appa-20130930.xsd#appa_PrincipalAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PrincipalAmountMember_lbl" xml:lang="en-US">Principal Amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrincipalAmountMember" xlink:to="appa_PrincipalAmountMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PrincipalAmountMember_lbl0" xml:lang="en-US">Principal Amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrincipalAmountMember" xlink:to="appa_PrincipalAmountMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_PrivatePlacement2011Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2011Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PrivatePlacement2011Member_lbl" xml:lang="en-US">Private Placement 2011 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacement2011Member" xlink:to="appa_PrivatePlacement2011Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_PrivatePlacement2011Member_lbl0" xml:lang="en-US">Private Placement 2011 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacement2011Member" xlink:to="appa_PrivatePlacement2011Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="appa_NetOfIssuanceCostsMember" xlink:href="appa-20130930.xsd#appa_NetOfIssuanceCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_NetOfIssuanceCostsMember_lbl" xml:lang="en-US">Net Of Issuance Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NetOfIssuanceCostsMember" xlink:to="appa_NetOfIssuanceCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="appa_NetOfIssuanceCostsMember_lbl0" xml:lang="en-US">Net Of Issuance Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NetOfIssuanceCostsMember" xlink:to="appa_NetOfIssuanceCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="appa_NetOfIssuanceCostsMember_lbl1" xml:lang="en-US">Net of issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NetOfIssuanceCostsMember" xlink:to="appa_NetOfIssuanceCostsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="appa_DocumentAndEntityInformationAbstract" xlink:href="appa-20130930.xsd#appa_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DocumentAndEntityInformationAbstract" xlink:to="appa_DocumentAndEntityInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_LimitationOnExercisableWarrants_lbl1" xml:lang="en-US">LimitationOnExercisableWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_LimitationOnExercisableWarrants" xlink:to="appa_LimitationOnExercisableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl1" xml:lang="en-US">IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:to="appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl1" xml:lang="en-US">ConvertibleDebtIssuableInConnectionWithPrivatePlacement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_EffectiveRateOfLiquidatedDamages_lbl1" xml:lang="en-US">EffectiveRateOfLiquidatedDamages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_EffectiveRateOfLiquidatedDamages" xlink:to="appa_EffectiveRateOfLiquidatedDamages_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl1" xml:lang="en-US">ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:to="appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_BeneficialOwnershipAfterConversion_lbl1" xml:lang="en-US">BeneficialOwnershipAfterConversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_BeneficialOwnershipAfterConversion" xlink:to="appa_BeneficialOwnershipAfterConversion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl1" xml:lang="en-US">NotesAuthorizedUnderPrivatePlacementInitialClosing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="appa_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_DebtInstrumentConversionRatioShares_lbl1" xml:lang="en-US">DebtInstrumentConversionRatioShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_DebtInstrumentConversionRatioShares" xlink:to="appa_DebtInstrumentConversionRatioShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PurchaseOptionUnderPrivatePlacement_lbl1" xml:lang="en-US">PurchaseOptionUnderPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PurchaseOptionUnderPrivatePlacement" xlink:to="appa_PurchaseOptionUnderPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl1" xml:lang="en-US">ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl1" xml:lang="en-US">SharesAvailablePerWarrantExercisedCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_SharesAvailablePerWarrantExercisedCommonStock" xlink:to="appa_SharesAvailablePerWarrantExercisedCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_PrivatePlacementCappedPenatly_lbl1" xml:lang="en-US">PrivatePlacementCappedPenatly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_PrivatePlacementCappedPenatly" xlink:to="appa_PrivatePlacementCappedPenatly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl1" xml:lang="en-US">NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl1" xml:lang="en-US">CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock_lbl0" xml:lang="en-US">IncomeLossFromDiscontinuedOperationsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock" xlink:to="appa_IncomeLossFromDiscontinuedOperationsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl0" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl0" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl0" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid_lbl0" xml:lang="en-US">Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" xlink:to="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl0" xml:lang="en-US">Paid-in-Kind Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl0" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>appa-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Nov 12 00:59:50 UTC 2013 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedBalanceSheet" roleURI="http://www.appharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedIncomeStatement" roleURI="http://www.appharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_ConsolidatedCashFlow" roleURI="http://www.appharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentation" roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note2CashEquivalents" roleURI="http://www.appharma.com/role/Note2CashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note3FairValueMeasurements" roleURI="http://www.appharma.com/role/Note3FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note4NetLossPerShare" roleURI="http://www.appharma.com/role/Note4NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensation" roleURI="http://www.appharma.com/role/Note5StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note6ComprehensiveLoss" roleURI="http://www.appharma.com/role/Note6ComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperations" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperations"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedParties" roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquity" roleURI="http://www.appharma.com/role/Note9StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_AccountingPoliciesByPolicy" roleURI="http://www.appharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note4NetLossPerShareTables" roleURI="http://www.appharma.com/role/Note4NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationTables" roleURI="http://www.appharma.com/role/Note5StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperationsTables" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable" roleURI="http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_StockbasedCompensationExpenseTable" roleURI="http://www.appharma.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_StockbasedOptionDetailsTable" roleURI="http://www.appharma.com/role/StockbasedOptionDetailsTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_IncomelossfromdiscontinuedoperationsTable" roleURI="http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetails" roleURI="http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetails" roleURI="http://www.appharma.com/role/Note5StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note6ComprehensiveLossDetails" roleURI="http://www.appharma.com/role/Note6ComprehensiveLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note7DiscontinuedOperationsDetails" roleURI="http://www.appharma.com/role/Note7DiscontinuedOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetails" roleURI="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetails" roleURI="http://www.appharma.com/role/Note9StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="appa-20130930.xsd#DocumentAndEntityInformation" roleURI="http://www.appharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAssetsAbstract" xlink:href="appa-20130930.xsd#appa_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="CurrentLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConvertibleNotesPayableRelatedPartiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedNetLossPerShareAbstract" xlink:href="appa-20130930.xsd#appa_BasicAndDilutedNetLossPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="BasicAndDilutedNetLossPerShareAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="appa-20130930.xsd#appa_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ChangesInOperatingAssetsAndLiabilitiesAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromInvestingActivitiesAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromFinancingActivitiesAbstract" xlink:href="appa-20130930.xsd#appa_CashFlowsFromFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromFinancingActivitiesAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note1BusinessandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note2CashEquivalents">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note3FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note4NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note6ComprehensiveLoss">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note9StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note4NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeLossFromDiscontinuedOperationsTableTextBlock" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="IncomeLossFromDiscontinuedOperationsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable">
    <loc xlink:type="locator" xlink:label="OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" xlink:href="appa-20130930.xsd#appa_OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingPotentiallyDilutiveOptionsWarrantsAndConvertibleNotesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/StockbasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="StockBasedCompensationExpenseAbstract" xlink:href="appa-20130930.xsd#appa_StockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqvXCrWYqEPZi4OOTOj1pi1uu5PaMKgzjzkRH+2HXYRuurqsWh/gsYiH1v1TiazCydkmHMyvf33yBogTjqCgXhS0TabwOS9uhxPpy1DP6yztCDWT9SfAYAkx7q5Jq5ihUvff/FiBWHGt91BeMJYU1ATQouNJLbVqoMH4Uo5HPP9IN2TfjECYpQ/A==] CSR-->
    <loc xlink:type="locator" xlink:label="OperatingExpensesAbstract0" xlink:href="appa-20130930.xsd#appa_OperatingExpensesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="OperatingExpensesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" xlink:href="appa-20130930.xsd#appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/StockbasedOptionDetailsTable">
    <loc xlink:type="locator" xlink:label="StockBasedOptionDetailsAbstract" xlink:href="appa-20130930.xsd#appa_StockBasedOptionDetailsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedOptionDetailsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable">
    <loc xlink:type="locator" xlink:label="IncomeLossFromDiscontinuedOperationsAbstract" xlink:href="appa-20130930.xsd#appa_IncomeLossFromDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="CosmeceuticalAndToiletryBusinessAbstract" xlink:href="appa-20130930.xsd#appa_CosmeceuticalAndToiletryBusinessAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="CosmeceuticalAndToiletryBusinessAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInEstimatesForGrossProfitGuarantees" xlink:href="appa-20130930.xsd#appa_ChangeInEstimatesForGrossProfitGuarantees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossFromDiscontinuedOperationsAbstract" xlink:to="ChangeInEstimatesForGrossProfitGuarantees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="Note1BusinessandBasisofPresentationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note1BusinessandBasisofPresentationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="Note1BusinessandBasisofPresentationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="DisclosureAxis" xlink:href="appa-20130930.xsd#appa_DisclosureAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsTable" xlink:to="DisclosureAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOfIssuanceCostsMember" xlink:href="appa-20130930.xsd#appa_NetOfIssuanceCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureAxis" xlink:to="NetOfIssuanceCostsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionMember" xlink:href="appa-20130930.xsd#appa_PurchaseOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureAxis" xlink:to="PurchaseOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureAxis" xlink:to="us-gaap_PrivatePlacementMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DisclosureDomain" xlink:href="appa-20130930.xsd#appa_DisclosureDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureAxis" xlink:to="DisclosureDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsTable" xlink:to="Note1BusinessandBasisofPresentationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="appa-20130930.xsd#appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:href="appa-20130930.xsd#appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note5StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="Note5StockBasedCompensationDetailsTable" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note5StockBasedCompensationDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note5StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="Note5StockBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlan1997Member" xlink:href="appa-20130930.xsd#appa_EmployeeStockPurchasePlan1997Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="EmployeeStockPurchasePlan1997Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsTable" xlink:to="Note5StockBasedCompensationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note6ComprehensiveLossDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note7DiscontinuedOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="Note8ConvertibleNotestoRelatedPartiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtSecurityAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="InitialClosingAmountMember" xlink:href="appa-20130930.xsd#appa_InitialClosingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="InitialClosingAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionMember" xlink:href="appa-20130930.xsd#appa_PurchaseOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="PurchaseOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmountMember" xlink:href="appa-20130930.xsd#appa_PrincipalAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PrincipalAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_PaymentInKindPIKNoteMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="appa-20130930.xsd#appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:href="appa-20130930.xsd#appa_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="NotesAuthorizedUnderPrivatePlacementInitialClosing" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionUnderPrivatePlacement" xlink:href="appa-20130930.xsd#appa_PurchaseOptionUnderPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="PurchaseOptionUnderPrivatePlacement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConversionRatioShares" xlink:href="appa-20130930.xsd#appa_DebtInstrumentConversionRatioShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="DebtInstrumentConversionRatioShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialOwnershipAfterConversion" xlink:href="appa-20130930.xsd#appa_BeneficialOwnershipAfterConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="BeneficialOwnershipAfterConversion" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:href="appa-20130930.xsd#appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:href="appa-20130930.xsd#appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="appa-20130930.xsd#appa_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="ConvertibleNotesPayableRelatedPartiesCurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note8ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/Note9StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="Note9StockholdersEquityDetailsTable" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note9StockholdersEquityDetailsLineItems" xlink:href="appa-20130930.xsd#appa_Note9StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="Note9StockholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioActualMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioActualMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioActualMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScenarioProposedMember" xlink:href="appa-20130930.xsd#appa_ScenarioProposedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="ScenarioProposedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockCompensationPlanMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacement2011Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2011Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivatePlacement2011Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacement2012Member" xlink:href="appa-20130930.xsd#appa_PrivatePlacement2012Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivatePlacement2012Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsTable" xlink:to="Note9StockholdersEquityDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" xlink:href="appa-20130930.xsd#appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesAvailablePerWarrantExercisedCommonStock" xlink:href="appa-20130930.xsd#appa_SharesAvailablePerWarrantExercisedCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="SharesAvailablePerWarrantExercisedCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:href="appa-20130930.xsd#appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LimitationOnExercisableWarrants" xlink:href="appa-20130930.xsd#appa_LimitationOnExercisableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="LimitationOnExercisableWarrants" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveRateOfLiquidatedDamages" xlink:href="appa-20130930.xsd#appa_EffectiveRateOfLiquidatedDamages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="EffectiveRateOfLiquidatedDamages" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementCappedPenatly" xlink:href="appa-20130930.xsd#appa_PrivatePlacementCappedPenatly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="PrivatePlacementCappedPenatly" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" xlink:href="appa-20130930.xsd#appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note9StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.appharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="appa-20130930.xsd#appa_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="6.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" order="7.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="8.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="9.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="14.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 7 - Discontinued Operations (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_IncomeLossFromDiscontinuedOperationsTableTextBlock', window );">Income (Loss) from Discontinued Operations [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1246.finRow.2">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.2.amt.D3" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1232">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1234">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.2.amt.D5" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1233">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1235">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.3">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D2" colspan="2">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1236">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1237">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1238">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D5" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1239">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1240">
            <u><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cosmeceutical and Toiletry Business</font></u>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.4-0">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1245">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Change in estimates for gross profit guarantees</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.2-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.2-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.2-0">
          -
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.2-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.3-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.3-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.3-0">
          128
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.3-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.4-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.4-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.4-0">
          -
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.4-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.5-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.5-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.5-0">
          (6
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.5-0" nowrap="nowrap">
          )
        </td>
      </tr>
    </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_IncomeLossFromDiscontinuedOperationsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_IncomeLossFromDiscontinuedOperationsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"7#_[BQ`$``'(2```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6
MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?FO"$O;W!HJZB
M.5A7:I41EJ0D`I5K6:I)1CY&+W&71,X+)46E%61D"8X,^I<7O='2@(O";N4R
M4GAO'BAU>0&U<(DVH,*=L;:U\.&MG5`C\JF8`.5IVJ&Y5AZ4CWTS@_1[3S`6
ML\I'SXOP\8K$0N5(]+A:V&1E1!A3E;GP@93.E=Q)B=<)2=C9KG%%:=Q5P"!T
M;T)SY_>`];ZW<#2VE!`-A?6OH@X8=%'1+VVGGUI/D\-#]E#J\;C,0>I\5H<3
M2)RQ(*0K`'Q=)>TUJ46I-MP'\MO%CK87=F:0YONU@T_DX$@XKI%PW"#AN$7"
MT4'"<8>$HXN$XQX)!TNQ@&`Q*L.B5(;%J0R+5!D6JS(L6F58O,JPB)5A,2O'
M8E:.Q:P<BUDY%K-R+&;E6,S*L9B5_Y=9?7BB!]J^_OV'VXXY\DCI_+("=^:_
M@:NAQY(+84&^>QNZC[,#_)Q]B",T`T.KC0L=B8733V%3@C2[8Q,&@?4E;&N0
M?77"-C'T*Z<'[O09T#0X$N2>;-HV1OUO````__\#`%!+`P04``8`"````"$`
MM54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?V
MA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:
MCAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AE
MW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+
MJ<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$N
MGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0!3=PU[
MK0$``#,1```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"\6,MJPS`0O!?Z#T;W
M1M[-HTF)DTLIY-JF'R!LQ3:Q)2.IC_Q]19HZ"83MQ>S%(`FOAMG=V;&7Z^^V
M23ZU\[4UF8!1*A)M<EO4ILS$^_;E82X2'Y0I5&.-SL1!>[%>W=\M7W6C0GS)
M5W7GDQC%^$Q4(71/4OJ\TJWR(]MI$T]VUK4JQ*4K9:?RO2JUQ#2=27<90ZRN
M8B:;(A-N4\3[MX<NWOQ_;+O;U;E^MOE'JTVX<87\LF[O*ZU##*I<J4,F^BTO
MCR?S440LY&TP,&9&`V,2#C<Y0+*#,V9V<$:QPYTK,E4(W-P`Q<TC,YI'"@P@
M,QI`$@XW.4"R@U-F=G!*L<.=*SI5W(H#I.)@G)ZLPPI3,E6+(>'X<&CB\.\'
MY^^:NI];\DC%XZX4LE"`G1J2&YP,62B]HSK72K]U,EDXH>J&6_!(O0-N-$#"
M06Y7@[2M&=2!AOC9H,]5<US*XY,L7^"672!E%P:5W;YUSKST6Z=N@@753=R]
M3;8V-S4D,\!-#9#<(+NU(KT5<MM@)&WP>-`F]Y5RNG@++O[GN/0TE]M_326O
M?G6L?@```/__`P!02P,$%``&``@````A`,Z"/V4A`P``8PD```\```!X;"]W
M;W)K8F]O:RYX;6R4EEU/VS`4AN\G[3]$N=_R53Z*:!$4T)`V5@T&EY:;G#86
MB=W9#J7_?B>N&DZH(VU7J9/XZ7O>\QZWYQ=O=16\@C9"R4F8?(W#`&2N"B%7
MD_#WX^V7TS`PELN"5TK")-R""2^FGS^=;Y1^62CU$B!`FDE86KL^BR*3EU!S
M\U6M0>*3I=(UM[C4J\BL-?#"E`"VKJ(TCH^CF@L9[@AG^E\8:KD4.5RKO*E!
MVAU$0\4MRC>E6)MP>KX4%3SM*@KX>GW/:]3]5H5!Q8V]*82%8A(>X5)MH'=#
M-^NK1E3X=)S%61A-NR+G.BA@R9O*/F)Y>SKZE8[2]+A]L[7B2<#&O&]JE\';
MLY"%VK2OHK7;;I6A@(U[]"P*6^+S.(Z[>]]`K$J[OXGXB/"=@_@][AI(5][>
M$78I"W8CK;!;=B=W[@N%+6Q=O\/*DC#09P(_Z+LB:853RDS)`J2!@EWQBLL<
MV$.[S[!9HS402HJIZ##I,.;!<HM^242H)?NY!LTMP62$XOSVB^E39MR4[)90
M1H0R^JCE7EE@";MJC)!@#,,D8W%&.$%S0DG'!'/DQ:3,???-GT:\\JJMBNS/
ML+V=)2X2M!@G(V.W7&CVQ*L&V`_@IM$[<RB&-NC$*V/$[L&R[PJKF8/&%O%>
M;[*4"#GU$H[8@U7Y"_J`K9ZI&F?5N!&B0FASQE[,L=NKH<3MXA6<)$J@C4EB
M+^*$70N3*PRL;%#++B'M+%,.CD7G;'(06F?M*4J1>(Q9L:B`M;<,LXK]HJ'-
MCBGG(+6.,]XY4ZJJP!.$M:VV6ZKEA#(.,GN9YZIIBUFQN:I$+E#&8KO[O&64
M0P<H\:?6UV?VR!=XDKEHM>.<T=0F_M@.=ANCUH%&-+Z)/[^#S>J!:(`3?X('
MY[$'HCE._$'V6G0-EI/*DIY%_B0/6H0:WBVB$X&G^8?#T^5G$(1[.U!*+<+%
M?X%PJ-Y!U*+4GVC?D+(/%J6]R@Y2[2H;;#ZU**4CCPM?98.@GD5TYE-_K@=G
MOI>BGB)_KKU#WWI$K![U!+E81ZX/^$.<\RK'?PCMI9U)EXQH__]H^A<``/__
M`P!02P,$%``&``@````A`!)-;*&0!```U1```!@```!X;"]W;W)K<VAE971S
M+W-H965T-"YX;6R<F%V/JS80AN\K]3\@[A,PWT1)CDY8;7ND5JJJ?EP3XB1H
M`4=`-KO_OF,/8&PV7[W9<[+S,CSSVIZ)=_GMHRR,=UHW.:M6)IG;ID&KC.WR
MZK`R__[K=1:91M.FU2XM6$57YB=MS&_KGW]:7EC]UAPI;0W(4#4K\]BVIX5E
M-=F1EFDS9R=:063/ZC)MX6-]L)I33=.=>*@L+,>V`ZM,\\K$#(OZD1QLO\\S
M^L*R<TFK%I/4M$A;X&^.^:GILY79(^G*M'X[GV89*T^08IL7>?LIDII&F2U^
M'"I6I]L"ZOX@7IKUN<6'2?HRSVK6L'T[AW06@DYKCJW8@DSKY2Z'"KCM1DWW
M*_,[622.8UKKI3#HGYQ>FM'_C>;(+K_4^>ZWO*+@-JP37X$M8V]<^F/'?P4/
M6Y.G7\4*_%$;.[I/ST7[)[O\2O/#L87E]J$B7MAB]_E"FPP<A31SQ^>9,E8`
M`/PTRIQO#7`D_1#_7O)=>UR9;C#W0]LE(#>VM&E?<Y[2-+)ST[+R7Q21+A4F
M<;HD+M!W<6?N1#[Q@_M9+"02!;ZD;;I>UNQBP*Z!=S:GE.]!LH#,?67(,=1Z
MK52HD2?YSK.(7%!%`^OSO@Z<I?4.EF:=9(.2T#0&"5$52:_@*P%T`R(4KB.Z
ML(1?F]\3\8=4(M=6W[>92C3F9*KP91*%$:P;,]YFX^*5"<D'*_Q(8T-))*R<
M><3QY'N%XXDB@"U`I)L*F/<,&!>K8(&K@:$$?DIV59'T"K$+AI@"!9O^<;>X
M6(/RAK3"C`U*/.&6XX9J-!E'B2>C"E+P#!(7:TB^^M(-2GR!%+FN9F,R#KMA
M*,,*%)R6QWWB8@TJT*!0@CZYL19-QE%G='X5)#[2M'YQ_S#RAU0TW9`-2A!M
MYMCZ253"43S4I;#%*MOM0\C%&I-^"%&"3#[1-ETRCL:1/)\*$H%&-?;K-I-0
M:U"R5MSKG0:I(D=?1"4\<WUII,JE]?T[7-B:QQTKD.>HXT(-[OB92X@[05,4
MQ(XB::D*Q_ON:)/=@<,NK<#I*TE0T\$1GVB"I!-T^\_W)+M*]E2?)]-&'TR6
M$S4WR%!PEXRWW9%G?)#?/Y@$F_78NU#NY&YA^X9^O>5W:;`(W_;B*\.(?V?Z
M'Y#3"1#*%W20?9._`8D2A'1M6]:I+O%3DX!,1T$HCUS'AAI<P6#T7A%.NA3@
M\A<C545[:AZ0Z4`8S9D.#37H"2&.]*1CZV?"?;8O!H,'CM\YN]/)$,JFT#&.
M>[^CS=F$C*/DRAPEVF1X\'!,1T2HO7XC,J_,SL#0T^*)$O==.!M?CRY'FQ./
M$8JGU'D1RLZ%]G4:))RY=FQK+2A1%)YCCU9`V7Z.-C,>9)S.CE"?'2)S[R)W
M22LB400DC*\B\C[_=!>$JZ/^72#4!L2FT^`W<L?Q8ZT&?O_D25``I]R3&=!%
MO%WBY:ND]8$FM"@:(V-G?G,D\$UQ^"W>:C=PJQ570&L(P*7RE![H[VE]R*O&
M*.@>'K7G(1RT&J^E^*%E)W'YV;(6KI/BOT?X\P&%NYH]!_&>L;;_P*];PQ\D
MUO\!``#__P,`4$L#!!0`!@`(````(0`:H$&8G@(``),&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;)25W6[C(!"%[U?:=T#<U]A.[#11G*I)U=U*
M6VFUVI]K@K&-:HP%I&G??@=H7*=IJ_;&,?AP^&8&)LN+!]FB>ZZ-4%V!DRC&
MB'=,E:*K"_SG]_79.4;&TJZDK>IX@1^YP1>KKU^6>Z7O3,.Y1>#0F0(WUO8+
M0@QKN*0F4CWOX$NEM*06AKHFIM><EGZ1;$D:QSF15'0X."ST1SQ450G&KQ3;
M2=[98*)Y2RWPFT;TYN`FV4?L)-5WN_Z,*=F#Q5:TPCYZ4XPD6]S4G=)TVT+<
M#\F4LH.W'YS82\&T,JJR$=B1`'H:\YS,"3BMEJ6`"%S:D>95@2^3Q2;#9+7T
M^?DK^-Z,WI%IU/Z;%N4/T7%(-I3)%6"KU)V3WI1N"A:3D]77O@`_-2IY17>M
M_:7VW[FH&PO5SB`@%]>B?+SBAD%"P29*/093+0#`$TGA3@8DA#[XW[TH;5/@
M21YELWB2@!QMN;'7PEEBQ';&*ODOB!('-9BD3R83H'_ZGD?3-)N=?\"%!"(?
MX!6U=+74:H_@T,">IJ?N""8+<#Y$%CB&6-\*%?"<R:5S*?`,(XC"0'GN5VDV
M7Y)[R"E[TJR#!I[/FFE^K-F\HLGC04.`>0"'=(S!7R_%@<^)'9_+IP->AXDQ
MS"09]O&2S:DDS9\U1RR0N#&+2^($#MG[3&X1Z$;Y2++TF&$=--.1)CM6;-Y3
M'#&"R><9W:("0R:>:Y:_9`R:]QB#XMR?B_ET&L=OE!3NPN<1W:*7B)/C)*V#
M)@`D">P_(@C%#HK7@PAI#,TAW!W)=<TWO&T-8FKG+GX"P0VS0T^Z3'U;&3Y`
M3^AIS6^IKD5G4,LK6!I',]A=AZX2!E;U_F9NE85NX%\;:/X<3FX<@;A2RAX&
MKF\-?R>K_P```/__`P!02P,$%``&``@````A``T>`+FR`@``\P8``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%7);MLP$+T7Z#\0O$>;+2^"Y2"V
MG#9`"A1%ES--4181411(.D[^OD/14BP[3=*++0[?/,V;38OK)U&A1Z8TEW6*
M0R_`B-54YKS>I?C7S]NK&4;:D#HGE:Q9BI^9QM?+SY\6!ZD>=,F80<!0ZQ27
MQC2)[VM:,D&T)QM6PTTAE2`&CFKGZT8QDK=.HO*C()CX@O`:.X9$?81#%@6G
M+)-T+UAM'(EB%3$0ORYYHSLV03]")XAZV#=75(H&*+:\XN:Y)<5(T.1N5TM%
MMA7H?@K'A';<[>&"7G"JI):%\8#.=X%>:I[[<Q^8EHN<@P*;=J18D>*;,-F,
ML;]<M/GYS=E!GSPC7<K#%\7S>UXS2#:4R19@*^6#A=[EU@3._H7W;5N`[PKE
MK"#[ROR0AZ^,[TH#U8Y!D-65Y,\9TQ02"C1>%%LF*BL(`'Z1X+8S("'DJ?T_
M\-R4*1Y-O'@:C$*`HRW3YI9;2HSH7ALI_CA0>*1R)-&1!#R.)&'D1;,XC"?O
ML_@NHE9@1@Q9+I0\(&@:>*=NB&W!,`'F3IF+H]?Z+ZF@T9+<6):6"U1H*,_C
M,HHG"_\1<DJ/F)7#3#'J,>/Y$++N(#:#EC?K#"\^X=!ETR%L^4!2KPNR=:KK
M]4IUX5OP>?C3X8M6KV"&B/4E(@Z&D.P2$@T1FTO$"<E`X>A_%%HP=-U)\F=G
ML:T<9'P"B8>QK=]%9.\B-F\A!O(@D-,"VL8<P>"^74CKE&+(8=]C43P;JE@Y
MS+SMTBL8H?,F'-Q/O+.&RP;7X]`[+^#@/HR]ES%P\MR2<3,HF-JQ-:LJC:C<
MVP4205B]U>VV59C`8$!_G]DSV'FMW>\O8.<T9,>^$;7CM485*X`R\*8PV,IM
M+7<PLFG;?2L-;)OVL82/"X.1"SP`%U*:[F`'J_]<+?\"``#__P,`4$L#!!0`
M!@`(````(0#0$%.]2@,``.`*```9````>&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;)Q676^;,!1]G[3_@'@OWX0D2E(U5-TF;=(T[>/9`1.L`D:VT[3_?M>8
M!.RT&=U+"?6Y)\?GGEQ[=?M<5]839IS09FW[CF=;N,EH3IK]VO[U\^%F;EM<
MH"9'%6WPVG[!W+[=?/RP.E+VR$N,A04,#5_;I1#MTG5Y5N(:<8>VN(&5@K(:
M"7AE>Y>W#*.\*ZHK-_"\F5LCTMB*8<FF<-"B(!F^I]FAQHU0)`Q72(!^7I*6
MG]CJ;`I=C=CCH;W):-T"Q8Y41+QTI+959\LO^X8RM*M@W\]^A+(3=_=R05^3
MC%%."^$`G:N$7NYYX2Y<8-JL<@([D+9;#!=K^\Y?IGY@NYM59]!O@H]\]-GB
M)3U^8B3_2AH,;D.?9`=VE#Y*Z)=<_@N*W8OJAZX#WYF5XP(=*O&#'C]CLB\%
MM#N&'<F-+?.7>\PS<!1HG""63!FM0`#\M6HBHP&.H.?N>22Y*-=V.'/BQ`M]
M@%L[S,4#D92VE1VXH/4?!?)[*D42]"3P[$G\V(F".)F_AR7L6>!Y8IE-9G'5
MOCJ;[I%`FQ6C1PNR!\IYBV22_24P2W^B-_T!8V3-G2SJ2@'-H:E/FR"*5^X3
M-"+K,=M+C*\CTDM$$,W.&!<$GE6"<Z;*$++P>A=/*F61KC*:G^F[C6PO(8&.
M2"\1X;`/32.X-]9X79L$0Y9L:^1@HG_U5F&B$<;P.+V&T+0!R71M$KRV8>,C
M;:9Q"A-WO8<0APO3MS%@/HN2@4`3!E$;"Y/Q^W=C99$I<&&8IS"+3J#G1/IJ
M:JP.XC5QL_\1)XL,<;&G?_U68<"BP>%X2%47S?0US!LZ$UWG]>1)L*[/#X?F
MJ)^%PJCN)K,D-'.GUL?Z!X3FH#Q&1]/ENC()UI5!L`SG%.:MMJK5";H6[]$E
MP;HN/S3CIC#*L9LH#`S=J5J?H,R'L3;=L@ZM:PMB(^S;'G0R+1AFK$I:OSY%
MG'%:7.^GKP;\>)#XT1!A%;4>U#L7AM'""&/:(Z;(D\-Z%+=ITP2N'V9_@WC(
M<R]3@4X>1L:LEG<827)-I+JCJ,.W17O\#;$]:;A5X0+&@.<D,)28NJ&H%T';
M[OC:40$WB^YC"3=)#">PYP"XH%2<7N0=Z'PWW?P%``#__P,`4$L#!!0`!@`(
M````(0![+A`[K@,``"<-```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;)177:^;.!!]7VG_`^*]?),O):E*X+:5NM)JM6V?'7`2=`$CV[FY]]_OV`X$
MFQ;NOB2!.7/PF3,VD^W'U[JR7C!E)6EVMN]XMH6;G!1E<][9W_]]^K"R+<91
M4Z"*-'AGOV%F?]S_^<?V1N@SNV#,+6!HV,Z^<-YN7)?E%UPCYI`6-Q`Y$5HC
M#I?T[+*68E3(I+IR`\];N#4J&ULQ;.A[.,CI5.8X)?FUQ@U7)!17B,/ZV:5L
M6<=6Y^^AJQ%]OK8?<E*W0'$LJY*_25+;JO/-UW-#*#I6H/O5CU#><<N+$7U=
MYI0P<N(.T+EJH6/-:W?M`M-^6Y2@0)3=HOBTLS_YF\SW;7>_E07Z4>(;&_RV
MV(7</M.R^%8V&*H-/@D'CH0\"^C70MR"9'>4_20=^)M:!3ZA:\7_(;<ON#Q?
M.-@=@R(A;%.\I9CE4%&@<8)8,.6D@@7`IU67HC6@(NA5?M_*@E]V=KAPXJ47
M^@"WCICQIU)0VE9^99S4/Q5(*NI)@CL)9-Q)_,`)5K$?+^997+4B*3!%'.VW
ME-PLZ!IX)FN1Z$%_`\R=,K6.7NOOI()&0?))L$@N4,'`GY=]$*ZW[@O4-+]C
M$H59VE:/B0S(H8.("@K>M+OQR/%UUJQ#"/M`4J\+JF7J"L'W7SO6R1!)NHQH
MI3\O&4,"'7$8(V)/AZ1CB$&2C1$#$DUH.!8:_;8U.Z$B"9IPX$40&8M,%"8:
M8&)=QF$6D<XBLBF$IA,6,C1TVD@!WME0Q+[7@LCHG$1A5K);(V]MBAN&_?7*
MJ$XZ#*_",-1+DPW#X7+Y"&N:P*>A)K'YYKT32:8VHWT2A5E+;9[C&=(/T^'4
M"#\6+S=E9H0?S]:T+<;:YC>@2#*U&8]/%`8*W'MK6C>+2&<1V11"TPD'VO_W
M4"3-[3^%F=(YBTAG$=D40M,I9IG!BV)Z_PFPZ:/1A(G"1+)'XRC2-]!A&`W7
M2SV:JF@L<WUO91S2F1Y>/)ZL*5KKBL3NF^]0D60J,]:>*,R4<[.(=!:132$T
MG3Z\]X;6O>^8D5ES/7H'34F=AZ3SD&P2HJL5$\&[&Q6FQK&?CWZ1!UYR!ZE7
M11C'1OR@Q?UX99Q8J19?!I%Q7HG152Q"\0=+WSQ1U5RJQK8:TS,^X*IB5DZN
M8N8,8!?T=]4\G/@;F*5@)#+NIV).EI-N'X`QM45G_!>BY[)A5H5/0.DY2SCD
MJ1ITU04GK9R,CH3#@"I_7N`/"88IS7,`?"*$=Q=B%NO_XNS_`P``__\#`%!+
M`P04``8`"````"$`]Q*BGM<#```+#@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6R4E]N.HS@0AN]7VG=`W#?'D)-"6LUI=Z19:36:F;TFX"16`T:V
MT^E^^RWCA,0F`SU]D0[FJS]5O\NDLGE^KROC#5&&21.:KN68!FH*4N+F$)H_
MOF=/2]-@/&_*O"(-"LT/Q,SG[9]_;,Z$OK(C0MP`A8:%YI'S=FW;K#BB.F<6
M:5$#=_:$UCF'2WJP64M17G9!=65[CC.WZQPWIE18T\]HD/T>%R@AQ:E&#9<B
M%%4YA_S9$;?LJE87GY&K<_IZ:I\*4K<@L<,5YA^=J&G4Q?K+H2$TWU50][L[
MRXNK=G<QD*]Q00DC>VZ!G"T3'=:\LE<V*&TW)88*A.T&1?O0?''7F>N8]G;3
M&?03HS.[>V^P(SG_17'Y%3<(W(9]$CNP(^15H%]*L03!]B`ZZW;@7VJ4:)^?
M*OZ-G/]&^'#DL-T!5"0*6Y<?"6(%.`HREA<(I8)4D`"\&C46K0&.Y._=_S,N
M^3$T_;D5+!S?!=S8(<8S+"1-HS@Q3NK_).1>I*2(=Q'Q(?O+_<":><%B^3LJ
MLXO*O%?Y?"JV+*MS*<EYOMU0<C:@]2!QUN:BD=TU"%_MD<7TAOW*+S!*B+P(
ME=!<F`98P6"3W[:>M]S8;[`QQ86))`.O-\:9JTP\9%R52(:$YZU4)I7,?3::
M2G8E1.>`$;T;L%'W;CQNDFO1`A9%BZ81+D37A;L*?4?-+7[`J$0B"<CPYI.N
MDCY@5)5L2`2W5)2:H2GO:Q8=X,,Q&Z]=!"FUZPNQOI#(!;4N;5_23S#9.*.4
M!B?F]TL306"!XK^GNAM)!E[[/0I4(IXDDDDBG22R,4)Q`IY5NA/SR4T60:$)
MG=17Z?F^6F<DF:`[\RM'_JE(+!%(M9?1S$KN18).0Y5()R6R,4)Q`AYRNA,S
M"!YO=Q&D.S%3<XPD<W%"5G$[<=T#(I;(F!.31'K_,>XCO[,Q#<4*>$+J5DPW
MA0C2K=#V,Y+,2)WQ))%,$JDD`NFX8RVU++(Q!<4',>MIWX'33T`1I/N@?9U%
MDAGS89)()HE4$M*&I>-X"[4QL_O[P3)8W!ZZB@NKH0N+R8,A@G07M,^/)#/F
M@B16W4/$L;2#E4S&IVJ\?RNP.W:9>MN[W5;JARETT`;3QZ&+TAT8C#Y".C3'
M++CHC"#)-))>$-D+_CR8+S0SQ:S]ZU2D'W*6EE-BC>@!Q:BJF%&0DYB39[!+
M_6H_P[_X8@S2UE,QVS]8C[QU](B/O36,#6(FZX5@%&_S`_HGIP?<,*-">TC!
ML41C4CG,RPM.VFZ6W1$.0WCW]@@_NA",98X%\)X0?KT0']#_C-O^#P``__\#
M`%!+`P04``8`"````"$`R'-2/E,"``"Q!0``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6R4E-F.FS`4AN\K]1TLWP=#`MD$&<TD2CM21ZJJ+M>.,<$*
MQLAVMK?O,4Y0EG:4N0&,__/QG\6D3P=9H1W71J@ZPU$08L1KIG)1KS/\Z^>R
M-\;(6%KGM%(US_"1&_PT^_PIW2N],27G%@&A-ADNK6VFA!A6<DE-H!I>PTZA
MM*06EGI-3*,YS=L@69%^&`Z)I*+&GC#5CS!440C&%XIM):^MAVA>40O^32D:
M<Z9)]@A.4KW9-CVF9`.(E:B$/;90C"2;OJYKI>FJ@KP/44S9F=TN[O!2,*V,
M*FP`..*-WN<\(1,"I%F:"\C`E1UI7F3X.9K.8TQF:5N?WX+OS<4S,J7:?]$B
M_R9J#L6&-KD&K)3:..EK[EY!,+F+7K8-^*Y1S@NZK>P/M?_*Q;JTT.T$$G)Y
M3?/C@AL&!05,T$\<B:D*#,`52>$F`PI"#^U]+W);9G@P#))1.(A`CE;<V*5P
M2(S8UE@E_WA1=$)Y2/\$&8#[TWX2Q/UD-'Z`0KRC-L$%M726:K5',#3P3=-0
M-X+1%,@NL_B_F4%*+N;9!;6AH#;0C=VL/XQ3LH,2LI/FY5X33ZXE\WM)U"D(
M^.M,0NJW)@?0Q'^7_VS2!5V;'(0=OLWCY5Z2W$CF[TJN3$+U/F[2!<$T8'11
MR>3&I=?$%YH;Q?P]Q95'@'S<HPO*,!2B\Q@EXQN/7C-N9R'JW^S"T70$O]L;
M=J'>FC]U?B@;NN9O5*]%;5#%"_A@&(Q@'+4_<WYA5=/V=:4LG)7VL81?(X?)
M#`,0%TK9\\*=ZNYG._L+``#__P,`4$L#!!0`!@`(````(0"\Y]_K^0@``"(_
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)S;VW+B.A8&X/NIFG>@
MN&_`YDPEV=7@\[FF]IZY)N`D5`.F,.ETO_TL68(@V:V?T!<D47\L;.NW;`1Z
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M8_N[,<O,0;O[]%`=H/]N\H_RZO=6^59\N,?-.MKL<SK:U$^L!YZ+X@>C_IHU
MT9.[M6<[50]DQ]8Z?UF^;T__*3Z\?//Z=J+N'M(>L1V;K7];>;FB(TIE.N:0
M55H56]H`>FSM-BP:=$26OZJ?'YOUZ>VQW1]UAN->WR#>>L[+D[-A)=NMU7MY
M*G;_X\@0I7@14Q3IT]:+_Q]V!N9P//E*E8&H,OJL8G;,R=`8CKZP+6-1A7Z>
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M(G<UC)GCX>4%JF%YS@T]7H8Z12R@L*"PH7"@<*'PH/"A"*`(H8B@B*%(H$BA
MR'1"BA?=%MT1+_:LQS:-69?HF(9R+S'GAC;D8M1X06%!84/A0.%R,>%7@6&/
M_9-/%0_6\*$(H`BAB*"(H4BXT.QM"FMD.B'%BVYI[X@7>Y82K[%RLS?G1A<O
M*"PH;"@<*%PNAE6\C,9X0>'#5PF@"*&(H(BA2*!(H<AT0HH7O>.Y(U[L66J\
MU-&+&UV\H+"@L*%PH'"A\*#PN>`1[5<#H#("!K!&"$4$10Q%`D4*1:834KS8
MG*/Z[AS?>[%GJ?%2WK?-N='%"PH+"AL*!PH7"@\*'XJ`"QY`DXV1\@4XA!4B
M*&(H$BA2*#*=D,)%LVQWA(L]2PV7\LYJSHTN7%!84-A0.%"X4'A0^%`$4(1<
MB$MT+7T1+!!#D4"10I'IA)0M-@E[1[BJIRGIFBBGXEP@7;PPL3"Q,7$P<3'Q
M,/$Q"3`),8D$T5R*8UPED:H8_(HNCZ@IKI)IB9PW-BGZ]2LEF^571[.),G<S
M%TB;-UY'0RQ<Q<;$P<3%Q,/$QR3`),0DPB069,@SV>NH\^Z)"I29M12_1J8E
M<M383.EUU/038>P#H%K$E`V<"Z3)SP(3"Q,;$P<3%Q,/$Q^3`),0DPB36)`1
MGX(9]`WE?CG!-5),,BV14\9F:*]3=MNTJ\$G=J6)L8GR@<%<(&W:>!T-L7`5
M&Q,'$Q<3#Q,?DP"3$),(DU@0D3:#OCH@7QL37"/%)-,2.6W4T5+:P)C&N'J;
M]OGQ`9_=-SC21&B!B86)C8F#B8N)AXF/28!)B$F$22R(N&Q..],IGU@1CWW[
MFW(92G#1%)-,2^38L6E<=9`;4".('Y_]E0<Y96Y_SKYO01G5Q@\2"U>Q,7$P
M<3'Q,/$Q"3`),8DPB1N(.5$FT9,&I'1DBDFF)7+BV,SN'8GC$\)RXM096_;U
M&4H<OTL=34?5>28/[`MA-*FT,+$Q<3!Q,?$P\3$),`DQB3"),4DP23')M$0.
M')OKO0X<&-KXU+`<-.5>=&[HYH^KB^\"$PL3&Q,'$Q<3#Q,?DP"3$),(DQB3
M!),4DTP0/J2,V33*93R14\8F?:]3=N.[!3Y7+*=-G<PU=!/*(FV<B,T<7&]F
M!2Q1@P/3F-2$C5_%P<3%Q,/$QR3`),0DPB3&),$DQ233$CEL;!;XCK#QR6,I
M;-///(LW#;H99A$V3GB6C'Y3VJY%O[H07TZ;JH9M7`MS1-_`5S;$$4)SH78Q
M\3#Q,0DP"3&),(DQ23!),<FT1`J;J7Z0H+]^5EQY9SI5WEW/!=+T[4(0'K+)
MI#Y@65#8^&4<J<A@6L^ABXMXF/B8!)B$F$28Q)@DF*2"_+F#,FT1.6/JAP<@
M8PT?&DR5M])S$WXBL,#$PL3&Q,'$Q<3#Q,<DP"3$),(DQB3!)!6$QVPP'=8'
M@DQ;1<X97?ONN'":[&GJF*;.Z0JD'=-X'0VQ<!4;$P<3%Q,/$Q^3`),0DPB3
M&),$DU00D;?>F&Y,E#N33%M%SMM]GR&8#9\A3-7978$T85I@8F%B8^)@XF+B
M8>)C$F`28A)A$F.28)(*PO-FF.QFNB%QN@^#Y,11'J01#EQ)&5='-F7^;TYK
M0=%$KB#\*\7CAG<$"-CX11Q,7$P\3'Q,`DQ"3"),8DP23%),V(K?/_<RSQA?
MT<M7+^[RXVN^R+?;LK4JWMEJ7?JNR-/#I?FRE/A[GZUG4]HM8T:+!.OMKC&C
MA7_U]L"8T4*]>OO<G,V;ZB_,&2UKJGO+G-'JIGJ[;<YHD5.]W3%GM-:IWNZ:
M,UKR1.W=RX[1"N7#\C6/E\?7S;YL;?,7.B:]#ELW>^1KG/D?I^)0+?I\+DZT
M-KGZ]8W6HN>T3++7(?Q2%*?S'^P%+JO;G_X/``#__P,`4$L#!!0`!@`(````
M(0#+TC(;9@H``"9.```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)S<
MVW+:.AL&X/,UL^Z!X;R`[9`$)LF:&N_WFW]S3(F3,`6<`=*T=[\D)`.2';TD
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MG`Q)I8>[QR79`WK8>]OJZ;[_79N6^G5_^'!W.$#_6U;ON[/_]W8O];N[73Y&
MRTU%CC9YG>@K\*.N?U+J/](FLO&PM;5S>`6R;>^Q>IJ_K?9%_>Y5R^>7/7FY
MQV2/Z(Y-'_]8U6Y!CB@I,]#'M-*B7I$G0/[MK9<T&N2(S'\?;M^7C_N7^[YQ
M/1C?C`R-\-Z/:K=WEK1DO[=XV^WK]?\9TG@I5D3G1<@M+Z)IGRYB\"+DMBE"
MZEWX#*[XQN0Y-QN/!U?Z^.;V,_MQS:N0VZ;*]>>KW/`JY+:IH@]NM-'$N+G\
MD)+S\_"ZD-MCD8N/QH1O3&[YQOIXH%V-KC_QFFHDBBP9-)/L5==O/UWEF*]3
M-@SCT]G0FG!HIUTRM,'M>'QU?8N/ZI"%_G`.6?/]_.%N6[_W2,=$GMWN=4Z[
M.6U*2S=G#\OZ\7SZZ'0BYQ&M\IV6N>^3UYN<*3O2!_QZT"?7=\-?Y+Q=<&-V
MF)%D9HVAIRDM;+$&\N]9X1NQL-TVFBB<MM`GMZ)Q&],\M"<W^*Q!V$EY!X+&
M-%5"N4HD-\1-P]DNRF63#C.1#D/:9:2=S#K,2*J3=QA](AZLHL/(=<H.,SG5
M&9(`'E-(3@TAA=U]=Q,VJFG8FF-L-@WG1U#:\UF',4;B7ED=1C-$8W<843A0
MN&UAC*3GXG49*=8^,^0XGTX.\;D$4(101!U"/G+Q!2;I,/+133N,N$=96QCR
MV9)W&2D/19>1>J.R;?3CLQ'R2SKG3^27:B&_<L-,;K#D!EMN<.0&5V[PY`:?
M-9S'QQB==O#0_P9=1CHEPBYS=3Q0ASK1!2;N,F.Q3G*!22\P69>1.\(+3'&!
M*=5&"!(9Q7TB2%0+09(;9G*#)3?8<H,C-[AR@R<W^*SA/$CZC=2?!1>8L#%-
MQQ[)#7'3<-;CR8^4-*:IDLH-6=.@J)(WIJE2R`WE68/P&I(AKO`:TB&508:0
MZC<UNA5Q9WVY,3J]6QY.(I,9\KC'_EXZ/6906%#84#A0N%!X4/A0!%"$4$10
MQ%`D4*109%#D4!10E"HAA)A\`!1"K`XOU?=]\G9Y#*:A21V`R8PJO%!84-A0
M.%"X3(P/'V.T\8C_B&]$GH"ZC0\?*H`BA"*"(H8B@2*%(H,BAZ*`HE0)(<'D
M<YJ0X,NZ8;J5G&1IV&TRHTHR%!84-A0.%"X3DT.21X.1M".>^FX?U@^@"*&(
MH(BA2*!(H<B@R*$HH"A50H@OG9Z6)V;P*()N)<=7&M*;S*CB"X4%A0V%`X4+
MA0>%WP@Z)R6_)P7G=^K2&U;8W'EZ4Y-&6Q$4,10)%"D4&10Y%`44I4H(T273
MB*WH7L,!,-U*C*YN2)\T3694T66"O7=/.M^Y+5C$AL*!PH7"@\*'(H`BA"*"
M(H8B@2*%(H,BAZ*`HE0)(<5T^K\5XRLR@%8/A0^;R3F69D-,CE1!YH0GF8]"
MQ3&HA<O8F#B8N)AXF/B8!)B$F$28Q)@DF*289)CDF!28E$HB)IO.S']^;*'1
MS<1D&_($KLF1,MFLCH)8N(J-B8.)BXF'B8])@$F(2<0)ZQ18GR!V"3$NDF"2
M8I)ADF-28%(JB9AK.E__A5RS:7YQ]J+58S.D".U,@\3"Q,;$P<3%Q,/$QR3`
M).2$SZ>P,9F8V@A7B3%),$DQR3#),2DP*95$##9=0?A"L-G"@QALZ3.,2;]8
M0'IU9;`AL7`5&Q,'$Q<3#Q,?DP"3$),(DY@3?GI<L_-#6HE,<)T4DPR3'),"
MDU))Q&B3X'TEVG0S>2PB'3138T@9;4@L7,7&Q,'$Q<3#Q,<DP"3$),(DYH1%
M^Y8E6^I_$EPFQ23#),>DP*14$C'9=*U%[K0O^/S(EFC$3EM:F3;I]QM1IPV)
MA:O8F#B8N)AXF/B8!)B$F$28Q$="IQ5'`TWZ=DERO/_#R<,4DPR3'),"DU))
MQ%33]1<YU7A>6F/+-N>IUN4)5Y.CV\-RQ7C4]?EFQHVB3[<PL3%Q,'$Q\3#Q
M,0DP"3&),(DQ23AA+Y)^U36<3W&9#)-<>*3N.!2B,=CH2?QP42H?2@PW79WY
M0KC9HLYYN`VY1S`UU<K/X>L=,TRL(V']CO1F:A_O_K#;<3!Q,?$P\3$),`DQ
MB3"),4DP23'),,DQ*3`IE40,-5VWD4-]P3B$+?>(H9:_D*2IUH1XJ"&QCE7X
MFVDKU;"$<RSQ8?!=3#Q,?$P"3$),(DQB3!),4DPR3'),"DQ*)1%33==QSE,-
M5F78LH^0YO;X0[4VQ-,,B47_BD(]-K<Q<3@9L\].D\&D6<QD;[B&_4U:UG=Q
M40\3'Y,`DQ"3"),8DP23%),,DQR3`I-2281\Z_+JHSK?!R[-A^C2UWU,CA1C
MYQDF%B8V)@XF+B8>)CXF`28A)A$F,28))BDGO&MH?ZTKPS5R3`I,2O&9:(.K
MB?ASWDF)Z997($&Z.U8>=:G_,W6XK#C#Q,+$QL3!Q,7$P\3'),`DQ"3"),8D
MP23EY)1N:58WPS5R3`I,RM8S.8U^Q3"3484P%*'?-,4#;)UN)G;9NG9Z"/:-
M?XZ473:KHR`6KF)CXF#B8N)AXF,28!)B$F$28Y)PPD9JNL[FN<4YB!27R3#)
M,2DP*95$3/;7UAWUCG5'7?XJ'T>*V,XPL3"Q,7$P<3'Q,/$Q"3`),8DPB3%)
M..%+D^2Z%N1'#C9<&\[P`^7"`Y$_'6D_4(&KE$HB!IO$KM5EXUELG6XF=MF&
M+G]3A"-EL%D=!;%P%9L3-A/;-?/IX"(N)AXF/B8!)B$F$28Q)@DF*289)CDF
M!2:EDHBY[EISO"#7'6N.NC0+9](K9ZCG-6:86)C8F#B8N)AXF/B8!)B$F$28
MQ)@DF*289)SP;G_$^GVIX\]QG0*34DG$:,L+C^`C8WO!T="ECQ(FN2P1C#0D
M%JYB8^)@XF+B8>)C$F`28A)A$F.28))BDG'2_"7<6#_^6>=AK"'-)>2X8H$)
MO>K5Q_%BX697M6)7Y%E7V^=J5JU6N]ZB?J-7K")?Z7ZX.S8?+Z?U_8I>^D1J
M-[4IN7I.N]W7IN2B-.UV4Y^:775F^I1<-:#M+7U*+A[0;K?U*;F&0+O=T:?D
M4@+M=E>?DBL*M-L]?4HN+$#:A\<=(U?I>IT_5_%\^[S<['JKZHD<D]&`7NUH
MRZ[SQ7[9UZ^'"QG]J/?D^ER'_[Z0Z[%5Y/I!HP'!3W6];WZA#W"\PMO#OP``
M`/__`P!02P,$%``&``@````A`,-Y'"(`!```H@T``!@```!X;"]W;W)K<VAE
M971S+W-H965T,BYX;6R<5U%OHS@0?C_I_@/BO0$#3D@4LMI0]6ZE6VFUNMM]
M)L1)4`$C3)KVW]_8XP(V;3?9ES8PG[]\\\TP3-:?GJO2>6*M*'B=N&3FNPZK
M<[XOZF/B_O?OPUWL.J++ZGU6\IHE[@L3[J?-GW^L+[Q]%"?&.@<8:I&XIZYK
M5IXG\A.K,C'C#:LA<N!ME75PV1X]T;0LVZM#5>D%OC_WJJRH7618M==P\,.A
MR-D]S\\5JSLD:5F9=:!?G(I&O+)5^35T5=8^GIN[G%<-4.R*LNA>%*GK5/GJ
MR['F;;8K(>]G$F7Y*[>ZF-!71=YRP0_=#.@\%#K->>DM/6#:K/<%9"!M=UIV
M2-S/9)62A>MMULJ@'P6[B-%G1YSXY:^VV/]3U`S<ACK)"NPX?Y30+WMY"PY[
MD],/J@+?6F?/#MFY[+[SR]^L.)XZ*#>%C&1BJ_W+/1,Y.`HTLX!*IIR7(`#^
M.E4A6P,<R9[5_TNQ[TZ)&\YG=.&'!.#.CHGNH9"4KI.?1<>KGP@BF@I)`DT2
M@GH=#V9!3`F=_YK%0T4JP?NLRS;KEE\<Z!KX3M%DL@?)"IAE9B'X\W9FD)(\
M\UD>4D<!+:`<3YM@N?:>P,%<0[8(6;C.`#$1Z101DA[B@;Q>(V1^NT9YR-08
M^CV]2F.+$-4WZD8ZNF$(`&/&`CXV1X(3%ZCZS,/`^F*$Q.A<0)<+,YZ.XS2D
M_KR/&[(B4]9UM9.'+'EA3X^^("12\A9S*YJ.HS2.^K.&-&CKZQV38$O20(N2
M$$+1L3"<6Z5,QW$:^<LA;LB:WR)+@BU9M,\692%$RXJI7<=QF"SHT`:&*'A(
MKO=*@BU10W>@*(1@^0BURV=$1X^$(4F^N$93X>.&EV!+DF7$%B':IWFX&,JC
M)*?C.(7GX1VGEK?(DF!+5FR5#R%:5D!M5>,P69)W1!$8E]>;I="6K,GLE(R)
M^]KMDV;7'!B'OAIT&T4DOS?;<2Z/YU<T?`%VF&).7&RQ.+9L38UPM'S/-SEM
MKVXR@K/9D#6\+K0LQ*`O-%I.=(WC$:'#D#%]NVG<D^F\CX:,M3#$H+"0$,O/
M5'/HN!^\)\P:^!\_EF0ZZ2-K&&PU!K\XB`(:6[V8FH@P"./!==.UFT:^W)ZL
MIS,:LM:NC8?Z71!$<6#-E533H/X[$H<T'B"FO)M&/YG._LB>_1JCO?/CT=!2
M^E,#0$E,AGXTI5DO@.O>X[#O3ARTWP0:HQ>--^:N`7AK\.)*C!MCQ=HC2UE9
M"B?G9[GN!O`^[N_B*KXE*]BK8`6V[J>PHJO[7A^`#;G)CNQKUAZ+6C@E.P"E
M/UM`V5O<L?&BXXU:Y':\@]U8?3S!;R$&FZ@_`_"!\^[U0F[Q_:^KS?\```#_
M_P,`4$L#!!0`!@`(````(0"^C>.54P0``,T.```8````>&PO=V]R:W-H965T
M<R]S:&5E=#,N>&ULE)==;Z,X%(;O5]K_@+@/V.8KB9*,AD!W1YJ55JO]N";$
M25`!1Y@T[;_?8PPQ-IE,VHNV<%Z_^/$Y_EI]>:]*ZXTVO&#UVL8.LBU:YVQ?
MU,>U_<_?+[.Y;?$VJ_=9R6JZMC\HM[]L?OUE=67-*S]1VEK@4/.U?6K;\])U
M>7ZB5<8==J8U1`ZLJ;(6'INCR\\-S?9=HZIT"4*A6V5%;4N'9?.,!SL<BIPF
M++]4M&ZE24/+K(7^\U-QYH-;E3]C5V7-Z^4\RUEU!HM=41;M1V=J6U6^_':L
M69/M2N!^QWZ6#][=P\2^*O*&<79H';!S94>GS`MWX8+39K4O@$`,N]70P]K^
MBI<I]FQWL^H&Z-^"7OGH?XN?V/6WIMA_+VH*HPUY$AG8,?8JI-_VXA4T=B>M
M7[H,_-E8>WK(+F7[%[O^3HOCJ85T!T`DP);[CX3R'$84;!P2"*><E=`!^&U5
MA2@-&)'LO?M[+?;M:6U[H1-$R,,@MW:4MR^%L+2M_,);5OTG1;BWDB:D-X$6
MO0DF#ID'.`A_[N+*'G6`2=9FFU7#KA94#7R3GS-1@W@)S@.9[,>-]4>HP"A,
MO@J7S@LH..3G;>-'*_<-AC3O);&41+:E)`M=LATD8@"%;3*\4&VPWB0=%")[
M0'3#@L$RL3Q(^_V$#12BD4$QU[\73R5$5VRGB@#IDF0J,4S2J6)DHH%Z.NAC
M0"%>VV!^RT%@#&@L)?,NA\%\'NA=WX[#7DA"/9R,P\3#<V/XTG$<(T04MP;E
M?P9*B`TH9=O542PE00<51I%9=^,P\8G1Z60<QI'O&?%T'`_P7(VHQ@23:UR1
MCQ,EQ`:3IP]U+"62"9,P]/7X=AP/46"$DW'81Y-,IN,X#@A2G]>HPL]0";%!
M970KEA))-;N'I0GN<&GQ>V":X`$9K%3/YTN(#3)CYL12XG<U."/(K$$MC!=&
MZT0+A]@8ME0+^TC5OY8L<1P9K?6/2U"(#21CML=2<DO6/%)%TLV[K28(B6]`
M)UK<Q\0W5LI4$\!&A]2X:&0+G4SL8C]?[D4C@]#<M*0$)KA:,(UI-BC$GH<G
M2\<0_6'[=%"(]C,UP!H=AIWK^<1U:H/+6++B7B.7>9AGT]3IBA`3M:SU>[/H
MU-KN+>XE3[>`[&'EH?.)77Q4F,^E#\N]7]O-C`*+>\U"SCKD(&/B;"<"-75Z
M3/F5FP,V:CS5'2('Z3]1.E.6.K78Y$?4CZ<CED>",6UHS):XU]SZ.J65)DJ@
MNM;3&H(IK2;X#*W8^D>T3^98'A@T:E5$79]C./B+0I3+D(<B?Z&F4:?8:@H2
M^;YY+DDTA8="9'J(ZX7Z"B$!"E4AR+3*VX,\7%>T.=(M+4MNY>PB;@8$2O#V
M5MY:8KR$(R^<7(WWB;C-=/>16P`N$^?L2/_(FF-1<ZND![!$3@2[=".O(_*A
M9>?N`+MC+5PCNG]/<&VD<)A&#H@/C+7#@S@RWRZBF_\!``#__P,`4$L#!!0`
M!@`(````(0#U,X\32#(``.B;```4````>&PO<VAA<F5D4W1R:6YG<RYX;6SD
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M'W^=?!B/9K<YC_:R7OW;BVRRG>SO;"9[.[O[]2]/NS.^W&W_LB`#=K20D?S8
MN<IGT[0[^U_U8;^J?Q`6<9[=]/4*2SM)AUG]J:\Z9\G9MYWS#YWD^.0@>7IX
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M\`Z#:RZNS6#JKX?9V@?X\WZ=RH,Q\ASEK.)M.DA'W0PMPDGDR494TS#@QU$Z
M[_5ASY-DX^/%8?+X27VHXU%R>3N>YQAGOHDO&61YGHQGM]GTKI]G23[)NOWK
M?M,?'&;=PN3WZH,>I/EM(G/OZH_L;_/^IW20C68-YIQ-LTG:[R799[Q?CAGH
M)9L]Z0:]2_.<E=5GN!S/4.O5SYQ-\:E3G)X&%1$3&=%F,LIF]>%.M>`$7WVS
M-<NFPV35I.W?H8KRP'DR2>_3JT'#(/E^.D=@<:5U"A`I\636Y]5D-)[!BC!0
M,ALGTVQ@.CY)>2)#3BPA&5\G/9R19JT/MLB=03^]Z@_Z>K/^8'!%N5Q1_;M.
M#\TA3L!GR6BK/T*<DSY\;SS9)=#,G<1>=MWO]I=09//<C@<]G,!7)I)9PZB=
M]@K-)KZ'O%E:A3Q4)F&CRM?)*5J0:B78QY<:1/:YFTUF">;DCCKII;/T2^QD
M_\%1M6%%YUE.E.FZ)?6R3]E@;!I<9_\WV8@%#HQ/:6_8'UEPG/4_-930>2NK
M@!]X\F7*&#C&$X-QWE":XQ$VD@%DPNNM%O6>%Y/KZ7@(6`%ZC.::+\R,).IK
M.`8]#;-D0_,]\?=,N>U5S&;YFR>80AN5:PA(-M#GP_%@D$XQ-<2;*PXWW&,<
M_8&/AV`^EVO&;EG39#[+DJLT[W=-/KW^@`]Z9L"BNIS:9O#W&U0LTVSSL^\&
MX[L':7;)D0>R]C`#@';[9CNN74-!@)_M@[H$#<YLL5)6IW7CSUN?ZU3&,!^6
M7<V6.C*QWV*(<12)E;H+8.Q_:G5J9W.,!CK,^">M0:!.?&.>/MXX-QM9,<]T
MW,VR7E#SG`BG];!VH3MS6(6C[@,V+$YWQWDSF!&H*@-A+PN1(+GNCWBW!1@N
MOG>73@T29Y^S:9?875_CXM-&'^R47\20'_(*,3(I%L)*S6)R,`/N/-&71\/)
M8'R?@4843Y(HA^0,C%*GIN`X`OK4)^%(KN[+E2;+N:X7^Z,NF1'P9*.7^5]/
M^,PUY2&P8RD^V4RNR"U&(W-6US).0&"=]!5O`]2E`^WOG1#6D]UD*WD[S_LC
MX2S1^A;?8)H*%LH)6:U&<TB@QUW,IUERF7V>)6\'8O#RS*EU4)ONHG\S`M!U
ME3P%S*+%GHT'A&U,YL=R_$8^MK'[Y-=?WGZ\.#XYNKA(.B>'R=O.Q?%%<OHN
M.3L_NC@ZN>Q<'I^>U/G5V3[;3LYPKT,B)XY^.]F0MOSC[__G`#^1CNXW__'W
M_ZM_WF7QKWFNC\0>/A[/I_P+"<,P!Z3I`%0WL1&[V7S&:L""/E82`J46A6KU
MYEU`@/A]D_2%SG`'TWYFR<C;_KA[.QV/"#S3?_S'_TLFX\$]?P8?UIO.;QAL
M0!@E<9F`;I0Y;X.6H:/]2U'8RW(X[.Z_/Y1R9V8;`ICIQ(@5$=<D0M*4_NBO
M67<FP%A;3RY[B*X`XGE_Z'&Q6-7L-ITEPSF!^`K#M(&8=ZQT8(Q!WO7Y0Y&M
ME]XK&"V^-\)SZ=/%5P?W_CY@@T63)_E(X^0NRW[*M^N2O42,08;_^/O_SI,!
MY8HX#]8XZO6!2]EFTCE[]URU`_ASE4D404B0`%.-/T2:3VB_O!%LN2('P`<H
M=JH\8AE!.KD'@R)0WB*M`1N9@GP:#XD"C+EQ<'SR/=B!`2<8D:$_\TTW8WUM
M0P['^"I(8IU2KMO^S2U_`A5GXYML1(RNSF:/M-.'7J3WT*$IE\Y8F6S)#-O)
MJ5A\;1P8$AI@C$%UZ(?D'+^89-?7:(AY"#C:19Y5&C>=!!B;&O?U6E?,,3<T
MI;(TD],H`[ZY%QMMA@N="21+IP%TDLYX9!H0U<GT\OG6MY?[\&*6WHP%+9-T
M8FJ]3':!-UN@/%RU.+29Y&.6R/C(#V,U*9/YN<.3&TS`7JF1K`RG2RXQ):X@
MEF28Z8T!@"GK;0=%DEW,*(3EQK<&?3>$0>+?#-.6;&)F0H#`B!;TE74L>@-W
M!C7SSN]SLHG-Y.ZV+S`^,+S%4(4]FS<8"*!#D9F4RG2B,"CX-4Y$9I@G=WTI
M-I(=W6#R^?P*'4]'&0EXL&`,(/@8O;0EVV4Y-R:=JF_IXEC<<J(NX@]=[&+Y
M=O)-A0MW:9[D5$JZ@I[2:#=(C-%UI4](%6T,A:M#+-UI_XI'<4&3VWNP:S^%
MV8[M8&J*.Z"@`D!"0?KY+4^"$\=3BWUY>IW%G/M:@:9[W_`;QZ/D`PNCHOD:
MMF;$_0%C2#KC:9_XB[Q/LKOD4"ZX,YD0FEQG-DX..T]82?:3]-SUD&<K*S+^
M:J"/VQ?;R;LQ)1P9NH]4R8U8Q<8[!C/=3_@+!E`/XFE3D$&&YSG/\HF4.'F?
MS<AX;!H-'9@'+<B,A2A%H\BSLTUP2ZB3HBQ7/,Y'>[8Z^#F_PDF)^7I?+SYH
M#9`E#Q&G>.7U51LS'8U(_.4*+0IH6"WB%O^[=B%1DQ$W#I?BCI0#;8*3]J[,
MBLB"'G0'<SQ0P>?@J!;7KZ@:ZS"RMNWD!Q(>XB9#VG*K8\HAP3.L/4E[/1B3
MR\5LFHS0`WU^-YZ:=)5<6@%BGJ.4F%5DHPVZ2(.6?]V?XIO^-L>!P'Q(A?_/
M&IH';:H"Z@4F&O2D\PDZ=\LJF",,*Y41+9"J)\G"(0%MO_&<XFK>'_2D@?I2
M>%_H6=P;74]3"M-@#CG=4=;5`@FDC%P^UO^Y4*$PONDJ&@G0$74-HE&K$\P]
M:M6^:0!I_HS4S%06/X;3&VH>V";J-=2D/T$,'F!R8(+[(VI)!ITC'"`JCR1G
MLRAHOE,`]]'2Z4UF@4CKY+U^=FT^FD"U!1:],<=,;6BT_>LODCJ%Z#&BC)J)
M0._Z`ZI'\RFFA65-]&*A34:I-E`T9F!\8;XW8_C)YSV"_TBU_H(.X!ZUK/LH
MFR**^=,>ELO0H\<*-(!"9^2,"&Y-X-_X]NC@28*XJ2!I;0=>BY0>6J24;HQ8
M:@R$'H(T_&2&=RUC);EAP#>M=#)-F[`7?`C2EC`M7PNELW)B14Y"N.\.('T]
M"4205>,R#00@W?&4TKU[4&GBK<43/3KB90>538S.D]]F"J&79:3+`W[G(W\W
MC$7PF&!W$H&&%2-(+^*\TIUH%:9EZ.<TNR(^F=+QDO0KX,B&^S`:PSRF3ME0
MD4Y69'RY[5_/?`U2,$/P$5X*W,CPL`BSP;1BA8+;N':K;Z]()W!-Q`5J:I5P
M4ZAK0W;B2THAV&;4._-8?V?F6+(/Z3SZC4G&,N5MBK>\RC*T527Q*6:-YFJL
M:<\*!V89YBC02OEJE)&O%6WP55Y\UHS@&6H%$\KX%#L5`[_I=,X<%0-)R&?)
M(KR>``$X+-MNE!'*:Q3F![8R-\87YA??\5BB;3%[K".,!GS9W9'$V8U3[5=C
M7&S]3S":$0TM@_M-2?8^Z8U5TF:V$$_P"4'H=0*NQ^,9CT+\5`5[L0$,HG7\
M^HL68N8D_EJ`+A=2<I+Y&3[M_16'YQ7@#7BE^0)\PW3Y1PI%Y*,#YE'P$N=&
M!I6?2%("WIJ[].`RXS2Y3ONX5;09Q?(5EW(+JP.DX@GMXXQ-C[EY:.)_SGJD
MCI;E*,).Q_.;6]-\Y4C\0<B%6^ADV[)`28I'AE'`!*1U[A$5%`?$KL+-W$ZI
MOTB6U#"R!.>I'5T\!*LIW4K<Q[4@)]'$A?;1JHC14<@@I3B))YP`MRMB(N&Y
M@).RWWOMB#*16,GFD$6K7W^)F\+*(XV'6*+O[WB-Q/%7:1Q783\+4`GX![9"
M0F.T/?BK3!)K04[`9$"M*LTB(^QWM3/1Q[-E>&)Z-4<MR;K&:-P#5;1=/<W,
M;#$(\,%6+SF):!^3OZ8DHM35QO,!BB^_*3Q'86L\^BMHSVRLL-'5*Y4&F"'%
M4:-^:CPYSLYH-$?_?5N7Q`^P[#;^7:%,4:3PMRF#B"*56SA^+RB[D$U9:=8T
M\>AS<-^X^"$J+$^Q<:$(RQ\&GW_])?0.)!M"S?(TWSUI>-?W]#GT@82-+:-H
M<"Q1@;I'>E46N<J*L>KMR-F,([O!?M!P*RY?6T9G*E3N,]AS9L<*LLT=+FGF
MX[V]9]NODB$HQURHJ6O3S+:30_B!7;"X71NWR`UP">9I\,U*D66\P?QY/+WA
MW^;$(K.!9EXLG0.Z?3-.H.^:.D<LC>.]+!'I$`D&-J/!Q86)M$DG^`@#RCG<
M/J5KY`+E1F2%'E8\GVB^Q\^VG\=5F[]S9`7G#1)][E-V4"KY>'=[/SZWI!:^
M69JN(UHJ>0A*W)*@Q/MR'_+Q_O9.'$_<*ERH'*.%24BL/%]?BY+LD'FB92AN
MBHG)@49/!U1%5W.V)PD7E,RL&M$'0+(T7I6MEGQ=Q:KKN0)TJ*MK,;Q*["@S
MC3C3:G(WR!/!_L2'5Z2JQZ/D3W.\NM3HRX2*+GQ2E*&,B6=6')(L48$\:I;%
M%T76*:43E&EQ(\-D$388`!8%5:]#`JVA2D6)8TJ0SK@_S>&&DUU58?,8-979
MVZM8%&3P?%>[+$OT)W#%A_=\.TSK:`\7XUL=I5G=R<\"*\A/ENGM\YU2P<6+
M-434.-)9X@=,9DK1S>M(O>V/2G^$YL*I;+^(6MYP@OBZ,KD&,LB5F]=#IC%U
MCIX!6)[/58-1,;3P$^C`2(6IBJLS[X-XGFTGWX[O5`LP4@UN!R"VH*=USP,-
ME?UI4Y;2[99;.<@*&(;/`<H0(U7TQIF,KY295BDM187T'.3ZP[1FP%J29`4U
M]:<8F4-')`5B9$R"P+P+?A%=UQDO0&&%CJ]KK6\'BE:J,@J[SK7G7-D1D9R.
MV`N43VOL6U_B$2:&V!T/(K]`/:.5J#0$<1`0=2`T3U7``IU#K6%=E@:9PW1$
MXFDVRD*&Z4]@K3B[NT0E)+9OA_^Z&H-@KN=6;RB@)6J16M78'%8Z],84J&3W
MMG1DK72:SX4)109C($*@?B:T$)$@7`*A]/K,(HJ55UA&$F`89E\2;0$B8F'7
MU\AN9!O93>KF&U"BH%RP%`"\,@HU?.V5>8:HY$WL6GB4$C/YMTE2^)2-'FV&
M:$3&^92RF4?<=/AI:5W@H@%"]+(P+*OA:H>1[A=I*>&5=<K[=_M3>ET0+`-#
M28TMTL3`E`A(JYP(X_@3,LDJ$>@JX<I;;ACYE+51A76U7,\GF92*_',@CH4J
M\48HP[!4PXN<>X9>57=2?:LH&MZH&PAJS@1ELD/Q0ZY32ZB(<&$(&9_C/HNZ
MRY_K.382=Q^2LR@CAU,HJ)`>)J(7UQ)#Z3S4M'$U"[Q1CHK!5,0O7F+')8CL
MXF=8S80XC&^081?X4E]!P[RY-V91>X_=7MLN/L+"E_3`V??2T?J#*_9WE[]3
MV2E>N96[]R0YZ%Q\FQS]^>/Q]YWW[-U>U(4N%4P_I?V!;&`+W[5E/0YY!=U;
MH&OF!M)D+%7.!D:2A%($&*;3GTCI!%6I%E&'P!R)VCPI]R^/Z]4-[6NP\S.:
ML0_;_8D1ROGP]G*<Q1Z!;6YYGL$T4AY\JVVS("TU,H;LDL:(>TV@?-Q$*P5H
MH4JI3#5-ZM:Z%]W]3@`#CG`M>0/565G`!B^3?Y4''\"[MF0!8XO5L*^TZS+Z
M*5I97C%!@W*]X%*$=>CT'5/YB#F#0HZ,KEH_DJD\#+^6$`_@65<,4^U]5/N=
MZB'?&U<_X"WGE/<17"-(5AXKU9-6@Z6-W\M>6-6;L/\D>=<Y/D]0YH]'R8>C
MSL7'\Z,/;7HM_EJJM<4N<55ZE(6IJY`!W"=69?X9[4-3T3>:GL@<Q;[^B(XN
M=13P'1P>VK*E7-?BA6L8:G1-9QEM6;]G[XAMP6277)<2T/23A9,P1C[7=F+.
MG@6.Q68BIKC8+#5SB\G_$,;`8L.+'L%P6YZ1K'G?_9LYM9*$#$-B[3U*;-T9
M9HC!J.[C__J#*;I3#EOGHR;M+-WK:1I&A:F$HOR,4,E`J'XP=HHLM'SX@Q%'
M$H%QF`$NFBO6ADPE$KK1EJ(HT)&_:7O;Y4)J,U$2*LR.2(%7%8C"OPQ5,)8`
M[7TE/\U%D1BHH@2:T1L+,C7#=F$C*OF/8IIVSXBG*Q5"*$8Q*E0:V4@-,,;4
M:)W\-EP2@R>V%K<S6TIU!J^\-SP6,XO8@Z+Z_':Q81SUPW4V/?BV1Z-J:K+@
MT\,&BGHI>JVN5([Z`?[Y$(<<8KB&9*];X-N+--3!IC/OQ_;:K$A%A$`JBR(&
M_HTJT!ED2+I5\V3<8(\4@!N<8>7!-L-+[6[N&6Y.+6?OU:QYALE<J$^T[A&/
MTJD4IO+$"N_6]O`JS_:,KJN3H\OD_2E=5V='Y\D%AUN.ZB2HY:MK&K^BQQ0[
M%72R%E0RX!Z[85:P)7):$ZVJ[6+C7:8MT:RWQ;;$E'0D&<UM]Q$!\#ZA,S;_
MD7X(#-L@JN_J91)Z[=@+.,<B[^'RME<ZK+7+[-[5FUTDY^K`!?#"4=GB5+@J
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MNE;IF=8R.<JQ*H#9M!'>UFACE0H2"892Y2KZ^(?XN(;`+736=+9QUN&'&'J2
M3H@]1Y^7=:>SKKH@B]?K7X31ZA^?6T>2XL*!,B@6JCK7)1"P_N2&SGSF#7I/
M*Q&0.L*?4K;5IO=)V-"J#Z*N//Q8_>.XQ,87&\\V]_?VZX\WB#CZ/+'-<@%>
M1'0-O&].LK&_O_GL]:OZ8+4%+)B]0E1C]B]I\_\!%]0C@,I01BL/""0;"^<%
ME.PDNZ]?O]Q._HQ$[`PBC;I^P"`'6K*[HH9&H4??I;/&%U62\3PJ30FV8$V$
M>!(S*A>2BNH'MQFE2]XJ=F#,4QH.EA5%+V%'&,K"WP)QQ5;,K[_`($2M%\U@
MB@Z=.3%=;MW635%!U43!4X,<)9H*<V/-)(<\+/LJ-K.6S"Z0]GQG9Y.3N^R>
M*1ZP'!V'9+6[]BG?1(!6C(QN-D7KV*C@!,ENUWO&/7H`%\D`&!EVO7K^N\!.
MSVQ"XN4(V_D</1?H,!X;U7DY%4HO4G6D+%O0%Y8`#>4:>,(SEG6F5[!D[Z5]
M^?S5YO.7NY$'JH<K+W0HZXN$XL<[V_N^'<M?>T@17JFI`:<YN(=D!5`<]J=0
M`3-6AU)[P;%E*[+MM/T7SS=?O'R6M+.^;H<G@DLO5#`$(DTS<M%<[EN)1_W1
MQ2>.P]DY/?G$=PM7EOY>D$\(IIP??0M2.?[^R#*+U7.PDU<"7$?UZM&9^(Z"
M"F?8#9P5Q,O'`VW^PF&914PM7-7LJ6)M"Z-Z[)4'>TAP`8SG["_O;;^.6V4F
M^,?/=K?WXB=UB2KB_:L(V',"7FSOQME\_MWGY>9=R_Q`,E,-:B1=Z\.S`*\T
MF^`:"M$\$Y(B_('Z6JIL=(,'`!;,#])HQ'?3IY?HD]`OL8TSF`@GX#+LIB[P
M)8_9LOB.YDT<P3?LN4_60.WJD]8P&+I+ETRP:02B"I0/5Q\_>HGB'AY?')R>
M7!Z??`1LGY(-&]*^J"^&/&'(!@4(J`O54JK+,4WF,V)`/'VU^,J4&S-T,\?O
M<]`D-W9@@>:2'[TYU:[[X!Y7_UP-V'*Z=ZY':D+SL@.LL6`#SK+-S%G6O1V-
M!^,;NO>]N5A^VL-+G;!9).PJ'@O#VYZ?_?K+!0<]I@"Z@TK_YL;Y61(^?T)]
M2R<(:%;K*[9A;P?D!-8]_VU&3^-MZ-;\6.Q>J;)E@8Z@6%:*;3TWH!9!$Q:4
M>L%L/DQNIC)[ZMW7;.]7P^H(`B,=U*@QJBOR5$S?W#R4\(X?O6(MIU-B(34F
M76PBGO2[8$#[D!Y;)*-O^C\E[]G,)&4@:NJ$.TZ-<V+^%9<7H'>JOS@EWSBM
M]W#`3O4PG]<8S;32KNVF6N?@]]##JL+ILZ@/9G-%2X([IM8)BJS+XBOK>_SZ
MV3-%6+-",=&[SM4^/TH""^^M%8Z8=V1[L/+A'\(9@9V7ZK:&7;5V+N08%(@Z
M*+<=*,*7#+:C512+J0[G:)$\6&QH'26=89>J_[':B#P;0-TK2K%AWYNJJ+6[
MW!V0^U0&P:*NLAG'NT941DT</J(`DC<;B5PY#WFH4K),0IG'VFI=OJ4DPR:(
M*MK9)VVY\EB9+E$H]NL(;#0ZA$H'2HNY)?G,;0IJN:M[12=*W+$M;%'?HW18
MAM]6^1E.>T>KL4%R85G5A"D17?754@XSIW,_>4*(UHY-V6H4$F?WUO1$T-=I
M)_]LDUW'#`(DA1"-:/VFRB+\>Z>K<W$`;,)KN*O!Q>B_,_ZG_Y1;=WY6>9);
M?'8>\2^D"#DL>XCSV=4GTW?PW1^Y[`]!(CH2<SZF/T#?7J=TG=V'$?3!4QMX
M]N:B[#4]THFZQMS_1?.*L[8E,I##BU"Q9+5I<8_CY-;_AQ74Y!(L&'ZJ,<%]
M-DY%E<60<(/?!"_L(!FI,T+EJ87Z=;R#:"\$0SA=N>#HTL+_>O<+ZBV"J_2L
M&CXK33.&O`G$$0U9Q%!R)Q.7J]?N6]%'<5!4X"]F*+E7K#"G,AY+67GA09<@
M8%IQ`Q52%:I4`)/1D&I4QDAG,TYR<<0L]-I4,4?15`(5#XY,ME4.4\!XED25
M7DH%F'J<E#!](VRQ4-4L1QWXH00X5S9TB,$+$:B(40WLLK48S&=O-E[4/T'Z
M`E^09/M3^$OMY#=+1H9)D:G\;%'H1B'4)B@#-T2V2B<DA2_$LK(<Y3/M&.Z5
MY01EM?F$1,$VT6)1]$QMBLW>I$/=K"#0%;'5TOW6QI.K"IZOZ!PX/?G^Z/SR
M^.W[H^3D]/+H(KD\3<Z/WG<N`65G';XY:B"R8V(56KNL)34E.V5_S'?SBV2[
M4^QFE]6!XK,GW@X0,9?.+/1G(#Z[LL8O<!C3R%F\2?%F\;"3M<W2*<6!(HL[
MUEWP'3%KE!S@[CDF@^<!NN`0)%1TM`^&P;C=8-Z.@5OZQZ'MF]I<]AG3>%K.
M>EO:+ALMM'(8%QP_1M^-";@0W$6QN^#R5KC;V]G;33;LWZ'QLH53(6Q[+4%T
MQV?@A:)Z:'%5<V[1Q`LP@-/T1*N;#1="RRN^U>,O"W0*B)$:KM:FR]%^G>\2
MR@IQ.\Z7%)*R<R!5.M0$J;'"_1-5LBR:>AL4-"QT_#Z02`-'1$S0P0Q]LY.F
M?G2RU`7\KA0E<#&L#_\`UBGX;EV1N5<!8(*I@#MTBV71/UBA2"4&;5Y:%D"B
M4*G`2!5`!2#TQU:=<1!5,!G3MV!F<0.OA/^K01NG;L-5PJ+GA1'5;,RXA*6V
MT0G<XJ0;0\8VM+K48GS6V+%CT=5=9YS=VWDD,Y%7VJN_5&TP(7QNK<EW?5^X
M03<3G1VC%151K]#CT%@-A7Q!>2]^%<0J@U('MF,2LK6"'POZA%"-6WCKUDYR
M3>HG5N7X]>JOOQ2]_NL-AO9`%AZ8&1D>*8__KE'>8BGD#Y-@LVXT6EG#.*UV
M(((/0GH@KH\YGBVCYCV.E7!FNP*8BXD+*VU$GTN&*TW#-EP9BMQ$"0:[ONJ%
M`X.&\U6:/*0OB]92=;KJ6A(S!3@6.YL<,K<T,GE^YG0$W\.DY(IR1<%@,+^]
MG=_]^HOB-MW-<T[KQ^O3PHE@7D$I3-S8(W]6L/Y:EV>59IWP"`N+O)OF1258
M\9L2HIC@I'HN"L[K.?M#2[(>*,@VAX%H7E1)#S<^*&]T/.5;";M5/EAG!;XF
MG&:0=]O;_4/"GK8\C9,12]&!9J=*=?/8B3,!.OK>:5Q7$#:^3`<FY4(KU^&P
M>IA[#<?E4BF'F$_E?V%^EN(U?$+*`>[5V]1),C,`9E41:65PN!7&\:&8Q#4W
M@%K^3+FRSZ>]\<.[H4E`*JT.*A]!?K&Z;IKA_1#5R"ZD,T55HQ&2UR8IQ03X
M\GK[]>O?Q<4'PQ']E2V=JI<GI2_7&5]SGG$U!T.'*C]\(M'QBK]E*U<<V50;
M/@$-&DAC;ON3"MVDQ+2%R[#N`$`L6T>W5(D/K`B4"8S(.UM;/D\@G(JN>+![
ML>L-D,XP[G-`C8@\00=\V(9@<%,\T-P=<'Y6'8I,"/\"7E)CM>$E63^WELRV
M8O:NFRFXL(I\I,S.C4G;R<<)&BOACCE/I?M4&829X9VGS?Q-OWZJ`SFU=ZNB
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MBRV[L-WU-E6E@F\U:N0"..OSXN#_E8#1+<8W!BOK<5>$AY^5^XQRB-@&`H`K
M@S$TPT<[=&7Z-<U03?K<.?\LY"%C]Z((+L?`75'<4UCE/\\;BIU#C7I-43UT
MXP4]<.[#(GV]R#^FDC;P>;0IPI`/C,7^+&/1EXY2E7@LDE3<C,,#83]/IR#L
M-*O9F)34!J'P'%VCVWX\J*GA']@+T@#O<F@3&%B>@GRY;_F`[#'<I+K%%2?@
M?OZ?GFU5("W7T*PE%HE'H:O\BB&@"M#%F+)NV2(B.9;`K\B.4+/2#3G^W9<5
M+(3H`O(*W3T(8^#M/B%FF<-C>2$ETOPN\99LX*77U,6.QWN[KVP+6]*M;,8>
MKYL/I9-N%`TQBRH16?!ERVS-7/8KQ.Z_?M%"[->U`+(ZO'8;IQ-6\NK5J\`?
MQP*@*07DXM"FWGW\;/,U&^!*04MM*I/Y<O@*SMFT\Q)U0V*/G-6^M%8#D*[G
MP(^?5P[AMDW@<C;*+)G.>C4@8<A,)L\5$AR@+H_TELFVW2I4:4+442N_0+G0
MO.`Z2@JBP4C#'D>=:NUZJ$M(%">O*;-=*)D/P/FKY,BV9>L/MSUCNKVB`7'Y
M.]7ZW*JJV^O09OCMZ?O#H_,+B./@SN5?ZL05=\5;K2=<U&&`Z;AZ#TS]M>/Z
MR6*[548AC#Q-!;95%\H4N%>:U6AMD3LLFV%05BNJ6M$$5[&[&3M9;&.50UTA
M2M"2L;.KVKHW<5!ETD&,B(B+2V]<L[YD4FG';NB>63?G)0NJK;Z8N70.JK.`
MW=DV3?^JLR(&M\6XA8X@U%6'M\F;(NQJ$4*)P7VSJC&*119-"'SE\CK;DX>-
M!8=-8%Z8Y..0*0F+D@;D-$T;WW,`O.W06.9>279*^S.Y5V6E`A=)(?Z\SW2`
M!_"]JN#<6&&9EQ6:=NTLQ.Z.Q.1_[^UX+!]3R;<2(1QU\LJ7M7D=%C"[)\+1
MHP608$]R`.P,O9@V?,F=7>?A/N+761)B$2<V2$AN,W30M"0FB<SGRXV0(ONL
M;E'*NN#LH#>^J#@O;T#J#<4,/::$2WKM@UCJ5:1=OBE8#(.FFU/SP%YQKK$/
MB0<:?(UI*B+RJRV%H5J.;3F-Q25^Z)NH,E9Z$M!F`XO6IKT;ZPDNS5%QL<!>
MGG(9A:LLWBFVN[[@1"3;M-'R*2*^ZC,1`8M,`*;O[_@J`J)I4<H&3C?':1<(
M-_9\.J@P1J9R#WGUD/MBK+`4^F=C]0-V5NY,T`L+5EG:DW!KMGB3%LT>+T,0
MT-X<Y0@E0F><GY?:+;B]80K<HV-BK106V\G<*!#F:V_GJY2-85)5?-9+%+:@
MI"+\5U0@>?2UE9PMYI=&7'T_6I@Z$A>D/JFDMZ&IW*CBN5(AEG/"E6^1IW8-
MG""P.:H6QJJO<W4S:)V_:_D*7%S90:E;#^2E8[@).S0/:9Q<4AUIZ*HJ@`I3
MMN6#EOA-&RU>OJ*0U*91*ZK^(058MPUF)9>XXX7HL"O6S2;7RMVS)Y1#*V(.
M9:30`F1YMQ6'=U]$+7RQRF5M7/CV@WGVXDP,$HOT).K$M!#[?.4X\21*V,A#
M0$5U'%3GM2%PP.ZK$@?8!4$M7&:%TNH%LRC'J(),5]AV6=G5,XC"8C5.K*B\
MOF-LJW&:<14+#<"VW&LL]AET=7)8GGQ%P1G=*[+$0#=T![&%+Z^K>0.JTNZ/
MW*["`N6^RY'*U<&AY\8A/>?+BYSU]I4^-U32(V9^.7#8&@(4$LG?V+W4BN6H
MK[E,CS.I7(`NO!"ZRO1%O)-']0VES-8]5;#GDB>**55B5H@,7?ON;KSP;K<+
M4Y[N@PF)'*WU,:L/ST1-M70B4A==IZC"Z$/?E/ZUA*\6W^P6APFKC&3%O#^2
M32N9]C54E.R!(%BB%9?#UW;^?Z%BN/@M[]ZQ;/ELSHS;;^C$B4P@<+A6]XY?
M&]LC$5(5K:12^UY9^EX8Q"/>E]6]%0_;@<I"[$#[;;U^\-BKU<#H(&D.[]E1
M%`P'/@@E`N.I7W,K()<F1!_56CPO%J[ZN<5?;3(4!4?9-+_\I+ANDWIV+V:O
MJ9/K]*E1;$,!"%._4]9*<2@[MCV7-CBSL8"B;I`F+W;MUN61E^"]4E+S]?05
MS=Y\;&^K7.F(T2.OOB8Q"UA,C=?4CLTQB&9N3Y.NN`FAKO)]P1CLZ]"ZCM'H
MGP\R#&=%9C\=43<.O[`_""LTQGN1CK8UG<+`70SN/=*IQ2UTN16=9M;/MK+#
M[8!^NJMIO][9MJ</[!?RK'KXQT?`_/&TTN[6WK+;;+@K2/G7-MN5`C&.NS#/
M@V.3SRFU(;0:+/%ZRDK9,VJIU7?F-W-:`IY5:_4'88\7G[*PQ?N;J^^VCE!Q
MDV)AC3&H6:]#^Y+*RGOQM-Q<;#8S3"&U6O*V)L7Y5$W;U9B>-50*2W$`>DZ/
M9K+[C,NI+JV'BRE\]\@N+BAOK-<1.GD/[]B10XFM/5&?(]\431@%VKRVK?V"
M?X;L13IC^9IX'9G(E@I\^>_=4?$-0=:X8ELDUO0B8[A1P.^P_RG+:%-"=DOT
M5;LF]`1[<V]EAP/^IRAR$1!L$WG#U,L\.#%"NPU^2CD<8_O_RF-4CCIY:#$N
M1_ZO-.AV42P&D!"2%[P"F_P16,2L&*`BX2XQS(%=M`G2XXJO=,@Y.FN8MPBM
MT\3EF3!^^/1WACRM2E.`)I^%C7120%6,4NP@;!>HL,/$GG9%;*`RM:-]?7=6
MSZ`V`543+H-W`!Q>98M9/P+#0EY`1(C/:%*MWS<RM@#FX?7XBTN\K_OVRCL\
MBX:I]@PA;L#(7^MD$^\7]1/[;2=]4MO^J9Q(*FX"U4(?<LQI4;K%*LB*BBL"
M8^)3@$%1$.%X#;C,WK"LO2:+6Y-40)*>7B2AEJU:4Y`W;1;2-#^G!N?%_LSX
M_31ORT;%D"BLTE%Z6KJS%]+)XE2CV$X!LENM4/K5L1<Q-UV:+#W?\VS)4)'$
M51UE51I9$^OS_8H,?/*&ZH:@W\[T>K89;F5N=@$?VY&1A2/@)@;A8BS+<X:5
MDEB4H=7N:H)<<"ZVRQ\"E@1IOT(1@,B>(Y&:6OQ6X"JQ&W=<;A4@ZXGL`EEE
M$\5RN%36B%]X?U*Q;Q6UZZ$Q3NKUKPARB[Q?X:`K3512RSIK6OWO\YK_U4ME
M83":W**#G8^<JU9UJC+?3D9;&EQT<ZWQO:]+WUO^D/1EQ90+C]7B=Q<N6:WZ
MW18']5O\[GYYM*CA!ME-5"B3!<6?/K,*@/WCGC[A<!UEXZ1]RXLK]OU.O'D$
M:9;G/%:><:1Q1!B`'\0H"-QT"N^3'P-Q*[8)BRNR%_K^U[]W45QH^.6_"J=C
M226UQ);J19)?0OR)=F';[UM*-BZ5531O7]!9R)[R`[$,><9+?RJ)5W+D-PR%
M9FBY`0[$6'[!2T<M-S?97,D*-ANEJVZV64IO9;N7R<WIA=M>1%?\S<RDHY]R
M]%M@[3!@]<%PWTW2N=/Q@Q_7$EME476<ZH3<J&,[@]X53X#N**?75N;Z\8T9
M*\X9+^6%=J1UW.F]G5LW!R#VN-,%[BV8C"65ZT3RL!]7U+%26KX&');?:/]1
M[-WD`U3PPPE'ZMZM@Z.7*[^E,KK\A[$/LV[Q9>/GX3N3*5]RO!B?W/A2=Y"=
M7MNOEEOOI5V$E/SXP7YGH?%+C6>AZA;[X9<]5R6V,64#S2R=SE3@BYG_XWOM
MV1[3%YDW%G`N">EP:F&?&_B8XE>F#_U7IAO>^:!R?.-0?6K'.KF@0@P8BB\C
MAOI!!<+&^EHX4/UAUOK@=;W`\UG37/).A_8O5)E&8BK*Y_H#>U/K@QM:API$
MJ*?I8.>L^OO"C545`YN-V))"YVQC"2O'.:`V36F'TT7Z0]TM'$`%WF'OU"HX
M/.[7I')H>MZX5\=$O,PY%_:TQ;W%Y85PK?>V>7,X4^*^U!(`S(0BK)X=A\IM
M:G7F>B_..GW^EX6`%:JI.8K+Y2K7T-4I#N)=:C1U=:J&K&7V:E)8'7@*62SQ
M;2_6>"]^?G"9#UIU\8_=U;-TK5]"]RJWL"Q^50.F-B&JSRW$R\WDI+C)L%-V
M3=KS>=(I.B/JPJP.6`V<OVGB_X[9B@B`B_#:2M7_`,NH]&/ZC74:#)"+P?<>
M^LW</,JO((=+]S#<56K0Z-)X".-60YS-8/3,;+=G63$JTA2O^VI<%B;OSKH?
M]BOO#R'RP6H5I;MP;Y!17F?VEUA%O$71^VH65)#+OW3!WC(P\T\O+EEID5*8
M%1<6UM?\FV[K>Z`8S^D!L9LV%%$.:7D;C"=6AXH<6N96O_&?5+-(U*G\2BC=
M/NM>_>TR=*P-G89%ETF/:MTJ+&IH(K"_-N#RZS!=0^N2^=>84F.4AU^P]]4K
MOSFE3EC\/'FY;X>;ZM^;;>&N'F;K1T5?PD.?;[E:[X%SF7*T7^FU/@D!L7[P
M'Y;"\\U'UE10'&@I;UBK<^.4$I#N#*K>(;:0:1$"O7!]F7ZNOVP$K\SEUL&+
M5\]6ZBNM3Q%?[+RLS_X^W`RC7Z35CG:XYR?CGP#G]_P*R!8AR5-WT)/=U@AO
MWMKI.H#D6=IO)&LLW0_BD?3Y7W:SH'.)E&*J0%>9N$[3%W!D2TV"E<LW#*VK
MS;7(:"NWARQ!9U\PPG+[-IH?>FO$>D7<62-1\MW8S5#GWC')CTX]'G`%A6IM
M'3\:M,P/5R'*4BQ)8`\7%*P9+5RI(&YP8]F23-DRX)W0R50G/T)'=JV^TX&=
MC;/C[^(->TO&^ZV\7Q5C?04E."6G5(]2,_FKL;NQG%I58,DP]=<\D;9?!+5H
MZHF+741P+F.,R-"<HL>61@I;&X.?K2\3OOB/<L0Z!8L)L,8JG%B1#5M!I/YB
M8]KB'!&4<Z3M0L<R>Q$,L].Y=H`/JNBJ,';(FU_V='*NFIY-.FT`;W=B=D3X
MM#@BW+'3UB6_Z_.=>(^2@V%N&\C'#*`%V89[ZY`!]^MRU/<Z=6S>-$K`\V]&
M;5XF\U4X65PG(9JL=QSYAK)M+*AE$D"F*DA+[:4B_G`N3-%XB?+(KV]Q[M)L
M,$JP3DC\/"(VKA4T/?'J;W`^5!C\B%C];5Q)\9UJR:8X5HUDEP"[YQJ(_GS8
M4.O%FHE>-.95JR#UF1HJ^4Y'(]V5K7WV([^&;(0BXTC=VI<JO*ZFOZ&B<EP8
M=B-W*UB*'U01#36Q!LF&\FK1R;+S4^L#S&J(N_<J686`Z7U=];4!CF7AR;]\
MU5YQO2`_UD^&63%<1PR6A9#R0?P41W*0S=)'+;T6."M*_7:<8-GS31>OVO#2
MX;V<ZQ7DO;I>M(ZUMV*L`JGM-L9ZJ,!71;7H.<22(H240:Y._N+C9[26XF""
M_[:*9?GK'`]$YY8[A8Z8>-C/[%<N&J*2"YV3BKYQ>70J("8>3/NO987)_9G<
M0I5ZN<7RK$(,8*O7>Q!^<C&,N##".__YOV4#62$:$FQ-50<0Q@K%'HB_I!Z;
MZZKW\:A!S8"K7;206-64=]=%?PL#EC=XT<^I8\V4XHHJ=WRCX68.EH\=D[50
MS2GGAY9`@-\G?T@?*K>S6S.2=A0:GCHLME-490B$D39"AO>]]EQ,QJDZ!^(S
M@93*#MUF'"?GDMGR*B*?D4I;1%T8()Y>\VI/H*&DK627,3HYY?YTI],V-")?
M&W06UPT(XFCCP3>%#1<<>CM7_9VF:T#?U'%UA@NDR[+Q?/S)C:A6]7VI2FK=
MD,0BF(OZ%-F[(,[&NVZ706.7E">U'VU/-!3-)/+`PN#3/)^]^4\!````__\#
M`%!+`P04``8`"````"$`\'DW!&@+``!I9@``#0```'AL+W-T>6QE<RYX;6SL
M7?]OXL@5_[U2_P?+VU9W4A/`F`"YD-/"QNU*V_1TFZJ5>E5EP"2^]1=JS&YR
MI_[O?6_\[0W&9HP')BOUT&VP8=[[O.\SSX-]\_VS[VF?G6CCAL%$[UUV=<T)
M%N'2#1XG^M\>K(N1KFUB.UC:7A@X$_W%V>C?W_[V-S>;^,5S/CXY3JP!B6`S
MT9_B>'W=Z6P63XYO;R[#M1/`)ZLP\NT8#J/'SF8=.?9R@X-\KV-TNU<=WW8#
M/:%P[2]$B/AV]&F[OEB$_MJ.W;GKN?$+HZ5K_N+Z_6,01O;<`ZC//=->9+39
M08F\[RZB<!.NXDL@UPE7*W?AE%&..^,.4+J]";:^Y<<;;1%N@WBB&_DI+?GD
M_7*B7^E:(O(L7`*(/_QG&\;?_2[Y\^:/;]YT__WM=__\T5G^ZZ=ORI_]]*W>
MR=@0FF"#>IJ7W5JR\'%"N9-*<'NS"@,BR`#4A-JZ_A2$7P(+/P-G`/'P:[<W
MFU^TS[8'9WH(;Q%Z8:3%8&60CYT);-])OC&S/7<>N?BUE>V[WDMRVL`3S#'2
M[_DNF`E/=A(.Y^4S1S293".$P<G4QS-4)A]$LO%DO4SVSWMDXG@-#O-JHS^.
M%Y.B7BYIO,I^4=)A&UZYK0B?Z'$^T2T+<DBOVT6U4H.=B-EXU@5^9V-V-3B;
M9'VK;PVE2L;Y8MENR+!OR53E`8;6V^&[LZE3/K,JZ=(T?*X(P("3JT470K<F
MOH<6OL[A)V<N:*>Q&*/*)7T6>D5N?'!]9Z/=.U^T'T/?#E"QM*BQ;W,UF7,\
M^>1STQ/2>6HO^YHT^+)Y<&Y,9-GO58W%.#'Y+0U"@EZ.EI@_;<#17,_+)\_]
M`4XOX<SM#<SC8R<*+#C0TO</+VN87`:PY$`/[23?._#MQ\A^Z1ELBB4V8!-Z
M[A)1/,[8E#:5=G9U9\WN&%^"3!1%!5'+F@U/0/1N.I[)1SH;CV43-2QX22;Z
M=H`OR40M^&\F3:=I^)NR0.;TM-C%)6CW<C@>CT>]J]%H-#;[/=-D2IZG'NT&
M2^?9P56I-#65$0P`P;@_&E\9`*1KCABKLR+H`X#A8#`:],:&"?^S*G9Z!+)U
M"JMPQ58E"!19E2!09%6V"NI(R/QII$!#2+%5"0)%5B4(%%EU*#D##Y5;E2!0
M9%6"0)%56>].8JQ"HU5QK!($BJQ*$"BRJK3)9YJ!Q\JM2A`HLBI!<&ZK9LNJ
MV=V=Q3HYY9F9M/EQR@LG\<UYL54CK%/G8;2$*V+999Y>']:(R;G;&\]9Q;`B
MC=S')_P;AVOX=Q[&,5P_NKU9NO9C&-@>O.UD([*_-2/A"AM<3)OH\9.[^`3,
MN`9.HIN$Q:DXY%G/Q-6$.32[0W-@7"4+-DFL?6?I;OVR=#GOO7X):D3='A:<
MZ##(F:3N4#01.VB%U'R"(YBIF:4%!X!/9"XA.$*&C$5#751&,D),1C)`4$8R
M0E1&")U]P95I<AENX>+NKH$M:]3M)KU+43[U!`GP/1ZS'P094];GP2%[-'IP
M3%-9(;^48F-JX(O-CO=(>F!$6<X#`_9(>6"$J(R\WV36Y8CGK0M,SWN0[.B;
M^_IQ,(!1,C##LY,$T_R$?>[DJHIPNN/%+?'9$446'V$Q]FBWE>AI-87BO'`\
M[R.6RW^L\@H-3:_;F^<5V3$!VUAP2P%NR,"WT%E.WR;5.#D`K54-,BH':?9Z
M[;W<;_VY$UEL;PMCP<YB![LXFK)I1''\UG,?`]]A;3L](?-#%,;.(F9[;UC;
MO0I/OP)/+R4D@J<-?[."/^A)6!]M^$-;:*\102]*^8-S"?.7Z0^XRRAU:C`!
M=>HZ/#(1P.(_0P!&4($`=T6E.@#W5($`%E49`G#0`@'`J?&*-G'0(]D,?*!@
M"?Q/Q1)R3"8EQ_*$4E:E7^!?(Z7%I=]6:B;Y%AR]4#,<U`!HQ;(JQ:I*,<3L
M$&F%"N"@1@465%TY):]7E?.5*80D7<!0:`320)U&Y'DER;G`LP!0KY&IQ'D(
M<0I,1:HA`!PE$(@A>HKJ;X]B4%2!J3<H*L$4`E>#SQ@3U!)<A52$`?`HB8IB
MGM#C*L89U4`@J,J0Q!L,52F28E"5(PM3&*I2)(&@*D-22ZA*D12#JAQ)3*$J
M11((H!$E&9):0E6*I!A4Y<C"%'U5*9)`4)4AB27Z)TZ1'=HV39JHI'\ZN#JJ
M?ZH]KPXV4GM5BR:P>S8\63TE*T>P!5M+D:4T_@[-SGJGVE,8N;_`(A-_C[:`
M9JH3Z?C[Q=A=T#-?(GO]X#S#4C2Y*O2\JN[U`I*LO['KC#S"2DP%?^A[ZUH3
MYM+UTP)+>T4<E!S[*@?[\CN.P?>V#SK(00RLL:`:!.HZQ2#=!22%"$:N:C5!
MD52.@9H*"J98KK!`<YA\&F0SO/S:,'F@>M(6.*#DIC1\ZOKZX?R\W<3NZJ69
M@MIGM!;I%!?!)[-.5OH.9COJO;(!-6&.:^%,&_W=U5B=LUJL?WK&2#HU.K9I
MHID?4U<Z-3S!-$0J>0-T^VLYGYV.,/C7H%+8;="IFX9R`;+;*GA=`7)B=&VM
M>6)X+0.D'MTK#9!ZT*WCEZFT28!(G^T<4T]IQ'*`\-)87<1.TRMRC8K:,0A)
MS>4`EO!5+FV;E/C>_V?'-6V&ZBIYR%WX@GB4\[3,6=Q\K0RW>=(Z2@BI=0'N
M950;H^J5SN7<,MRO1.F<ZY3RSE&5HU%.(FN>_@&-UH%1X;#U*9M'*R>!$V5)
M8;ZO$]7$>M45%OKEKZ+"5F=U.;[>5H,</M[_&P$\RO\%JPX`666]4.*!.^%Z
M>KAMZPN7ZLH)FP]8]?7E`-Q77%]..<\\9IIMP%QB=:H^K%1`Y;D;[Y5'A?DQ
M"#'FA3166=C:9L8J!&45G4TI-%D#O#E;)N(EUC(F16;#K3QB=N,!"EFQ>;EX
M;7"@P&;:>25M6GJQ4_Q"HTCN%S)IEAJ*RRC9F8/30/3YE8+KCVRK!&R.(#\U
MXW]HEF^ET/"V>G`;X.[OM0OM[0(ERQ>5V`N9;UT/;B>!`8S;7!9P!2OTI\G)
M=&-"':U\BFM@I2:TP,N:T@(*R739P*U/A!;,MYK2`O8)K3Y(2VC!K_`:TX+M
M:"DMW)A6X#+AXG-37#`DI<7K?B"H>W.?'7$%0G"AR"*X**W"CCC_+F2$.^`U
MIE78$0Q':8'(37$5=@2$A)8)3)K2*NP(5J"TP-V:TLKM:/*Z'PCJ_FJO'7E?
MQ?U6(K@HK<*.O*_V!7V5TBKLR/LJBMP45V%'H$IU#Q\TI578D<\3IF">H#(6
M=N1U/Q#4_6Y&Y3W>$/3XA$IA.WA'=(156D1'"97":KR7]P6]/*%2V(OW;U/0
MOQ,JA:6`'I'(A`_$)<IMU.>U:PIJ=VHOLZS+.PS6&1$8<,/XQ=:#&_F'^!@`
MMI\05\Y$()SC"5%Z<A:?M!G\/#PGQ,<#EE$10G?/:\\.[#B,7C3<0YB3XXT^
M$"3WIS#,=<13,.!0!-"?X:$)\#P&#?22:(CW89S6-2&3QP*O'OQ!41,R,#I!
MP_L?KF&:D('1"1D^J>+\283,^V"]S2W$YU(LW2(D/KC!)V?)>PZO80-`BE"Z
M=[9Q9.?^QX>4(:B8>[RI0$Z#3Q')K7FS.R"D\\][N(=`ID2<[I/8P3FT"/"_
M;F.B1AQ%B&!W0X3(@QO#G5FR(.9(("PA$B'LZ\U)[&0401I_MZ,`HX4+W1T?
MK9"HV"4-L__E<W&#":;W&!\KPFX]D:\'0%%+9V5OO?@A_W"B%^__PNYY!,Z4
M?NL']W,8,Q(3O7C_`6\F!5$,%\`AW7S8P`V*X*^VC=R)_NO==#A^=V<9%Z/N
M='1A]IW!Q7@P?7<Q,&?3=^^L<=?HSOX+*L-GL%S#0SQ:/..$/8L%]DGWS.N-
M!T]"B5)A4_`?BW,3G1PD\-D=9``V['+)A.AL\F?$W/X/``#__P,`4$L#!!0`
M!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q9
M3V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#
MNF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:
M@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%
MFRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F
M)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPET
MB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4
MP2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUN
MM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P
M!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+
M"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%
M353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI??
M?O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O'
M)?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69E
MN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B
M5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAU
MC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(
MS$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!
M^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y
M*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&
M2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N
M0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'
M0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QH
MADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$
M0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[
MF)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL
M&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&
MQR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-
M#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S"R/:=O8U
M+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3IBI=B!F?'
M,4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%[R=P!;$^
MUA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+
MPZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#
MFWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-
M36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U
M,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@7
M2#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[
MM;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>
MF#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`*(.^4C&`P``E`T``!@`
M``!X;"]W;W)K<VAE971S+W-H965T,2YX;6R4E]%NHS@4AN]7VG=`W$_`)"%M
M%#(J5-T=:5<:S>[,7#O@)%8!L[;3M&^_QYB`;9H.N4D"_/SG\_$YMK/Y_%J5
MW@OA@K(Z\=$L]#U2YZR@]2'QO__[].G.]X3$=8%+5I/$?R/"_[S]_;?-F?%G
M<21$>N!0B\0_2MFL@T#D1U)A,6,-J>')GO$*2[CDAT`TG."B?:DJ@R@,XZ#"
MM/:UPYI/\6#[/<W)(\M/%:FE-N&DQ!+XQ9$VXN)6Y5/L*LR?3\VGG%4-6.QH
M2>5;:^I[5;[^<J@9Q[L2QOV*%CB_>+<7(_N*YIP)MI<SL`LTZ'C,]\%]`$[;
M34%A!"KM'B?[Q']`ZPS%?K#=M`GZ0<E9&+\]<63G/S@M_J(U@6S#/$F\^X>4
M))>D@)GS/34C.\:>U:M?X%8(040K4$'$?Y<P#Y&*$O1AS-^7D$_MM'WE7D'V
M^%3*;^S\)Z&'HX1(2TB#RL:Z>'LD(H=I@%BS:*E<<U:"!7QZ%57U!&G$KYJ.
M%O*8^/-XMER%<P1R;T>$?*+*TO?RDY"L^JE%J+/2)E%G`M]G_3P*9XMHN;J[
MQ67>N<!WYX+`\&.$0`^GS=0CEGB[X>SL09T"L&BPJGJT!L/WTP%Y4-H')4[\
M%4Q8X@N8DY=MN`E>(.MYITBU`CY[!;(5V46A)@X8>A`8PG00)58@:IX46:IO
MF'$C)^Y8,>\5%@ADP011A3*'&OTX,^HET!GC7O3NFE`K%H9B:2NRCQ06(9B8
MA!^3*7'BP^C[&8GMN*E6F&0K6Y&-%0.[10:M,)U,B6VR.SMNJA4FV;VMR,:*
M*V3Q+61*;),AM]"UQ$1#;J6/)5?8H*',K$VK./62P^B4?*HE)N,`T!9EIA7+
MMI7G:!ZC>!X/*;:F5NV>DQ<*)7;@AF[3_:`E)AQR6B8;2P9^B^W^%C8E=M@&
M6\VF)1:;TS396#*86&P(UH[IB6O5#IW3C6FGL?"<SLG>T5SC4PORY(E%>ODV
MEQ,T%(S.7J<Q^2*G?;)W--?XU,(]G4\O\R9?Y/1EJG9+J`"+SVF=[!W--3ZU
M;$_GTXN\Q>=V!AIO!./\C377^&"<-_`IM5U_D=.6*=*:N%TU%FBY<`HTZP1F
M@J_!W;1AJ/.:"S<8=\4WWA$BMW<[GRE\-VT;<.@=\3FY23N-&3L:->^O=PY]
MYM4GN8KP`\E(60HO9R=UAD4P-?W=_E#>G9;[!W"\;?"!_(WY@=;"*\D>7@UG
M*\@@UP=D?2%9TYX3=TS"P;;]>81_/P3.7>$,Q'O&Y.5"G>KZ_U/;_P$``/__
M`P!02P,$%``&``@````A`#!,9Y<C`P``/PH``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3DN>&ULE%9=;YLP%'V?M/]@^;U\AJ2)DE1-JFZ55FF:]O'L@`E6
M`2/;:=I_OVL<&#BKF[XD@(\/YYYC<[V\>:E*]$R%9+Q>X=`+,*)URC-6[U?X
MU\_[JVN,I")U1DI>TQ5^I1+?K#]_6AZY>)(%I0H!0RU7N%"J6?B^3`M:$>GQ
MAM8PDG-1$06W8N_+1E"2M9.JTH^"8.I7A-78,"S$)1P\SUE*[WAZJ&BM#(F@
M)5&@7Q:LD1U;E5Y"5Q'Q=&BN4EXU0+%C)5.O+2E&5;IXV-=<D%T)=;^$$Y)V
MW.W-&7W%4L$ESY4'=+X1>E[SW)_[P+1>9@PJT+8C0?,5O@T7VS#$_GK9&O2;
MT:,<7"-9\.,7P;)OK*;@-N2D$]AQ_J2A#YE^!)/]L]GW;0+?!<IH3@ZE^L&/
M7RG;%PKB3J`B7=@B>[VC,@5'@<:+$LV4\A($P"^JF%X:X`AY:?^/+%/%"L=3
M+YD%<0APM*-2W3--B5%ZD(I7?PRHK:@GB4XD,:@_C4=>=)V$R?1]%M\H:@N\
M(XJLEX(?$:P:>*=LB%Z#X0*8N\J,CK[6MTJ%&C7)K69IN:`*"?D\KZ,H6OK/
MX&EZPFP,9H91CPG'B&V'T%&`O%XC5&YKC"'#_[O?2=*3QI+B8/R^S3G$TKP]
M1R3_2$8:P;NA1K<V#5YA(.^MB*+8$F<PDP$F&2.V+L1(&Y`,M>F,)V^NWLX_
M/0G6Z>#]4309*]@8C$NC"S'2"'J&&MW^:;#MG^7.QF"2=C'"-HOG=K9#P'0V
MG[P1[/0CPC38%C:U3#,8EVDNQ,@TV$Q#TRX+5D]Z+UB#<6ET(48:=0\<?&#<
MP6JP[9\=K,&88&?S>#8;^[L=CE]/AN,C7?./Z-)@6Y?UWHW!N#QS(4;:0OBZ
M#4V[+-AVUGO)GD`NF4[(6*?5/=SA0H<^=]%.]P3J]FT\3RR?=:/7-"=$"%O7
MWKFFCYLV5U&QIUM:EA*E_*![=`B?A/ZI.3]L]/FA/0'T`]"^&[*GCT3L62U1
M27.8&G@S^&H(<P`P-XHW;9?9<06-N[TLX*!&H2L&'H!SSE5WH_M:?_1;_P4`
M`/__`P!02P,$%``&``@````A`/V`!P&J!0``D!8``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3<N>&ULK)A9D[(X%(;OIVK^`\7])X+B0JE?M2)NN-8LUS1&
MI5J(!?3R_?LY(1`AA['LFKGIQH>3-\EYLY'!SZ_PJGR0.`EH-%3U1E-52.33
M8Q"=A^J??S@_>JJ2I%YT]*XT(D/U%TG4GZ/??QM\TO@MN1"2*J`0)4/UDJ8W
M2],2_T)"+VG0&XG@S8G&H9?"S_BL);>8>,>L4'C5C&:SHX5>$*E<P8J?T:"G
M4^`3F_KO(8E2+A*3JY="^Y-+<$L*M=!_1B[TXK?WVP^?AC>0>`VN0?HK$U65
MT+<6YXC&WNL5^OVEMSV_T,Y^(/DP\&.:T%/:`#F--Q3WN:_U-5`:#8X!]("E
M78G)::B^Z-:AKVJC09:?OP+RF92>E>1"/V=Q<'2#B$"RP29FP"NE;RQT<60(
M"FNHM),9L(N5(SEY[]?T0#_G)#A?4G#;A`ZQ?EG'7S9)?$@HR#0,DRGY]`H-
M@+]*&+"1`0GQOH:J`14'Q_0R5%N=AMEMMG0(5UY)DCH!DU05_SU):?@W#])S
M*2[2SD7@?RYB-(R>J9L=)O*@(+S-:H?_>4&]T3/-=J?7?5P01F]6$/[7%'RR
MV?U<!/[G(JUO=UV'Q&4M80_?Z[S>*HK"0TTO'N1-[Q1%X:&FZ),)T+N%##R(
MQK<-L]O[COUZX09[$*UY<A!I?$!FX]OV4F\TB.FG`FL&#+GDYK$52+>8<#&R
M>5K$6/^WH0YCG*F\,)FA"OV#49S`]/P8&<W60/N`.>7G,6,<HU<C)D4$FT!,
MUI;!5`:.#&8RF,M@(8.E#%8R<&6PEL%&!EL9[&2PE\&A!#2P1W@$8_[_\(C)
M,(^*[(X+4#)-,J2(*(K8,IC*P)'!3`9S&2QDL)3!2@:N#-8RV,A@*X.=#/8R
M.)1`Q1!829`A+=A4ZK>#8HZP4K#PE^:(;AK5A(]YC`$344PDLQHR$2'"%$2F
MB#B(S!"9([)`9(G("A$7D34B&T2VB.P0V2-R*).*1[!+(H_8EOW-A8W)P-H(
MU0A#C&:[:LF8!SUT380(UQ"9(N(@,D-DCL@"D24B*T1<1-:(;!#9(K)#9(_(
MH4PJKH%!%=<>SR@6G9E3)'7,2:LG%KD)(C8G!NSIPE+=D+:BJ0@JI!U$9HC,
M$5D@LN2DU,05(JXH56ZBM)^N15#1Q`TB6T1VB.P1.7#"FUBQ!W)6L8>?%AKL
M&)E>`O]M3"&EL(W5V-:"4P$_*S"1JFN<E%(R0<3FQ"@?,71#6CZG(JA(B8/(
M#)$Y(@M$EIR4FKA"Q!6ERJY)35R+H**)&T2VB.P0V2-RX*3&-<C9?W>-B51=
MRTG[/M<0L3EI]?,CH2Z-X:EX7V3#01HS1.:B%#]HZE*.%^)]H;I$&BM$7%$J
M5Y7:NA;O"]4-TM@BLA.EZMNZ%^\+U4-9HS+[X%10\;%FEL&78#'-6'35,$[,
M\EZFF_+Q(B]V/R;:.;FOJ5,4XW!B9%_1V2R?H9@YTEF@F"726:$8%^FL4<P&
MZ6Q1S`[I[%',H:Q3\0*^9BM>L)4P6YR>7@:90M4?3@Q8/^\;D]FKGC4F>9`A
M9IW-2:MBJR'9.LV#8(TH:?>KVDZNS6\PV`?8#-4V?Z:VA:B-#7K=D/JP1/6L
M4#WN,_6L13T/>K5!M6U1;;MG:MO7U=9I5G,(MU#,5G8C<T]T^WZZX(.(7S3Q
M#_&0Q&<R(==KHOCTG5TBZ6RY%%A<<+UDGDM\#!=?V361S`T+/E]@39%YRX(S
M,^8O;>LENT"3X]L6G-9PO&M:<'"HX1T+MB;,#Z8%&Q3F=M>"30#S>=>"91QS
MMVO!0HSYKFO!4HKYV+3&=?5.3`L.&3C>-BTXL]7PC@6G`LR7I@5G`\Q7I@4G
M!.":2"A<"-Z\,UE[\3F($N5*3N!U,SL\Q?Q*D?](Z0W&`%P+TA2N`K/'"]S\
M$IB/S0:,JQ.E:?&#52#NDD?_````__\#`%!+`P04``8`"````"$`R[C:=/H-
M``"'1P``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*R<67/B2!+'WS=B
MOP/!^QC$84#1[HE&]XE0S.X^TQBWB3;&`?3TS+??+)52I:J_!IO9G8>A_:NL
MS%)E91VIX].O?QQ>>K_O3N?]\?6A;]T-^[W=Z_;XN'_]]M#_UV_^+_-^[WS9
MO#YN7HZONX?^G[MS_]?/__S'IY_'T_?S\VYWZ9&&U_-#__ER>;,'@_/V>7?8
MG.^.;[M7*GDZG@Z;"_UY^C8XOYUVF\>JTN%E,!H.[P>'S?ZU+S78IX_H.#X]
M[;<[][C]<=B]7J22T^YE<Z'VGY_W;V?6=MA^1-UA<_K^X^V7[?'P1BJ^[E_V
MES\KI?W>86M'WUZ/I\W7%[KN/ZS)9LNZJS]`_6&_/1W/QZ?+':D;R(;B-2\&
MBP%I^OSI<4]7(+J]=]H]/?2_6'8YGO4'GS]5'?3O_>[GN?7OWOGY^#,X[1_3
M_>N.>IO\)#SP]7C\+D2C1X&H\@!J^Y4'BE/O<?>T^?%R*8\_P]W^V_.%W#VE
M*Q(79C_^Z>[.6^I14G,WF@I-V^,+-8#^WSOLQ="@'MG\\=`?D>']X^7YH3^^
MOYO.AF.+Q'M?=^>+OQ<J^[WMC_/E>/B/%+)J55+)N%9"OZQDHI1<J3BI*])O
M7?'^;F8-%^,9&;]2CTJK5M-O74^T]DJ%^[H"_=85IG?SZ71R/W_'TJRN2+^W
M71H%6-5$^KWITA9U/?JMZUGSN]%\:DWOW[E&BP9/9=(B;]W66(O<+ZNJ<?`Q
M3UCL>_&/6QO,[A<#]L8&LT,MY=$/-I@]:BF7?KB'V:F6\NKXZD@?R'"KHM?=
M7#:?/YV./WLT)9*+SF\;,<%:MM#&<2O'<!/)?Q7(%,%"RQ>AYJ%/5T(Q>J;9
MY_?/EG7_:?`[S1C;6F;9(:-+."PAI@>AUC6!9P+?!($)0A-$)HA-D)@@-4%F
M@MP$*Q,4)EB;H&R!`;FG\1'%PO_#1T*-\!'W[I*!<MK(<`A+<!77!)X)?!,$
M)@A-$)D@-D%B@M0$F0ER$ZQ,4)A@;8*R!32'T!0##IG0W-&]V'&,B%JTK&DQ
M,M,[?"EE1A2(32!-=1&G$6F<`L0#X@,)@(1`(B`QD`1("B0#D@-9`2F`K(&4
M;:+YB.9T\)&8WV^<V(0:FAO)3.,0RYKK+EE*H:M>:T0:KP'Q@/A``B`AD`A(
M#"0!D@+)@.1`5D`*(&L@99MH7B,':5Z['E%"NG(.=^I2DA%M6EKN6NCN<AHA
MKN8"\8#X0`(@(9`(2`PD`9("R8#D0%9`"B!K(&6;:+Z@'<T-OA#2NB\DH:C@
M;G:`N$`\(#Z0`$@()`(2`TF`I$`R(#F0%9`"R!I(V29:Q],VZH:.%])ZQTLR
MIFVX"H+1T`B"1HB]XP+Q@/A``B`AD`A(#"0!D@+)@.1`5D`*(&L@99MHOJ"5
M^`9?"&G=%Y*T@P"("\0#X@,)@(1`(B`QD`1("B0#D@-9`2F`K(&4;:)U/$WA
M-W2\D-8[7A*9\J@.$TY-U'SD2C*B0&P%BJ4'BM<(<:#X0`(@(9`(2"S)6#4H
M`9(VM=I-'.M-S!HA;F(.9`6D`+(&4DHBFZBY1QSR-?_(@^.=2&-<GO?;[\LC
M]2F=:#I6\#$=$.MCH]"B^ZU23-MD=4YQ&*F.<FLTHKAMN<XXOGA*BCO&1Q0@
M"A%%B.(:M1V(*%45KS0U4U+<U!S1"E&!:(VHK%&7(\6I$S,`MSI2GEUIG\S-
M7XKLC_#MI$$.(K=&XT65-!@-+6-L>TJ`-?NH)D`4JHHB'4&:C=$1*0'6'*.:
M!%&J*M::C39G2H`UYZAFA:A0%;O;O%8"K+G4U.@Q*LZO;==VQ"+E\II@E,==
MS8<UDAE;D9)Q1(I.N%4A%Y&'R$<4(`H118AB1`FB%%&&*$>T0E0@6B,J-:3[
M0AQ4;_"%/-=JOJB1OEI-]*7`$2=5X9[V7`G(0RD?48`H1!0ABA$EB%)$&:(<
MT0I1@6B-J-20[AYQ(KW!/?(`2_HX#)<TSXF.']&LUZQ(4V,OX;#0J*GG,B(G
M-?7HGH?N5H^E1M4T.9T8;O>Y7$5EP$C9"AE=M16QE+0U7A@YJIC+E:V$D;*5
M,KIJ*V.I275=UG!NI%9R%E#&5HR4L8+156-KEF)C]X9[2A:HC.GC0YR2V^/C
M[VUWY%E;&S8U:D?UU%BI')&W$D&M]D1NC<;R!IB8F3U&M=^FYNCS:X%1=2>O
MVH`%J#ED-4ISQ$AJMJ9S8\&+47."FE-6HS1GC*3FV6AB#/P<-:]0<\%JE.8U
M(ZEY-#.7_U+3K#M;G,S_=V<++>2T]APAD39'6"/C/HDC;B6)F42-;[=&XZOC
MVV,I.;XGPX71F3YK5L$4,%+&0E9SU5C$4G4P+>9&@B%FS<I8PD@92UG-56,9
M2TEC\_'8&(`Y:U;&5HR4L8+57#6V9BEI;#R;&<9*UMPQ38@\PK61\]OQC89$
MYZFHO1.3Z0AMZ-09"G6!CKAQ2.-DK)"+R$/D(PH0A8@B1#&B!%&**$.4(UHA
M*A"M$94:TJ-;I!Q,'U4'R8\?6V760O-/G<AH+__6R%@Z'7&'U0QMB=X+[5KJ
MOEHGAW=#8^GR6;,:#`$C%0!AC:X;BUCJKXS%K%D92Q@I8RFKN1IM&4LUQHQH
MRUFS,K9BI(P5K.:JL35+-<:,E;9DS94Q?=B(5(@Y;*RI.B=_,+1E1D4;.G7:
M16W9'0N0B\A#Y",*$(6((D0QH@11BBA#E"-:(2H0K1&5&M)\1#L;W4?7#[R5
MN+Y"U\C(G1N;4D=)\?;?1>0A\A$%B$)$$:(848(H190ARA&M$!6(UHA*#>GN
M$1FA=@B]XQXA;KA'HG8Z76RFQ)2JHL=%Y"'R$06(0D01HAA1@BA%E"'*$:T0
M%8C6B$H-Z;ZX+3=$FU'PA41&J)CW6NN*)*5"I:G(R$,I'U&`*$04(8H1)8A2
M1!FB'-$*48%HC:C4D.X>6L=N"14A;H2*1*VX<$:`7$0>(A]1@"A$%"&*$26(
M4D09HAS1"E&!:(VHU)#NB]MR0R/,#=6('A'B$>\@<AG1\4]E@L;&L<I34JS+
M9Z34!XA"1KIZ8Q\9*2E6'S-2ZA-$*2-=O;&9RY04J\\9X9:+3D0W!0%F5RH-
M#WVMXZ54"[DL==^XQT/D,U+=$"`*%6H[T=AF1DJ*NR%&E"!*&>F];&0#,R7%
MZG-&';U,NFZ9:H2X,=5(U.I21]Q3):D6<AFU>[F64LAGJ78O@ZZ0I=2B'R&*
M&2E=":)4H;;'C-1)IJ14E[;;I<\8[Z4!/G1S5)Q)S9Z6J-6M3BW50BXCE2[T
M$/F,5.\$B$)&BR8V(D0Q(Z4K0936:*H]F#(VTE^9DE(]W;YLO:?%N?B&+:4\
M1K=/7[1`5KVLFNX@<A%YB'Q$`:(0480H1I0@2A%EB'(-Z?UGGFK?V9+CZ54\
M:R=&*05#:]4R$Q\LI8:DRTC%L,=(W@R>WT]FQLG+KR7HC,&#(^!*2G7(B%RK
MVF3>4XE8:E;G5";&+!VCL:1&$V4_937J.C)&4O/\SEIH_QF+8J[9T=PC-M<W
M#.]*7)^;:R0.`JHKQD:W.BRE$BHN(Y6^]AC)Q.CL?C8V9DF?)50P!8R4ZI`1
M;4=5F\`]+"43^,,[8Y&+N5S92A@I6RFB#%&N(=T#XGCY\0F&[L>8<S8C/4#,
M<Q)+J5'L,E(#RV-$\Z'JN8FQ1?1K*7$0;TD9.[U`Z>)0"AE=CQN6XK@Q;V#$
MRCYK3E0=1BFB#%&N(=TSY@GV;]V2&^/!MD9ZR)B3@\-2:JRY-9JHNU`>([+2
M<H4Q`?BLB[:F+2EPF&PJ'1JY#T.N^$XD-17%4R442<;L'+.:=B@U==A8RE+*
M?H8HUY#N,''\;(?2WW.8/,2VEW"1SH8ER+Q%[K!4.\)DQ4E[CJM1?5MK-!TO
MC&7!KQ6UUR#4'3)Z)Y;JIG,LP20GRUNVDEIQ>PE2MMA9&:-Z"=(?)\CK4JE6
M=Y)YV#6=]+$T]Q@/P36BO0@WTD'D(O(0^8@"1"&B"%&,*$&4(LH0Y8A6B`I$
M:T2EAG0?W78NIAN$L"9)--6G)6,U=^J*),4><Q%YB'Q$`:(0480H1I0@2A%E
MB')$*T0%HC6B4D.Z>\2YL#W/7=]3C^4Q4IO0)-)"!9!;5VQ)>8A\1`&B$%&$
M*$:4($H198AR1"M$!:(UHE)#NB_$R;'M"S&=C:9W-/YO?!&,'DB&*))(;!Y;
MR[9QGG7JBB2EHJBIR,A#*1]1@"A$%"&*$26(4D09HAS1"E&!:(U(?))`]*KL
M'.DY^8D!^9+R87?ZMG-V+R_GWO;X0WP^8#*GTUJ#Y;<-EN,)?=R@>LX82J94
M4FUKH.2>2JK$$Y3,J*3:)9@E<[NL5B^36PM;W)4D9YHEHZ$M;HAUE=`'&6B+
MV54RHI)JS@5M8RJI-BM&"251[9P2)ZB-OOOPI5,7F>^V3B8Z]"S)=)?E+Q/[
M2W=GD4\Z74(>Z70(^:/3'>2-K@NCM+0M\DYXR92=MD7Z"4LH26V+%'17R91*
MNMI%^4$JZ6H9Y;.HI,O.DNPL.TLH[V^+E!VV@-+_MDC380GE]VV1K<,22O/;
M(FF')93MMT4NOZMD2B5=5TI952KINE+*`E))EYUT8:^[!CZ]]6"+]Q#0?BEB
MI:N`7@6PQ=/^6(4>Y;?%T_I80H_BV^)I>RRA1^FI`5TERX6][&R`L[#%JR:H
MRUW8]/9.!Z>+%.^%8$F\L,7;(5B0+.Q$%@R:$*;/H+QMONVRS>G;_O7<>]D]
MT3PWK!XL.<D/J<@_+O6S8U^/%_H`"J5YZ&L-],&;'3W[.10+VM/Q>.$_R/*@
M^83.Y_\"``#__P,`4$L#!!0`!@`(````(0"*L>%ZDP4``(\5```8````>&PO
M=V]R:W-H965T<R]S:&5E=#@N>&ULK)A;;[,X$(;O5]K_@+C_0B"G!B7YU(2S
M=J75:@_7E#@):H@CH*=_OS,8`_9DHU;J3=,\&;\P[]AX\.KG>W$V7EE9Y?RR
M-NW1V#38)>/[_')<FW__%?QX,(VJ3B_[],PO;&U^L,K\N?GUE]4;+Y^K$V.U
M`0J7:FV>ZOKJ6E:5G5B15B-^91?XY<#+(JWA:WFTJFO)TGTSJ#A;SG@\MXHT
MOYA"P2T_H\$/ASQC'L]>"G:IA4C)SFD-]U^=\FLEU8KL,W)%6CZ_7']DO+B"
MQ%-^SNN/1M0TBLR-CQ=>ID]GR/O=GJ:9U&Z^$/DBSTI>\4,]`CE+W"C->6DM
M+5#:K/8Y9("V&R4[K,U'VTWLF6EM5HU!_^3LK1K\;U0G_A:6^?ZW_,+`;:@3
M5N")\V<,C?>(8+!%1@=-!?XHC3T[I"_G^D_^%K'\>*JAW#/("!-S]Q\>JS)P
M%&1&3G,;&3_##<!?H\AQ:H`CZ7OS^9;OZ]/:=!Y&"WN\G"Q`Y8E5=9"CI&ED
M+U7-BW]%D(TWU8DXK0A\MB*3^6BV&$]LN.9G12:MR+03L9>]R)VKPR6:%."S
MO;H-&G<&S-L!L`;D@,]=:=D.A$\Y\/Z5;*BGL!<+VUIW]UJ6J$]3;B^MT\VJ
MY&\&K"&H0'5-<47:+LK*0HL\N]+_7^6A6JCRB#)K<V$:4-0*INOKQAXO5M8K
M3+&LC=G>B%$C=C(")P'*>CKP=1#H(-1!I(-8!\D`6&!+YPW,N^_P!F70&YG5
M5H+>+$<S0D;((9X.?!T$.@AU$.D@UD$R`(H1L(:^PPB469OP=S!)'M3,MR+&
M@374!<W4D%T7TKE#B$](0$A(2$1(3$@R)(I)L&2_PR24@<4(E^D,@,>F:L%6
M!-UUJ0OI7"+$)R0@)"0D(B0F)!D2Q25XFBHNW=Y0Y&,%HQLS9!);01QX5/;V
MV&/5GET7)(=YA/B$!(2$A$2$Q(0D0Z+D#AO$%W+':#5W0:#J,JT=(1XA/B$!
M(2$A$2$Q(<F0*(G"/J`DBIN*,QN!,5_<5E!(]4"0">Q4@_K;6OV[(&F41XA/
M2$!(2$A$2$Q(,B2*+=@<#_?:^W,?H]7<!1G6GQ"/$)^0@)"0D(B0F)!D2)1$
M875^(5&,5A-MR;2?Z(1X@C@P!P<30=M'_2Y(3H2`D)"0B)"8D$00Z`A!6<D=
MFR@E>=%1C;#OK4]Y]KSE<,/0<MRH_@0ZI[:?0A75E$88T,`5BKP6.8NF"7/&
M]D1=&WX?T'E"94**HGX@MG>@K)D=]P%2.5%D5)NPZ?K\8K!%CP;;HM3>2B1>
M/[!=W%'D4>13%%`44A11%%.4*$C-&?NK+^0LVC$EYQ:ILUXK\<YNH_J6TY.H
MWSM\B9:B77=FDZ56T:`-<9IWQ69BAG)4KQU)U&O'$@GM^6(YU;;H1)%67<(.
MZPLNB89,<:GMT6#.#)X-4W4A[+#%@B7F.-V4\B3J9YDOT;1Q:0'OK]IK32`C
M^GD82M1+1Q+UTK%$0OIA2J03&=%(JR9A@S4TJ=EBY_@R?NO!`KA[LHC6#*3[
ME=0B=5;I;3>^_>(CJ:^\)U%?>5\B.:LFRQDQ3`@ILXIH1U*HUXXE:K5MF%=D
M6@VU5<>P+1LZ=N/Y.[0)P[4'L$##_1>/1'`.]3?I4>13%%`44A11%%.$YT#]
M38B<Q;F.>-$O6'ED.W8^5T;&7_#,!GS<K#HL#I2V<Q?Z.9@2.E^XT-#<X`\N
M[/\WN#V3)U.:DK=T81^E(V#+<G%7HK_`EN/BKD)_@>.OQV9Q:=?8XK'8C?BM
MX\+++=793EQXH:/\<>H^@JWTA^W4A7>;&QRR%JNTNR,X#KNF1_9[6A[S2V6<
MV0&L'S=]0"D.U,27FE^A)'">Q6LX"&O^/<'!)X,-;8PM\X'S6GZ!"UO=4>KF
M/P```/__`P!02P,$%``&``@````A`'K5:JZ1`@``B08``!@```!X;"]W;W)K
M<VAE971S+W-H965T-RYX;6R455MOFS`4?I^T_V#YO1AR+PJITE7=*JW2-.WR
M[)@#6,$8V4[3_OL=XX2299?T!>/#Y^\[5[.\>58U>0)CI6XRFD0Q)=`(G<NF
MS.CW;_=7"TJLXTW.:]U`1E_`TIO5^W?+O39;6P$X@@R-S6CE7)LR9D4%BMM(
MM]#@ET(;Q1UN3<EL:X#GW2%5LU$<SYCBLJ&!(367<.BBD`+NM-@I:%P@,5!S
MA_[;2K;VR*;$)72*F^VNO1):M4BQD;5T+QTI)4JD#V6C#=_4&/=S,N'BR-UM
MSNB5%$9;7;@(Z5AP]#SF:W;-D&FUS"5&X--.#!0972?I[9RRU;++SP\)>SMX
M)[;2^X]&YI]E`YAL+),OP$;KK8<^Y-Z$A]G9Z?NN`%\,R:'@N]I]U?M/(,O*
M8;6G&)"/*\U?[L`*3"C21*.I9Q*Z1@?P293TG8$)X<_=NI>YJS(Z3J+%=#J9
M+>9(LP'K[J7GI$3LK-/J9T`E!Z[`,CJPX'IDF473>3Q.4/0_)"QXU`5XQQU?
M+8W>$VP:E+0M]RV8I$C\YX@P%(]=>W!&YY2@KQ:K\+1*XM&2/6'JQ`%S&S#X
M?,7T"(:BO3*J7:[LP5[9Y]:[<AL,0YE71TYDQF^1\6`LSM#Y>-R['Y0#9C+`
M3'O$B3)"+@_0@[$&I]*3GCA(!]`%TM@/ETM[<"?=)_=@P3EY+6+\ERAG;Y'R
MX%.I8)ETXS?L#FRR801^XL;)=82>_;M%_;E3A8-EV"I)/.LS&TH61C],A@)3
MP@>H:TN$WOFQ'F&O]];^QEF/O->_VR?INFM3UG_`FZ#E)3QR4\K&DAH*I(PC
M/_DFW"5AXW2+GN,D:X=70/=:X94/V.ZQ#[S0VATW*,SZG\CJ%P```/__`P!0
M2P,$%``&``@````A`+0C4@1[`@``0`8``!@```!X;"]W;W)K<VAE971S+W-H
M965T-BYX;6R45%UOFS`4?9^T_V#YO3'0?#0H4*6+LE7:I&G:Q[-C+F`58V0[
M3?OO=XU;1MI*HR\(+L?GW(]SO;E^4`VY!V.E;C,:SR)*H!6ZD&V5T5\_]Q=7
ME%C'VX(WNH6,/H*EU_G'#YN3-G>V!G`$&5J;T=JY+F7,BAH4MS/=08M_2FT4
M=_AI*F8[`[SH#ZF&)5&T9(K+E@:&U$SAT&4I!>RT."IH72`QT'"'^=M:=O:9
M38DI=(J;NV-W(;3JD.(@&^D>>U)*E$AOJU8;?FBP[H=XSL4S=__QBEY)8;35
MI9LA'0N)OJYYS=8,F?)-(;$"WW9BH,SH-DYO5I3EF[X_OR6<[.B=V%J?/AM9
M?)4M8+-Q3'X`!ZWO//2V\"$\S%Z=WO<#^&Y(`24_-NZ'/GT!6=4.I[W`@GQ=
M:?&X`RNPH4@S2Q:>2>@&$\`G4=([`QO"'S*:H+`L7)W1R^5LL8HN8X23`UBW
MEYZ2$G&T3JL_`13W206N/K4==SS?&'TB.&Y$VXY[\\0I$K^="R;AL5L/SNB*
M$I2QV+_[?+W:L'NL63Q!;@($GP,D'A`,-0=A%)LN[,%>V#?%9W(3`F.9Y&V9
MR_?(>#!V=93\^FJ@#<(!,A]!%@/BK#Z$3*_/@W$"9\KK@3<H!\P$933#=&4/
M[I6'UCY%T-[_1AA%0S)G12[?(^7!YU(A,N\-.O8&.FQ<0;\H2_3Z__SISYTK
M/$7&1HFCEXX,&QO60H&IX!,TC25"'_TV)FCT(3I<%-O$9_TR/D^WO4G9\`,7
MN.,5?..FDJTE#91(&<U66(L)5T#X<+K#S'&-M</5[5]KO*D!S1[YPDNMW?,'
M"K/A[L__`@``__\#`%!+`P04``8`"````"$`&]^,[2\$``#G$```&````'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;)Q8VXZC1A!]CY1_0+ROH1O?97LUD]$D
M*V6E*$IVGWN@;:,!&M'M\<S?IZH;,,W%`WFQ3+DX5:<N!]J[K^]IXKSQ0L8B
MV[MDYKL.ST(1Q=EI[_[[S_.7M>M(Q;*()2+C>_>#2_?KX==?=E=1O,HSY\H!
MA$SNW;-2^=;S9'CF*9,SD?,,?CF*(F4*+HN3)_."LTC?E"8>]?VEE[(X<PW"
MMAB#(8['..1/(KRD/%,&I.`)4Y"_/,>YK-#2<`Q<RHK72_XE%&D.$"]Q$JL/
M#>HZ:;C]=LI$P5X2X/U.YBRLL/5%!SZ-PT)(<50S@/-,HEW.&V_C`=)A%\7`
M`,ON%/RX=Q_(]C$(7.^PTP7Z$?.K;'QWY%E<?R_BZ,\XXU!MZ!-VX$6(5W3]
M%J$);O8Z=S_K#OQ5.!$_LDNB_A;7/WA\.BMH]P(8(;%M]/'$90@5!9@972!2
M*!)(`#Z=-,;1@(JP][U+(7`<J?/>#9:SQ<H/"+@[+URJYQ@A72>\2"72G\:)
MZ*0,ED[MB2EVV!7BZD"_P5OF#*>';`&XRLD@U%D.)0G9(<@#HNS=E>M`?`F5
M?3NL-COO#8H1EBZ/Q@4^:Q=2>WB03)T19-',J+\Z56!TQL!8+<SDT1B:86A_
MF&!*&'2&<C>27_LUK`EL7.8-ET7M8?$#E_'\T!E:8T6^U<U$-CXC(L.4-"-C
MK^D29VU@!*LBXWTZB;K*I056H.[F>J#.2SOH_7:BLQW)6.9ZAIM3`K/6YD+F
MT/;[^'B7C5]:F@.S#OH;ASK<6)7[D=#9CF0L728;&Q:[$@1T1%OP1CM$:;'(
MS/O)$.C=>#;:VXY5FKI\"(1O(FM)V<!>WB^8OJT5`I'`9/$9V"HR23:T=RN8
M48X>/KC9C;XCGP69K3Y=&]S:5H,J$\2Z+<YRH$.3A(+42E$O:6GJ883KVV)$
M%L$82ETIP"=8ITFK`4J3Q(!TU:`T]5#Z?WI`NH)0F:RA6P_PF20)I*L)I:F'
M3X\JS/WUF!9U98'TZ<+M^6P]G>@D7=#>]AZ5IBXEVM*%^W*@O5O(I1PTGSJ;
MVV/8IC%)#JC9?=C.>GE*4P^-'CD(UL$(O:9=/:A,S6';W)[O-J5)>D"[>E":
M>BCUZ8%/1PP;OCNT)*XR690&W@WH)#W0WJV1&'H]H"T]^&38NC*@`2"8-6P#
M+P9TD@QH[Q:-H7<#VB,#E*QF4/9/&'550&-!7*LQ`V\'P205T-XVH]+4G;4`
ME[CQ[+E/0WNWD!$`3%9C!EX*@DDJH+U;P8PP]-#H40$R:F7@A-E>F<ID=:;]
M5F".E>;LEO+BQ'_C22*=4%SPR$CAT%5;Z^/L`T5!:]OGVP=SS/7J7^"8F;,3
M_\Z*4YQ))^%'P/2U`!3FH&HNE,BA0'#8%`H.F/KK&?Y0X'#R\G$HCT*HZ@(B
M>_5?%(?_````__\#`%!+`P04``8`"````"$`JIH=(\T$``"R%```&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6R<F%V/LC@4Q^\WV>]`N!^!`KX0]<DH
MKV8WV3QY=O<:L2H9H`:8<>;;[RD%QA:7CG,C>OSQ[^'\3X%V^>,]SY0W7%8I
M*5:J,=%5!1<).:3%::7^_<M_FJM*5<?%(<Y(@5?J!Z[4'^O??UM>2?E2G3&N
M%5`HJI5ZKNN+HVE5<L9Y7$W(!1?PSY&4>5S#S_*D59<2QX?FI#S3D*Y/M3Q.
M"Y4I..57-,CQF";8)<EKCHN:B90XBVO(OSJGEZI3RY.OR.5Q^?)Z>4I(?@&)
M?9JE]4<CJBIYXD2G@I3Q/H/K?C>L..FTFQ\#^3Q-2E*18ST!.8TE.KSFA;;0
M0&F]/*1P!;3L2HF/*_79<':&KFKK95.@?U)\K6Z^*]697(,R/?R1%ABJ#3Y1
M!_:$O%`T.M`0G*P-SO8;!_XJE0,^QJ]9_9-<0YR>SC78;<,5T0MS#A\NKA*H
M*,A,D$V5$I)!`O"IY"EM#:A(_-X<K^FA/J]4<SJQ9[II`*[L<57[*954E>2U
MJDG^+X.,5HJ)H%;$A.S;_^V)A>S9_!$5JU6!<3L5<S(S](4Y^WHJTU8$CIT(
MFJ"Y;=C3!RYHUJK`\5/%L/1'-&"&-96%8ZMA@@>/9K)H5>#8JB#[X:)``[8N
MT_YB#J'9EY/16,\T+>C&=;Q>EN2JP+R&KJ@N,;U+&`X=HVL^UBI]._Y?-T(;
M4I5G*K-2H=;0:!5,H;<UTNVE]@9MG[3,AC'P><-,>68[9`R><#N"S@,ZM"<&
M?#$0B(&0!?ALA4RBCNG&V74JM^G/^N0TJ&=?5)A,7%'OS^2N=I2FM>M&VG2!
MVY'F_4C-56^'C*WSB#M$$$]X0\(4RNT/$:0O>)G@#F,(R82,@1I^FB\R$6-L
MJ^D?R]"G@LCNGHC9)\-9`/>Q!RR@-&>!&-B*`5<,>&+`%P.!&`A9@"^*8$!T
MCQ%\W-UCK/MU@3LT5Q<ZWTV8]^,M2L\"CG-/G-Z,@<_>88'82@E72GA2PI<2
M@90(I40D)79C!->J\&3\AB7TK)4*,Z(O-S*$>]B&,9!(SXB62`F7$?-F3CXA
M9,W13->%B>EQD#$W[?D0\J5C!5(BE!*1E-B-$9PQ\`+R#6/H6:(QG\^)YNZ]
M8<R8,5+"E1*>E/"E1,`(F]V2;7!>]#Z4:D128C=&<);`,YNS9/RV16G1"N%!
MNF',F!6,8"4PFPH([>]*-3PIX4N)0$J$C&"9&BS5_BG0-%YT2]R]EMW8*)P5
M=/DIOCE:,+?&+:%GB98([Q,;QHQ9(B5<*>%)"5]*!%(BE!*1E-@Q@MF*T)R?
MA)PGL,08>")_NM.S!$^0T.(;QK`<;/W>C6#+D!';7"GA20E?2@12(I02D938
MC1&<)W15]0U3FM-$5X27PTT+C=1\VR+L`3[5=8OV#W]7<#D&(7LQ?'I['&.;
M-KR=BSH^QQBSQ<P:,$'+C*0<RI%(CM`M&]K6]P=B#K$M&;8>SG%YPEN<9962
MD%>ZW4)+UD?[K:!GDR[4A'AH.+!@',8WR-G<X[?(@17%D'>1`PN+8=Q##JPO
MAG$?.;#,&,8#Y,!J`^):GRCL&%WB$_XS+D]I42D9/L(EZA.Z+U.R/2?VHR:7
M9E=@3VK8*VJ^GF%O$,-26Y\`?"2D[G[0`?K=QO5_````__\#`%!+`P04``8`
M"````"$`V$'=?X`"``!#!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6R45%UOFS`4?9^T_V#YO1@(:5(44J6KNE7:I&G:Q[-C+F`%8V0[3?OO=XU3
M2M9*2U\07([/N1_G>G7]J%KR`,9*W14TB6)*H!.ZE%U=T%\_[RZ6E%C'NY*W
MNH."/H&EU^N/'U8';7:V`7`$&3I;T,:Y/F?,B@84MY'NH<,_E3:*._PT-;.]
M`5X.AU3+TCB^9(K+C@:&W)S#H:M*"KC58J^@<X'$0,L=YF\;V=MG-B7.H5/<
M[/;]A="J1XJM;*5[&D@I42*_KSMM^+;%NA^3C(MG[N'C%;V2PFBK*Q<A'0N)
MOJ[YBETQ9%JO2HD5^+83`U5!-TE^LZ!LO1KZ\UO"P4[>B6WTX;.1Y5?9`38;
MQ^0'L-5ZYZ'WI0_A8?;J]-TP@.^&E%#Q?>M^Z,,7D'7C<-IS+,C7E9=/MV`%
M-A1IHG3NF81N,0%\$B6],[`A_+&@*0K+TC4%G5U&\T4\2Q!.MF#=G?24E(B]
M=5K]":!D2"IP#:G=<L?7*Z,/!,>-:-MS;YXD1^*W<\$D/';CP05=4((R%OOW
ML$ZRQ8H]8-'BB+D)&'R^8$8$0]%1&=7.5_9@K^R[XE.Y"8&I3/JVS.P],AZ,
M;9TDOXQ'VB`<(-D$,A\1)_4AY/SZ/!A',%5.LN5('*0#Z`QIM,/YTAX\2(^]
M/4;0X"\SS*[&9$ZJO'R/E`>?2H5(-EAT:@[TV+2"8572I=^+_UC4'SR5.$:F
M5DGF+U,-U82E#9NAP-3P"=K6$J'W?B%3]/H8'>^*3>K3_C>>Y9O!IFS\@3O<
M\QJ^<5/+SI(6*J2,HP768L(M$#Z<[C%SW&3M<'N'UP8O:T"[QQ&"*ZW=\P<*
ML_'Z7_\%``#__P,`4$L#!!0`!@`(````(0#O+]1A?0,``"D,```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;)16WV^;,!!^G[3_`?'>$),$FBBD2E=U
MJ[1)T[0?SPZ8Q"I@9#M-^]_OSB8$`FG)2Q2.\_?==W<^;GGWFF?."Y.*BR)R
MR6CL.JR(1<*+;>3^^?UX<^LZ2M,BH9DH6.2^,>7>K3Y_6AZ$?%8[QK0#"(6*
MW)W6Y<+S5+QC.54C4;("WJ1"YE3#H]QZJI2,)N90GGG^>!QX.>6%:Q$6<@B&
M2%,>LP<1[W-6:`LB648UQ*]VO%1'M#P>`I=3^;PO;V*1EP"QX1G7;P;4=?)X
M\;0MA*2;#'2_DBF-C]CFH0.?\U@*)5(]`CC/!MK5//?F'B"ME@D'!9AV1[(T
M<M=D<>\3UULM38+^<G90C?^.VHG#5\F3[[Q@D&VH$U9@(\0SNCXE:(+#7N?T
MHZG`3^DD+*7[3/\2AV^,;W<:RCT#12ALD;P],!5#1@%FY,\0*189!`"_3LZQ
M-2`C]#5R?2#FB=Y%[B08S<+QA("[LV%*/W*$=)UXK[3(_UDGH\BS6":T!ZKI
M:BG%P8%Z@[<J*78/60#P,2:+4$=Y*4B(#D'6B!*YH>L`OX+,OJQ(X"^]%\A&
M7/G<6Q_X/?G4'AY$4X<$831#ZD_/D1F=D1G3A:'<6T.3YA1(BV9R#0TZ0[Z;
MP0>3.GS+;'VF#9]9[=%B!I?A`M$9BM.FGM;`EMHZ#:"&1FE28[G]`-OM0A<>
MTXSG3!1UGBL+W()3/8,+@H,VZ_L51><VE;5,S>5J-@KT6T?,;#8*/U2#!]L4
ME:79-B0(ZBRWRH?SN'%EWE>#SFTJ:^FJF;=AS4T,YP-J@P?;%)6EK2;L5T.@
M@L/E&.\V667J"B+`WT0>KLB</&-!,#"U-=U>T'35""'5R)B<ADAEZM&$E[Q1
M?*/)OQU0);S!9V4ZFMJ:YA<T734U2#TVZ@M;F7HTX54^TS2'KGB_L?'+=:ZG
M,K7TA.,+>JX:"J0[%2I3CYZ>N4"F$-0'@KI3@?2-A9!<$'357"#=P5"9>@3U
MC(;)Q!_2=-W90/J&0WCA&^E?-1R,=_O:5J:N)A_J<=YT9-!%,B?/6!#L?#B$
MI^^S'=]V,;/;3\[DEGUA6::<6.QQZ?)A;:FM]4*X]G$HG-NGBS5$`2^\^@TL
M:B7=LA]4;GFAG(RE@#DVWR)I5SW[H$4)@<*Z)C2L:.;O#E9R!JO+>`3W)Q5"
M'Q^0H%[R5_\!``#__P,`4$L#!!0`!@`(````(0!+,1!;&`L``%<R```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*R;6W/J.!*`W[=J_P/%^P`VYN9*
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M+_#</RUGMT?=U2],_?&P/Y7G\O'2`W5].5#^S+/^K`^:[FX>#O`$PNV=4_%X
MV[VWW*T]ZO;O;BH'_?=0_#@W?NZ<G\L?P>GPD!Y>"_`VQ$E$X$M9?A6BT8-`
MT+G/>OM5!-:GSD/QN/OV<MF6/\+B\/1\@7"/X(G$@[D/O[SBO`>/@IJ>',:^
M?($!P/^=XT%,#?#([N=MUP;#AX?+\VUW..Z-)H.A!>*=+\7YXA^$RFYG_^U\
M*8__DT*6&%2MQ%%*X!.5]*:CD3.>3D#)E8[06EF'3]71<GJ6,Q@+XU?ZC54_
M^,1^GQXTK(#*-GPJ'>.>8X\FT^K)KQB?J8[PB<;''WM<"[Q<V10_U$9K;U^Q
M:0VQ)_R`5B?ZF:]U16=936_I\'PPQM8$1P`_J!$XC<>^KJ8OIUTUB[W=97=W
M<RI_="`UP,0ZO^U$HK%<"T*!\U<^4#VC_VI"PR046NZ%FMLNC`SFZAE6X?<[
MR$,W_>^P<O9*9LYE+%-B@1)B;@NU'@5+"GP*`@I""B(*8@H2"E(*,@IR"E84
MK"G84+!M@#Z$IXX13-;_1XR$&A$C].X<02-H)"`H@5T\"I84^!0$%(041!3$
M%"04I!1D%.04K"A84["A8-L`1D`@!["`.)`QVY,^KA'1"])[8XU8UL1T^%S*
MV+`0ZX4T,D46M4@=%$:6C/B,!(R$C$2,Q(PDC*2,9(SDC*P863.R863;)$:,
M8"]D,1(;\R<3FU`#N1',U`&Q!R1OS:70U:C5(G74&%DRXC,2,!(R$C$2,Y(P
MDC*2,9(SLF)DS<B&D6V3&%&#`!E1N[ZBA'05''3J7)*A3G(+1:9UVO,DL6$W
MKD-JV22DRUH(5?N,!(R$C$2,Q)(,]8`21M*Z5W.(0S,19+40#C%G9,7(FI$-
M(UM)Y!"-\(#/C/#(TT)/G#(OSX?]UWD)+H5MK"5L0S@5R+."4&)&39)FU!31
M3O(DL9M'#,NV39<L:R%TB<](P$C(2,1(+$DS:HRD=:]FU,@0LUH(AY@SLF)D
MS<B&D:TD+5$#G_WSJ`DE9M04<>J5M6#$DV0X4T="B\SA9=V.WO"9CH"1L.XE
M#YH6\7%4MZ/6F.E(&$GK7DHK&6M6MZ/6G.E8,;*N>[6/=5.WH]9M4X>Q^N!4
M8,2Q997!O0V7F9`V`Z9(=1NNEN*"$8^1)2,^(P$C(2,1(S$C"2,I(QDC.2,K
M1M:,;!C9-HGA>+AI?L+Q0MITO"*P0!L[CF/FKH42:J0\1I:,^(P$C(2,1(S$
MC"2,I(QDC.2,K!A9,[)A9-LD1BPL*-%\(AB5N!D-A6S8I^IPC,C^OT`AN\YN
M'J+F61!J%688ERAE5REOY)`P^]BN5V&`2-L*$5VU%:&4M#6<D=M$C.W:5H)(
MVTH17;65H913/9<UF$[-!\]10!M;(=+&UHBN&MN@%!H;D_!L4:`R9LX/<8OF
M%8U/GE$L>1>'<S^FY3FBYBH>D9UG@4+Z`.HI-)0E.U'66")2<1O1V><K`;NJ
M/5:I.N":0U2C-4>(I&9K-"6;6,PU)UQSBFJTY@R1U#RQ'3+Q<ZYYQ36O48W6
MO$$D-=L3NIUO#<UFL,4-_9\'6][SC6!+9.0(RQZ;4WXARHB0ZFT]OSV%AE?G
M]Q*EY/QV!C/B3!\UZ\44(-+&0E1SU5B$4FHQS::D,!>C9FTL0:2-I:CFJK$,
MI:2QZ7!()F".FK6Q%2)M;(UJKAK;H)0T-IQ,B+$M:FY)$Z#YZLSYHWR#;:/U
M*M,X9(G"`-GL%1KJ!UQPY'&TY,CG*.`HY"CB*.8HX2CE*.,HYVC%T9JC#4=;
M`YFK6Y0)Z.JN;H`?OFM:LM(`-G0>5\6'YO9OV63K7*B.QM*6'=];VDIJ7.V3
M@QXM%OFH6<^/`)%>`*%"UXU%*/57QF+4K(TEB+2Q%-5<76T92M7&R&K+4;,V
MMD*DC:U1S55C&Y2JC9&==HN:*V/FM!'E"SIMK)$^`7QP:<LJB)B>]3'1'I!A
MS$5)46P!<'>HI4@R7V@9G(0>1TN.?(X"CD*.(HYBCA*.4HXRCG*.5ARM.=IP
MM#60&4=1T&C&\?I]5WR]1E.Q1%":1\<OE%0#>8B:!SMK2#;)I99"73XBK3[@
M*$1DJB<'VDA+H?H8D5:?<)0B,M63I9EI*52?(VI90*("43L>\MD[CE<%BV:.
ME:CAY87X_A+"TT`>HG$=GB5'/B+MAH"C4".]#JTA6:V1ED(WQ!PE'*6(3"^3
MNUVFI5!]CJC%RZ+<\`DOJ^I$T\L2-5RZ$%_A4B\KU/0R0S[O&'`4(M)%BHBC
M&)&.6,)1JE$S8B1W9EI*N[3YC&;&$%6#IDO_5GW:4K6'IJ<E,CS-D*<Z.OKR
MM^3(1Z2]$W`4(IK5:R/B*$:D=24<I0J-H')2[U'6D%QF,BVE/=U\1L/3<#,U
M/7T]153B9A4&D1[Z@B./HR5'/D<!1R%'$4<Q1PE'*4<91[F!3/\958IW4ZRX
MAY*]#9&9D>@Q%J7TE/00Z36\1"3+]-.Q,R'%'5])P`/AY`BPDU8=(H(%JB<:
MK9!%*#51)V2'9.F8&TL4<K3]%-7HY\@02<W3GC4S_I%-,3?LF.$QZ@KOAX<7
M$.#B("(F3&A7#(E;%RBEC\<>(IU]EHCD-7<RG@Q)EO110B^F`)%6'2)JGFA9
M`3-"*5F.&?3()A=CN[:5(-*V4HXRCG(#F1&`01JI_)T$(\1)@E'(7"`S4L*Q
ME92>Q1XB/;&6B.`,HZ/ID".BKZ3$JF](D9->H'7A4@H1O;-NZJ&*KY+@?4*2
MP6-M'S4GJ%D_7LI1QE%N(#,RXH+[CS=96V@A`9/(7#(T.2Q41Y@Y^)">0HZN
M*2X1P2ILA((D`!]UB:^O\;TURV$!4^/2%D/L"!'1'7FBJSO*@#DD.\>HIKF4
MZC[X>"E*:?L91[F!S(`9]V'0_[=.15#T8@%3R%AA]`N/!7;44]!3R&GF.*G+
M445*>S2<D6W!5[V,/4B-0.L.T=P[:ZGNJ$)CIH68VTIPT,TM2&G1F2)#\VH+
M,M7FAEH9)/EFL7PG\UB<GHI%\?)R[NS+;^*M87@GXNZFQO*59KBYN3F<UF""
MD!9XV?F^FB6$S^$EZ&IQ4&[#R]$M>N9#=UO%ALC?.^X]U%VXX;GC;MOXO36"
M$573FZB"P@F,J:T%[KVN.-AR*W#]=<7YEK?`+=@5=]RVE@FT5/.#C``N(-!2
MA8ZUS*"ES<X<[,Q;6Z"PX"Y:6Z"^X(I[`!\;%!!<<1W@+5!'<,6M@+=`.<$5
MQ8*VE@FTM#TI7-N@I>U)X9H!+6UVTI&[:8M..G8W;=:W$,XV[DU<>,FC9;0P
MV#:>0KC:^'KB;MKX?.3.V^PN1NZBC7LC%][)XN/QP*UM\O'(A7=_N'PR<I.*
M]^O)`Z_UO^V>BFQW>CJ\GCLOQ2,LX$%5=CS)/PR0OUS4-PM?R@N\T%]]R?`,
M?\!1P#>#@QYDE,>RO.`O8+A?_TG(W9\```#__P,`4$L#!!0`!@`(````(0#H
ML)HR7P0``#\/```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*R7VXZC
M.!"&[U?:=T#<3SCET*`DHR2$DW:EU6IF]YHF3H(:<(1)I_OMIXRQ@^W,:%KJ
MFT[S4?ZA?A=E>_GUK:Z,5]22$C<KTYG8IH&:`A_*YK0ROW^+OCR9!NGRYI!7
MN$$K\QT1\^OZSS^6-]R^D#-"G0$*#5F9YZZ[!)9%BC.J<S+!%]3`G2-NZ[R#
MR_9DD4N+\D,_J*XLU[;G5IV7C<D4@O9W-/#Q6!8HQ,6U1DW'1%I4Y1V\/SF7
M%\+5ZN)WY.J\?;E>OA2XOH#$<UF5W7LO:AIU$:2G!K?Y<P5YOSG3O.#:_84F
M7Y=%BPD^=A.0L]B+ZCG[EF^!TGIY*"$#:KO1HN/*W#A!YMBFM5[V!OU7HAL9
M_6^0,[[%;7GXJVP0N`WS1&?@&>,7&IH>*(+!EC8ZZF?@G]8XH&-^K;I_\2U!
MY>G<P73/(".:6'!X#Q$IP%&0F;@SJE3@"EX`_AIU24L#',G?5J8+#RX/W7EE
M>O/);&%[#H0;SXAT44DE3:.XD@[7_[,@9Y!B(A#9B\#O(/)Q#7_0@-^/:E@L
MI]ZB,._R];+%-P/J#MZ:7'):Q4X`DV!P<U@JPJZ?N04V494-E5F9"],`(PA,
M\>O:\9^6UBM,2S'$;!_$R!$['D'G@,J&*MBK(%)!K()$!:D*LA&PP!;A#4SX
M9WA#9:@W/*LM!W>S7,4('L&'A"K8JR!20:R"1`6I"K(1D(SP/L<(*@,?S[A(
M;+5(6(P+O5=4TDPQ1X0(=S2RUTBDD5@CB492C61C(IDT_1R3J`Q\C/`888#C
M^[(%6Q;T2Y=$B'!)(WN-1!J)-9)H)-5(-B:22]#_I&_J<1/F;85&]V;P)+8#
MF8JO::>1D!%W/K;043ZQO0CBTI%&8HTD&DDUDC'B]*\HY0XO).7.>NUD`0.Z
M<UF\;#%;1AYXXD%/99V6BLB6#&1DB49"1MQ%WYI=V_'D@MJ+^\(-32/62")&
MT88/JHK'J;C/5;.QAN0-+!V2-P\\@-66FT"C91,&PM9ONG;L-!)J9*^12".Q
M1A*-I!K)QD1*E.XJQPONKQ.ET7*B`P$C[_U!G<[=$'1?<\*!/(GO9C\0GZW6
M[LSSE>F+6(3;[Z[ZXHLUW433327=^<*?VG*M96-9R1K8UWS`&AHM6\.("\OY
MR)JI_/3=$.0*(\*!>(+L!S+MK5GXWF(ABT1#P+W:8DTVT6132?9IJLEF8UG)
M&;HSDZRAK<.=T_WJ3[:Q_$OI1\HV<227D+K*\JA1#7$T*B*.>!5Y_DSU:@@9
MEQ$?===..+IKIQP-V@[4DEI*DC9SC!T#V!ZW1NT)[5!5$:/`5[K%IUJ"LN-'
M.`N@B4.'4OD\@+:H\V0>0&/3.1QC-GU5*3I;>KQY$+]U`]APZ3I;+X!-ALXW
MTV`#^>HWMM,`UEO@EG@R'%\N^0G]G;>GLB%&A8Z0N]VO-"T[`+&+#E^@-N`0
M@SLXN/3_GN&@BJ!_VA.HK2/&';^@#Q!'W_4/````__\#`%!+`P04``8`"```
M`"$`B;N7(7X(``!5*```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RL
MFEU3XS@6AN^W:O]#*O=#XH0$<`%3'>+O;]?L['4(!E*=Q%1LFNY_OT>695EZ
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M3,C3_>W3CIZ`#?OH5#S?C;\99F[<C"?WM\T`_;DK/JK>_Z/JM?QP3KNG<'<L
M:+1))Z;`8UE^9Z;>$T-4>0*U[4:!]#1Z*IXW[_LZ+S_<8O?R6I/<"WHB]F#F
MTZ]U46UI1,G-Q6S!/&W+/76`_HX.._9JT(AL?MZ-9]3P[JE^O1O/EQ>+J^G<
M(//18U'5]HZY'(^V[U5='O[+C8S6%7<R;YW0YX"3,Q4OVXKTV5:\NKA>+"Z7
MUU?4^IF*5-ITFS[;BKU>GZFW;.M==?7ZCWNF(L5+TR!]?JVG-VU%^FPK,GG.
MM&30.]`T9="@MU4^V4F#5.15I9R?'%!#:,C^^=*0&D)$]EQ?[*^0PZ!_VJJ?
M[2\IR!]52FG0.WZ],!9+]NJ>&V$AIB'5//OZ3'C0-#&XWM2;^]M3^3&BB8T4
MJMXV;)HT3.9,1!]OO(O'OPI'BD/FY1MS<S>F!Z%(JV@.^7%O+(S;R0^*^VUK
MLQJP42T>A`4+<N9VK0-+![8.'!VX.O!TX.L@T$&H@T@'L0X2':0ZR'20]\"$
MY.DTHE#X?VC$W#"-Q.BN!)"BS31!A(6HLM:!I0-;!XX.7!UX.O!U$.@@U$&D
M@U@'B0Y2'60ZR'M`$80F&!!D3I/>\)(E8H35HL5)B1%MP%?<9D:!V`720M.D
M,^E$`6(!L8$X0%P@'A`?2``D!!(!B8$D0%(@&9"\3Q2-:$X'C>2Z]>F)C;FA
MN9&:Z00Q%G-5DA4W.JM:9]*I!L0"8@-Q@+A`/"`^D`!(""0"$@-)@*1`,B!Y
MGRBJT;*GJ'8^HIAU(XX8U!4G,]JJ].2Z5.5ZZ(Q$M340"X@-Q`'B`O&`^$`"
M("&0"$@,)`&2`LF`Y'VB:$$[FB]HP:Q5+3BAJ!##_`!D#<0"8@-Q@+A`/"`^
MD`!(""0"$@-)@*1`,B!YGR@#3]NH+PP\LU8'GI,%K5Z](-"7D<Y(J+,&8@&Q
M@3A`7"`>$!](`"0$$@&)@21`4B`9D+Q/%"UH)?Z"%LQ:U8*3?A``60.Q@-A`
M'"`N$`^(#R0`$@*)@,1`$B`ID`Q(WB?*P-,4K@P\2TSFU^P(H$V,/KV$,T^J
M*)RP'5LO0);:*M$9=0$"Q`)B`W&`N$`\(#Z0`$@()`(2`TF`I$`R('F?*#JQ
M9%\1ZOR2W9BK:K2H'R.(UH@L1#8B!Y&+R$/D(PH0A8@B1#&B!%&**$.4*TC5
M@F60_6S^;[3@"2=M;L4KOF(G-A0L6FA<::$AK43%-2(+D8W(0>0B\A#YB`)$
M(:((48PH090BRA#E"E+E8?GD%^3AZ:<B#T=*J`!:LT,T$K%G92&R$3F(7$0>
M(A]1@"A$%"&*$26(4D09HEQ!JA8L<?R"%CS/5+3@:-[;W[(TD46/1.L6S6BS
M)]>:F78T9DDK$5`V(@>1B\A#Y+>HUZ\`42@K]KNJY;J1M!)=C1$EB%)$&:*\
M1;RKJF(L:>PKQH\J+]@Y>_VZVWY?E33"-'\-3'IS.I)L#RIYZDG-B.ZOV/&O
MJMH#HG6+9K13[`FIG=]8TDJXMQ$YB%Q$'B*_18J0T/M05CS3U4A:B:[&B!)$
M*:(,4=ZB(2%9QOG/A>1YJR)DBRX[;1_8B0]I2YT1#[ENT?RF.::>30WM#;>D
M@:ACHQL'D2LKL@-P\JR]'9XT$)Y]=!,@"F7%UK/6YT@:",\QNDD0I;+B<)\S
M:2`\YXH;-4993MN7=B`6:0??!2-/@14-.5K03"K#;*$GK^S7%B:K/,Q>"R3G
M7DL@:66W:-;\)-G,"`Y:N0))7YY`TI>/O@*T"@62OB*!I*\8?25HE0HD?64"
M25^YXDN5AZ6Y?7G8%-K,:)^?/WFFK$C&T8RFWIYDU_J>L;6:]2*1H[FB]4S3
MVB*1F^F9).^YOU'=VZT5O5SB-74$DBVZPM?9%CUAM>0_9,VT1_&%8]E6()!L
M*Q1>SK85":NS3Q<+][+%1"#98BI\G6TQ$U9*B\NI.IZY<$_SIQSU2[EO4=\K
MEL7K[Y6QD$OS'^7;7RW-_>F`'P8H[U;_?*")UP?V*R7%?F]WNT9D(;(1.8A<
M1!XB'U&`*$04(8H1)8A21!FB7$&J1BR#[VOT-U,S3_@5+;HS@-XKL92O1"M/
M9R4"<4VW1YH(EI.NA<A&Y"!R$7F(?$0!HA!1A"A&E"!*$66(V#T:.1)<'GXO
MAO\F?RA.+\5#L=]7HVWYSNZ\T"\9][<=YA=R5C<F'<?0Z.K<F-)-G6:0H83=
MX6ENO$#)C$J:.01*KJFD66F@A#I`3X(]H*M"WX9]484!^Q4U/F@_-^F'O0'_
ME^:WP897ER;]IH055@LS;^9,_1&6)AV_#]A?F704/,!I+(:&@G(FDV4Q6(,V
MX50RU"=*<6@TADIH:VJRW2=ZHZVER7:/6$);0Y/M_K"$MG;4@Z&2%?6`93U8
MYX%*6/*#)93(4@^&GI0R(RH9JD-YI\E2%O1&Z:<9\))))PU=ZGK;O!31YO2R
M.U:C??%,`3!M%I$3OQ;&O]3M8O)8UG2=JUE77NGZ7D$71J87M%X]EV4MOE#3
MD^Y"X/W_````__\#`%!+`P04``8`"````"$`L@:N-4P$```0$0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6R46%UOHS@4?5]I_@/B?0(V^2(*J=*M
MNCO2CC1:[<P\4W`25,`(.TW[[_?:)@:#T\!+E%R.[_'].L;9/KP7N?-&:I;1
M,G+1S'<=4B8TS<ICY/[\[_GKVG48C\LTSFE)(O>#,/=A]^6/[876K^Q$"'?`
M0\DB]\1YM?$\EIQ($;,9K4@)3PZT+F(./^NCQZJ:Q*E<5.0>]OVE5\19Z2H/
MFWJ,#WHX9`EYHLFY("573FJ2QQSVSTY9Q:[>BF2,NR*N7\_5UX06%;AXR?*,
M?TBGKE,DFV_'DM;Q2PYQOZ-YG%Q]RQ\#]T66U)31`Y^!.T]M=!ASZ(4>>-IM
MTPPB$&EW:G*(W#W:/`;(]79;F:!?&;FPSG>'G>CEKSI+_\E*`MF&.HD*O%#Z
M*J#?4F&"Q=Y@];.LP(_:2<DA/N?\7WKYFV3'$X=R+R`B$=@F_7@B+(&,@IL9
M7@A/"<UA`_#I%)EH#<A(_!ZY&(BSE)\B-UC.%BL_0`!W7@CCSYEPZ3K)F7%:
M_%8@&9&G?,FM/<4\WFUK>G&@WH!F52RZ!VW`L7TOL`F!W0MPY*Y<!V@8)/!M
MAT*T]=X@Z*3!/"H,?+88C?"`5#,#VWAF`1;,(BMB*X_*T*7!=II@"HT`0UJ[
MFP];OXI98>8=S,+.#)#Q`0HPU,"D#K1C1:U`(ZBA'[K4LM/FD*S/RRM6R3WH
M+#>6;IK7[::,<BY-RL^9!-AD4I:Y'*!NET"S]2,)`BP&Y$XP8J%)T5B,8.8Z
MPT8P0G)'3X4`FTS*,@PF--W*LH1WITZL,OTW%B.2&TV(0*;&AR+1)E=C&@:#
M@+[K642S0+/5W<K(A3T2X0M,D`LM&^NEO38"U.7]O-,DND>FM,,2D1CM3MF5
M0`=C0E*B`..K1T>,L@C)*-+J1DB3I`)IK6C)KLH`%J.1Q?DR".F^$LAEO:S9
MM&!](YZ>&*A$7L\E??;=&V&D9:+M"A2V(ZM$L4&-4$5D$9.YOQY3WZ&:2&?]
M^H8W\C%)3Y`6E&[8[7PW85]%I@6U$+,'>K)S9V"&<H,:$TB)GL[0MX>*)^F-
M1)M]UIB&TXDM>A.L@Q%'@5S98VD$ISN=G5<9(W]XDN!(=(_LEN!@F^#X>$1#
MRI4]%HO@=%Y>S)`F"0[6@M/6'X6M/*N&;%`CYE`<WEU1^KPA);H7:J-%1D/>
M>"_!/2VZ0Z8E1VNK=!"YEH:TR`E&JQEL[@[)4$UP8S+ZL54ZLWB3U`1;U:0]
MB)KBC583/$E-)+I7/)N:W)"N8)*:2+1)UIB&Q8.+GM&#\H@:-7IR98_%IB;M
M?*CJJ7NANGP5I#Z2/TF>,R>A9W'G6\)U2EOU?72/Q0M%WS[?[.&`MCQ`2W@B
M+TG])6B]V8-F6-9@\`;=9WL":]1]V-/NX#Y:Q4?R/:Z/6<F<G!Q@[[X4K%K=
M:-4/3BM($=Q**8>;J/QZ@G\>"%S=?#$@!TKY]0=0>_J_C-W_````__\#`%!+
M`P04``8`"````"$`TK8.P^P#``#T#P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6R45UUOXR@4?5]I_H/E]XD-29H/):G:K;H[THXT6NW,/%.;)*BV
ML8`T[;_?"[A.P+BU7Z+DYG`/APL'[N;VM2RB%RHDX]4V1I,TCFB5\9Q5AVW\
M\[_'K\LXDHI4.2EX1;?Q&Y7Q[>[+'YLS%\_R2*F*($,EM_%1J7J=)#([TI+(
M":]I!?_LN2B)@I_BD,A:4)*;0661X#2]24K"JMAF6(LA.?A^SS+ZP+-322ME
MDPA:$`7SET=6R_=L938D74G$\ZG^FO&RAA1/K&#JS22-HS);?SM47)"G`G2_
MHAG)WG.;'YWT)<L$EWRO)I`NL1/M:EXEJP0R[38Y`P5ZV2-!]]OX#JWOIRA.
M=ANS0+\8/<NK[Y$\\O-?@N7_L(K":D.==`6>.'_6T&^Y#L'@I#/ZT53@AXAR
MNB>G0OW+SW]3=C@J*/<<%&EAZ_SM@<H,5A323/!<9\IX`1.`SZAD>FO`BI#7
M;8R!F.7JN(VG-Y/Y(ITB@$=/5*I'IE/&47:2BI>_+<@H2FPN,[4'HLAN(_@Y
M@GH#6M9$[QZTAL3AN<`D-/9.@[?Q(HZ`1L("ONS08K9)7D!TUF#N+08^+Y@6
MD0!IRPQLPYDU6#/K5=%3N;>!:QH<IIF.H=%@6-;KR2_F;5[+;#&S*\P%X0@$
MR'"!&@PU<*EO/&H+&D`-^V$XM08;ZG9QFPCL\$L1%XMV,H[*FS%4&NQ2V<C,
M')SKW0&;;+@"#7;3VLC\>G^@Q3*L0/OKX".@P2Z5C705K-RTYK2C^036]N-#
MIL>Y#$W$%;,*BT%0M.%J#-HE:T)=/0CXKS-K07@&&_9C.6:81Z$S0<@1M$Q[
M!(WR"=3XPO3B%$TH($B?Y,&%UT?3JTL3<G?9$O7H&&4'J/6#]E`VH8`.[[2;
MPJ2SR>+3K:9O'U]3$W)KT^.M:-3A-VAO)_0=?S3J_!NTESGD`,MI3VU&60#J
M>D`3"M0FX`*S=#4!W9\<FZX-H)`/+"_WKV/+>)0/&+2[@$VH*PD'?&"0)#/0
M(PDZ0<]]BD<Y@4%[;-8<`I(\)]`G:`4+^'&)<-<1WD/NZ;E<XVZ)1CD"[CI"
M$PKH\1SA$QU=%]`/2C`&S]EZ7@!XE`L8M%>7/A?`G@L,OD/-0(_$&H)WZ?0\
M"?`H0S!HCZWO58`#AH`'F;49Z;$$':'G93`=Y0@&[;(UH>YV@Z;)N4AUF>9H
MP/UC!GHD(4=8^6\#VV/91J:DXD#_I$4AHXR?=/^$H35IHVUO=X?UF\"/S]9W
MMN=+VG^@YZK)@7XGXL`J&15T#SE3(T?8KLW^4+R&N4/GQ15T6^;K$;IK"NU)
MJI]Y>\[5^P]@3MI^??<_````__\#`%!+`P04``8`"````"$`+**W#L`"```Z
M"```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````"<5M]OVD`,?I^T_P'EO0U0UG952-5"JTY:6S1H
M]W@Z+@9.#7?9V4%E?_V<1$#8<I'6M_OAS_[\V?$ENGY?IYT-.-36#(/>:3?H
M@%$VT68Y#%YF]R>700=)FD2FUL`PV`(&U_'G3]'$V0P<:<`.NS`X#%9$V548
MHEK!6N(I7QN^65BWEL1;MPSM8J$5C*W*UV`H['>[YR&\$Y@$DI-L[S"H/%YM
MZ*-.$ZL*?O@ZVV9,.(YNLBS52A)G&3]JY2S:!77NWA6D45B_C)C=%%3N-&WC
M;A36M]%4R11&[#A>R!0A"@\'T0/(0K2)U`[C:$-7&U!D70?U;Y:M'W3F$J&@
M,PPVTFEIB&D59M6F7*<9DHM_6O>&*P#"*&2#ZK!<UFWK:SV(^Q>E!:^.+0L/
M%1.^..8XTY0"/B\FTE$3Y8LZYY)%Q;@BM*NBN#&)N#/$>HEOIJJVMG7F^QQ&
ME@MM$!)Q*U-I%(AIF:88Y<ZQFGO#0I<JR@$R)4E0M`T*NQ#/W'N2_@LRDK@2
M]XV0)TL@>N(V1VT`47"[,T749:B)'](7I=.[7[G><&<P-[_MF;CGUA"O,LU!
M/(+$W%7I^"$#\00DOEMF-`''8DF/2B7_+V)*5KTQ;Q9X9-?\^6'9\/X`YZ6=
M@Q6;Z@V4H?S6%V*L45DNM<DY1%4"_J!:DK[D`(:G"^EY"J*@B8*L^-%<[#*-
MKU4:*YLF/)5$H2UM&TG=*&7S@LU23"Q_W3R*Q'Q;K;>B$5)&:))5S.2<)\&^
M[PX=V*YMSX_QRM6"\?9@"Z8QG3&0]%/SMDK_`YBS#V`&?DQ33XKV=+Q*MZ3C
MQ;2DX^WFENHTMG.13UV!HR']UUC^KLT;OF0S.^;YMWMWC@^C<C(D/)%W]X>#
MZ(&?')<63D8K:9:0[&S^O2A>R=?J5R#N#4Z[9UU^`&MG47AX].,_````__\#
M`%!+`P04``8`"````"$`?HJ`1S$!``!``@``$0`(`61O8U!R;W!S+V-O<F4N
M>&UL(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````G)%!
M3\,@&(;O)OZ'AGM+68T:TK)$S4XN,7%&XPWA6TLLE`#:[=]+NZ[.Z,DC>5\>
MGN^C7.YTFWR"\ZHS%2)9CA(PHI/*U!5ZVJS2:Y3XP(WD;6>@0GOP:,G.STIA
MJ>@</+C.@@L*?!))QE-A*]2$8"G&7C2@N<]BP\1PVSG-0SRZ&ELNWGD->)'G
MEUA#X)('C@=@:F<BFI!2S$C[X=H1(`6&%C28X#')"/[N!G#:_WEA3$Z:6H6]
MC3--NJ=L*0[AW-YY-1?[OL_Z8M2(_@2_K.\?QU%3989="4!LV$_+?5C'56X5
MR)L]V[VY-O&^*?'OK)1BM*/"`0\@D_@>/=@=D^?B]FZS0FR1DR(E)"6+#2GH
MQ17-R6N)CZWI/IN!>A+X-_$(8*/WSS]G7P```/__`P!02P$"+0`4``8`"```
M`"$`EP_^XL0!``!R$@``$P``````````````````````6T-O;G1E;G1?5'EP
M97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````````````
M`````/T#``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0!3=PU[K0$``#,1
M```:`````````````````",'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+`0(M`!0`!@`(````(0#.@C]E(0,``&,)```/`````````````````!`*
M``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`$DULH9`$``#5$```
M&`````````````````!>#0``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M`BT`%``&``@````A`!J@09B>`@``DP8``!D`````````````````)!(``'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`#1X`N;("
M``#S!@``&0````````````````#Y%```>&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+`0(M`!0`!@`(````(0#0$%.]2@,``.`*```9````````````````
M`.(7``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A
M`'LN$#NN`P``)PT``!D`````````````````8QL``'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`]Q*BGM<#```+#@``&0``````
M``````````!('P``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`
M!@`(````(0#(<U(^4P(``+$%```9`````````````````%8C``!X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A`+SGW^OY"```(C\`
M`!D`````````````````X"4``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"+0`4``8`"````"$`R](R&V8*```F3@``&0`````````````````0+P``
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0##>1PB
M``0``*(-```8`````````````````*TY``!X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"+0`4``8`"````"$`OHWCE5,$``#-#@``&```````````````
M``#C/0``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A
M`/4SCQ-(,@``Z)L``!0`````````````````;$(``'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L!`BT`%``&``@````A`/!Y-P1H"P``:68```T`````````````
M````YG0``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E;90&``"G
M&P``$P````````````````!Y@```>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M
M`!0`!@`(````(0"B#OE(Q@,``)0-```8`````````````````#Z'``!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`,$QGER,#```_
M"@``&0`````````````````ZBP``>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+`0(M`!0`!@`(````(0#]@`<!J@4``)`6```9`````````````````)2.
M``!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`,NX
MVG3Z#0``AT<``!@`````````````````=90``'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+`0(M`!0`!@`(````(0"*L>%ZDP4``(\5```8````````````
M`````*6B``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`"```
M`"$`>M5JKI$"``")!@``&`````````````````!NJ```>&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`+0C4@1[`@``0`8``!@`````
M````````````-:L``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`
M!@`(````(0`;WXSM+P0``.<0```8`````````````````.:M``!X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`JIH=(\T$``"R%```
M&0````````````````!+L@``>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M`0(M`!0`!@`(````(0#80=U_@`(``$,&```9`````````````````$^W``!X
M;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`.\OU&%]
M`P``*0P``!D`````````````````!KH``'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"+0`4``8`"````"$`2S$06Q@+``!7,@``&0``````````````
M``"ZO0``>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````
M(0#HL)HR7P0``#\/```9``````````````````G)``!X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L!`BT`%``&``@````A`(F[ER%^"```52@``!D`````
M````````````G\T``'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4
M``8`"````"$`L@:N-4P$```0$0``&0````````````````!4U@``>&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0#2M@[#[`,``/0/
M```9`````````````````-?:``!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L!`BT`%``&``@````A`"RBMP[``@``.@@``!``````````````````^MX`
M`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`?HJ`1S$!``!``@``
M$0````````````````#PX@``9&]C4')O<',O8V]R92YX;6Q02P4&`````"0`
,)`"N"0``6.4`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (41,240)<span></span></td>
        <td class="num">$ (15,611)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">237<span></span></td>
        <td class="nump">147<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">8,333<span></span></td>
        <td class="nump">3,773<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="nump">396<span></span></td>
        <td class="nump">262<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(202)<span></span></td>
        <td class="num">(89)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">514<span></span></td>
        <td class="nump">980<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump">826<span></span></td>
        <td class="num">(352)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(31,136)<span></span></td>
        <td class="num">(10,884)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(1,518)<span></span></td>
        <td class="num">(546)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(1,518)<span></span></td>
        <td class="num">(546)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,491<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible note financing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
        <td class="nump">600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercise</a></td>
        <td class="nump">1,120<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from the issuance of shares under the Employee Stock Purchase Plan</a></td>
        <td class="nump">25<span></span></td>
        <td class="nump">13<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">1,745<span></span></td>
        <td class="nump">53,504<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(30,909)<span></span></td>
        <td class="nump">42,074<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">53,506<span></span></td>
        <td class="nump">17,974<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">$ 22,597<span></span></td>
        <td class="nump">$ 60,048<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Comprehensive Loss<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Income (Loss) Note [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA850">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(6)&#160;COMPREHENSIVE LOSS</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA852">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Comprehensive loss for the periods reported was comprised solely of our net loss. The comprehensive loss for the three and nine months ended September 30, 2013 was $12.9 million and $41.2 million, respectively. The comprehensive loss for the three and nine months ended September 30, 2012 was $6.1 million and $15.6 million, respectively. There were no changes in equity that were excluded from our net loss for all reported periods.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e689-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669619-108580<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e640-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 17<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e716-108580<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e709-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Reclassification Adjustments<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNoteTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 7 - Discontinued Operations (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">84 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2007</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid', window );">Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 944,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Increase (Decrease) in Other Accrued Liabilities</a></td>
        <td class="nump">$ 1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of guaranteed minimum benefit payments to policyholders and contract holders, during the period presented, resulting in a decrease to the liability for expected guaranteed minimum benefits in excess of projected account values.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6588021&amp;loc=d3e7104-158389<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 80<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6484115&amp;loc=d3e19393-158473<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EO5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business and Basis of Presentation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">7 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Net Of Issuance Costs [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>Purchase Option [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011

</div>
          <div>Private Placement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_Note1BusinessandBasisofPresentationDetailsLineItems', window );"><strong>Note 1 - Business and Basis of Presentation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (224,827,000)<span></span></td>
        <td class="num">$ (183,587,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1', window );">Convertible Debt Issuable In Connection With Private Placement1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet', window );">Proceeds From Sale Of Units Of Common Stock And Warrants Net (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,800,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement (in Dollars)</a></td>
        <td class="nump">50,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,048,000<span></span></td>
        <td class="nump">$ 22,597,000<span></span></td>
        <td class="nump">$ 53,506,000<span></span></td>
        <td class="nump">$ 17,974,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible debt issuable in connection with private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_Note1BusinessandBasisofPresentationDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_Note1BusinessandBasisofPresentationDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Inflow from sale of units of common stock and warrants net of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKTAK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">28 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="1">28 Months Ended</th>
        <th class="th" colspan="1">7 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">7 Months Ended</th>
        <th class="th" colspan="1">15 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 29, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 28, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Scenario, Actual [Member]

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Scenario, Proposed [Member]

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Compensation Plan [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Stock Compensation Plan [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Private Placement 2011 [Member]

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 30, 2012

</div>
          <div>Private Placement 2012 [Member]

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 30, 2012

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_Note9StockholdersEquityDetailsLineItems', window );"><strong>Note 9 - Stockholders' Equity (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">95,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance', window );">Increase in the Number of Shares of Common Stock Reserved for Issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">160,000,006<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80,000,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.18<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement (in Dollars)</a></td>
        <td class="nump">$ 50,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 24,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,500,000<span></span></td>
        <td class="nump">$ 53,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_SharesAvailablePerWarrantExercisedCommonStock', window );">Shares Available Per Warrant ExercisedCommonStock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit', window );">Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Item)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_LimitationOnExercisableWarrants', window );">Limitation On Exercisable Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.99%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_EffectiveRateOfLiquidatedDamages', window );">Effective Rate Of Liquidated Damages</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.50%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_PrivatePlacementCappedPenatly', window );">Private Placement Capped Penatly</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet', window );">Proceeds From Sale Of Units Of Common Stock And Warrants Net (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">102,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.525<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_EffectiveRateOfLiquidatedDamages">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Failure to keep the registration statement continuously effective for a designated time will result in the rated penalty of liquidated damages</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_EffectiveRateOfLiquidatedDamages</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase Price Unit (1 Warrant to Purchase 0.5 shares of Common Stock)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in the number of shares of common stock reserved for issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_IncreaseInTheNumberOfSharesOfCommonStockReservedForIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_LimitationOnExercisableWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company's outstanding shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_LimitationOnExercisableWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_Note9StockholdersEquityDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_Note9StockholdersEquityDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_PrivatePlacementCappedPenatly">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of penalty that may not exceed stated percentage of original purchase price of Private Placement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_PrivatePlacementCappedPenatly</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Inflow from sale of units of common stock and warrants net of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ProceedsFromSaleOfUnitsOfCommonStockAndWarrantsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_SharesAvailablePerWarrantExercisedCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of shares available to be exercised per warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_SharesAvailablePerWarrantExercisedCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E54CI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 8 - Convertible Notes to Related Parties (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 29, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Initial Closing Amount [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Purchase Option [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Principal Amount [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>Senior Notes [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 01, 2011

</div>
          <div>Senior Notes [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Senior Notes [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Senior Notes [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Payment in Kind (PIK) Note [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems', window );"><strong>Note 8 - Convertible Notes to Related Parties (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1', window );">Convertible Debt Issuable In Connection With Private Placement1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_NotesAuthorizedUnderPrivatePlacementInitialClosing', window );">Notes Authorized Under Private Placement Initial Closing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_PurchaseOptionUnderPrivatePlacement', window );">Purchase Option Under Private Placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_DebtInstrumentConversionRatioShares', window );">Debt Instrument Conversion Ratio, Shares (in Shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May
				02,
				 2021<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt Instrument, Maturity Date Range, Start</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May
				02,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_BeneficialOwnershipAfterConversion', window );">Beneficial Ownership After Conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.99%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes', window );">Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">61 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes', window );">Common Shares Registered For Resale In Connection With Convertible Notes (in Shares)</a></td>
        <td class="nump">69,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-Kind Interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense, Debt, Excluding Amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">74,000<span></span></td>
        <td class="nump">218,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">134,000<span></span></td>
        <td class="nump">396,000<span></span></td>
        <td class="nump">262,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Carrying Value of Notes Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">888,000<span></span></td>
        <td class="nump">888,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">492,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">888,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,958,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,070,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Debt Instrument, Convertible, Number of Equity Instruments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">124,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 74,000<span></span></td>
        <td class="nump">$ 74,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_BeneficialOwnershipAfterConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage amount the holder would beneficially own of the company's outstanding common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_BeneficialOwnershipAfterConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares registered for resale in connection with convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible debt issuable in connection with private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ConvertibleNotesPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_DebtInstrumentConversionRatioShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_DebtInstrumentConversionRatioShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_Note8ConvertibleNotestoRelatedPartiesDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_NotesAuthorizedUnderPrivatePlacementInitialClosing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes authorized under private placement initial closing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_NotesAuthorizedUnderPrivatePlacementInitialClosing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice period associated with beneficial ownership percentage limitation, convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_PurchaseOptionUnderPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase option under private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_PurchaseOptionUnderPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Conversion Rate<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Earliest date the outstanding debt instruments are required to be repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDateRangeStart1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebtExcludingAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 7 - Discontinued Operations (Details) - Income (loss) from discontinued operations (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_IncomeLossFromDiscontinuedOperationsAbstract', window );"><strong>Income (loss) from discontinued operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ChangeInEstimatesForGrossProfitGuarantees', window );">Change in estimates for gross profit guarantees</a></td>
        <td class="nump">$ 128<span></span></td>
        <td class="num">$ (6)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ChangeInEstimatesForGrossProfitGuarantees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ChangeInEstimatesForGrossProfitGuarantees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_IncomeLossFromDiscontinuedOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_IncomeLossFromDiscontinuedOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Cash Equivalents<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA821">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(2) CASH EQUIVALENTS</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA823">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Our available-for-sale securities as of December&#160;31, 2012 consisted of money market funds primarily containing U.S. government-backed securities, with original maturities of ninety days or less. The carrying value of our money market funds was included in cash equivalents and approximated their fair value. We have no available-for-sale securities as of September 30, 2013. The Company's bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 8).</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 6.H.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section H<br><br> -Subsection 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA829">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(4)&#160;NET LOSS PER SHARE</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA831">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the applicable period. Diluted net loss per share excludes the effect of outstanding potentially dilutive securities because they are anti-dilutive. The following table shows the outstanding potentially dilutive options, warrants and convertible notes for the nine months ended September 30, 2013 and 2012 (in thousands):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1175.finRow.1">
        <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.1.lead.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1163">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended September 30,</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.1.trail.D3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.2">
        <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1164">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1165">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.trail.D3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.3">
        <td style="WIDTH: 70%">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.lead.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.symb.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.amt.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.trail.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.lead.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.symb.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.amt.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1166">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Options outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.amt.2">
          125,392
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.amt.3">
          67,940
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1169">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Warrants outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.amt.2">
          79,377
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.amt.3">
          84,377
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1172">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Common stock underlying convertible notes outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.amt.2">
          123,957
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.amt.3">
          116,790
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 7 - Discontinued Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA854">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(7)&#160;DISCONTINUED OPERATIONS</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA856">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>Cosmeceutical and Toiletry Business</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA858">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On July&#160;25, 2000, we completed the sale of certain technology rights for our cosmeceutical and toiletry business to RP&#160;Scherer Corporation (RP Scherer), a subsidiary of Cardinal Health, Inc. Under the terms of the agreement, we guaranteed a minimum gross profit percentage on RP Scherer's combined sales of products to Ortho Dermatologics (Ortho) and Dermik Laboratories, Inc. (Dermik) (Gross Profit Guaranty), both of which were acquired by Valeant Pharmaceuticals in July 2011. The Gross Profit Guaranty expense totaled $944,000 for the first seven guaranty years. Effective March 2007, in conjunction with a sale of assets by RP Scherer&#8217;s successor company to an Amcol International subsidiary (Amcol), a new agreement was signed between us and Amcol to provide continuity of product supply to Ortho and Dermik. We had previously recorded a liability of $1.1 million related to the amount that Amcol
      asserted was due under the Gross Profit Guaranty. In February 2013, an arbitrator ruled that no additional amounts were owed. This event qualified as an adjusting event under ASC 855, <i>Subsequent Event</i>, and in light of the arbitrator&#8217;s decision in February 2013, which was final and binding, we reversed this accrual as of December 31, 2012.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA860">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The cosmeceutical and toiletry business is reported as discontinued operations for all periods presented in our accompanying Condensed Statements of Operations. Income (loss) from discontinued operations primarily represents the income (loss) attributable to changes in estimates of our cosmeceutical and toiletry business that was sold to RP Scherer on July&#160;25, 2000, as follows (in thousands):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1246.finRow.2">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.2.amt.D3" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1232">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1234">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.2.amt.D5" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1233">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1235">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.2.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.3">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D2" colspan="2">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1236">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1237">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1238">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.3.amt.D5" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1239">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1246.finRow.3.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1240">
            <u><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cosmeceutical and Toiletry Business</font></u>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1246.finRow.4-0">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1245">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Change in estimates for gross profit guarantees</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.2-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.2-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.2-0">
          -
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.2-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.3-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.3-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.3-0">
          128
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.3-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.4-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.4-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.4-0">
          -
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.4-0" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.lead.5-0">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.symb.5-0">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.amt.5-0">
          (6
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1246.finRow.4.trail.5-0" nowrap="nowrap">
          )
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA863">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">There was no material basic and diluted loss per common share resulting from discontinued operations for the three and nine months ended September 30, 2013 and 2012.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA836">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(5) STOCK-BASED COMPENSATION</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA838">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table summarizes the stock-based compensation expense for all awards (in thousands, except per share amounts):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1205.finRow.2">
        <td style="WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.2.amt.D3" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1176">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1178">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.2.amt.D5" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1177">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1179">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.3">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1180">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1181">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1182">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D5" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1183">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.4">
        <td style="WIDTH: 52%">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1184">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Operating expenses:</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1185">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Research and development</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.2">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.2">
          544
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.3">
          397
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.4">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.4">
          1,088
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.5">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.5">
          1,061
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.7">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1190">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">General and administrative</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.2">
          3,551
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.3">
          1,583
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.4">
          7,245
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.5">
          2,712
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1195">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Total stock-based compensation expense</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.2">
          4,095
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.3">
          1,980
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.4">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.4">
          8,333
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.5">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.5">
          3,773
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.9">
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.10">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1200">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Impact on basic and diluted net loss per common share</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.2">
          0.01
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.3">
          0.01
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.4">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.4">
          0.03
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.5">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.5">
          0.02
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA841">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In the three months ended September 30, 2013, we recorded additional stock-based compensation expense as a result of accelerated vesting of stock options in connection with the resignation of our former chief executive officer.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA842">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table summarizes stock option activity for the nine months ended September 30, 2013:</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1230.finRow.4">
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1206">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Shares (in thousands)</b></font></b>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D3" colspan="2">
          <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b></b></font></b>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1209">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted- Average Exercise</b></font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1211">
            <b>Price</b>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D3">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D4">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D4" colspan="2">
          <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b></b></font></b></font></b></font></b>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1207">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-</b></font></font></font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1208">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Average</font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1210">
            <b>Remaining Contractual Term</b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1212">
            (Years)
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D4">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1230.finRow.5">
        <td>
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1213">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Outstanding at January 1, 2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.2">
          86,478
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.3">
          0.42
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.4">
          8.2
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.7">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1217">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Granted</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.amt.2">
          76,735
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.amt.3">
          0.40
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1220">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Exercised</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.amt.2">
          (4,323
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.trail.2" nowrap="nowrap">
          )
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.amt.3">
          0.26
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.9">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1223">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expired and forfeited</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.amt.2">
          (33,498
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.trail.2" nowrap="nowrap">
          )
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.amt.3">
          0.47
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.amt.B4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.10">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1226">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Outstanding at September 30, 2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.2">
          125,392
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.3">
          0.40
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.4">
          8.0
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA847">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>Employee Stock Purchase Plan</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA848">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We adopted an Employee Stock Purchase Plan (Purchase Plan) in 1997. Qualified employees may elect to have a certain percentage of their salary withheld to purchase shares of our common stock under the Purchase Plan. In June&#160;2011, our stockholders authorized an increase in the number of shares reserved for issuance under the Purchase Plan by 500,000, for a total of 1,000,000 shares reserved at September 30, 2013. The purchase price per share is equal to 85% of the fair market value of the stock on specified dates. Sales under the Purchase Plan during the nine months ended September 30, 2013 and 2012 consisted of 80,027 and 58,571 shares at an average price of $0.31 and $0.21, respectively. Shares available for future purchase under the Purchase Plan were 365,674 at September 30, 2013.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>26
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T)A
M;&%N8V5?4VAE971S7T-U<G)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7U-T871E;65N='-?;V9?3W!E<F%T/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D
M7U-T871E;65N='-?;V9?0V%S:%]&/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F]T95\Q7T)U<VEN97-S7V%N9%]"87-I<U]O9E]0
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\R
M7T-A<VA?17%U:79A;&5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y.;W1E7S-?1F%I<E]686QU95]-96%S=7)E;65N=',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S1?3F5T
M7TQO<W-?4&5R7U-H87)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3F]T95\U7U-T;V-K0F%S961?0V]M<&5N<V%T:6]N/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\V7T-O;7!R
M96AE;G-I=F5?3&]S<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYO=&5?-U]$:7-C;VYT:6YU961?3W!E<F%T:6]N<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?.%]#;VYV97)T
M:6)L95].;W1E<U]T;U]293PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5?.5]3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C;W5N=&EN9U]0;VQI
M8VEE<U]B>5]0;VQI8WE?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3F]T95\T7TYE=%],;W-S7U!E<E]3:&%R95]486)L/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\U7U-T;V-K
M0F%S961?0V]M<&5N<V%T:6]N,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DYO=&5?-U]$:7-C;VYT:6YU961?3W!E<F%T:6]N<S$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S%?
M0G5S:6YE<W-?86YD7T)A<VES7V]F7U`Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3F]T95\T7TYE=%],;W-S7U!E<E]3:&%R95]$
M971A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T
M95\U7U-T;V-K0F%S961?0V]M<&5N<V%T:6]N,CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-5]3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;C,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S5?4W1O8VM"87-E9%]#;VUP96YS871I;VXT/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\V7T-O;7!R96AE;G-I
M=F5?3&]S<U]$971A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F]T95\W7T1I<V-O;G1I;G5E9%]/<&5R871I;VYS,CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-U]$:7-C;VYT
M:6YU961?3W!E<F%T:6]N<S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y.;W1E7SA?0V]N=F5R=&EB;&5?3F]T97-?=&]?4F4Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\Y7U-T
M;V-K:&]L9&5R<U]%<75I='E?1&5T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T
M<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T
M+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*
M("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U
M<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD
M;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^
M#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B
M92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B
M.&-C-3!?938X8E\T-#1B7SEF96-?96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A
M,3)D83$T-V0T8R]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.
M1T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I
M='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y/8W0N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I
M;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=!4"!02$%234$@24Y#("]$12\\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<M+3$R+3,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO
M;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$S+#8Q-BPS-CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<P,#`P.#$X,#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P;W)T:6YG(%-T
M871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)UEE<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=!8V-E;&5R871E9"!&:6QE<CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!796QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)
M"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M43,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M159+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($)A;&%N
M8V4@4VAE971S("A#=7)R96YT(%!E<FEO9"!5;F%U9&ET960I("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R,BPU.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S+#4P-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E
M<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPS-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PP.3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPX-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@;&]N9RUT97)M(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPS
M-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-2PY-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PY,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S8P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE(&YO=&5S('!A>6%B;&4@=&\@<F5L871E9"!P87)T:65S+"!N970@
M;V8@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D
M:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T,BPU.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,S(L,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,C0L.#(W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X,RPU
M.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+#@W,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#@Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I
M;&ET:65S(&%N9"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-BPS-S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U+#DW,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T
M-#1B7SEF96-?96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7
M;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5&5$%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!3=&%T96UE;G1S(&]F($]P97)A
M=&EO;G,@*%5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X
M8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#@X-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPV,C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S+#$X.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`L,#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0R.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#0S.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPV-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#`U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#8R-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#(P,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG
M(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#8V-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M+#`U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T,"PV,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,34L,C`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS92P@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DU*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8Q-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,#(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!F<F]M(&-O;G1I;G5I;F<@;W!E<F%T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L.#<S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,C0Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Q+#(T,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PV
M,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-O;64@*&QO<W,I(&9R;VT@9&ES8V]N=&EN=65D(&]P97)A=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPX
M-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@V+#$R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#0Q+#(T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#$U+#8Q,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!C;VYT
M:6YU:6YG(&]P97)A=&EO;G,@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!L;W-S("AI;B!$;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XP-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!U<V5D('1O(&-O;7!U=&4@8F%S:6,@
M86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E("AI;B!3:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#<L-#DV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<T+#0X.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M-BPP.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C4L,#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14Q4044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N9&5N
M<V5D(%-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H56YA=61I=&5D*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0Q+#(T,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$U+#8Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQO<W,@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO
M;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<W,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R
M<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDX,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@
M:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,Q+#$S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,"PX.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PU,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-30V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-3$X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O8VLL(&YE
M="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P+#0Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VYV97)T:6)L92!N;W1E
M(&9I;F%N8VEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M('=A<G)A;G0@97AE<F-I<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<W1O
M8VL@;W!T:6]N(&5X97)C:7-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F('-H
M87)E<R!U;F1E<B!T:&4@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H
M('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<T-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#4P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S
M92`H9&5C<F5A<V4I(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P+#DP.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPP-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&)E9VEN;FEN9R!O9B!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#4P-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#DW-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@96YD(&]F('!E<FEO9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,BPU.3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P+#`T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B.&-C
M-3!?938X8E\T-#1B7SEF96-?96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D
M83$T-V0T8R]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$@+2!"=7-I;F5S<R!A;F0@
M0F%S:7,@;V8@4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!497AT($)L;V-K
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$
M4$%203<Y,SX@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQB/B@Q*28C,38P.T)54TE.15-3($%.1"!"05-)4R!/1B!04D5314Y4
M051)3TX\+V(^/"]F;VYT/B`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203<Y-3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G/D$N4"X@4&AA<FUA+"!);F,N("AT:&4@)B,X,C(P
M.T-O;7!A;GDL)B,X,C(Q.R`F(S@R,C`[=V4L)B,X,C(Q.R`F(S@R,C`[=7,F
M(S@R,C$[(&%N9"`F(S@R,C`[;W5R)B,X,C(Q.RD@:7,@82!S<&5C:6%L='D@
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M92!O<B!T=V\@=V5E:W,N/"]F;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$W.3@^("`@("`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>28C.#(Q-SMS
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M;VYL>2!O;F4@:6YJ96-T86)L92`U+4A4,R!A;G1A9V]N:7-T(&%P<')O=F5D
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M9&%Y(')A;F=E(&ES(&1E<VEG;F5D('1O(&-O=F5R('1H92!D96QA>65D(`T*
M("`@("`@<&AA<V4@;V8@0TE.5BX@1W)A;FES971R;VX@=V%S('-E;&5C=&5D
M(&9O<B!!4$8U,S`@8F5C875S92!I="!I<R!W:61E;'D@<')E<V-R:6)E9"!B
M>2!P:'ES:6-I86YS(&)A<V5D(&]N(&$@=V5L;"UE<W1A8FQI<VAE9"!R96-O
M<F0@;V8@<V%F971Y(&%N9"!E9F9I8V%C>2X\+V9O;G0^("`@("`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@P,#X@("`@(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN($UA>2`R
M,#`Y+"!W92!F:6QE9"!T:&4@;W)I9VEN86P@3F5W($1R=6<@07!P;&EC871I
M;VX@*$Y$02D@<V5E:VEN9R!A<'!R;W9A;"!F;W(@05!&-3,P('=I=&@@=&AE
M(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H1D1!*2X@5&AE
M($9$02!I<W-U960@82!#;VUP;&5T92!297-P;VYS92!,971T97(@9F]R('1H
M92!!4$8U,S`@3D1!(&EN($UA<F-H(#(P,3`N($EN(%-E<'1E;6)E<B`R,#$R
M+"!W92!R97-U8FUI='1E9"!T:&4@3D1!('-E96MI;F<@87!P<F]V86P@9F]R
M($%01C4S,"!W:71H('1H92!&1$$N($]N($UA<F-H(#(X+"`R,#$S+"!W92!A
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M:&4@9FER<W0@<75A<G1E<B!O9B`R,#$T+CPO9F]N=#X@("`-"B`@("`\+W`^
M/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@P,CX@("`-"B`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY792!O=VX@=&AE
M('=O<FQD=VED92!R:6=H=',@=&\@05!&-3,P(&%N9"!A<F4@:6X@=&AE(&5A
M<FQY('-T86=E<R!O9B!B=6EL9&EN9R!T:&4@8V]M;65R8VEA;"!I;F9R87-T
M<G5C='5R92!N96-E<W-A<GD@=&\@8V]M;65R8VEA;&EZ92!!4$8U,S`@:6X@
M=&AE(%4N4RX@;VX@;W5R(&]W;BX\+V9O;G0^("`@("`-"B`@("`\+W`^/&)R
M+SX\<"!I9#TS1%!!4D$Q,C0Y('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&QI;F4M:&5I9VAT.B`Q+C(U.R!M87)G:6XZ(#!P=#LG/B`@#0H@("`@("`\
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M=',@<F5C96EV:6YG(&AI9VAL>2!E;65T;V=E;FEC(&-H96UO=&AE<F%P>2`H
M2$5#*2!A9V5N=',N)B,Q-C`[($-U<G)E;G1L>2!T:&5R92!A<F4@;F\@87!P
M<F]V960@-2U(5#,@<F5C97!T;W(@86YT86=O;FES=',@9F]R('1H92!T<F5A
M=&UE;G0@;V8@9&5L87EE9"!(14,N/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R
M+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@
M,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@P,SX@("`@(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN(%-E<'1E;6)E<B`R
M,#$S+"!O=7(@<W1O8VMH;VQD97)S(&%P<')O=F5D(&%N(&%M96YD;65N="!T
M;R!O=7(@8V5R=&EF:6-A=&4@;V8@:6YC;W)P;W)A=&EO;B!T;R!C:&%N9V4@
M;W5R(&YA;64@9G)O;2!!+E`N(%!H87)M82P@26YC+B!T;R!(97)O;B!4:&5R
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M9B!!4$8U,S`N/"]F;VYT/B`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ
M(#!P="<@:60],T1005)!.#`U/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P="<^5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@
M8V]N9&5N<V5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P
M87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@52Y3+B!G96YE<F%L;'D@86-C97!T
M960@86-C;W5N=&EN9R!P<FEN8VEP;&5S("A5+E,N($=!05`I(&9O<B!I;G1E
M<FEM(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!A;F0@=VET:"!T:&4@:6YS=')U
M8W1I;VYS('1O($9O<FT@,3`M42!A;F0@07)T:6-L92`Q,"!O9B!296=U;&%T
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M:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@87)E(&YO="!N
M96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U;'1S('1H870@;6%Y
M(&)E(&5X<&5C=&5D(&9O<B!T:&4@>65A<B!E;F1I;F<@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,R!O<B!F;W(@86YY(&]T:&5R('!E<FEO9"X@5&AE(&-O;F1E
M;G-E9"!B86QA;F-E('-H965T(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3(@:&%S(&)E96X@9&5R:79E9"!F<F]M('1H92!A=61I=&5D("`-"B`@("`@
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M971O(&EN8VQU9&5D(&EN(&]U<B!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M
M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,BP@
M=VAI8V@@=V%S(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA
M;F=E($-O;6UI<W-I;VX@*%-%0RD@;VX@36%R8V@F(S$V,#LQ+"`R,#$S("@R
M,#$R(#$P+4LI+CPO9F]N=#X@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ
M(#!P="<@:60],T1005)!.#`W/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQB/DQI<75I9&ET>3PO8CX\+V9O;G0^/"]F;VYT/B`-"B`@("`\+W`^
M/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@P.3X@("`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)SY792!H879E(&EN8W5R<F5D('-I9VYI9FEC
M86YT(&]P97)A=&EN9R!L;W-S97,@86YD(&YE9V%T:79E(&-A<V@@9FQO=W,@
M9G)O;2!O<&5R871I;VYS(&%N9"!H879E(&%N(&%C8W5M=6QA=&5D(&1E9FEC
M:70@;V8@)#(R-"XX(&UI;&QI;VX@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S
M+B!$=7)I;F<@,C`Q,2!A;F0@,C`Q,BP@=V4@96YT97)E9"!I;G1O('1H<F5E
M(&9I;F%N8VEN9R!A9W)E96UE;G1S+"!W:&EC:"!P<F]V:61E9"!U<R!C87!I
M=&%L('1O(&9U;F0@;W!E<F%T:6]N<RX@26X@07!R:6P@,C`Q,2P@=V4@96YT
M97)E9"!I;G1O(&1E9FEN:71I=F4@86=R965M96YT<R!F;W(@82!C;VYV97)T
M:6)L92!N;W1E(&9I;F%N8VEN9R!O9B!U<"!T;R`D-"XU(&UI;&QI;VXN(%=E
M(')E8V5I=F5D(&%P<')O>&EM871E;'D@)#$N,R!M:6QL:6]N+"!N970@;V8@
M:7-S=6%N8V4@8V]S=',L(&9R;VT@=&AE(&EN:71I86P@8VQO<VEN9R!A;F0@
M86X@861D:71I;VYA;"`D,RXP(&UI;&QI;VX@=&AR;W5G:"!T:&4@:7-S=6%N
M8V4@;V8@861D:71I;VYA;"!C;VYV97)T:6)L92!N;W1E<R!I;B!-87D@,C`Q
M,B!A<R!A(')E<W5L="!O9B!T:&4@<'5R8VAA<V5R<R!W:&\@<&%R=&EC:7!A
M=&5D(&EN('1H92!!<')I;"`R,#$Q(&-O;G9E<G1I8FQE(&YO=&4@9FEN86YC
M:6YG(&9U;&QY(&5X97)C:7-I;F<@=&AE:7(@<FEG:'1S('1O('!U<F-H87-E
M(&%D9&ET:6]N86P@8V]N=F5R=&EB;&4@;F]T97,@*'-E92!.;W1E(#@I+B!)
M;B!*=6YE(#(P,3$L('=E(&5N=&5R960@:6YT;R!D969I;FET:79E(&%G<F5E
M;65N=',@9F]R(&$@<')I=F%T92!P;&%C96UE;G0@;V8@=6YI=',L('=H:6-H
M('=E<F4@(`T*("`@("`@8V]M<')I<V5D(&]F(&-O;6UO;B!S=&]C:R!A;F0@
M=V%R<F%N=',@*'-E92!.;W1E(#DI+B!4:&4@=6YI="!F:6YA;F-I;F<L('=H
M:6-H(&-L;W-E9"!I;B!*=6QY(#(P,3$L('!R;W9I9&5D('5S('=I=&@@87!P
M<F]X:6UA=&5L>2`D,C(N."!M:6QL:6]N(&]F('!R;V-E961S+"!N970@;V8@
M:7-S=6%N8V4@8V]S=',N($EN($IU;'D@,C`Q,BP@=V4@8VQO<V5D(&$@8V]M
M;6]N('-T;V-K(&9I;F%N8VEN9R!W:&5R96)Y('=E(')E8V5I=F5D(&%P<')O
M>&EM871E;'D@)#4P+C4@;6EL;&EO;B!O9B!P<F]C965D<RP@;F5T(&]F(&ES
M<W5A;F-E(&-O<W1S("AS964@3F]T92`Y*2X@07,@;V8@4V5P=&5M8F5R(#,P
M+"`R,#$S+"!W92!H860@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!O9B`D
M,C(N-B!M:6QL:6]N+CPO9F]N=#X\+V9O;G0^(`T*("`@(#PO<#X\8G(O/CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U
M.R!-05)'24XZ(#!P="<@:60],T1005)!.#$Q/B`@("`@#0H@("`@("`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G/E=E(&)E;&EE=F4@=&AA="!O=7(@8W5R<F5N="!W;W)K
M:6YG(&-A<&ET86P@:7,@<W5F9FEC:65N="!T;R!F=6YD('!L86YN960@;W!E
M<F%T:6]N<R!I;G1O(#(P,30N($AO=V5V97(L('=E('=I;&P@<F5Q=6ER92!A
M9&1I=&EO;F%L(&-A<&ET86P@=&\@9G5N9"!O=7(@9&5V96QO<&UE;G0@86YD
M(&]P97)A=&EN9R!A8W1I=FET:65S+B!)9B!W92!A<F4@=6YA8FQE('1O(&]B
M=&%I;B!S=69F:6-I96YT(&9I;F%N8VEN9R!O;B!A8V-E<'1A8FQE('1E<FUS
M(&]R(&]T:&5R=VES92P@=V4@;6%Y(&)E(')E<75I<F5D('1O(')E9'5C92!O
M<B!D969E<B!O=7(@86-T:79I=&EE<RX\+V9O;G0^/"]F;VYT/B`@(`T*("`@
M(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#$T/B`@("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^0W)I
M=&EC86P@06-C;W5N=&EN9R!0;VQI8VEE<R!A;F0@17-T:6UA=&5S/"]B/CPO
M9F]N=#X@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!
M4D$X,34^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
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M<&]L:6-I97,@86YD(&5S=&EM871E<R!A<F4@9&ES8W5S<V5D(&EN(&]U<B`R
M,#$R(#$P+4LN/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203@Q-SX@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO
M=6YC96UE;G1S/"]B/CPO9F]N=#X@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)
M3CH@,'!T)R!I9#TS1%!!4D$X,3D^("`@("`-"B`@("`@(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)SY4:&5R92!H879E(&)E96X@;F\@<F5C96YT
M(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',@;W(@8VAA;F=E<R!I;B!A8V-O
M=6YT:6YG('!R;VYO=6YC96UE;G1S(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S+"!A<R!C;VUP87)E9"!T;R!T:&4@
M<F5C96YT(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',@9&5S8W)I8F5D(&EN
M(&]U<B`R,#$R(#$P+4LL('1H870@=V4@8F5L:65V92!A<F4@;V8@<VEG;FEF
M:6-A;F-E+"!O<B!P;W1E;G1I86P@<VEG;FEF:6-A;F-E+"!T;R!U<RX\+V9O
M;G0^(`T*("`@(#PO<#X\8G(O/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T-#1B7SEF96-?96$Q,F1A
M,30W9#1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,R8CAC8S4P
M7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7;W)K<VAE971S+U-H965T
M,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.
M;W1E(#(@+2!#87-H($5Q=6EV86QE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I
M=F%L96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S($1I
M<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X,C$^("`@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^*#(I($-!
M4T@@15%5259!3$5.5%,\+V(^/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR
M-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@R,SX@("`@(`T*("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/D]U<B!A=F%I;&%B;&4M9F]R
M+7-A;&4@<V5C=7)I=&EE<R!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$R
M(&-O;G-I<W1E9"!O9B!M;VYE>2!M87)K970@9G5N9',@<')I;6%R:6QY(&-O
M;G1A:6YI;F<@52Y3+B!G;W9E<FYM96YT+6)A8VME9"!S96-U<FET:65S+"!W
M:71H(&]R:6=I;F%L(&UA='5R:71I97,@;V8@;FEN971Y(&1A>7,@;W(@;&5S
M<RX@5&AE(&-A<G)Y:6YG('9A;'5E(&]F(&]U<B!M;VYE>2!M87)K970@9G5N
M9',@=V%S(&EN8VQU9&5D(&EN(&-A<V@@97%U:79A;&5N=',@86YD(&%P<')O
M>&EM871E9"!T:&5I<B!F86ER('9A;'5E+B!792!H879E(&YO(&%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q
M,RX@5&AE($-O;7!A;GDG<R!B86YK(&%C8V]U;G1S(&AA=F4@8F5E;B!P;&%C
M960@=6YD97(@82!C;VYT<F]L(&%G<F5E;65N="!I;B!A8V-O<F1A;F-E('=I
M=&@@=&AE($%P<FEL(#(P,3$@8V]N=F5R=&EB;&4@;F]T92!F:6YA;F-I;F<@
M*'-E92!.;W1E(#@I+CPO9F]N=#X@("`@#0H@("`@/"]P/CQB<B\^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@,R`M($9A:7(@5F%L=64@365A<W5R
M96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M(%9A;'5E($1I<V-L;W-U<F5S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M.#(U/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\
M8CXH,RD@1D%)4B!604Q512!-14%355)%345.5%,\+V(^/"]F;VYT/B`-"B`@
M("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@R-SX@("`@
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!T
M:')E92UT:65R(&9A:7(@=F%L=64@:&EE<F%R8VAY('5T:6QI>F5D('!R:6]R
M:71I>F5S('1H92!I;G!U=',@=7-E9"!I;B!M96%S=7)I;F<@9F%I<B!V86QU
M92!A<R!F;VQL;W=S.B!,979E;"`Q*2!O8G-E<G9A8FQE(&EN<'5T<R!S=6-H
M(&%S('%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',[($QE=F5L(#(I
M(&EN<'5T<R!O=&AE<B!T:&%N('1H92!Q=6]T960@<')I8V5S(&EN(&%C=&EV
M92!M87)K971S('1H870@87)E(&]B<V5R=F%B;&4@96ET:&5R(&1I<F5C=&QY
M(&]R(&EN9&ER96-T;'D[(&%N9"!,979E;"`S*2!U;F]B<V5R=F%B;&4@:6YP
M=71S(&EN('=H:6-H('1H97)E(&ES(&QI='1L92!O<B!N;R!M87)K970@9&%T
M82P@=VAI8V@@<F5Q=6ER92!U<R!T;R!D979E;&]P(&]U<B!O=VX@87-S=6UP
M=&EO;G,N(%1H92!H:65R87)C:'D@<F5Q=6ER97,@=7,@=&\@=7-E(&]B<V5R
M=F%B;&4@;6%R:V5T(&1A=&$L('=H96X@879A:6QA8FQE+"!A;F0@=&\@;6EN
M:6UI>F4@=&AE('5S92!O9B!U;F]B<V5R=F%B;&4@:6YP=71S('=H96X@9&5T
M97)M:6YI;F<@9F%I<B!V86QU92X@5V4@;65A<W5R960@;W5R(&%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S(&%T(&9A:7(@=F%L=64@;VX@82!R96-U
M<G)I;F<@8F%S:7,N(%=E('5S960@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@
M;6%R:V5T<R`H3&5V96P@;"D@=&\@;65A<W5R92!T:&4@9F%I<B!V86QU92!O
M9B!O=7(@8V%S:"!E<75I=F%L96YT<R!O;B!O=7(@0V]N9&5N<V5D($)A;&%N
M8V4@4VAE971S(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(N($-A<V@@
M97%U:79A;&5N=',@8V]N<VES=&5D(&]F(&AI9VAL>2!R871E9"!M;VYE>2!M
M87)K970@9G5N9',@=VET:"!M871U<FET:65S(&]F(&YI;F5T>2!D87ES(&]R
M(&QE<W,N($1U92!T;R`@("`-"B`@("`@('1H92!H:6=H(')A=&EN9W,@86YD
M('-H;W)T+71E<FT@;F%T=7)E(&]F('1H97-E(&9U;F1S+"!W92!C;VYS:61E
M<F5D('1H92!I;G!U=',@=7-E9"!T;R!V86QU92!A;&P@8V%S:"!E<75I=F%L
M96YT<R!A<R!,979E;"`Q(&EN<'5T<RX\+V9O;G0^("`@#0H@("`@/"]P/CQB
M<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C
M,F(X8V,U,%]E-CAB7S0T-&)?.69E8U]E83$R9&$Q-#=D-&,-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S)B.&-C-3!?938X8E\T-#1B7SEF96-?
M96$Q,F1A,30W9#1C+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-"`M($YE="!,;W-S
M(%!E<B!3:&%R93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%87)N
M:6YG<R!097(@4VAA<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X,CD^
M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXH
M-"DF(S$V,#M.150@3$]34R!015(@4TA!4D4\+V(^/"]F;VYT/B`@("`@#0H@
M("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.
M12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X,S$^("`@
M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY"87-I
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M960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R("AI;B!T:&]U<V%N9',I
M.CPO9F]N=#X@("`@(`T*("`@(#PO<#X\8G(O/CQT86)L92!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!X.R!724142#H@,3`P)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G
M(&ED/3-$5$),,3$W-2!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^("`@(`T*("`@("`@/'1R(&ED/3-$5$),,3$W-2YF:6Y2
M;W<N,3X@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%=)1%1(.B`W,"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX@("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C$N;&5A9"Y$,SX@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXQ+F%M
M="Y$,R!C;VQS<&%N/3-$-CX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,38S/B`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0G/DYI;F4@36]N=&AS($5N9&5D(%-E<'1E;6)E<B`S
M,"P\+V9O;G0^("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,3<U+F9I;E)O=RXQ+G1R86EL
M+D0S/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$Q-S4N9FEN
M4F]W+C(^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!724142#H@-S`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,3<U+F9I;E)O=RXR+FQE860N1#(^("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C(N86UT+D0R(&-O;'-P
M86X],T0R/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!
M4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3$V-#X@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T)SXR,#$S/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I
M9#TS1%1"3#$Q-S4N9FEN4F]W+C(N=')A:6PN1#(^("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60]
M,T140DPQ,3<U+F9I;E)O=RXR+FQE860N1#,^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C(N86UT+D0S(&-O;'-P86X],T0R
M/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P="<@:60],T1005)!,3$V-3X@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR
M,#$R/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"
M3#$Q-S4N9FEN4F]W+C(N=')A:6PN1#,^("`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@
M(#QT<B!I9#TS1%1"3#$Q-S4N9FEN4F]W+C,^("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#<P)2<^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N
M9FEN4F]W+C,N;&5A9"Y",CX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N9FEN
M4F]W+C,N<WEM8BY",CX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N9FEN4F]W
M+C,N86UT+D(R/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O=RXS+G1R
M86EL+D(R/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N9FEN4F]W+C,N;&5A
M9"Y",SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N9FEN4F]W+C,N<WEM8BY"
M,SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!I9#TS1%1"3#$Q-S4N9FEN4F]W+C,N86UT+D(S/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O=RXS+G1R86EL+D(S/B`@("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,3$W-2YF:6Y2;W<N-#X@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@-S`E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@
M("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z
M(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I
M9#TS1%!!4D$Q,38V/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D]P=&EO;G,@;W5T
M<W1A;F1I;F<\+V9O;G0^(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$Q-S4N9FEN4F]W+C0N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C0N<WEM8BXR/B`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXT+F%M="XR/B`@#0H@
M("`@("`@("`@,3(U+#,Y,B`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$Q-S4N9FEN4F]W+C0N=')A:6PN,B!N;W=R87`],T1N;W=R87`^(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-"YL
M96%D+C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF
M:6Y2;W<N-"YS>6UB+C,^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$Q-S4N9FEN4F]W+C0N86UT+C,^("`-"B`@("`@("`@("`V-RPY-#`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C0N
M=')A:6PN,R!N;W=R87`],T1N;W=R87`^(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT
M<B!I9#TS1%1"3#$Q-S4N9FEN4F]W+C4^("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#<P)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3$V.3X@("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T)SY787)R86YT<R!O=71S=&%N9&EN9SPO9F]N=#X@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C4N;&5A
M9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN
M4F]W+C4N<WEM8BXR/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,3<U+F9I;E)O=RXU+F%M="XR/B`@#0H@("`@("`@("`@-SDL,S<W("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C4N;&5A9"XS/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C4N<WEM8BXS/B`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+F%M
M="XS/B`@#0H@("`@("`@("`@.#0L,S<W("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+G1R86EL+C,@;F]W<F%P/3-$;F]W
M<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,3<U+F9I;E)O
M=RXV/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`W,"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`-"B`@
M("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P
M<'0G(&ED/3-$4$%203$Q-S(^("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^0V]M;6]N
M('-T;V-K('5N9&5R;'EI;F<@8V]N=F5R=&EB;&4@;F]T97,@;W5T<W1A;F1I
M;F<\+V9O;G0^("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,3<U+F9I;E)O=RXV+FQE860N,CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,3<U+F9I;E)O=RXV+G-Y;6(N,CX@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-BYA;70N,CX@(`T*("`@
M("`@("`@(#$R,RPY-3<@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,3<U+F9I;E)O=RXV+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C8N;&5A
M9"XS/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN
M4F]W+C8N<WEM8BXS/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,3<U+F9I;E)O=RXV+F%M="XS/B`@#0H@("`@("`@("`@,3$V+#<Y,"`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C8N
M=')A:6PN,R!N;W=R87`],T1N;W=R87`^(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`\+W1A
M8FQE/CQB<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C,F(X8V,U,%]E-CAB7S0T-&)?.69E8U]E83$R9&$Q-#=D-&,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S)B.&-C-3!?938X8E\T-#1B
M7SEF96-?96$Q,F1A,30W9#1C+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@;V8@0V]M<&5N
M<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S
M=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60]
M,T1005)!.#,V/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<^/&(^*#4I(%-43T-++4)!4T5$($-/35!%3E-!5$E/3CPO8CX\
M+V9O;G0^("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$
M4$%203@S.#X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T:&4@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&%L;"!A=V%R9',@
M*&EN('1H;W5S86YD<RP@97AC97!T('!E<B!S:&%R92!A;6]U;G1S*3H\+V9O
M;G0^("`@(`T*("`@(#PO<#X\8G(O/CQT86)L92!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!X.R!724142#H@,3`P)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$
M5$),,3(P-2!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^("`@(`T*("`@("`@/'1R(&ED/3-$5$),,3(P-2YF:6Y2;W<N,CX@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@-3(E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXR+FQE
M860N1#,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C(N86UT+D0S(&-O;'-P86X],T0V/B`-"B`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N
M=#X@("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,3<V/B`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^5&AR964@36]N=&AS($5N9&5D/"]F;VYT/CPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3$W.#X@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T)SY397!T96UB97(@,S`L/"]F;VYT/B`@("`@#0H@("`@("`@
M("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G
M(&ED/3-$5$),,3(P-2YF:6Y2;W<N,BYT<F%I;"Y$,SX@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60]
M,T140DPQ,C`U+F9I;E)O=RXR+FQE860N1#4^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C(N86UT+D0U(&-O;'-P86X],T0V
M/B`-"B`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@("`@(`T*("`@("`@("`@(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!
M4D$Q,3<W/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^3FEN92!-;VYT:',@16YD960\
M+V9O;G0^/"]F;VYT/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@
M,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED
M/3-$4$%203$Q-SD^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^4V5P=&5M8F5R(#,P+#PO
M9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`Q
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C(N=')A
M:6PN1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C`U+F9I
M;E)O=RXS/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/B`@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N,RYL96%D+D0R/B`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXS+F%M="Y$,B!C;VQS
M<&%N/3-$,CX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-
M05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q.#`^("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^,C`Q,SPO9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,C`U+F9I;E)O=RXS+G1R86EL+D0R/B`@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N,RYL96%D+D0S/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXS+F%M="Y$,R!C;VQS<&%N/3-$
M,CX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM
M0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q.#$^("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^
M,C`Q,CPO9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!0041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T14
M0DPQ,C`U+F9I;E)O=RXS+G1R86EL+D0S/B`@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),
M,3(P-2YF:6Y2;W<N,RYL96%D+D0T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C`U+F9I;E)O=RXS+F%M="Y$-"!C;VQS<&%N/3-$,CX@#0H@
M("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-
M.B`P<'0G(&ED/3-$4$%203$Q.#(^("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,SPO
M9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$
M24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U
M+F9I;E)O=RXS+G1R86EL+D0T/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N,RYL96%D+D0U/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C`U+F9I;E)O=RXS+F%M="Y$-2!C;VQS<&%N/3-$,CX@#0H@("`@("`@
M("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G
M(&ED/3-$4$%203$Q.#,^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,CPO9F]N=#X@
M#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/
M5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O
M=RXS+G1R86EL+D0U/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T14
M0DPQ,C`U+F9I;E)O=RXT/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)
M1%1(.B`U,B4G/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+FQE
M860N0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+G-Y;6(N
M0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+F%M="Y",CX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D(&ED/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I;"Y",CX@("`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+FQE860N0C,^("`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+G-Y;6(N0C,^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+F%M="Y",SX@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I;"Y",SX@("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60]
M,T140DPQ,C`U+F9I;E)O=RXT+FQE860N0C0^("`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T14
M0DPQ,C`U+F9I;E)O=RXT+G-Y;6(N0C0^("`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ
M,C`U+F9I;E)O=RXT+F%M="Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N-"YT<F%I;"Y"-#X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I
M;E)O=RXT+FQE860N0C4^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O
M=RXT+G-Y;6(N0C4^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT
M+F%M="Y"-3X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I
M;"Y"-3X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C4^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#4R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@
M(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U14
M3TTZ(#!P="<@:60],T1005)!,3$X-#X@("`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY/
M<&5R871I;F<@97AP96YS97,Z/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXU+FQE860N0C(^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C4N<WEM8BY",CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YA;70N0C(^(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M-2YT<F%I;"Y",CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C4N;&5A9"Y",SX@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YS
M>6UB+D(S/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60]
M,T140DPQ,C`U+F9I;E)O=RXU+F%M="Y",SX@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXU+G1R86EL+D(S
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),
M,3(P-2YF:6Y2;W<N-2YL96%D+D(T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXU+G-Y;6(N0C0^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C4N86UT+D(T/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C4N=')A:6PN0C0^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O
M=RXU+FQE860N0C4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C4N<WEM8BY"-3X@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YA
M;70N0C4^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N-2YT<F%I;"Y"-3X@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@
M("`\='(@:60],T140DPQ,C`U+F9I;E)O=RXV/B`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`U,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/
M4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q.#4^("`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P="<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F
M;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O
M=RXV+FQE860N,CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C`U+F9I;E)O=RXV+G-Y;6(N,CX@#0H@("`@("`@("`@)"`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C8N86UT+C(^(`T*("`@("`@("`@(#4T-"`@("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C8N;&5A9"XS/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C8N<WEM8BXS/B`-"B`@
M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYA;70N,SX@
M#0H@("`@("`@("`@,SDW("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C8N=')A:6PN,R!N;W=R87`],T1N;W=R87`^(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYL
M96%D+C0^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N-BYS>6UB+C0^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C`U+F9I;E)O=RXV+F%M="XT/B`-"B`@("`@("`@("`Q+#`X."`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV+G1R86EL+C0@
M;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C8N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C8N<WEM8BXU/B`-"B`@("`@("`@
M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYA;70N-3X@#0H@("`@
M("`@("`@,2PP-C$@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P
M-2YF:6Y2;W<N-BYT<F%I;"XU(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@
M(`T*("`@("`@/'1R(&ED/3-$5$),,3(P-2YF:6Y2;W<N-SX@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@-3(E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q
M,3DP/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D=E;F5R86P@86YD(&%D;6EN:7-T
M<F%T:79E/"]F;VYT/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C<N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C`U+F9I;E)O=RXW+G-Y;6(N,CX@("`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@.24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C<N86UT+C(^("`@("`-"B`@("`@("`@("`S+#4U,2`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M-RYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-RYL96%D+C,^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C<N<WEM8BXS/B`@("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-RYA;70N,SX@("`@(`T*
M("`@("`@("`@(#$L-3@S(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P>#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,C`U+F9I;E)O=RXW+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O
M=RXW+FQE860N-#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M-RYS>6UB+C0^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O
M=RXW+F%M="XT/B`@("`@#0H@("`@("`@("`@-RPR-#4@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,7!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C<N=')A:6PN-"!N
M;W=R87`],T1N;W=R87`^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C<N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,C`U+F9I;E)O=RXW+G-Y;6(N-3X@("`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C<N86UT+C4^("`@("`-"B`@("`@("`@("`R
M+#<Q,B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N-RYT<F%I;"XU(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@
M("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R,#4N9FEN4F]W+C@^("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!
M,3$Y-3X@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@97AP96YS93PO9F]N=#X@("`@(`T*("`@("`@("`@(#PO
M<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N;&5A9"XR/B`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N."YS>6UB+C(^(`T*("`@("`@
M("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N86UT+C(^(`T*("`@("`@("`@(#0L
M,#DU(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N=')A:6PN,B!N;W=R87`],T1N;W=R
M87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C@N;&5A9"XS/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2
M;W<N."YS>6UB+C,^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N
M86UT+C,^(`T*("`@("`@("`@(#$L.3@P(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N
M=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N;&5A9"XT/B`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N."YS>6UB+C0^(`T*("`@("`@("`@
M("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@
M.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C@N86UT+C0^(`T*("`@("`@("`@(#@L,S,S
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C@N=')A:6PN-"!N;W=R87`],T1N;W=R87`^
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W
M+C@N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M."YS>6UB+C4^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N86UT
M+C4^(`T*("`@("`@("`@(#,L-S<S(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N=')A
M:6PN-2!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@
M:60],T140DPQ,C`U+F9I;E)O=RXY/B`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`U,B4G/B`@
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN;&5A9"Y",CX@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,3(P
M-2YF:6Y2;W<N.2YS>6UB+D(R/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+F%M
M="Y",CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+G1R86EL+D(R/B`@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N.2YL96%D+D(S/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O
M=RXY+G-Y;6(N0C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN86UT+D(S/B`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+CDN=')A:6PN0C,^("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U
M+F9I;E)O=RXY+FQE860N0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN<WEM
M8BY"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8G(&ED/3-$5$),,3(P-2YF:6Y2;W<N.2YA;70N0C0^("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),
M,3(P-2YF:6Y2;W<N.2YT<F%I;"Y"-#X@("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R,#4N9FEN4F]W
M+CDN;&5A9"Y"-3X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8G(&ED/3-$5$),,3(P-2YF:6Y2;W<N.2YS>6UB+D(U/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@
M:60],T140DPQ,C`U+F9I;E)O=RXY+F%M="Y"-3X@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I
M;E)O=RXY+G1R86EL+D(U/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60]
M,T140DPQ,C`U+F9I;E)O=RXQ,#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(P,#X@("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T)SY);7!A8W0@;VX@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO
M<W,@<&5R(&-O;6UO;B!S:&%R93PO9F]N=#X@("`@(`T*("`@("`@("`@(#PO
M<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+FQE860N,CX@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YS>6UB+C(^("`-"B`@
M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@
M5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YA;70N,CX@(`T*("`@("`@
M("`@(#`N,#$@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%2
M1TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+G1R86EL+C(@;F]W
M<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N,3`N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C$P+G-Y;6(N,SX@(`T*("`@("`@("`@("0@(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C$P+F%M="XS/B`@#0H@("`@("`@("`@,"XP,2`@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`S<'@[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N,3`N=')A:6PN,R!N;W=R87`],T1N;W=R87`^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O
M=RXQ,"YL96%D+C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2
M;W<N,3`N<WEM8BXT/B`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M,3`N86UT+C0^("`-"B`@("`@("`@("`P+C`S("`@("`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#-P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I
M;E)O=RXQ,"YT<F%I;"XT(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+FQE860N-3X@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YS>6UB+C4^
M("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YA;70N-3X@(`T*
M("`@("`@("`@(#`N,#(@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+G1R86EL
M+C4@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`\+W1A8FQE
M/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X-#$^("`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN('1H92!T:')E
M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S+"!W92!R96-O<F1E
M9"!A9&1I=&EO;F%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M(&%S(&$@<F5S=6QT(&]F(&%C8V5L97)A=&5D('9E<W1I;F<@;V8@<W1O8VL@
M;W!T:6]N<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(')E<VEG;F%T:6]N(&]F
M(&]U<B!F;W)M97(@8VAI968@97AE8W5T:79E(&]F9FEC97(N/"]F;VYT/B`@
M#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X-#(^
M("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4
M:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@<W1O8VL@;W!T:6]N(&%C
M=&EV:71Y(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P
M+"`R,#$S.CPO9F]N=#X@("`-"B`@("`\+W`^/&)R+SX\=&%B;&4@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)R!I9#TS1%1"3#$R,S`@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R,S`N
M9FEN4F]W+C0^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^("`-"B`@("`@("`@("`\8CXF
M(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,C,P+F9I;E)O=RXT+FQE860N1#(^("`-"B`@("`@("`@
M("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N-"YA
M;70N1#(@8V]L<W!A;CTS1#(^(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C`V/B`@
M#0H@("`@("`@("`@("`\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E-H87)E<R`H:6X@=&AO=7-A;F1S*3PO
M8CX\+V9O;G0^/"]B/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/
M33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXT
M+G1R86EL+D0R/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N-"YL96%D+D0S/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@
M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C0N86UT+D0S(&-O;'-P86X],T0R
M/B`-"B`@("`@("`@("`\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/CPO8CX\+V9O;G0^/"]B/B`@(`T*("`@
M("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T)R!I9#TS1%!!4D$Q,C`Y/B`@#0H@("`@("`@("`@("`\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^/&(^
M5V5I9VAT960M($%V97)A9V4@17AE<F-I<V4\+V(^/"]F;VYT/CPO9F]N=#X\
M+V(^("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`@(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q
M,C$Q/B`@#0H@("`@("`@("`@("`\8CY0<FEC93PO8CX@(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!C
M96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I
M9#TS1%1"3#$R,S`N9FEN4F]W+C0N=')A:6PN1#,^("`-"B`@("`@("`@("`\
M8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXT+FQE860N1#0^("`-"B`@("`@
M("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N
M-"YA;70N1#0@8V]L<W!A;CTS1#(^(`T*("`@("`@("`@(#QB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQB/CPO8CX\+V9O;G0^/"]B/CPO9F]N=#X\+V(^/"]F;VYT/CPO8CX@
M("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM
M0D]45$]-.B`P<'0G(&ED/3-$4$%203$R,#<^("`-"B`@("`@("`@("`@(#QB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P="<^/&(^5V5I9VAT960M/"]B/CPO9F]N=#X\+V9O;G0^/"]F;VYT
M/CPO9F]N=#X\+V(^(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR
M-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$
M4$%203$R,#@^("`-"B`@("`@("`@("`@(#QB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY!=F5R86=E/"]F;VYT
M/CPO9F]N=#X\+V(^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`@(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS
M1%!!4D$Q,C$P/B`@#0H@("`@("`@("`@("`\8CY296UA:6YI;F<@0V]N=')A
M8W1U86P@5&5R;3PO8CX@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`@
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z
M(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I
M9#TS1%!!4D$Q,C$R/B`@#0H@("`@("`@("`@("`H665A<G,I("`@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$585"U!
M3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXT+G1R86EL+D0T/B`@#0H@("`@
M("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O
M=RXU/B`@("`-"B`@("`@("`@/'1D/B`@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S
M,"YF:6Y2;W<N-2YL96%D+D(R/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N-2YS>6UB+D(R/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2
M;W<N-2YA;70N0C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N
M=')A:6PN0C(^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YL
M96%D+D(S/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YS>6UB
M+D(S/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YA;70N0C,^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N=')A:6PN0C,^("`@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YL96%D+D(T/B`@("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YS>6UB+D(T/B`@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D(&ED/3-$5$),,3(S,"YF:6Y2;W<N-2YA;70N0C0^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I
M9#TS1%1"3#$R,S`N9FEN4F]W+C4N=')A:6PN0C0^("`@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@
M#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O=RXV/B`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`U-24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2
M1TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$R
M,3,^("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P="<^3W5T<W1A;F1I;F<@870@2F%N=6%R
M>2`Q+"`R,#$S/"]F;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(S,"YF:6Y2;W<N-BYL96%D+C(^("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N-BYS>6UB+C(^(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N86UT+C(^("`-
M"B`@("`@("`@("`X-BPT-S@@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,S`N9FEN4F]W+C8N=')A:6PN,B!N;W=R87`],T1N;W=R87`^(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N-BYL
M96%D+C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N-BYS>6UB+C,^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3(S,"YF:6Y2;W<N-BYA;70N,SX@(`T*("`@("`@("`@(#`N-#(@("`@(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N=')A
M:6PN,R!N;W=R87`],T1N;W=R87`^(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N;&5A9"XT/B`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXV+G-Y;6(N-#X@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N-BYA
M;70N-#X@(`T*("`@("`@("`@(#@N,B`@("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C,P+F9I;E)O=RXV+G1R86EL+C0@;F]W<F%P/3-$;F]W
M<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O
M=RXW/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@#0H@("`@("`@("`@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q
M,C$W/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D=R86YT960\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C<N;&5A
M9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN
M4F]W+C<N<WEM8BXR/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C,P+F9I;E)O=RXW+F%M="XR/B`@#0H@("`@("`@("`@-S8L-S,U("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXW+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C<N;&5A9"XS/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C<N<WEM8BXS/B`-"B`@
M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C<N86UT+C,^
M("`-"B`@("`@("`@("`P+C0P("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C,P+F9I;E)O=RXW+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P
M/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ
M,C,P+F9I;E)O=RXW+FQE860N0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N-RYS>6UB+D(T/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R
M,S`N9FEN4F]W+C<N86UT+D(T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N-RYT<F%I;"Y"-#X@("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,3(S,"YF:6Y2;W<N.#X@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*("`@("`@("`@(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM
M5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(R,#X@
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^(`T*("`@("`@
M("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C@N;&5A9"XR/B`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C@N
M<WEM8BXR/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P
M+F9I;E)O=RXX+F%M="XR/B`@#0H@("`@("`@("`@*#0L,S(S("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXX+G1R86EL+C(@
M;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`I("`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3(S,"YF:6Y2;W<N."YL96%D+C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,3(S,"YF:6Y2;W<N."YS>6UB+C,^(`T*("`@("`@("`@("0@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N."YA;70N,SX@(`T*("`@("`@
M("`@(#`N,C8@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M,S`N9FEN4F]W+C@N=')A:6PN,R!N;W=R87`],T1N;W=R87`^(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,S`N9FEN4F]W
M+C@N;&5A9"Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,C,P+F9I;E)O=RXX+G-Y;6(N0C0^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N
M."YA;70N0C0^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,C,P+F9I;E)O=RXX+G1R86EL+D(T/B`@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@
M#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O=RXY/B`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@
M34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C(S/B`@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0G/D5X<&ER960@86YD(&9O<F9E:71E9#PO9F]N=#X@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXY+FQE860N
M,CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N.2YS>6UB+C(^
M("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N.2YA;70N
M,CX@#0H@("`@("`@("`@*#,S+#0Y."`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXY+G1R86EL+C(@;F]W<F%P/3-$
M;F]W<F%P/B`@("`@#0H@("`@("`@("`@*2`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N
M9FEN4F]W+CDN;&5A9"XS/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,S`N9FEN4F]W+CDN<WEM8BXS/B`-"B`@("`@("`@("`D("`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(
M.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+CDN86UT+C,^("`-"B`@("`@("`@("`P
M+C0W("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S
M,"YF:6Y2;W<N.2YT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,S`N9FEN
M4F]W+CDN;&5A9"Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXY+G-Y;6(N0C0^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2
M;W<N.2YA;70N0C0^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N.2YT<F%I;"Y"-#X@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO
M='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O=RXQ,#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/
M4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$R,C8^("`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P="<^3W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P
M+"`R,#$S/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(S,"YF:6Y2;W<N,3`N;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,S`N9FEN4F]W+C$P+G-Y;6(N,CX@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(S,"YF:6Y2;W<N,3`N86UT+C(^("`@#0H@("`@("`@("`@,3(U
M+#,Y,B`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P
M+F9I;E)O=RXQ,"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YL96%D+C,^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W
M+C$P+G-Y;6(N,SX@(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S
M,"YF:6Y2;W<N,3`N86UT+C,^("`@#0H@("`@("`@("`@,"XT,"`@("`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C$P
M+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YL96%D+C0^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YS>6UB
M+C0^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I
M;E)O=RXQ,"YA;70N-#X@("`-"B`@("`@("`@("`X+C`@("`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C$P+G1R86EL
M+C0@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T86)L93X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#0W/B`@("`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CX\:3Y%;7!L;WEE
M92!3=&]C:R!0=7)C:&%S92!0;&%N/"]I/CPO8CX\+V9O;G0^(`T*("`@(#PO
M<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#0X/B`@("`@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^5V4@861O<'1E
M9"!A;B!%;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N("A0=7)C:&%S92!0
M;&%N*2!I;B`Q.3DW+B!1=6%L:69I960@96UP;&]Y965S(&UA>2!E;&5C="!T
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M97(@=&AE(%!U<F-H87-E(%!L86X@8GD@-3`P+#`P,"P@9F]R(&$@=&]T86P@
M;V8@,2PP,#`L,#`P('-H87)E<R!R97-E<G9E9"!A="!397!T96UB97(@,S`L
M(#(P,3,N(%1H92!P=7)C:&%S92!P<FEC92!P97(@<VAA<F4@:7,@97%U86P@
M=&\@.#4E(&]F('1H92!F86ER(&UA<FME="!V86QU92!O9B!T:&4@<W1O8VL@
M;VX@<W!E8VEF:65D(&1A=&5S+B!386QE<R!U;F1E<B!T:&4@4'5R8VAA<V4@
M4&QA;B!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,R!A;F0@,C`Q,B!C;VYS:7-T960@;V8@.#`L,#(W(&%N9"`U."PU
M-S$@<VAA<F5S(&%T(&%N(&%V97)A9V4@<')I8V4@;V8@)#`N,S$@86YD("0P
M+C(Q+"!R97-P96-T:79E;'DN(%-H87)E<R!A=F%I;&%B;&4@9F]R(&9U='5R
M92!P=7)C:&%S92!U;F1E<B!T:&4@4'5R8VAA<V4@4&QA;B!W97)E(#,V-2PV
M-S0@870@4V5P=&5M8F5R(#,P+"`R,#$S+CPO9F]N=#X@("`-"B`@("`\+W`^
M/&)R+SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`V("T@0V]M<')E
M:&5N<VEV92!,;W-S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!497AT($)L;V-K(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*2!.;W1E(%M497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ
M(#!P="<@:60],T1005)!.#4P/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T)SX\8CXH-BDF(S$V,#M#3TU04D5(14Y3259%($Q/
M4U,\+V(^/"]F;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@
M,'!T)R!I9#TS1%!!4D$X-3(^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T)SY#;VUP<F5H96YS:79E(&QO<W,@9F]R('1H92!P
M97)I;V1S(')E<&]R=&5D('=A<R!C;VUP<FES960@<V]L96QY(&]F(&]U<B!N
M970@;&]S<RX@5&AE(&-O;7!R96AE;G-I=F4@;&]S<R!F;W(@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@=V%S
M("0Q,BXY(&UI;&QI;VX@86YD("0T,2XR(&UI;&QI;VXL(')E<W!E8W1I=F5L
M>2X@5&AE(&-O;7!R96AE;G-I=F4@;&]S<R!F;W(@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(@=V%S("0V+C$@
M;6EL;&EO;B!A;F0@)#$U+C8@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!4:&5R
M92!W97)E(&YO(&-H86YG97,@:6X@97%U:71Y('1H870@=V5R92!E>&-L=61E
M9"!F<F]M(&]U<B!N970@;&]S<R!F;W(@86QL(')E<&]R=&5D('!E<FEO9',N
M/"]F;VYT/B`@(`T*("`@(#PO<#X\8G(O/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T-#1B7SEF96-?
M96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,R
M8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7;W)K<VAE971S
M+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY.;W1E(#<@+2!$:7-C;VYT:6YU960@3W!E<F%T:6]N<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-O
M;G1I;G5E9"!/<&5R871I;VYS(&%N9"!$:7-P;W-A;"!'<F]U<',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&ES<&]S86P@1W)O=7!S+"!);F-L=61I;F<@1&ES8V]N=&EN=65D($]P
M97)A=&EO;G,L($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!
M4D$X-30^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQB/B@W*28C,38P.T1)4T-/3E1)3E5%1"!/4$52051)3TY3/"]B/CPO9F]N
M=#X@("`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!.#4V/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^/&(^/&D^0V]S;65C975T:6-A;"!A;F0@5&]I;&5T<GD@0G5S:6YE
M<W,\+VD^/"]B/CPO9F]N=#X@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203@U.#X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;'DF(S$V,#LR-2P@,C`P,"P@=V4@
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M;VQO9VEC<R`H3W)T:&\I(&%N9"!$97)M:6L@3&%B;W)A=&]R:65S+"!);F,N
M("A$97)M:6LI("A'<F]S<R!0<F]F:70@1W5A<F%N='DI+"!B;W1H(&]F('=H
M:6-H('=E<F4@86-Q=6ER960@8GD@5F%L96%N="!0:&%R;6%C975T:6-A;',@
M:6X@2G5L>2`R,#$Q+B!4:&4@1W)O<W,@4')O9FET($=U87)A;G1Y(&5X<&5N
M<V4@=&]T86QE9"`D.30T+#`P,"!F;W(@=&AE(&9I<G-T('-E=F5N(&=U87)A
M;G1Y('EE87)S+B!%9F9E8W1I=F4@36%R8V@@,C`P-RP@:6X@8V]N:G5N8W1I
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M;&EO;B!R96QA=&5D('1O('1H92!A;6]U;G0@=&AA="!!;6-O;"`@#0H@("`@
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M960@=&AI<R!A8V-R=6%L(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+CPO9F]N
M=#X@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!
M4D$X-C`^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)SY4:&4@8V]S;65C975T:6-A;"!A;F0@=&]I;&5T<GD@8G5S:6YE<W,@
M:7,@<F5P;W)T960@87,@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,@9F]R(&%L
M;"!P97)I;V1S('!R97-E;G1E9"!I;B!O=7(@86-C;VUP86YY:6YG($-O;F1E
M;G-E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,N($EN8V]M92`H;&]S<RD@
M9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T:6]N<R!P<FEM87)I;'D@<F5P<F5S
M96YT<R!T:&4@:6YC;VUE("AL;W-S*2!A='1R:6)U=&%B;&4@=&\@8VAA;F=E
M<R!I;B!E<W1I;6%T97,@;V8@;W5R(&-O<VUE8V5U=&EC86P@86YD('1O:6QE
M=')Y(&)U<VEN97-S('1H870@=V%S('-O;&0@=&\@4E`@4V-H97)E<B!O;B!*
M=6QY)B,Q-C`[,C4L(#(P,#`L(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ
M/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\=&%B;&4@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I
M9#TS1%1"3#$R-#8@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/B`@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R-#8N9FEN4F]W
M+C(^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!724142#H@-3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^("`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,C0V+F9I;E)O=RXR+FQE860N1#,^("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C(N86UT+D0S(&-O;'-P86X]
M,T0V/B`-"B`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@("`@(`T*("`@("`@("`@(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS
M1%!!4D$Q,C,R/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^5&AR964@36]N=&AS($5N
M9&5D/"]F;VYT/CPO9F]N=#X@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@
M("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P
M="<@:60],T1005)!,3(S-#X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY397!T96UB97(@
M,S`L/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U14
M3TTZ(#%P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(T-BYF:6Y2;W<N
M,BYT<F%I;"Y$,SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C0V+F9I;E)O=RXR+FQE
M860N1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN
M4F]W+C(N86UT+D0U(&-O;'-P86X],T0V/B`-"B`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N
M=#X@("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C,S/B`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^3FEN92!-;VYT:',@16YD960\+V9O;G0^/"]F;VYT/B`@(`T*("`@
M("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T
M.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$R,S4^("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P="<^4V5P=&5M8F5R(#,P+#PO9F]N=#X@("`@(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!C
M96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C(N=')A:6PN1#4^("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@
M("`@("`\='(@:60],T140DPQ,C0V+F9I;E)O=RXS/B`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#4R)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(T-BYF:6Y2
M;W<N,RYL96%D+D0R/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C0V+F9I;E)O=RXS+F%M="Y$,B!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M)SX\+V9O;G0^("`@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(S-CX@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T)SXR,#$S/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C,N=')A:6PN1#(^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,C0V+F9I;E)O=RXS+FQE860N1#,^("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C,N86UT+D0S(&-O;'-P
M86X],T0R/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!
M4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(S-SX@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T)SXR,#$R/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C,N=')A:6PN1#,^("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60]
M,T140DPQ,C0V+F9I;E)O=RXS+FQE860N1#0^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C,N86UT+D0T(&-O;'-P86X],T0R
M/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P="<@:60],T1005)!,3(S.#X@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR
M,#$S/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"
M3#$R-#8N9FEN4F]W+C,N=')A:6PN1#0^("`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ
M,C0V+F9I;E)O=RXS+FQE860N1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C,N86UT+D0U(&-O;'-P86X],T0R/B`-"B`@
M("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ
M(#!P="<@:60],T1005)!,3(S.3X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR,#$R/"]F
M;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C,N=')A:6PN1#4^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C0^("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(T,#X@("`@(`T*("`@
M("`@("`@("`@/'4^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T)SY#;W-M96-E=71I8V%L(&%N9"!4;VEL971R>2!"=7-I
M;F5S<SPO9F]N=#X\+W4^(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R-#8N9FEN4F]W+C0N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N<WEM8BXR/B`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT+C(^(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(T-BYF:6Y2;W<N-"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N
M-"YL96%D+C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T
M-BYF:6Y2;W<N-"YS>6UB+C,^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(T-BYF:6Y2;W<N-"YA;70N,SX@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O
M=RXT+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+FQE860N-#X@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+G-Y
M;6(N-#X@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I
M;E)O=RXT+F%M="XT/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N=')A:6PN-"!N
M;W=R87`],T1N;W=R87`^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C0N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N<WEM8BXU/B`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT+C4^
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YT<F%I;"XU(&YO=W)A<#TS1&YO=W)A
M<#X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R-#8N9FEN
M4F]W+C0M,#X@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@-3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@
M("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T)R!I9#TS1%!!4D$Q,C0U/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D-H86YG
M92!I;B!E<W1I;6%T97,@9F]R(&=R;W-S('!R;V9I="!G=6%R86YT965S/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I
M;E)O=RXT+FQE860N,BTP/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V
M+F9I;E)O=RXT+G-Y;6(N,BTP/B`@(`T*("`@("`@("`@("0@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C0N86UT+C(M,#X@("`-"B`@("`@("`@("`M("`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`S<'@[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YT<F%I;"XR
M+3`@;F]W<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C0V+F9I;E)O=RXT+FQE860N,RTP/B`@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+G-Y;6(N,RTP/B`@(`T*("`@("`@
M("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT+C,M,#X@("`-"B`@("`@("`@
M("`Q,C@@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M-#8N9FEN4F]W+C0N=')A:6PN,RTP(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YL96%D
M+C0M,#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YS
M>6UB+C0M,#X@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+F%M
M="XT+3`^("`@#0H@("`@("`@("`@+2`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N=')A:6PN-"TP(&YO=W)A<#TS
M1&YO=W)A<#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T
M-BYF:6Y2;W<N-"YL96%D+C4M,#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3(T-BYF:6Y2;W<N-"YS>6UB+C4M,#X@("`-"B`@("`@("`@("`D("`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C0V+F9I;E)O=RXT+F%M="XU+3`^("`@#0H@("`@("`@("`@*#8@("`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`S<'@[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YT
M<F%I;"XU+3`@;F]W<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@*2`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T86)L
M93X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#8S/B`@("`-"B`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4:&5R92!W87,@
M;F\@;6%T97)I86P@8F%S:6,@86YD(&1I;'5T960@;&]S<R!P97(@8V]M;6]N
M('-H87)E(')E<W5L=&EN9R!F<F]M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS
M(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B`S,"P@,C`Q,R!A;F0@,C`Q,BX\+V9O;G0^("`@("`-"B`@("`\+W`^/&)R
M+SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,R
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`X("T@0V]N=F5R=&EB
M;&4@3F]T97,@=&\@4F5L871E9"!087)T:65S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!$:7-C;&]S=7)E
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E8G0@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203@V-3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQB/B@X*2!#3TY615)424),12!.3U1%4R!43R!214Q!5$5$
M(%!!4E1)15,\+V(^/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2
M1TE..B`P<'0G(&ED/3-$4$%203@V-SX@("`@(`T*("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN($%P<FEL(#(P,3$L('=E(&5N=&5R
M960@:6YT;R!A(%-E8W5R:71I97,@4'5R8VAA<V4@06=R965M96YT("A0=7)C
M:&%S92!!9W)E96UE;G0I('=I=&@@8V5R=&%I;B!I;G-T:71U=&EO;F%L(&EN
M=F5S=&]R<R`H4'5R8VAA<V5R<RDL(&EN8VQU9&EN9R!A(&9U;F0@869F:6QI
M871E9"!W:71H($ME=FEN($,N(%1A;F<L('=H;R!I<R!T:&4@0VAA:7)M86X@
M;V8@;W5R($)O87)D(&]F($1I<F5C=&]R<R`H0F]A<F0I+"!F;W(@82!P<FEV
M871E('!L86-E;65N="!O9B!U<"!T;R`D-"XU(&UI;&QI;VX@:6X@4V5N:6]R
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M($YO=&5S(&%T(&%N>2!T:6UE('5N=&EL($UA>2`R+"`R,#$S("A0=7)C:&%S
M92!/<'1I;VXI+B!4:&4@3F]T97,@87)E(&-O;G9E<G1I8FQE(&EN=&\@<VAA
M<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%T(&$@
M<F%T92!O9B`R-2PP,#`@<VAA<F5S(&9O<B!E=F5R>2`D,2PP,#`@;V8@<')I
M;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T(&1U92!U;F1E<B!T:&4@3F]T
M97,@*$-O;G9E<G-I;VX@4VAA<F5S*2X\+V9O;G0^("`@("`-"B`@("`\+W`^
M/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@V.3X@("`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!C87-H(')E
M8V5I=F5D(&9R;VT@=&AE(&EN:71I86P@8VQO<VEN9R!O9B!T:&4@3F]T92!F
M:6YA;F-I;F<L('=H:6-H(')E<W5L=&5D(&EN('1H92!I<W-U86YC92!O9B`D
M,2XU(&UI;&QI;VX@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@3F]T
M97,L('=A<R!A<'!R;WAI;6%T96QY("0Q+C,@;6EL;&EO;BP@;F5T(&]F(&ES
M<W5A;F-E(&-O<W1S+B!);B!-87D@,C`Q,BP@=&AE(%!U<F-H87-E<G,@97AE
M<F-I<V5D('1H96ER(%!U<F-H87-E($]P=&EO;B!I;B!F=6QL+"!A;F0@=V4@
M<F5C96EV960@)#,N,"!M:6QL:6]N(&]F(&-A<V@@=&AR;W5G:"!T:&4@:7-S
M=6%N8V4@;V8@=&AE(')E;6%I;FEN9R`D,RXP)B,Q-C`[;6EL;&EO;B!A9V=R
M96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B!.;W1E<RX@07,@82!R97-U;'0@
M;V8@=&AE(&5X97)C:7-E(&]F('1H92!0=7)C:&%S92!/<'1I;VXL('1H92!0
M=7)C:&%S97)S(&AA=F4@<'5R8VAA<V5D('1H92!F=6QL(&%M;W5N="!O9B!.
M;W1E<R!T:&%T('1H92!#;VUP86YY('=A<R!O8FQI9V%T960@=&\@<V5L;"!U
M;F1E<B!T:&4@4'5R8VAA<V4@06=R965M96YT+CPO9F]N=#X@("`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@W,3X@("`@(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!.;W1E
M<R!A<F4@<V5C=7)E9"!B>2!S=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4@87-S
M971S(&]F('1H92!#;VUP86YY+"!I;F-L=61I;F<@<&QA8VEN9R!O=7(@8F%N
M:R!A8V-O=6YT<R!U;F1E<B!A(&-O;G1R;VP@86=R965M96YT+B!4:&4@3F]T
M97,@:6YI=&EA;&QY(&)O<F4@:6YT97)E<W0@870@,C`E)B,Q-C`[<&5R(&%N
M;G5M+"!P87EA8FQE('%U87)T97)L>2!I;B!C87-H(&]R(&EN(&%D9&ET:6]N
M86P@<')I;F-I<&%L(&%M;W5N="!O9B!.;W1E<R!A="!T:&4@96QE8W1I;VX@
M;V8@=&AE(%!U<F-H87-E<G,N($EN($IU;F4@,C`Q,2P@=&AE($YO=&5S('=E
M<F4@86UE;F1E9"!T;R!R961U8V4@=&AE(&EN=&5R97-T(')A=&4@=&\@-B4F
M(S$V,#MP97(@86YN=6T@969F96-T:79E($IU;'DF(S$V,#LQ+"`R,#$Q+B!4
M:&4@3F]T97,@;6%T=7)E(&]N($UA>2`R+"`R,#(Q.R!H;W=E=F5R+"!T:&4@
M:&]L9&5R<R!O9B!T:&4@3F]T97,@;6%Y(')E<75I<F4@<')E<&%Y;65N="!O
M9B!T:&4@3F]T97,@870@86YY('1I;64@8F5G:6YN:6YG(&]N(&]R(&%F=&5R
M($UA>28C,38P.S(L(#(P,3(L(&%T(&5A8V@@:&]L9&5R)W,@;W!T:6]N+CPO
M9F]N=#X@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!.#<S/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^5&AE<F4@:7,@;F\@<FEG:'0@=&\@8V]N=F5R="!T:&4@3F]T97,@
M=&\@=&AE(&5X=&5N="!T:&%T+"!A9G1E<B!G:79I;F<@969F96-T('1O('-U
M8V@@8V]N=F5R<VEO;BP@=&AE(&AO;&1E<B!W;W5L9"!B96YE9FEC:6%L;'D@
M;W=N(&EN(&5X8V5S<R!O9B`Y+CDY)2!O9B!T:&4@0V]M<&%N>2=S(&]U='-T
M86YD:6YG(&-O;6UO;B!S=&]C:RX@16%C:"!H;VQD97(@;V8@=&AE($YO=&5S
M(&-A;B!I;F-R96%S92!O<B!D96-R96%S92!T:&ES(&)E;F5F:6-I86P@;W=N
M97)S:&EP(&-O;G9E<G-I;VX@;&EM:70@8GD@=W)I='1E;B!N;W1I8V4@=&\@
M=&AE($-O;7!A;GDL('=H:6-H('=I;&P@;F]T(&)E(&5F9F5C=&EV92!U;G1I
M;"`V,2!D87ES(&%F=&5R(&1E;&EV97)Y(&]F('1H92!N;W1I8V4N/"]F;VYT
M/B`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M.#<U/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&4@0V]M<&%N>2!W87,@
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M97,N/"]F;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T
M)R!I9#TS1%!!4D$X-S<^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T)SY0=7)S=6%N="!T;R!T:&4@4'5R8VAA<V4@06=R965M
M96YT+"!T:&4@0V]M<&%N>2!F:6QE9"!A(')E9VES=')A=&EO;B!S=&%T96UE
M;G0@;VX@1F]R;2!3+3$L(')E9VES=&5R:6YG(&9O<B!R97-A;&4@-CDN-B8C
M,38P.VUI;&QI;VX@<VAA<F5S('5N9&5R;'EI;F<@=&AE($YO=&5S+B!4:&4@
M<F5G:7-T<F%T:6]N('-T871E;65N="!W87,@9&5C;&%R960@969F96-T:79E
M(&]N($IU;'DF(S$V,#LR.2P@,C`Q,2X@5&AE(%!U<F-H87-E<G,@:&%V92!A
M9W)E960@=&\@=V%I=F4@=&AE:7(@<FEG:'0@=&\@<F5Q=6ER92!T:&4@0V]M
M<&%N>2!T;R!M86EN=&%I;B!T:&4@969F96-T:79E;F5S<R!O9B!T:&4@<F5G
M:7-T<F%T:6]N('-T871E;65N="!A;F0@=&\@<F5G:7-T97(@=&AE(&%D9&ET
M:6]N86P@<VAA<F5S('5N9&5R;'EI;F<@=&AE($YO=&5S('5N=&EL('1H97D@
M<')O=FED92!N;W1I8V4@;W1H97)W:7-E+CPO9F]N=#X@("`@#0H@("`@/"]P
M/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X-SD^("`@("`-"B`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4:&4@3F]T97,@
M8V]N=&%I;B!A;B!E;6)E9&1E9"!C;VYV97)S:6]N(&9E871U<F4@=&AA="!W
M87,@:6XM=&AE+6UO;F5Y(&]N(&)O=&@@:7-S=6%N8V4@9&%T97,N($)A<V5D
M(&]N(&%N(&5F9F5C=&EV92!F:7AE9"!C;VYV97)S:6]N(')A=&4@;V8@,C4L
M,#`P('-H87)E<R!F;W(@979E<GD@)#$L,#`P(&]F('!R:6YC:7!A;"!A;F0@
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M="!D96)T(&1I<V-O=6YT(&]V97(@=&AE(')E<W!E8W1I=F4@,3`M>65A<B!O
M<B!R96UA:6YI;F<@=&5R;2!O9B!T:&4@3F]T97,N($1U<FEN9R!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,RP@86-C<G5E9"!I
M;G1E<F5S="!O9B!A<'!R;WAI;6%T96QY("0W,RPP,#`@=V%S('!A:60M:6XM
M:VEN9"!A;F0@<F]L;&5D(&EN=&\@=&AE('!R:6YC:7!A;"!B86QA;F-E(&]F
M('1H92!.;W1E<RP@=VAI8V@@<F5S=6QT960@:6X@86X@861D:71I;VYA;"!F
M=6QL(&1E8G0@9&ES8V]U;G0@9F]R('1H92!R97-P96-T:79E('!E<FEO9',N
M($9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B`S,"P@,C`Q,RP@:6YT97)E<W0@97AP96YS92!R96QA=&EN9R!T;R!T:&4@
M<W1A=&5D(')A=&4@;V8@=&AE($YO=&5S('=A<R!A<'!R;WAI;6%T96QY("0W
M-"PP,#`@86YD(`T*("`@("`@)#(Q."PP,#`L(')E<W!E8W1I=F5L>2X@26YT
M97)E<W0@97AP96YS92!R96QA=&EN9R!T;R!T:&4@86UO<G1I>F%T:6]N(&]F
M(&1E8G0@9&ES8V]U;G0@9F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S('=A<R!A<'!R;WAI;6%T96QY("0Q
M,S0L,#`P(&%N9"`D,SDV+#`P,"P@<F5S<&5C=&EV96QY+CPO9F]N=#X@#0H@
M("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.
M12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X.#$^("`@
M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY!<R!O
M9B!397!T96UB97(@,S`L(#(P,3,L('1H92!C87)R>6EN9R!V86QU92!O9B!T
M:&4@3F]T97,@=V%S(&%P<')O>&EM871E;'D@)#@X."PP,#`L('=H:6-H(&ES
M(&-O;7!R:7-E9"!O9B!T:&4@)#0L.34X+#`P,"!P<FEN8VEP86P@86UO=6YT
M(&]F('1H92!.;W1E<R!O=71S=&%N9&EN9RP@;&5S<R!D96)T(&1I<V-O=6YT
M(&]F("0T+#`W,"PP,#`N($EF('1H92`D-2XP(&UI;&QI;VX@<')I;F-I<&%L
M(&%M;W5N="!O9B!.;W1E<R!I<R!C;VYV97)T960L('1H92!#;VUP86YY('=O
M=6QD(&ES<W5E(#$R-"XP(&UI;&QI;VX@<VAA<F5S(&]F(&ET<R!C;VUM;VX@
M<W1O8VLN($%C8W)U960@:6YT97)E<W0@;VX@=&AE('!R:6YC:7!A;"!B86QA
M;F-E('=A<R`D-S0L,#`P(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,RX\+V9O;G0^
M("`-"B`@("`\+W`^/&)R+SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T
M92`Y("T@4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q
M=6ET>2!.;W1E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4@
M1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@X,SX@("`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXH.2D@
M4U1/0TM(3TQ$15)3)R!%455)5%D\+V(^/"]F;VYT/B`@(`T*("`@(#PO<#X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#@U/B`@("`@#0H@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^/&D^06UE;F1M
M96YT<R!T;R!!<G1I8VQE<R!O9B!);F-O<G!O<F%T:6]N/"]I/CPO8CX\+V9O
M;G0^("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03@X-SX@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/DEN($IU;F4@,C`Q,2P@=V4@86UE;F1E9"!O=7(@8V5R=&EF:6-A=&4@
M;V8@:6YC;W)P;W)A=&EO;B!T;R!I;F-R96%S92!T:&4@;G5M8F5R(&]F('-H
M87)E<R!O9B!A=71H;W)I>F5D(&-O;6UO;B!S=&]C:R!T;R`Q+#4P,"PP,#`L
M,#`P+"!P87(@=F%L=64@)#`N,#$@<&5R('-H87)E+B!0<FEO<B!T;R!T:&4@
M86UE;F1M96YT+"!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!A=71H;W)I>F5D
M(&-O;6UO;B!S=&]C:R!W87,@,3`P+#`P,"PP,#`L('!A<B!V86QU92`D,"XP
M,2!P97(@<VAA<F4N(%1H92!C97)T:69I8V%T92!O9B!A;65N9&UE;G0@=V%S
M(&%P<')O=F5D(&)Y(&$@;6%J;W)I='D@;V8@;W5R('-T;V-K:&]L9&5R<R!O
M;B!*=6YE)B,Q-C`[,CDL(#(P,3$N/"]F;VYT/B`-"B`@("`\+W`^/&)R+SX\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR
M-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@X.3X@("`@(`T*("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN(%-E<'1E;6)E<B`R,#$S
M+"!O=7(@<W1O8VMH;VQD97)S(&%P<')O=F5D(&$@<')O<&]S86P@=&\@875T
M:&]R:7IE(&]U<B!";V%R9"!T;R!E9F9E8W0@82!R979E<G-E('-T;V-K('-P
M;&ET(&]F(&%L;"!O=71S=&%N9&EN9R!S:&%R97,@;V8@;W5R(&-O;6UO;B!S
M=&]C:R!A="!A;GD@<F%T:6\@870@:71S(&1I<V-R971I;VXL(&9R;VT@,2UF
M;W(M,3`@=&\@,2UF;W(M,C`@86YD('1O(&=R86YT('1H92!";V%R9"!D:7-C
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M92!R871I;R!O9B!T:&4@<F5V97)S92!S=&]C:R!S<&QI="X\+V9O;G0^("`-
M"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@Y,3X@
M("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB
M/CQI/E-T;V-K(%!L86YS/"]I/CPO8CX\+V9O;G0^("`@(`T*("`@(#PO<#X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#DS/B`@("`@#0H@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^070@;W5R(&%N;G5A
M;"!M965T:6YG(&]F('-T;V-K:&]L9&5R<R!I;B!*=6YE(#(P,3$L(&]U<B!S
M=&]C:VAO;&1E<G,@87!P<F]V960@86X@86UE;F1M96YT('1O(&]U<B`R,#`W
M($5Q=6ET>2!);F-E;G1I=F4@4&QA;B!T;R!I;F-R96%S92!T:&4@;6%X:6UU
M;2!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A=F%I;&%B;&4@
M9F]R(&=R86YT(&)Y(#DP+#`P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:RP@<F5S=6QT:6YG(&EN(&%N(&%G9W)E9V%T92!O9B`Y-2PP,#`L,#`P('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4@
M<'5R<W5A;G0@=&\@87=A<F1S(&=R86YT960@=6YD97(@;W5R(#(P,#<@17%U
M:71Y($EN8V5N=&EV92!0;&%N+B!4:&4@<W1O8VMH;VQD97)S(&%L<V\@87!P
M<F]V960@86X@86UE;F1M96YT('1O(&]U<B`Q.3DW($5M<&QO>65E(%-T;V-K
M(%!U<F-H87-E(%!L86X@=&\@:6YC<F5A<V4@=&AE(&YU;6)E<B!O9B!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC92!U;F1E
M<B!T:&4@<&QA;B!B>2`U,#`L,#`P+"!F;W(@82!T;W1A;"!O9B`Q+#`P,"PP
M,#`@<VAA<F5S(')E<V5R=F5D(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RX\
M+V9O;G0^(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!.#DU/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^/&(^/&D^,C`Q,2!0<FEV871E(%!L86-E;65N=#PO:3X\+V(^/"]F
M;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS
M1%!!4D$X.3<^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)SY);B!*=6YE(#(P,3$L('=E(&5N=&5R960@:6YT;R!A(%-E8W5R
M:71I97,@4'5R8VAA<V4@06=R965M96YT('=I=&@@8V5R=&%I;B!P=7)C:&%S
M97)S("A396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="DL('!U<G-U86YT
M('1O('=H:6-H('=E(&%G<F5E9"!T;R!S96QL(#$V,"PP,#`L,#`V('-H87)E
M<R!O9B!O=7(@8V]M;6]N('-T;V-K("A3:&%R97,I(&%N9"!W87)R86YT<R!T
M;R!P=7)C:&%S92`X,"PP,#`L,#`U('-H87)E<R!O9B!O=7(@8V]M;6]N('-T
M;V-K("A787)R86YT<RD@=VET:"!A;B!E>&5R8VES92!P<FEC92!O9B`D,"XQ
M."!P97(@<VAA<F4@*#(P,3$@4')I=F%T92!0;&%C96UE;G0I+"!F;W(@86X@
M86=G<F5G871E('!R:6-E(&]F("0R-"XP(&UI;&QI;VXN(%1H92`R,#$Q(%!R
M:79A=&4@4&QA8V5M96YT(&-L;W-E9"!O;B!*=6QY(#$L(#(P,3$N($9O<B!E
M86-H('-H87)E('!U<F-H87-E9"P@=&AE(&EN=F5S=&]R<R!R96-E:79E9"!O
M;F4@5V%R<F%N="!T;R!P=7)C:&%S92`P+C4@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R`H=&]G971H97(@=VET:"!A(%-H87)E+"!A(%5N:70I+"!A="!A('!U
M<F-H87-E('!R:6-E(&]F("0P+C$U('!E<B!5;FET+B!4:&4@5V%R<F%N=',@
M=V5R92!I;6UE9&EA=&5L>2!E>&5R8VES86)L92!A;F0@97AP:7)E(&]N('1H
M92!F:69T:"!A;FYI=F5R<V%R>2!O9B!T:&4@8VQO<VEN9R!D871E(&]F($IU
M;'D@,2P@,C`Q,2X@5&AE(%=A<G)A;G1S(&UA>2!B92!E>&5R8VES960@9F]R
M(&-A<V@@;VYL>2!O<BP@:68@82!R96=I<W1R871I;VX@<W1A=&5M96YT(&ES
M(&YO="!T:&5N(&5F9F5C=&EV92!A;F0@879A:6QA8FQE(&9O<B!T:&4@<F5S
M86QE(&]F('1H92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5A8FQE('5P
M;VX@97AE<F-I<V4@;V8@=&AE("`-"B`@("`@(%=A<G)A;G1S+"!B>2!S=7)R
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M/B`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203@Y
M.3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
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M(&YO="!A8FQE('1O('-E;&P@=&AE(`T*("`@("`@4F5G:7-T<F%B;&4@4V5C
M=7)I=&EE<R!W:71H;W5T(&QI;6ET871I;VX@=6YD97(@4G5L92`Q-#0L(&%N
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M;VYT:6YU;W5S;'D@969F96-T:79E(&9O<B!A(&1E<VEG;F%T960@=&EM92`H
M=VET:"!L:6UI=&5D(&5X8V5P=&EO;G,I/"]F;VYT/B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T)SYD=7)I;F<@=&AE('!E<FEO9"!T:&4@0V]M<&%N>2!I<R!O
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M/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03DP,3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1H92!#;VUP86YY(')E8V5I=F5D('1O=&%L('!R;V-E961S(&]F("0R
M,BXX(&UI;&QI;VX@9G)O;2!T:&4@,C`Q,2!0<FEV871E(%!L86-E;65N="P@
M=VAI8V@@=V%S(&YE="!O9B!I<W-U86YC92!C;W-T<R!O9B!A<'!R;WAI;6%T
M96QY("0Q+C(@;6EL;&EO;BX@1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY(')E8V5I=F5D("0P
M+C8@;6EL;&EO;B!F;W(@86X@97AE<F-I<V4@;V8@82!787)R86YT+CPO9F]N
M=#X@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Y
M,#,^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)SX\8CX\:3XR,#$R(%!R:79A=&4@4&QA8V5M96YT/"]I/CPO8CX\+V9O;G0^
M("`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03DP-3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/DEN($IU;'D@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@
M<V5C=7)I=&EE<R!P=7)C:&%S92!A9W)E96UE;G0@=VET:"!C97)T86EN('!U
M<F-H87-E<G,L('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY(&%G<F5E
M9"!T;R!S96QL(#$P,BPP,#`L,#`P('-H87)E<R!O9B!I=',@8V]M;6]N('-T
M;V-K("@R,#$R(%-H87)E<RD@870@82!P=7)C:&%S92!P<FEC92!O9B`D,"XU
M,C4@<&5R('-H87)E(&]F(&-O;6UO;B!S=&]C:RP@9F]R(&%N(&%G9W)E9V%T
M92!P<FEC92!O9B!A<'!R;WAI;6%T96QY("0U,RXV(&UI;&QI;VX@*#(P,3(@
M4')I=F%T92!0;&%C96UE;G0I+B!4:&4@,C`Q,B!0<FEV871E(%!L86-E;65N
M="!C;&]S960@;VX@2G5L>2`S,"P@,C`Q,BX\+V9O;G0^("`-"B`@("`\+W`^
M/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203DP-SX@("`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEN(&-O;FYE8W1I
M;VX@=VET:"!E;G1E<FEN9R!I;G1O('1H92!S96-U<FET:65S('!U<F-H87-E
M(&%G<F5E;65N="P@=&AE($-O;7!A;GD@86QS;R!E;G1E<F5D(&EN=&\@82!R
M96=I<W1R871I;VX@<FEG:'1S(&%G<F5E;65N="X@3VX@075G=7-T(#(T+"`R
M,#$R+"!T:&4@0V]M<&%N>2!F:6QE9"!A(')E9VES=')A=&EO;B!S=&%T96UE
M;G0@=VET:"!T:&4@4T5#('1O(')E9VES=&5R('1H92`R,#$R(%-H87)E<R!F
M;W(@<F5S86QE+B!4:&4@<F5G:7-T<F%T:6]N('-T871E;65N="!W87,@9&5C
M;&%R960@969F96-T:79E(&]N(%-E<'1E;6)E<B`V+"`R,#$R+B!)9B!T:&4@
M0V]M<&%N>2!F86EL<R!T;R!K965P('1H92!R96=I<W1R871I;VX@<W1A=&5M
M96YT<R!C;VYT:6YU;W5S;'D@969F96-T:79E(&9O<B!A(&1E<VEG;F%T960@
M=&EM92`H=VET:"!L:6UI=&5D(&5X8V5P=&EO;G,I+"!T:&4@0V]M<&%N>2!M
M87D@8F4@;V)L:6=A=&5D('1O('!A>2!T;R!E86-H(&AO;&1E<B!O9B!T:&4@
M,C`Q,B!3:&%R97,@86X@86UO=6YT(&5Q=6%L('1O(#$N-24@<&5R(&UO;G1H
M(&]F('1H92!A9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@=&AE('5N<F5G
M:7-T97)E9"`R,#$R(%-H87)E<R!H96QD(&)Y('-U8V@@:&]L9&5R+"!C87!P
M960@870@82!T;W1A;"!P96YA;'1Y(&]F(#DN,"4N/"]F;VYT/B`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203DP.3X@("`@(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP
M86YY(')E8V5I=F5D('1O=&%L('!R;V-E961S(&]F("0U,"XU(&UI;&QI;VX@
M9G)O;2!T:&4@,C`Q,B!0<FEV871E(%!L86-E;65N="P@=VAI8V@@=V%S(&YE
M="!O9B!I<W-U86YC92!C;W-T<R!O9B!A<'!R;WAI;6%T96QY("0S+C$@;6EL
M;&EO;BX\+V9O;G0^("`@#0H@("`@/"]P/CQB<B\^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14I#04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<RP@8GD@4&]L:6-Y("A0
M;VQI8VEE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYA='5R
M92!O9B!/<&5R871I;VYS(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!-SDU
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY!+E`N(%!H87)M82P@
M26YC+B`H=&AE("8C.#(R,#M#;VUP86YY+"8C.#(R,3L@)B,X,C(P.W=E+"8C
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M;'D@;VYC92!E=F5R>2!O;F4@;W(@='=O('=E96MS+CPO9F]N=#X@("`-"B`@
M("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203<Y.#X@("`@
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#
M;VUP86YY)B,X,C$W.W,@;&5A9"!P<F]D=6-T(&-A;F1I9&%T92P@05!&-3,P
M+"!I<R!B96EN9R!D979E;&]P960@9F]R('1H92!P<F5V96YT:6]N(&]F(&)O
M=&@@86-U=&4@8VAE;6]T:&5R87!Y+6EN9'5C960@;F%U<V5A(&%N9"!V;VUI
M=&EN9R`H0TE.5BD@9F]R('!A=&EE;G1S('5N9&5R9V]I;F<@8F]T:"!M;V1E
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M(&-O;G1A:6YS('1H92`U+4A4,R!A;G1A9V]N:7-T(&=R86YI<V5T<F]N(&9O
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M=&AE(&1E;&%Y960@#0H@("`@("!P:&%S92!O9B!#24Y6+B!'<F%N:7-E=')O
M;B!W87,@<V5L96-T960@9F]R($%01C4S,"!B96-A=7-E(&ET(&ES('=I9&5L
M>2!P<F5S8W)I8F5D(&)Y('!H>7-I8VEA;G,@8F%S960@;VX@82!W96QL+65S
M=&%B;&ES:&5D(')E8V]R9"!O9B!S869E='D@86YD(&5F9FEC86-Y+CPO9F]N
M=#X@("`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!.#`P/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^26X@36%Y(#(P,#DL('=E(&9I;&5D('1H92!O<FEG:6YA;"!.97<@
M1')U9R!!<'!L:6-A=&EO;B`H3D1!*2!S965K:6YG(&%P<')O=F%L(&9O<B!!
M4$8U,S`@=VET:"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T
M:6]N("A&1$$I+B!4:&4@1D1!(&ES<W5E9"!A($-O;7!L971E(%)E<W!O;G-E
M($QE='1E<B!F;W(@=&AE($%01C4S,"!.1$$@:6X@36%R8V@@,C`Q,"X@26X@
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M92!!4$8U,S`@3D1!(&EN(&ET<R!C=7)R96YT(&9O<FTN(%=E(&)E;&EE=F4@
M=&AE(&ES<W5E<R!T:&%T(')E;6%I;B!A<F4@861D<F5S<V%B;&4L(&%N9"!W
M92!A<F4@=V]R:VEN9R!E>'!E9&ET:6]U<VQY('1O(')E<W5B;6ET('1H92!!
M4$8U,S`@3D1!(&EN('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,30N/"]F;VYT
M/B`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!.#`R/B`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/E=E(&]W;B!T:&4@=V]R;&1W:61E(')I9VAT<R!T;R!!4$8U,S`@86YD
M(&%R92!I;B!T:&4@96%R;'D@<W1A9V5S(&]F(&)U:6QD:6YG('1H92!C;VUM
M97)C:6%L(&EN9G)A<W1R=6-T=7)E(&YE8V5S<V%R>2!T;R!C;VUM97)C:6%L
M:7IE($%01C4S,"!I;B!T:&4@52Y3+B!O;B!O=7(@;W=N+CPO9F]N=#X@("`@
M(`T*("`@(#PO<#X\8G(O/CQP(&ED/3-$4$%203$R-#D@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@;&EN92UH96EG:'0Z(#$N,C4[(&UA<F=I;CH@,'!T
M.R<^("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^
M26X@3F]V96UB97(@,C`Q,RP@=V4@:6YI=&EA=&5D(&$@<')O9W)A;2!T;R!E
M>'!A;F0@;W5R('!I<&5L:6YE(&]F('-U<W1A:6YE9"!R96QE87-E('!R;V1U
M8W1S+"!I;F-L=61I;F<@82!N97<@<')O9W)A;2!T87)G971I;F<@=&AE(')E
M;&EE9B!O9B!P;W-T+7-U<F=I8V%L('!A:6XN)B,Q-C`[(%=E(&%L<V\@86YN
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M97)E(&%R92!N;R!A<'!R;W9E9"`U+4A4,R!R96-E<'1O<B!A;G1A9V]N:7-T
M<R!F;W(@=&AE('1R96%T;65N="!O9B!D96QA>65D($A%0RX\+V9O;G0^("`@
M(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!.#`S
M/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@
M06-C;W5N=&EN9RP@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203@P-3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^5&AE
M(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@8V]N9&5N<V5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I
M=&@@52Y3+B!G96YE<F%L;'D@86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP
M;&5S("A5+E,N($=!05`I(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!I;F9O<FUA
M=&EO;B!A;F0@=VET:"!T:&4@:6YS=')U8W1I;VYS('1O($9O<FT@,3`M42!A
M;F0@07)T:6-L92`Q,"!O9B!296=U;&%T:6]N(%,M6"X@06-C;W)D:6YG;'DL
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M96UB97(@,S`L(#(P,3,@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E
M(&]F('1H92!R97-U;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D(&9O<B!T:&4@
M>65A<B!E;F1I;F<@1&5C96UB97(F(S$V,#LS,2P@,C`Q,R!O<B!F;W(@86YY
M(&]T:&5R('!E<FEO9"X@5&AE(&-O;F1E;G-E9"!B86QA;F-E('-H965T(&%S
M(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(@:&%S(&)E96X@9&5R:79E9"!F
M<F]M('1H92!A=61I=&5D("`@("`-"B`@("`@(&9I;F%N8VEA;"!S=&%T96UE
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M<B!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD
M960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,BP@=VAI8V@@=V%S(&9I;&5D('=I
M=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*%-%
M0RD@;VX@36%R8V@F(S$V,#LQ+"`R,#$S("@R,#$R(#$P+4LI+CPO9F]N=#X\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:7%U:61I='D@1&ES8VQO<W5R92!;4&]L:6-Y(%1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@
M,'!T)R!I9#TS1%!!4D$X,#<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CY,:7%U:61I
M='D\+V(^/"]F;VYT/CPO9F]N=#X@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3CH@,'!T)R!I9#TS1%!!4D$X,#D^("`@("`-"B`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<^5V4@:&%V92!I;F-U<G)E9"!S:6=N:69I8V%N="!O<&5R871I
M;F<@;&]S<V5S(&%N9"!N96=A=&EV92!C87-H(&9L;W=S(&9R;VT@;W!E<F%T
M:6]N<R!A;F0@:&%V92!A;B!A8V-U;75L871E9"!D969I8VET(&]F("0R,C0N
M."!M:6QL:6]N(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RX@1'5R:6YG(#(P
M,3$@86YD(#(P,3(L('=E(&5N=&5R960@:6YT;R!T:')E92!F:6YA;F-I;F<@
M86=R965M96YT<RP@=VAI8V@@<')O=FED960@=7,@8V%P:71A;"!T;R!F=6YD
M(&]P97)A=&EO;G,N($EN($%P<FEL(#(P,3$L('=E(&5N=&5R960@:6YT;R!D
M969I;FET:79E(&%G<F5E;65N=',@9F]R(&$@8V]N=F5R=&EB;&4@;F]T92!F
M:6YA;F-I;F<@;V8@=7`@=&\@)#0N-2!M:6QL:6]N+B!792!R96-E:79E9"!A
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M07!R:6P@,C`Q,2!C;VYV97)T:6)L92!N;W1E(&9I;F%N8VEN9R!F=6QL>2!E
M>&5R8VES:6YG('1H96ER(')I9VAT<R!T;R!P=7)C:&%S92!A9&1I=&EO;F%L
M(&-O;G9E<G1I8FQE(&YO=&5S("AS964@3F]T92`X*2X@26X@2G5N92`R,#$Q
M+"!W92!E;G1E<F5D(&EN=&\@9&5F:6YI=&EV92!A9W)E96UE;G1S(&9O<B!A
M('!R:79A=&4@<&QA8V5M96YT(&]F('5N:71S+"!W:&EC:"!W97)E("`-"B`@
M("`@(&-O;7!R:7-E9"!O9B!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S("AS
M964@3F]T92`Y*2X@5&AE('5N:70@9FEN86YC:6YG+"!W:&EC:"!C;&]S960@
M:6X@2G5L>2`R,#$Q+"!P<F]V:61E9"!U<R!W:71H(&%P<')O>&EM871E;'D@
M)#(R+C@@;6EL;&EO;B!O9B!P<F]C965D<RP@;F5T(&]F(&ES<W5A;F-E(&-O
M<W1S+B!);B!*=6QY(#(P,3(L('=E(&-L;W-E9"!A(&-O;6UO;B!S=&]C:R!F
M:6YA;F-I;F<@=VAE<F5B>2!W92!R96-E:79E9"!A<'!R;WAI;6%T96QY("0U
M,"XU(&UI;&QI;VX@;V8@<')O8V5E9',L(&YE="!O9B!I<W-U86YC92!C;W-T
M<R`H<V5E($YO=&4@.2DN($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=V4@
M:&%D(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@;V8@)#(R+C8@;6EL;&EO
M;BX\+V9O;G0^/"]F;VYT/B`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203@Q,3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)SY792!B96QI979E('1H870@;W5R(&-U<G)E;G0@=V]R:VEN9R!C87!I=&%L
M(&ES('-U9F9I8VEE;G0@=&\@9G5N9"!P;&%N;F5D(&]P97)A=&EO;G,@:6YT
M;R`R,#$T+B!(;W=E=F5R+"!W92!W:6QL(')E<75I<F4@861D:71I;VYA;"!C
M87!I=&%L('1O(&9U;F0@;W5R(&1E=F5L;W!M96YT(&%N9"!O<&5R871I;F<@
M86-T:79I=&EE<RX@268@=V4@87)E('5N86)L92!T;R!O8G1A:6X@<W5F9FEC
M:65N="!F:6YA;F-I;F<@;VX@86-C97!T86)L92!T97)M<R!O<B!O=&AE<G=I
M<V4L('=E(&UA>2!B92!R97%U:7)E9"!T;R!R961U8V4@;W(@9&5F97(@;W5R
M(&%C=&EV:71I97,N/"]F;VYT/CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!!
M8V-O=6YT:6YG(%!O;&EC:65S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M.#$T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CY#<FET:6-A
M;"!!8V-O=6YT:6YG(%!O;&EC:65S(&%N9"!%<W1I;6%T97,\+V(^/"]F;VYT
M/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03@Q-3X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M,3(@,3`M2RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5W($%C8V]U;G1I;F<@4')O;F]U;F-E
M;65N=',L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!
M4D$X,3<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E)E8V5N
M="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]B/CPO9F]N=#X@("`@#0H@
M("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.
M12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$X,3D^("`@
M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4:&5R
M92!H879E(&)E96X@;F\@<F5C96YT(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N
M=',@;W(@8VAA;F=E<R!I;B!A8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S(&1U
M<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S
M+"!A<R!C;VUP87)E9"!T;R!T:&4@<F5C96YT(&%C8V]U;G1I;F<@<')O;F]U
M;F-E;65N=',@9&5S8W)I8F5D(&EN(&]U<B`R,#$R(#$P+4LL('1H870@=V4@
M8F5L:65V92!A<F4@;V8@<VEG;FEF:6-A;F-E+"!O<B!P;W1E;G1I86P@<VEG
M;FEF:6-A;F-E+"!T;R!U<RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T-#1B7SEF
M96-?96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7;W)K<VAE
M971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.;W1E(#0@+2!.970@3&]S<R!097(@4VAA<F4@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%87)N:6YG<R!097(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@06YT
M:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO
M;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6U1A8FQE(%1E>'0@0FQO8VM=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'@[(%=)1%1(.B`Q,#`E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,3<U(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$Q-S4N9FEN
M4F]W+C$^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!724142#H@-S`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,3<U+F9I;E)O=RXQ+FQE860N1#,^("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N,2YA
M;70N1#,@8V]L<W!A;CTS1#8^("`-"B`@("`@("`@("`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM
M5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3$V,SX@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T)SY.:6YE($UO;G1H<R!%;F1E9"!397!T96UB97(@
M,S`L/"]F;VYT/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3$W-2YF:6Y2;W<N,2YT<F%I
M;"Y$,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,3<U+F9I
M;E)O=RXR/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@5TE$5$@Z(#<P)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/B`@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G(&ED/3-$5$),,3$W-2YF:6Y2;W<N,BYL96%D+D0R/B`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXR+F%M="Y$,B!C;VQS
M<&%N/3-$,CX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-
M05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q-C0^("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^,C`Q,SPO9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,3<U+F9I;E)O=RXR+G1R86EL+D0R/B`@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED
M/3-$5$),,3$W-2YF:6Y2;W<N,BYL96%D+D0S/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXR+F%M="Y$,R!C;VQS<&%N/3-$
M,CX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM
M0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q-C4^("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^
M,C`Q,CPO9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!0041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T14
M0DPQ,3<U+F9I;E)O=RXR+G1R86EL+D0S/B`@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@
M("`\='(@:60],T140DPQ,3<U+F9I;E)O=RXS/B`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U=)1%1(.B`W,"4G/B`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U
M+F9I;E)O=RXS+FQE860N0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I
M;E)O=RXS+G-Y;6(N0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O
M=RXS+F%M="Y",CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3$W-2YF:6Y2;W<N,RYT
M<F%I;"Y",CX@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O=RXS+FQE
M860N0C,^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O=RXS+G-Y;6(N
M0C,^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@:60],T140DPQ,3<U+F9I;E)O=RXS+F%M="Y",SX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D(&ED/3-$5$),,3$W-2YF:6Y2;W<N,RYT<F%I;"Y",SX@("`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$Q-S4N9FEN4F]W+C0^
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#<P)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@(`T*("`@("`@
M("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@
M:60],T1005)!,3$V-CX@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY/<'1I;VYS(&]U
M='-T86YD:6YG/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,3<U+F9I;E)O=RXT+FQE860N,CX@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,3<U+F9I;E)O=RXT+G-Y;6(N,CX@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-"YA;70N,CX@(`T*
M("`@("`@("`@(#$R-2PS.3(@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,3<U+F9I;E)O=RXT+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C0N
M;&5A9"XS/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N
M9FEN4F]W+C0N<WEM8BXS/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,3<U+F9I;E)O=RXT+F%M="XS/B`@#0H@("`@("`@("`@-C<L.30P
M("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXT
M+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\
M='(@:60],T140DPQ,3<U+F9I;E)O=RXU/B`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`W,"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@
M,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q-CD^("`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P="<^5V%R<F%N=',@;W5T<W1A;F1I;F<\+V9O;G0^("`-
M"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+FQE
M860N,CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I
M;E)O=RXU+G-Y;6(N,CX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3$W-2YF:6Y2;W<N-2YA;70N,CX@(`T*("`@("`@("`@(#<Y+#,W-R`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-2YT
M<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+FQE860N,SX@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXU+G-Y;6(N,SX@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-2YA
M;70N,SX@(`T*("`@("`@("`@(#@T+#,W-R`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3$W-2YF:6Y2;W<N-2YT<F%I;"XS(&YO=W)A<#TS1&YO
M=W)A<#X@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,3$W-2YF:6Y2
M;W<N-CX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@-S`E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@
M("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T)R!I9#TS1%!!4D$Q,3<R/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D-O;6UO
M;B!S=&]C:R!U;F1E<FQY:6YG(&-O;G9E<G1I8FQE(&YO=&5S(&]U='-T86YD
M:6YG/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3$W-2YF:6Y2;W<N-BYL96%D+C(^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,3$W-2YF:6Y2;W<N-BYS>6UB+C(^(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$Q-S4N9FEN4F]W+C8N86UT+C(^("`-"B`@
M("`@("`@("`Q,C,L.34W("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3$W-2YF:6Y2;W<N-BYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXV+FQE
M860N,SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I
M;E)O=RXV+G-Y;6(N,SX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3$W-2YF:6Y2;W<N-BYA;70N,SX@(`T*("`@("`@("`@(#$Q-BPW.3`@
M("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,3<U+F9I;E)O=RXV
M+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`U("T@4W1O8VLM
M0F%S960@0V]M<&5N<V%T:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#
M;VUP96YS871I;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N
M=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&ES8VQO<W5R92!O9B!3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G1S(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'1A8FQE('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'@[(%=)
M1%1(.B`Q,#`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@("`@(`T*
M("`@("`@/'1R(&ED/3-$5$),,3(P-2YF:6Y2;W<N,CX@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=724142#H@-3(E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^("`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXR+FQE860N1#,^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C(N86UT+D0S
M(&-O;'-P86X],T0V/B`-"B`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@("`@(`T*("`@
M("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T)R!I9#TS1%!!4D$Q,3<V/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^5&AR964@
M36]N=&AS($5N9&5D/"]F;VYT/CPO9F]N=#X@("`@#0H@("`@("`@("`@/"]P
M/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P="<@:60],T1005)!,3$W.#X@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY3
M97!T96UB97(@,S`L/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$
M1$E.1RU"3U143TTZ(#%P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P
M-2YF:6Y2;W<N,BYT<F%I;"Y$,SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I
M;E)O=RXR+FQE860N1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C(N86UT+D0U(&-O;'-P86X],T0V/B`-"B`@("`@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#X@("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z
M(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,3<W/B`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P="<^3FEN92!-;VYT:',@16YD960\+V9O;G0^/"]F;VYT
M/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q-SD^
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P="<^4V5P=&5M8F5R(#,P+#PO9F]N=#X@("`@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4
M+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C(N=')A:6PN1#4^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO
M='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C`U+F9I;E)O=RXS/B`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$
M5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/B`@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),
M,3(P-2YF:6Y2;W<N,RYL96%D+D0R/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C`U+F9I;E)O=RXS+F%M="Y$,B!C;VQS<&%N/3-$,CX@#0H@
M("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-
M.B`P<'0G(&ED/3-$4$%203$Q.#`^("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,SPO
M9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$
M24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U
M+F9I;E)O=RXS+G1R86EL+D0R/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N,RYL96%D+D0S/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C`U+F9I;E)O=RXS+F%M="Y$,R!C;VQS<&%N/3-$,CX@#0H@("`@("`@
M("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G
M(&ED/3-$4$%203$Q.#$^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,CPO9F]N=#X@
M#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/
M5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O
M=RXS+G1R86EL+D0S/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M,RYL96%D+D0T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U
M+F9I;E)O=RXS+F%M="Y$-"!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR
M-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$
M4$%203$Q.#(^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,SPO9F]N=#X@#0H@("`@
M("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@
M,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXS+G1R
M86EL+D0T/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N,RYL96%D
M+D0U/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O
M=RXS+F%M="Y$-2!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2
M1TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q
M.#,^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P="<^,C`Q,CPO9F]N=#X@#0H@("`@("`@("`@
M/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,7!X.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXS+G1R86EL+D0U
M/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C`U+F9I;E)O
M=RXT/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`U,B4G/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+FQE860N0C(^("`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+G-Y;6(N0C(^("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+F%M="Y",CX@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I;"Y",CX@("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60]
M,T140DPQ,C`U+F9I;E)O=RXT+FQE860N0C,^("`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T14
M0DPQ,C`U+F9I;E)O=RXT+G-Y;6(N0C,^("`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ
M,C`U+F9I;E)O=RXT+F%M="Y",SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N-"YT<F%I;"Y",SX@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I
M;E)O=RXT+FQE860N0C0^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O
M=RXT+G-Y;6(N0C0^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT
M+F%M="Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D(&ED/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I
M;"Y"-#X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+FQE860N
M0C4^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+G-Y;6(N0C4^
M("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@:60],T140DPQ,C`U+F9I;E)O=RXT+F%M="Y"-3X@("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D(&ED/3-$5$),,3(P-2YF:6Y2;W<N-"YT<F%I;"Y"-3X@("`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R,#4N9FEN4F]W+C4^("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@(`T*("`@("`@("`@
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q
M+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60]
M,T1005)!,3$X-#X@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY/<&5R871I;F<@97AP
M96YS97,Z/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,C`U+F9I;E)O=RXU+FQE860N0C(^("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C4N<WEM
M8BY",CX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N-2YA;70N0C(^(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YT<F%I;"Y",CX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+C4N;&5A9"Y",SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YS>6UB+D(S/B`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I
M;E)O=RXU+F%M="Y",SX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<@:60],T140DPQ,C`U+F9I;E)O=RXU+G1R86EL+D(S/B`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M-2YL96%D+D(T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,C`U+F9I;E)O=RXU+G-Y;6(N0C0^("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C4N86UT
M+D(T/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C4N=')A:6PN0C0^("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<@:60],T140DPQ,C`U+F9I;E)O=RXU+FQE860N0C4^
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+C4N<WEM8BY"-3X@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2;W<N-2YA;70N0C4^(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(P-2YF:6Y2
M;W<N-2YT<F%I;"Y"-3X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T14
M0DPQ,C`U+F9I;E)O=RXV/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`U,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'
M24XM0D]45$]-.B`P<'0G(&ED/3-$4$%203$Q.#4^("`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/B`-"B`@("`@
M("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV+FQE860N,CX@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV
M+G-Y;6(N,CX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C8N86UT+C(^(`T*("`@("`@("`@(#4T-"`@("`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV+G1R86EL+C(@;F]W<F%P
M/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+C8N;&5A9"XS/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C8N<WEM8BXS/B`-"B`@("`@("`@("`D("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYA;70N,SX@#0H@("`@("`@("`@
M,SDW("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C8N=')A:6PN,R!N;W=R87`],T1N;W=R87`^(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYL96%D+C0^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYS>6UB
M+C0^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXV
M+F%M="XT/B`-"B`@("`@("`@("`Q+#`X."`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C`U+F9I;E)O=RXV+G1R86EL+C0@;F]W<F%P/3-$;F]W
M<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C8N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C8N<WEM8BXU/B`-"B`@("`@("`@("`D("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Y
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N-BYA;70N-3X@#0H@("`@("`@("`@,2PP-C$@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-BYT
M<F%I;"XU(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R
M(&ED/3-$5$),,3(P-2YF:6Y2;W<N-SX@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@-3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P
M=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,3DP/B`@("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0G/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT
M/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W
M+C<N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXW
M+G-Y;6(N,CX@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W
M+C<N86UT+C(^("`@("`-"B`@("`@("`@("`S+#4U,2`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-RYT<F%I;"XR(&YO
M=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N-RYL96%D+C,^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C<N<WEM8BXS/B`@("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(P-2YF:6Y2;W<N-RYA;70N,SX@("`@(`T*("`@("`@("`@(#$L
M-3@S(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#%P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I
M;E)O=RXW+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXW+FQE860N-#X@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-RYS>6UB+C0^("`@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXW+F%M="XT/B`@
M("`@#0H@("`@("`@("`@-RPR-#4@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!X.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C<N=')A:6PN-"!N;W=R87`],T1N;W=R
M87`^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C<N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I
M;E)O=RXW+G-Y;6(N-3X@("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@.24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C<N86UT+C4^("`@("`-"B`@("`@("`@("`R+#<Q,B`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N-RYT<F%I
M;"XU(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT
M<B!I9#TS1%1"3#$R,#4N9FEN4F]W+C@^("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3$Y-3X@("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T)SY4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M97AP96YS93PO9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C@N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N."YS>6UB+C(^(`T*("`@("`@("`@("0@(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+C@N86UT+C(^(`T*("`@("`@("`@(#0L,#DU(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+C@N=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N;&5A9"XS
M/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N."YS>6UB+C,^
M(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N86UT+C,^(`T*("`@
M("`@("`@(#$L.3@P(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%2
M1TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N=')A:6PN,R!N;W=R
M87`],T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R,#4N9FEN4F]W+C@N;&5A9"XT/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3(P-2YF:6Y2;W<N."YS>6UB+C0^(`T*("`@("`@("`@("0@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C@N86UT+C0^(`T*("`@("`@("`@(#@L,S,S(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+C@N=')A:6PN-"!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N;&5A9"XU/B`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N."YS>6UB+C4^(`T*
M("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N86UT+C4^(`T*("`@("`@
M("`@(#,L-S<S(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.
M+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C@N=')A:6PN-2!N;W=R87`]
M,T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C`U
M+F9I;E)O=RXY/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`U,B4G/B`@("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R
M,#4N9FEN4F]W+CDN;&5A9"Y",CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,3(P-2YF:6Y2;W<N.2YS
M>6UB+D(R/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+F%M="Y",CX@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T14
M0DPQ,C`U+F9I;E)O=RXY+G1R86EL+D(R/B`@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,3(P-2YF:6Y2
M;W<N.2YL96%D+D(S/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+G-Y;6(N0C,^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN86UT+D(S/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R,#4N
M9FEN4F]W+CDN=')A:6PN0C,^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+FQE
M860N0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN<WEM8BY"-#X@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$
M5$),,3(P-2YF:6Y2;W<N.2YA;70N0C0^("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,3(P-2YF:6Y2;W<N
M.2YT<F%I;"Y"-#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)R!I9#TS1%1"3#$R,#4N9FEN4F]W+CDN;&5A9"Y"-3X@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G
M(&ED/3-$5$),,3(P-2YF:6Y2;W<N.2YS>6UB+D(U/B`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U
M+F9I;E)O=RXY+F%M="Y"-3X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ,C`U+F9I;E)O=RXY+G1R86EL
M+D(U/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,C`U+F9I
M;E)O=RXQ,#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#4R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@
M(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U14
M3TTZ(#!P="<@:60],T1005)!,3(P,#X@("`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY)
M;7!A8W0@;VX@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R(&-O;6UO
M;B!S:&%R93PO9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,#4N9FEN4F]W+C$P+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,C`U+F9I;E)O=RXQ,"YS>6UB+C(^("`-"B`@("`@("`@("`D("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C`U+F9I;E)O=RXQ,"YA;70N,CX@(`T*("`@("`@("`@(#`N,#$@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,#4N9FEN4F]W+C$P+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2
M;W<N,3`N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN
M4F]W+C$P+G-Y;6(N,SX@(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W
M+C$P+F%M="XS/B`@#0H@("`@("`@("`@,"XP,2`@("`@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`S<'@[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF
M:6Y2;W<N,3`N=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YL96%D+C0^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N,3`N<WEM8BXT
M/B`@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(P-2YF:6Y2;W<N,3`N86UT+C0^("`-
M"B`@("`@("`@("`P+C`S("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#-P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YT<F%I
M;"XT(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+FQE860N-3X@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C`U+F9I;E)O=RXQ,"YS>6UB+C4^("`-"B`@("`@("`@
M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z
M(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C`U+F9I;E)O=RXQ,"YA;70N-3X@(`T*("`@("`@("`@(#`N
M,#(@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,#4N9FEN4F]W+C$P+G1R86EL+C4@;F]W<F%P/3-$
M;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`\+W1A8FQE/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3=&]C:R!/<'1I;VYS+"!!
M8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\=&%B;&4@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,S`@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`@
M#0H@("`@("`\='(@:60],T140DPQ,C,P+F9I;E)O=RXT/B`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2
M;W<N-"YL96%D+D0R/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C0N86UT+D0R(&-O;'-P86X],T0R/B`-
M"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U14
M3TTZ(#!P="<@:60],T1005)!,3(P-CX@(`T*("`@("`@("`@("`@/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\
M8CY3:&%R97,@*&EN('1H;W5S86YD<RD\+V(^/"]F;VYT/CPO8CX@#0H@("`@
M("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N-"YT<F%I;"Y$,CX@(`T*("`@("`@
M("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C0N;&5A9"Y$,SX@(`T*
M("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I
M;E)O=RXT+F%M="Y$,R!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\
M8CX\+V(^/"]F;VYT/CPO8CX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM
M5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(P.3X@
M(`T*("`@("`@("`@("`@/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E=E:6=H=&5D+2!!=F5R86=E($5X
M97)C:7-E/"]B/CPO9F]N=#X\+V9O;G0^/"]B/B`@("`@#0H@("`@("`@("`@
M/"]P/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)
M3BU"3U143TTZ(#!P="<@:60],T1005)!,3(Q,3X@(`T*("`@("`@("`@("`@
M/&(^4')I8V4\+V(^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/
M33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXT
M+G1R86EL+D0S/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N-"YL96%D+D0T/B`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@
M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C0N86UT+D0T(&-O;'-P86X],T0R
M/B`-"B`@("`@("`@("`\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\8CX\+V(^/"]F;VYT/CPO
M8CX\+V9O;G0^/"]B/CPO9F]N=#X\+V(^("`@(`T*("`@("`@("`@(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!
M4D$Q,C`W/B`@#0H@("`@("`@("`@("`\8CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E=E:6=H=&5D
M+3PO8CX\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]B/B`-"B`@("`@
M("`@("`\+W`^(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@
M34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C`X/B`@#0H@("`@("`@
M("`@("`\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P="<^079E<F%G93PO9F]N=#X\+V9O;G0^/"]B/B`@#0H@("`@
M("`@("`@/"]P/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(Q,#X@(`T*("`@("`@
M("`@("`@/&(^4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\+V(^("`@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!,3(Q,CX@(`T*("`@
M("`@("`@("`@*%EE87)S*2`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.
M1RU"3U143TTZ(#%P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N-"YT<F%I;"Y$-#X@(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@
M("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@
M("`@/'1R(&ED/3-$5$),,3(S,"YF:6Y2;W<N-3X@("`@#0H@("`@("`@(#QT
M9#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N;&5A9"Y",CX@
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N<WEM8BY",CX@("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N86UT+D(R/B`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@:60],T140DPQ,C,P+F9I;E)O=RXU+G1R86EL+D(R/B`@("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!I9#TS1%1"3#$R,S`N9FEN4F]W+C4N;&5A9"Y",SX@("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I
M9#TS1%1"3#$R,S`N9FEN4F]W+C4N<WEM8BY",SX@("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS
M1%1"3#$R,S`N9FEN4F]W+C4N86UT+D(S/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ
M,C,P+F9I;E)O=RXU+G1R86EL+D(S/B`@("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$R
M,S`N9FEN4F]W+C4N;&5A9"Y"-#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N
M9FEN4F]W+C4N<WEM8BY"-#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$R,S`N9FEN
M4F]W+C4N86UT+D(T/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ,C,P+F9I;E)O=RXU
M+G1R86EL+D(T/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),
M,3(S,"YF:6Y2;W<N-CX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@-34E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.
M+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C$S/B`@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/D]U='-T86YD:6YG(&%T($IA;G5A<GD@,2P@,C`Q,SPO9F]N=#X@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N;&5A
M9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN
M4F]W+C8N<WEM8BXR/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C,P+F9I;E)O=RXV+F%M="XR/B`@#0H@("`@("`@("`@.#8L-#<X("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXV+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N;&5A9"XS/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N<WEM8BXS/B`-"B`@
M("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N86UT+C,^
M("`-"B`@("`@("`@("`P+C0R("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C,P+F9I;E)O=RXV+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P
M/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O
M=RXV+FQE860N-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3(S,"YF:6Y2;W<N-BYS>6UB+C0^(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C8N86UT+C0^("`-"B`@("`@("`@("`X
M+C(@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2
M;W<N-BYT<F%I;"XT(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@
M("`@/'1R(&ED/3-$5$),,3(S,"YF:6Y2;W<N-SX@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)
M3BU"3U143TTZ(#!P="<@:60],T1005)!,3(Q-SX@("`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T)SY'<F%N=&5D/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C,P+F9I;E)O=RXW+FQE860N,CX@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXW+G-Y;6(N,CX@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N-RYA;70N
M,CX@(`T*("`@("`@("`@(#<V+#<S-2`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,3(S,"YF:6Y2;W<N-RYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A
M<#X@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O
M=RXW+FQE860N,SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C,P+F9I;E)O=RXW+G-Y;6(N,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,C,P+F9I;E)O=RXW+F%M="XS/B`@#0H@("`@("`@("`@,"XT,"`@
M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N
M-RYT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N-RYL96%D+D(T
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"
M3#$R,S`N9FEN4F]W+C<N<WEM8BY"-#X@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXW+F%M="Y"-#X@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R
M,S`N9FEN4F]W+C<N=')A:6PN0C0^("`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT
M<B!I9#TS1%1"3#$R,S`N9FEN4F]W+C@^("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]4
M5$]-.B`P<'0G(&ED/3-$4$%203$R,C`^("`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^
M17AE<F-I<V5D/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,C,P+F9I;E)O=RXX+FQE860N,CX@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C,P+F9I;E)O=RXX+G-Y;6(N,CX@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N."YA;70N,CX@(`T*
M("`@("`@("`@("@T+#,R,R`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(S,"YF:6Y2;W<N."YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@#0H@
M("`@("`@("`@*2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C@N;&5A9"XS
M/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W
M+C@N<WEM8BXS/B`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N
M9FEN4F]W+C@N86UT+C,^("`-"B`@("`@("`@("`P+C(V("`@("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXX+G1R86EL+C,@
M;F]W<F%P/3-$;F]W<F%P/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXX+FQE860N0C0^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2
M;W<N."YS>6UB+D(T/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C@N86UT+D(T/B`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF:6Y2;W<N
M."YT<F%I;"Y"-#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),
M,3(S,"YF:6Y2;W<N.3X@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*("`@("`@
M("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@
M:60],T1005)!,3(R,SX@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY%>'!I<F5D(&%N
M9"!F;W)F96ET960\+V9O;G0^("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(S,"YF:6Y2;W<N.2YL96%D+C(^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R,S`N9FEN4F]W+CDN<WEM8BXR/B`@("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R,S`N9FEN4F]W+CDN86UT+C(^(`T*("`@("`@("`@("@S,RPT
M.3@@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N.2YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@
M("`@("D@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXY+FQE860N,SX@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXY+G-Y
M;6(N,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O
M=RXY+F%M="XS/B`@#0H@("`@("`@("`@,"XT-R`@("`@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+CDN=')A:6PN,R!N
M;W=R87`],T1N;W=R87`^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<@:60],T140DPQ,C,P+F9I;E)O=RXY+FQE860N0C0^("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N.2YS>6UB+D(T/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)R!I9#TS1%1"3#$R,S`N9FEN4F]W+CDN86UT+D(T/B`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R,S`N
M9FEN4F]W+CDN=')A:6PN0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED
M/3-$5$),,3(S,"YF:6Y2;W<N,3`^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.
M12U(14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/
M33H@,'!T)R!I9#TS1%!!4D$Q,C(V/B`@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D]U
M='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,SPO9F]N=#X@("`@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C$P+FQE
M860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YS
M>6UB+C(^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C$P
M+F%M="XR/B`@(`T*("`@("`@("`@(#$R-2PS.3(@("`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N,3`N=')A:6PN,B!N
M;W=R87`],T1N;W=R87`^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,3(S,"YF:6Y2;W<N,3`N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YS>6UB+C,^("`-"B`@("`@
M("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R,S`N9FEN4F]W+C$P+F%M="XS/B`@
M(`T*("`@("`@("`@(#`N-#`@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M93L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,C,P+F9I;E)O=RXQ,"YT<F%I;"XS(&YO=W)A<#TS1&YO
M=W)A<#X@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF
M:6Y2;W<N,3`N;&5A9"XT/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3(S,"YF:6Y2;W<N,3`N<WEM8BXT/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(S,"YF:6Y2;W<N,3`N86UT+C0^("`@#0H@
M("`@("`@("`@."XP("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,C,P+F9I;E)O=RXQ,"YT<F%I;"XT(&YO=W)A<#TS1&YO=W)A<#X@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`\+W1R/B`@(`T*("`@(#PO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]C,F(X8V,U,%]E-CAB7S0T-&)?.69E8U]E
M83$R9&$Q-#=D-&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S)B
M.&-C-3!?938X8E\T-#1B7SEF96-?96$Q,F1A,30W9#1C+U=O<FMS:&5E=',O
M4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DYO=&4@-R`M($1I<V-O;G1I;G5E9"!/<&5R871I;VYS("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&ES8V]N=&EN=65D($]P97)A=&EO;G,@86YD($1I<W!O<V%L($=R;W5P
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-O;64@*$QO<W,I(&9R;VT@1&ES8V]N=&EN=65D($]P
M97)A=&EO;G,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'1A8FQE('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'@[(%=)1%1(.B`Q,#`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C0V
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@
M("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R-#8N9FEN4F]W+C(^("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@
M-3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<^("`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C0V
M+F9I;E)O=RXR+FQE860N1#,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R-#8N9FEN4F]W+C(N86UT+D0S(&-O;'-P86X],T0V/B`-"B`@("`@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X@("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!4D$Q,C,R/B`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P="<^5&AR964@36]N=&AS($5N9&5D/"]F;VYT/CPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@("`\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T1005)!
M,3(S-#X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T)SY397!T96UB97(@,S`L/"]F;VYT/B`@
M("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(T-BYF:6Y2;W<N,BYT<F%I;"Y$,SX@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<@:60],T140DPQ,C0V+F9I;E)O=RXR+FQE860N1#4^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C(N86UT+D0U
M(&-O;'-P86X],T0V/B`-"B`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@("`@(`T*("`@
M("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T)R!I9#TS1%!!4D$Q,C,S/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^3FEN92!-
M;VYT:',@16YD960\+V9O;G0^/"]F;VYT/B`@(`T*("`@("`@("`@(#PO<#X@
M#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]4
M5$]-.B`P<'0G(&ED/3-$4$%203$R,S4^("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^4V5P
M=&5M8F5R(#,P+#PO9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!C96YT97([(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C(N=')A:6PN1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60]
M,T140DPQ,C0V+F9I;E)O=RXS/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#4R)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,3(T-BYF:6Y2;W<N,RYL96%D+D0R
M/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXS
M+F%M="Y$,B!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^("`@
M("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P="<@:60],T1005)!,3(S-CX@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR
M,#$S/"]F;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"
M3#$R-#8N9FEN4F]W+C,N=')A:6PN1#(^("`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ
M,C0V+F9I;E)O=RXS+FQE860N1#,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C,N86UT+D0S(&-O;'-P86X],T0R/B`-"B`@
M("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ
M(#!P="<@:60],T1005)!,3(S-SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR,#$R/"]F
M;VYT/B`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C,N=')A:6PN1#,^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C0V+F9I
M;E)O=RXS+FQE860N1#0^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R-#8N9FEN4F]W+C,N86UT+D0T(&-O;'-P86X],T0R/B`-"B`@("`@("`@
M("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@
M:60],T1005)!,3(S.#X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR,#$S/"]F;VYT/B`-
M"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]4
M5$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R-#8N9FEN4F]W
M+C,N=')A:6PN1#0^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ,C0V+F9I;E)O=RXS
M+FQE860N1#4^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C,N86UT+D0U(&-O;'-P86X],T0R/B`-"B`@("`@("`@("`\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U
M.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P="<@:60],T10
M05)!,3(S.3X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SXR,#$R/"]F;VYT/B`-"B`@("`@
M("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`Q
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C,N=')A
M:6PN1#4^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C0^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#4R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@
M(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U14
M3TTZ(#!P="<@:60],T1005)!,3(T,#X@("`@(`T*("`@("`@("`@("`@/'4^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M)SY#;W-M96-E=71I8V%L(&%N9"!4;VEL971R>2!"=7-I;F5S<SPO9F]N=#X\
M+W4^(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W
M+C0N;&5A9"XR/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M-#8N9FEN4F]W+C0N<WEM8BXR/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT+C(^(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2
M;W<N-"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YL96%D+C,^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YS
M>6UB+C,^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF
M:6Y2;W<N-"YA;70N,SX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+G1R86EL+C,@
M;F]W<F%P/3-$;F]W<F%P/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,C0V+F9I;E)O=RXT+FQE860N-#X@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+G-Y;6(N-#X@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+F%M="XT
M/B`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,'!X.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N=')A:6PN-"!N;W=R87`],T1N;W=R
M87`^("`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N
M9FEN4F]W+C0N;&5A9"XU/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$R-#8N9FEN4F]W+C0N<WEM8BXU/B`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT+C4^(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T
M-BYF:6Y2;W<N-"YT<F%I;"XU(&YO=W)A<#TS1&YO=W)A<#X@("`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T
M<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$R-#8N9FEN4F]W+C0M,#X@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@-3(E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T)R!I9#TS1%!!
M4D$Q,C0U/B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D-H86YG92!I;B!E<W1I;6%T
M97,@9F]R(&=R;W-S('!R;V9I="!G=6%R86YT965S/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+FQE860N
M,BTP/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+G-Y
M;6(N,BTP/B`@(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N86UT
M+C(M,#X@("`-"B`@("`@("`@("`M("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`S<'@[($)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YT<F%I;"XR+3`@;F]W<F%P/3-$
M;F]W<F%P/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V
M+F9I;E)O=RXT+FQE860N,RTP/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,C0V+F9I;E)O=RXT+G-Y;6(N,RTP/B`@(`T*("`@("`@("`@("0@(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R
M-#8N9FEN4F]W+C0N86UT+C,M,#X@("`-"B`@("`@("`@("`Q,C@@("`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$R-#8N9FEN4F]W+C0N
M=')A:6PN,RTP(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YL96%D+C0M,#X@("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YS>6UB+C0M,#X@("`-
M"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT+F%M="XT+3`^("`@#0H@
M("`@("`@("`@+2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$R-#8N9FEN4F]W+C0N=')A:6PN-"TP(&YO=W)A<#TS1&YO=W)A<#X@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YL
M96%D+C4M,#X@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N
M-"YS>6UB+C4M,#X@("`-"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,C0V+F9I;E)O=RXT
M+F%M="XU+3`^("`@#0H@("`@("`@("`@*#8@("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`S
M<'@[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3(T-BYF:6Y2;W<N-"YT<F%I;"XU+3`@;F]W
M<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@*2`@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T86)L93X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3S5!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$@+2!"=7-I;F5S<R!A;F0@0F%S:7,@
M;V8@4')E<V5N=&%T:6]N("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C<@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^3F5T($]F($ES<W5A;F-E($-O
M<W1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA>2`S,2P@,C`Q,CQB<CY0=7)C:&%S92!/<'1I;VX@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,3QB
M<CY0<FEV871E(%!L86-E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#$@+2!"=7-I;F5S
M<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N("A$971A:6QS*2!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5T86EN960@16%R;FEN9W,@*$%C8W5M=6QA=&5D($1E
M9FEC:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C(T
M+#@R-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q.#,L-3@W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@1&5B
M="!)<W-U86)L92!);B!#;VYN96-T:6]N(%=I=&@@4')I=F%T92!0;&%C96UE
M;G0Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!#;VYV97)T:6)L92!$96)T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S($9R;VT@4V%L92!/9B!5;FET<R!/
M9B!#;VUM;VX@4W1O8VL@06YD(%=A<G)A;G1S($YE="`H:6X@1&]L;&%R<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L.#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!)<W-U86YC92!O9B!0<FEV871E(%!L86-E
M;65N="`H:6X@1&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L
M96YT<RP@870@0V%R<GEI;F<@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8P+#`T."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R+#4Y-RPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S+#4P-BPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$W+#DW-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14M'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M3F]T92`T("T@3F5T($QO<W,@4&5R(%-H87)E("A$971A:6QS*2`M($]U='-T
M86YD:6YG('!O=&5N=&EA;&QY(&1I;'5T:79E(&]P=&EO;G,L('=A<G)A;G1S
M(&%N9"!C;VYV97)T:6)L92!N;W1E<SQB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<75I='D@3W!T:6]N(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I
M=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A
M<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PS
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-RPY-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET
M:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R
M(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL,S<W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0L,S<W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!$96)T(%-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV
M92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R
M;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(S+#DU
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q-BPW.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,4Q!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#4@+2!3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^16UP;&]Y
M964@4W1O8VL@4'5R8VAA<V4@4&QA;B`Q.3DW(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^16UP
M;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B`Q.3DW(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B`Q.3DW(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO
M=&4@-2`M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<RD@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($YU;6)E<B!O9B!!
M9&1I=&EO;F%L(%-H87)E<R!!=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A
M>6UE;G0@07=A<F0L($YU;6)E<B!O9B!3:&%R97,@075T:&]R:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L(%!U<F-H87-E(%!R:6-E(&]F
M($-O;6UO;B!3=&]C:RP@4&5R8V5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!097)I
M;V0L(%-H87)E<RP@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#`R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#4W,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT<R!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@4&5R
M:6]D+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E("AI;B!$;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!.
M=6UB97(@;V8@4VAA<F5S($%V86EL86)L92!F;W(@1W)A;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-2PV-S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1457044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3F]T92`U("T@4W1O8VLM0F%S960@0V]M<&5N<V%T
M:6]N("A$971A:6QS*2`M(%-T;V-K+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E
M;G-E("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E
M(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"PP.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3@P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#,S,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPW-S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM
M<&%C="!O;B!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@8V]M;6]N
M('-H87)E("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP
M96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@061M:6YI<W1R871I
M=F4@17AP96YS92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-34Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4X,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-RPR-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L-S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14E!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`U
M("T@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS*2`M(%-T;V-K
M+6)A<V5D($]P=&EO;B!$971A:6QS("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K+6)A<V5D($]P=&EO;B!$971A:6QS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R-2PS.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-BPT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<X('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A<G,@-S,@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8L-S,U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A
M;G1E9"`H:6X@1&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-"PS,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D("AI;B!$;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&ER960@86YD(&9O<F9E:71E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S,L-#DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER960@86YD(&9O<F9E
M:71E9"`H:6X@1&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14A%04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3F]T92`V("T@0V]M<')E:&5N<VEV92!,;W-S("A$971A:6QS*2`H55-$
M("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E(%1E>'0@0FQO8VL@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I+"!.970@
M;V8@5&%X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R+CDI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@V+C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@T,2XR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,34N-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2$)!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY.;W1E(#<@+2!$:7-C;VYT:6YU960@3W!E<F%T:6]N<R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XX-"!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#`W/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I
M;VYS(&%N9"!$:7-P;W-A;"!'<F]U<',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET:65S
M(&9O<B!'=6%R86YT965S(&]N($QO;F<M1'5R871I;VX@0V]N=')A8W1S+"!"
M96YE9FET<R!086ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Y-#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-R96%S92`H1&5C<F5A<V4I(&EN($]T:&5R($%C8W)U
M960@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T-#1B7SEF96-?96$Q,F1A,30W9#1C
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,R8CAC8S4P7V4V.&)?
M-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7;W)K<VAE971S+U-H965T,C4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5'2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#<@
M+2!$:7-C;VYT:6YU960@3W!E<F%T:6]N<R`H1&5T86EL<RD@+2!);F-O;64@
M*&QO<W,I(&9R;VT@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YC;VUE("AL;W-S*2!F<F]M(&1I<V-O;G1I;G5E9"!O<&5R
M871I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@97-T:6UA=&5S(&9O<B!G<F]S
M<R!P<F]F:70@9W5A<F%N=&5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P134T0TD^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T
M92`X("T@0V]N=F5R=&EB;&4@3F]T97,@=&\@4F5L871E9"!087)T:65S("A$
M971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0U/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6PN(#(Y+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/DEN:71I86P@
M0VQO<VEN9R!!;6]U;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,3QB<CY0=7)C:&%S92!/<'1I;VX@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R
M+B`S,"P@,C`Q,3QB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,3QB<CY0<FEN
M8VEP86P@06UO=6YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA>2`S,2P@,C`Q,CQB<CY396YI;W(@3F]T97,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`P,2P@
M,C`Q,3QB<CY396YI;W(@3F]T97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,3QB<CY396YI;W(@3F]T
M97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CY396YI;W(@3F]T97,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY0
M87EM96YT(&EN($MI;F0@*%!)2RD@3F]T92!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#@@+2!#
M;VYV97)T:6)L92!.;W1E<R!T;R!296QA=&5D(%!A<G1I97,@*$1E=&%I;',I
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!$96)T($ES
M<W5A8FQE($EN($-O;FYE8W1I;VX@5VET:"!0<FEV871E(%!L86-E;65N=#$\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!!=71H;W)I>F5D(%5N9&5R
M(%!R:79A=&4@4&QA8V5M96YT($EN:71I86P@0VQO<VEN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4'5R8VAA<V4@3W!T:6]N(%5N9&5R(%!R:79A=&4@4&QA8V5M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT($-O;G9E<G-I;VX@4F%T
M:6\L(%-H87)E<R`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@26YS=')U;65N
M="P@0V]N=F5R=&EB;&4L($-O;G9E<G-I;VX@4F%T:6\\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@1&5B="P@3F5T(&]F($ES<W5A;F-E($-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L($EN=&5R97-T(%)A=&4L(%-T
M871E9"!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@26YS=')U;65N="P@
M36%T=7)I='D@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y-87D@,BP-"@D),C`R,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT
M+"!-871U<FET>2!$871E(%)A;F=E+"!3=&%R=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-87D@,BP-"@D),C`Q,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5N969I8VEA;"!/=VYE<G-H:7`@069T97(@0V]N=F5R<VEO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+CDY)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F]T:6-E(%!E<FEO9"!!<W-O8VEA=&5D('=I=&@@0F5N969I8VEA;"!/=VYE
M<G-H:7`@4&5R8V5N=&%G92!,:6UI=&%T:6]N+"!#;VYV97)T:6)L92!.;W1E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-C$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N(%-H87)E<R!296=I<W1E<F5D($9O<B!297-A
M;&4@26X@0V]N;F5C=&EO;B!7:71H($-O;G9E<G1I8FQE($YO=&5S("AI;B!3
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PV,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!A:60M:6XM2VEN9"!);G1E<F5S=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&5R97-T($5X<&5N<V4L($1E8G0L($5X8VQU9&EN9R!!;6]R=&EZ
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@1&5B="!$:7-C
M;W5N="`H4')E;6EU;2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,SDV+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(V,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%R<GEI;F<@
M5F%L=64@;V8@3F]T97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#@X+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M.#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5B="!);G-T<G5M96YT+"!&86-E($%M;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.34X+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E8G0@26YS=')U;65N="P@56YA;6]R=&EZ960@1&ES8V]U;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`W
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L($-O;G9E<G1I8FQE+"!.=6UB97(@
M;V8@17%U:71Y($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(T+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!0
M87EA8FQE+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S)B.&-C-3!?938X8E\T-#1B
M7SEF96-?96$Q,F1A,30W9#1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T8R]7;W)K
M<VAE971S+U-H965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+5$%+/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DYO=&4@.2`M(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$
M971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C(X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XR($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C(X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C<@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XW($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$U($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`R.2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#(X
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^4V-E;F%R:6\L($%C='5A;"!;365M8F5R73QB<CY#;VUM
M;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY38V5N87)I;RP@4')O<&]S960@6TUE
M;6)E<ET\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4W1O8VL@0V]M
M<&5N<V%T:6]N(%!L86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CY3=&]C:R!#;VUP96YS871I
M;VX@4&QA;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/E!R:79A=&4@4&QA8V5M96YT(#(P,3$@
M6TUE;6)E<ET\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^4')I=F%T
M92!0;&%C96UE;G0@,C`Q,2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E!R:79A=&4@4&QA8V5M
M96YT(#(P,3$@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5L+B`S,"P@,C`Q,CQB<CY0<FEV871E(%!L86-E;65N="`R,#$R
M(%M-96UB97)=/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E!R:79A
M=&4@4&QA8V5M96YT(#(P,3(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`S,"P@,C`Q,CQB<CY0<FEV871E(%!L86-E
M;65N="`R,#$R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4')I=F%T92!0;&%C96UE;G0@,C`Q
M,B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;W1E(#D@+2!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T
M86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C
M:RP@4VAA<F5S($%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!3=&]C:RP@4&%R(&]R(%-T871E9"!686QU92!097(@4VAA
M<F4@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VMH;VQD97)S)R!%<75I='D@3F]T92P@4W1O8VL@4W!L:70L($-O;G9E<G-I
M;VX@4F%T:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3G5M8F5R
M(&]F($%D9&ET:6]N86P@4VAA<F5S($%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($YU;6)E<B!O9B!3:&%R97,@075T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!T:&4@3G5M8F5R
M(&]F(%-H87)E<R!O9B!#;VUM;VX@4W1O8VL@4F5S97)V960@9F]R($ES<W5A
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@0V%P:71A;"!3:&%R97,@
M4F5S97)V960@9F]R($9U='5R92!)<W-U86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;&4@;V8@4W1O8VLL($YU;6)E<B!O9B!3:&%R97,@27-S=65D(&EN(%1R86YS
M86-T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V,"PP,#`L,#`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&%S<R!O9B!787)R86YT(&]R(%)I
M9VAT+"!.=6UB97(@;V8@4V5C=7)I=&EE<R!#86QL960@8GD@5V%R<F%N=',@
M;W(@4FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@P+#`P,"PP,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L87-S(&]F(%=A<G)A;G0@;W(@
M4FEG:'0L($5X97)C:7-E(%!R:6-E(&]F(%=A<G)A;G1S(&]R(%)I9VAT<R`H
M:6X@1&]L;&%R<R!P97(@271E;2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XQ.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!)
M<W-U86YC92!O9B!0<FEV871E(%!L86-E;65N="`H:6X@1&]L;&%R<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`L-3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P+#4P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S+#8P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R97,@079A:6QA8FQE(%!E<B!787)R86YT($5X97)C:7-E9$-O;6UO
M;E-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4@07)R86YG96UE;G0L(%=A
M<G)A;G1S(%1O(%!U<F-H87-E(%-H87)E<RP@4'5R8VAA<V4@4')I8V4@4&5R
M(%5N:70@*&EN($1O;&QA<G,@<&5R($ET96TI/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI;6ET871I
M;VX@3VX@17AE<F-I<V%B;&4@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+CDY)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C=&EV
M92!2871E($]F($QI<75I9&%T960@1&%M86=E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M:79A=&4@4&QA8V5M96YT($-A<'!E9"!096YA=&QY/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BXP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@1G)O;2!386QE($]F(%5N:71S($]F($-O;6UO;B!3=&]C:R!!
M;F0@5V%R<F%N=',@3F5T("AI;B!$;VQL87)S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT<R!O9B!3=&]C:R!)<W-U86YC92!#;W-T<R`H:6X@1&]L;&%R<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@5V%R<F%N="!%
M>&5R8VES97,@*&EN($1O;&QA<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S
M=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#(L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4@4')I8V4@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N-3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]
M7TYE>'1087)T7V,R8CAC8S4P7V4V.&)?-#0T8E\Y9F5C7V5A,3)D83$T-V0T
%8RTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>27
<FILENAME>0001193125-13-437144-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-13-437144-xbrl.zip
M4$L#!!0````(`,=%;$,N1C)5@V(``-[N!``1`!P`87!P82TR,#$S,#DS,"YX
M;6Q55`D``R8Q@E(F,8)2=7@+``$$)0X```0Y`0``[%WI;]O(DO^^P/X/O5E@
MD`"1Q4.GG1A0?"1Z26P]VYECOP04V9+[#:]AD[;U_OJM:I(229$6)5'7/`T&
M,S+9W77]JKKZY(?_J=7(9VI33_.I0883PB[>^M8[4B,7CN7>ZXST;1_>ZCY[
MHO#,?J(>_`WO'WW?/:W7GY^?3W0HRG7F4>X$GDXY/B"UVCG!?_[[OSX@D0N/
M(HE3\A!0<N,\$5DADG3:[)XV)?+CX8(HDJR&E:#&R]`SR8MEVOSCFP0A?'SB
M>..Z(DEJG=G<UVR=O@E+GN);MF1Y8U8A6;A5#U_&1377U5(MPX-'S;,T%+6.
MK$M=58I+&S33*J?ZR=AYJL,+4;@FR355CHL'O#;6-'=:9:3QH6`D>I%3Q63V
MGZ](BJ^'&J<)"O[$I3R7A'B30^/%?(7"[]^`1%R2<:>AR.W75!^6B"M$@)E6
MR`/0C(VLK,^J:%CN=KMU\79:E.>5`P;D^N_?O]WKC]32:E,4Q/`DY`,V<LK%
M^SLZ(J+14]3+QS><6:Z)BA3/'CTZ^O@&T5"+C7[RPHTW]?.P(=T!;WGQ"3,^
MOM&EGSU^.U*E>^IBX9`@%H."U/:9/SF?/H!'S,"'(P;>)5BA*6%B"%WTO[XY
ME^"?CMR15/5#?58MV7Y]1B!^Y%*/.4::I-"%?QX:OUM3I0_U^-FTI5F]4,9Z
M)&3<4EIH.11:OJ0ZM*KLM]!*#?Y5Y;6%5GY>>XXE_R,P49,/SC[;'`3U_$N(
MQ9'5V^#U'^JSIX0D2U/;2)0-$1(_6U%9:E)9RDQ9^XB5E+*4)92E5*2L1J0L
MS3X\9,G;1E8SJ:P#0U9I956%K%8J4,M[J*)$H)8K"M3M5)>\C[A(]4[5=,F=
MR-*WNK^GD2.5A\A2%9;N1I;NN=XAP%MJ5))\26$$C(3&"!C]_'E#_=M1G_,`
M<]\+A_O\.[6&U'N3C#2;U@S&/3JVZ$Q"\2P<:YW2%]=D.O-#QHC!H"!GCATF
MW*>7C.NFPP./]EX8?W,N'A:)]:&>V^AY@I/ZE)4U(K>P7,G(/;7RFI$;K"FL
M_%V;1/U<_//G`(9/CS#PNW5]4-S4PH=JW3QQBBU;L6DA_#:7Z)2;(FJM:UHE
MF<*@`T=YLOQSX+$G:'E@:CI%V1+N>X#FC:8V3O.EVIJ-Y242+QG3_RIL/#<`
MBG]N-19O8014C;H*AT`_[WU'_S,3ZO;=&V+@]Z!)@YD!SJO>4SWPF,\HOWK1
MS<"@!DJ,$["!KZ%TMZ,KS;.9/>8#ZMT_:A[]-,EO(.U=<PK:FF/M8O@G%X[_
MCDC97Z3L8NPKMPICRF^:YVFIWO4(DQE,4MIY!2)_AVC2+HPF1XSL(49V$D<Z
MA7$D6BIE0Y->TJ$_4]8,-4?,3#&S0%O;&LWO),YT"^/,$4,'B*%=Q"%%RDX;
M2/\(Q,^?5Y9K.A-*18(7SZ?`<-N6N]WV@4P0Q19.R7+[;%.//S(7A;FZOQW,
MIACXIPD^3$PDE=#"OLXYM"H!B)S>BW"$Q3[`8@/;+Q2E,",YFGP/3+[S=$-1
M"].-(T#V#2`[R24:19N9?MY13C502`\HT"=J.BY*>/7B@O;I@0&D;^N.!48&
M36$CWQQ=))_IE+*$P%L<FFQ]IY;2+-JJ=83"#J&PBWUH2O&,Z1$*.XT*V\\@
MBB=&CU#8:538?J[0*<P5PD,E)BBF9UC,9MSW-)R]R8+A4*:P2L&AE-!;73;9
M?L[0+<P9CI#8/21VD3NH4F'N<(3$[B&QBQQ"E0MSB",D=@^)7>02JI*%1/H,
MV9;,O7EU12<9UE57<A>A)$V7?*3VOJM+DLKW05BPD@40M9$^#_#SGMK,\6X<
M/[F:>B`AY9MCCWWJ6;C,^3!Q,UMJYR3;X`AD`V<8U&;&4GV;^4PS+TR',WO<
MLYP@N?7F,"R66)">).::BT7;:*S?A-5:&:L=Y$F$!>;:]G&$3=BI77A"Z,*Q
M+,<6RQX'%Q&GZ=757P'PB;M)'!O^G-LBDA&QT'K5YE.[."6D=@HM/?"8K3,7
M\LV##:9]<`,OP#:2_IDGU]_9Q-U"$Q_3F\HG6'=AX894>-3O:.%-3*%O_<1?
M(]R9-3WFEVO6HU7729S"P>::B5-C>L=+M,7R:+%-1MK64J<RI0K\,)Q/43J1
M61\<I1O]W-JP945=M6M*I[RNE.[ZNBK>(C30)FC^OOV5V<:@_Q71\_?RBF()
MMY1I[F)5K]',[!\^9A\5]U-5;0!N%&_4.=JL\IYJ%VMGC?`2(^R>;&5ZM<U^
M=5'I!*PE.IUU@1U>8X0=].&(W5E?[&B,'SEQ^HAA9C;KY[U.;0U:[^E^H)F'
M=SYU8]-X*S$QU68ZUN3H>'L]?W?K=^I)*^!OX#FNPZEQ8-/^^PP_,<&9K]_7
MUHK^#@B4,R/OZ>'&?>P"UAG(5K+2W52B5'V/E93M)RO(>YMJ6NSPRA=T87`P
ML>,&S_`<7-[;>]8\(R?A+19NL]%@$Y9K9,>61\MMUG)5C36;S:+(G),;9&]Z
MPV+)#/5`S+H?.4(PY,Q@FC>YUTQZ.Q)TT@NA!;K>YBGW[7=]K4P?<$3A?QX*
M-]%#M;-QKO!6SC2>#@1,>VG']5:$*EB9;7:*K+Z/*?7NU17=N+W/2LJN"U=P
MSWA+FLN!4E]HV"\%K(R2J@;SK?G!_'3I\!A*]RV45F;UN;,=4G0^L%R*IAQ3
MM*WA4=DR'I<\:]2N!(^SR:(C"O]349C^TDJ[BH%"JU$8YU['TX&`:2_MN/MH
M4G1-3FY.<[3Z1JR^]2U1K5:.K]M'7]];7U]UBC&P66CR@!O)]0>+:GB#W'GT
M;=/3'_>7'^KQ0S)K#^LG_DXV-\!KZ32/\@0N#/8$!DU)C55N`@L_TNLD]S"5
M86*F\FPKZ?8OJ>U8S([?Y=$0W]<]#1G.D71&)=O65-<SV1;H9JJ5C*X+6'B]
M,1?*I';!I%O#U_,Z6V0W!FE5.A/<7\-%G]<]19XW9+@XC]0XWH6$_\.$\PE"
M!^::_H7F>1-FCW_5S(`2K'R''])%CR*1OXD'<]_,)0;5F:69_..;FOKF7%&:
MW3:$O@_UI2B>5\]H]CNW&4:;:E-J5<'HP*.NQHSH(@AHX-9_I%Z/<^KSB\#S
MH)$U]-ENJ2DF2U`[KYC#18KL--;FL"IM*:J*-DUPDZ&[&M5%&FA(W?)4<6L0
M]7QQJZD/ZD&LB4O);NA:HG>:[8P=BNGD!(95V5J@&[G=5-9A*P&>&\?6UT:(
MW$S[4V[[5?"Q2"^JM!(?89%U<-)2VWE@/5^:T"*O@(Y`*4-(U_$L,!]H$VUH
MT@J"@-+,")A+83X(+<W((AMW965%1KR`&M^8-F2F^$!"%9$Q&QB+B,SW<"OQ
MLS@N+,V/&-8D/B(ACA-$NKRC)@P:C`&,,RK15Z?3$>PM33/ALY7RNT"?C:ZR
M-K_3HQQ5`J_9Z'92ABZP\#HL+-*-W&PLST)BQG7=I%B5Y338LVV?KTYZ@>RJ
MI#26(=TS#(:;WC1S`$E<W[[07.9KYCJ1IZ$T.]VTK^<3F>L9EN=E@38455$[
M\BJ\W%%?8S8UXB_?0+@*K$#XTR4=X23*&BJJ*4JCHZ33M\4$<S"['I<+E%>3
M.VJS4P&7`GR/CFE0CX>K'NO`2^IDTHSYYL_7H;\HS9%QEF\I^HGP`PEPM=J8
MR^X6$9OO[M=A;^F<<'GV7KW1^37>E*(ST?,CVDXS@_)72,Y'BA7YF_OJ<'SC
MYEQ,;RFM'?!7^)G?^2@K=SI+,5@1AX6?EYW+/B5)4=;@<,%MH)6@L-5NIWO-
M!43/*V.Q-!"A:^_LAL726)3;#75)'BMCLC0<L0]90X^W+LX\0_<;O7YUU%X:
M?[+2:J53QSDZ\\%Y*59*XZPE-4MPLCHCI='4D+*AMVJ=E`]A34525V8EO//X
MF\.KP4KM%;#,2*W-3VG`U(H1DV9G'6Y*HZ;V"FPJU$YIZ-1>P<YK_/2!F$>Y
M'Y:)4';CV$Y<><%4<7DX*5*ZZRM#^;Q:9LMC3>XV=\UL>2BVY,:NF2V/TX:D
MK,]LC.?P([8V%`N@9`1XQZXL`';::H;9193S/&P=;I<(CTHCZV!EF*V0UR6"
MIRQFL':JV65"*W0]%7.+'T,,JU%C5@NP?CMZT%YZON^Q8>#C#.^#<T==QQ-)
M@-BM4PE<Y$R67QEW.Q*\O#5;FY,[)3;4JCXCRP:D%)'L,*<T!TL$&5F17V-@
M-?KK!(YJ-+!4,)!?5<&R,6I`O4\:9SK.4N#'UJDA/K^>XG:V96T%Z"C`M70B
M-98)7P5,K1*#UY&O%#`C^90#E*\4\$/Y9/4`Y2OE5I']VAN1+U[$@`JB1*;6
M)KUL`>ELI*B"TQ7]90><KHC\'7"Z(H:7Y/0WRL:/\+SW!!`?TYL`=V_?CD35
MV\#'`S(&-%<HP.K`#5>4VXUN.C%:C:&MB%5^+KO=:&16+?98K-)9D"JUI,.Q
M5NG4"O=X97;&5B/6)74]H!1^`<XV>A;F[?\6?U:T-I9>0'^%7D6LE9]1;JS,
M6ARUJ)&\.*D2A754-6WG?%IS0ZKE62JM*+7=7HFEI`9O1WA1KAA#!K8_\*C%
M`JL2A:D9=U](-6?#WSJ,EO?AEK(NHY#\>13T?DG#__?M:/?Y)1U1SZ/YN]"K
M<>2YN<E56)F?K:Q8GM+6Z,Q-"*XD3@D397;!5F*-YMRT]@*J9;"T!*.EU2PV
M0VZ`T<S>V6I"KS(W_[60<%D$+,%O^?D6M;G()_,8SLX"X0&@@>?@>2KCT^0'
M1/6^/5T?Z^D^>ZI.Q355EM56=HJH)`<YNJZ&_25FN*1.YOC/6NQ'GV[@#TY/
M_RM@'BT\+5+-YI!F9NM>>?KSAZPJ8;W\EI%&:W7.RT"F;S]1O@G$SRF]/`/S
ML;`:YLOC/:OVY7C/'KC2*37$M%6?\T"S=7H[2FS/K@8G4J.;GH)>2'?^O-JT
M?.)@`>9GU633DB05,I@A^*H2?],\3\,]>]33654[?EJO,)<EF'<V=%9:Z#;\
M,"F/JQC5A#%QS*B`R5RR^>?_<F`A1C;\AVU0#SI3O`'@"5.^_`$/AIJ*DNMF
M"<@NS]LKR-Z4R.5'W]ESOAL1N2!>73,;"%0?[.5VHUDF7N;0SULCK8#U\H%3
MA="Y!N]E3K,/Q,T6V2RUHL12ZF8V42W#P^8D*&V`AB*U&VL)4.U]`JW4T09Y
M'NK=4NQN_N*#=NJ(2,YF6JG168=1@[+3<!_#'1V+K<FV?Z-9M"Q2SWL#,OC2
MN_O>(_V;"U*_O*I_J!<UFB9[Z>CBD\)X:WMI<K)4^V=((%D]W7!T#/":<5TS
M_Z":=Q7>0E.:2*TF*^*VTM=:.\\J,)%UA:$],5&]8*J\$\'Q5O>S_M^_N<8S
MAVI+;JFM;E*WK]%+Y`18H0>*,E!9UZ8V+JV&$3!`0XJI!L[GL',!;SS-[$-?
M]O*53DI32-ZK5-C:^3Q6(YM,=^+@O7L!+TWV#[S.9E%K&16&17]US,#V-6]R
MS4SJE:=XXR0)9EK)I21>70#.QHY77J$]7:<F#LXA&Q4M),FFFIR#[V_4-+_:
MSK-]#R'7L:$WA$R%>BN*6-#:^;S[SQSK&IZ45RG^-QT),BT5T@H[F>6H_3.7
M5J*E\[S0%KY?-OPHB6O3"EN;ZQ-Q+0R"R``"`92-%WKNV=AF(Z;CO$$X%PD`
M'SAX4QCE#\#-)Q-'IV59^\7TSUS"_8E)/_[R5^#X9P]7OS_4>M_ZGV].B4E'
M_AGYUK^YJGVYZG_^\G!*Y!.E>4:^]^X^]Z&`Y/IA+;S:*?PUZ-WUVETU_..7
M,;R:WI*$Q$;`6(K>]>W-0^VZ][W_[8]3\L`LR!!OZ#.Y<RS-?A\^>$\X:&IT
M1D39^_[_70$?4])(`UL>XH^W\KM?-,L]^U^Y)9U]^G$/K-_?D][-)?G4N^_?
MD]MK,KB[NK^Z>>@]]&]OL%Y]&+=01^8$RR''XID[;=^KQS\WH;%F4F-D&TKK
MG0Q.R`!Z&DM[3R!%.R%O_4=*0OUU%$4ZPP&+9D_>3Q_)9\G7S[3H3<"3+Z`+
M2[YT`B_Q]AUAG&B$N[B::?H3X@J.=!KX@'*3Z"$/T(.*@W_8][J>8P0Z+JUP
M_)/!+WCD>HQB#":?F*,_>H[M6#0FU.@H9\1US`D\J@UQ+$8,+QA#HR8,TJ".
M:VK^R/&L$_+P"/SDOT1.#<K!`Z&^[Q!F`=DG2E!KN,RBN8)I9&8$H9DX(\+L
M?U%=[#/-R,7)4/0"8@(%A(#Z%AF!F\ZD\Q\UGU@!]\F01@T!70>&EL3QB/_,
MX(>+UP]J$^0F7<^F(8_IJN8DK$^%7!#&PY8<\DSIG_PD[00S%&[5$3I;=X0'
ML%\$]1B8<ON,@PR:$:N5Z)B(&1"HWY/>X+JI2N\1#D.*QHNP"2H>H3ZA.=>#
M1[98U`84#!W_D6AZ@'T&V-D)P3*I,1N:AEJV%G"J"3]Y<BPF`/'VHG_SZSO1
MH`O!'Y-^2#H-ZHT=?"V:M!Q#Y`9@5JS[R,:/\)-:U'?&U`8D)JF)(OG\`=*U
M"?"!)`LI)H@54#@AM[9`/5*P'`"N0<5*CEA;(!P&YH2.1A1!"J5TG#;Q4BV\
M#UD0$0&UC]5T5`Z6!YXM2.0\2HSI[N[H=`#2A)&EC[TJNC"%0M!(!'B:=,-F
M[<N#"KKPM;&#9S>)Y@HO7J";&I"AOF`/`.5`06@?[`>^+$IZN!^#"YUI-H'L
M71,LXVTN>F!J'F@2E$8L:HBHANYY$@%)=-8:L[F@/L??&$9;#&A#1$,6HPL<
M@+8HGH?;N6`8QL),5.,3[E/K/7E^9#J@TS2=9YX*8Z*XB=#F422Q@,OP2@FA
MK!$TA-&'DV>&`"<8CD'%/!@"UC6;.@&/5`\JBD(K5JIAR`*QQC0;4G6P1&B%
M&).Q^T/X#&&`)C@AGQ-:>=8X^+@9!CED+-+KD(;8P9LGD4<#L8MFTCTVA*)#
M[&PF'%(GG"<,NP5H3H-H:)HURA$PC#_"4X_JCF<@=:Z-J!_Z$D`9;*E/]B%L
M=B1IZV&S;Y/O8$=%DKJ`(DJPSS.$[1R/C9D-,,=&+Q%&/1<OLPU=Y>W-9>\=
MM$[_1/<.W0_*)@PGX(0-_3BY/R'7CF,(A8<M)<Y<8V/7T)AP>0*_P,XP*H'2
MPB],"@'WCG(7?9=\H[X/V(J]/")U@Y50$`^<`')BZ012(0+YL1_>[8N3-$(Z
M@$TPA-CL1S)BQ5(R`%L8&&,2G??8IBK:U&P;,GA=M`A]=E2:/$*WLU"0V'&G
MUQ>C#^#N.C.L&^4!N$O,#"#P3GF,XG-:?LRAXGOSPCSH-PK^8S(:Y3?)-C$.
M,Q'DB&88H!B.D?6]L!%*!<^?'4]HAKY`KXA7^`3<%%E*K,8<'O#)B'D0\OX*
M(&Z"\H%5T%5CSL%6=J]_03;%1I/5/$Q)>=CF_0LL`.-MH190IVE@`",>[J,4
M\3A2'BH=-1XI$`;+H&@(76,JNL5AP$PC2C`QE[9PD0DQ8H\\#;P(4AOL46VJ
MHQF]21B$XV+LWU,C1>T+C\2>,?"0NU5B7TJMLM+H1NI.*A`'KS6@/[;CF&A"
MMU-[%-M(8XM9F@=A1ECLK/1X$Q_41IK%S,E"TXBR')00FN8L%?MNH*N*0T3H
MSA"7?"8Z9PW[8.BX+50G^``:"37F,I>B(*(G`2R&?:D'?1=V;G$&#YFEC4XK
M0@N8YGG6&DA,X_$"UF-T)/(,2+9J/`!U8'+A0K,GLV$PNC(,.)Q$N`%FGYD)
M)0,/W!K9Q0:F(4)PS*,$*!O/QDX81`Q(V^PP#D?\0-9@XNF^""K3C"R98L[2
M*"PVS3,A2E'VA`TM2&+??KFZ>$<`W5`K*6,TYX=!1F1_Z!*V,TONPK0*R;@^
M!.E9?L6G/4(NOT!N'N,[Z-[5773OJ6X0,(X0YHE;H&;JQ9PWGE)&S&-)'8>V
MF"+YT5`8<BC7B?IM##./(@/$HC:N4(C1[_RD!)3\0C'->YCEICQZA]V^J!NU
M!6D>IMQ(#IM%<P,_,5W1B4<A3_B6C;XW]*(I_:ACC#+JN1XP24<X#[4P)\40
M*?3RR$9^*(,63S7$`T,KY"*<R`!YM&0D#A/;1?,?T+M"#VRELHVI<U;70:X.
MT.W/7Z'Q-3W23[@FHT'0Q/@+(RH#-\#"<"!<``9M\?A;/AP2K">T+;4Q/0+`
MA,,I;,LS<%`:!CO1U8W#RWYPA*UC[$"L3^==H3J@FD%^QLE;4?QSKS<(!^T,
MKT-@5H(!Z'(ALPKA+U*E.*+B9W,0E6(H"_"XQKDF7!@3Q7HXA(11E2RAP>_^
MO[TO46[<2!;\%6QOST8K'B43O&G/*$(MJ6W9W9*>I!Z/W\:&`R*+$FP0H'%(
M+7_]9E85[@((4CA*)%[$^*E)$)65E7?E01[0`<1WW![^!UQ("C3Z74`B\+(7
M96Z!X'.Y"D')'YA\20`6EN6:V((4N("FI5&7"/<1"E;<$-W/S+=#11@%.&`9
M;8[V%4/Q![XN]RYM*@)`F2$`!C(FR&O$H$D]^@,\,8P/(`RA+8+K:LI"TVUE
M%0F#1\Z/[W).N95^3(`S/*J$P=!T8%_(>]2A1^O5MKP'AG0,Y01FMR/>%NA)
MFYN^L$*0)4F-6".J.1YM0BA*353NH!?=1T<!<0A0A#(40T8H1[EN<H.-@BD2
MA!*>@@"*OP@+`X*C!0XXFM.!EXL/O8"]APLA5&?P.EPH/+R^RE>TF-^#XH=J
M4H6-[6`"-&26>\V@Y`\^+RAIC1J0F6_M`;X==@IP;CJ-H*#T0[!\/@RD@!"[
M;`&Z/Q98N_=<=-;G%I!D01H6TR_E0[H[FN]04"S@^ZBDI^^D=@1PH_-H><8<
ML6]C/!`$!;SF#["C*`P!$_MK9+XY_E:?</%]J#Y.3-.#W[`[2S2P?2'P2^JL
MX4?9A^*[A1@380YY`.$M,AW+P4%XSK]Q98;WSD#CU)N^1>O*XLYJ^':?CC[0
M<T>H#I(ZIP&5,ZY=Y=1P@_59!U(&4GK)N)MJ^*)JTIWN$-9]I:&SIOZ@,\+K
M525H7*08EN-PKC')`Y/2,\UY5!8T:$K%GA7VJJ&Q>'RM1HT*O^<NB$G6Y1=$
MV?M>;W`T4<`+-:@DHY(PK2J.E#-FJF)2$WUO$(\BM-T2R@_7X@IHX2>[@7\$
M_Z:BQY<'*YX8I^`=.6_5##]<>.B9!J#3X-<)6#4&73&]$&X!O5S<7+`&U].S
M,!V8"KL(/+`Y;X7KO1\<#?U=4YW-'#^TJM"J_:8OV0W#>_6H[S_7`:13I.D\
MU1)6<G!G@;IACC?8RG!0OF&/N`^Z1ROO^T?=`-M1,R!X)YHGX?/)O3@L2/C"
M%)^&]Q-,/_MZ"3SI&1KRX!0]/UH\\*^OHJ'Z$*]YJ%IX:&P2E@S,/6NP?\*X
MC[]2/K@?'"`(["^O3`[HJ?[L@66R^:&NV*`RO`-ED\KH6<+3`651&RF0`F@F
MVC1Y&F]X:$83<QF9R<N2LJ/@37GTE@Z("M#@OQQ/E&'P9\]XX?!':9G=/,1I
MI]>+L!:].&+INAF$Q-'#7L^8BR^KQ7<0'M(S:G&P-9ZS"7C8#2F]`!`)C)QD
M"`0*'<:'J?A!E-(_2)@9R*7+T2A@,ZG4AZKNEOH((P1@Q=*H!X^B^Q%P7]CJ
M#C@D>&.D\Q`)%;W`5B:&`"/:@[(D#7LK/UG/&-+O!/$Z;N?&6#\IS+UXV$$+
M!3Q*QB`-&JA^X4?KP4)&R8%QFWN,248AC0AQD_O`[&%B+QUT+*A#\0PL3\'D
MCDI@D-.0/]YRXZ-S+$^E$$;@R"'/)JQ*==`(@5)#[Q3-<PSZA*E=BI_;Q6QV
MQZ4"QI$F<6FB-A/X88$;S;^E%WI=S%5#?Q&CTF%,A\8T.(4ZE!QA=>V!^,'+
MI?8G:$@?U<R:P.#;BIMW]Q;XJ0N/7IP$D05@?XWF-C!O<$G+A#$M`/RYT`;(
M]`YC@2RJPC&VXWHT6,("`3/JA\[U!3(1@F;K-##%S2#06"'0U+;R0R%,+OFT
M%0U?16DKW#!UK>&_/-,$\Q!9-)3>P,.[8H\^ZJ`=;?IJ#$_8(#5F+!@"7SYI
M-M[]\:A#%(L48\\1`6IQ%]NQ3%[0/>>I`#/=!B,:4Z%G`K2@Q.%(\0W"*";X
M>]@35"!&@*!Q+9/)4GCSU69XTG@JBN<XH2,?>,@R7!NHS;C(5##=L.![5)1A
M4AY>0%&RETB$U>_2LA2E,(YI6OYE12RZ',47)58:L7'\:+7XN3ES&6DDJT`X
M$F\6V"T#U]<L^+@&F'F019.D^TZ*M7GT-_2M9V`K8)89B#F3.F[QKP`&+YF,
MF$,58:W,:U*F4Y77-#!]M8CTH&TZJ7I8ATW;9@6W6<'Y6<%M3G";$]SF!+<Y
MP6U.<)L3W.8$MSG!;4YPFQ/<Y@2W.<%M3G";$]SF!,N9$QS29:1E4BK"E8R!
M\7A:(FKVPOXK2[.!6.IQFVW<9ANWV<;[FFVLM`G'^Y)P+%)HQ=15HNEBD&^+
M_>P-"PQF(H]F&]>AV:1+:F[&FF[SFMN\YC:ON<UK;O.:V[SF-J^YS6NN+J]9
M9+OFF:%^6`8X4?L^T72?MA^'OR],^,)DMZJ_@NRX9O+MVA=O:EY3XBEO2@R2
M/-4]>?CNF+8)QY[$KP)@35O[#:87J%UFB7-PT1+G?_Y.)SS[+=E/40!]H8(F
MN26UO]E<@W+@5AG<H&]Y>VW_S]^ON?)CLP#$,&\ZBR%*-;&A`R!0KQ9?4=?%
M1DN<F',^-`$'9>=NI!=UA?``^`Q']??DL8NWTJ-#RP.2VARZ@@,[DM#D;BHU
MC=+_,PG]L#O,.8GLU5.#^=Y"+]=80<2;J(%H)M.Z+8-HRR#:,HAU91`BTZ=P
M?G9RY,ASY/%8=KJ4UU1J;<&\5Y5?-",]VPH,V2LPA#?(&[*@P`40CS>1,!;?
MBSOX=?:T[QTHIR>W/RGG__WUXM\GG\\O[VZEXMY>_8DHJ**T)TTW4$<>@FUS
MZ&B891RY<5IWGTCO@!V71?2`0\D+)H_]25P:;\",:=!O]+:4YV(C#[);>DQ(
M-I',#^^UV9\87@_6[3`#*\AVI=GI#")8!J4!V&`T/QK8SR".PV]%^30?Y8D.
M$.*Y*@*H\)HM>I67"I-1*RH,V<UYG)5>:].7AY?7F`M5`(>B\'VL/&)E.3]@
MKK3YIR^N8DD/Z/[,N?U!H^FN;1EA1%:4#%$\K!R+!V_""^LF+(GC,''A]0F0
M2N<OA0_+X[?UHAY)G>*J?Z!\.KFX44!4?3U7OIR?W'Z].?^2)[4:$%GU%\;>
M^:D;A\!;488$UX'8>/W]PK(E_R988:1;R(1_LQM\X)&51TO;&-<OP3]@-D;D
M-7@!;]&2C>^5SQ@I5=0#Q;H'N)ZH)\'?X7B8(N,H"!A;:>;;,_2JA(D;YP?^
M#E`^_(?,>0'3@OEP:W[/?4$T/$(0B$[?,0>/<X9YF31SR?\7*PEDJP(->68:
M=EB%W9^X?CF/H;NN08.PIN5+RKGF:OY%BQ]9]N@=$P\@^YG*42>(R;3P*`+'
MF/V2UAN%\"16`C$72%*6\X[^,ZB,):8"TCQ85J@BVA3]^9Q@X)DIF82L9H=-
M6`A\C<!VHP1!ZU;"Y*?0@Z5DM.[\/K"3,`[H7A@,S'F/K,#T5/JNAEFDIT'Z
MRT>>ZW.+N3[KE?.1<II\94Q=\X1@-A=+I"51B110O6<>];@C_.]2(GAX5-C%
M`M.GSJ-ENX=X0#R#C-^.8B(7KL?NUL*<LB3'PA*<10U#H+$=GUWYCS:I;0C5
M6*XR2B2]G&LV4AJ.9Z2CYN116C%'L$ZM-8@,CKH\OU,^7]W>*M?G-\KM3R<W
MYSGV=@/:JU__92/F5LTH,\QUPW-IXJ1+$TAHM3&=@HCR&-U8^O4]AJ.>=)HK
M&#QZ_\)*5VC)!ID?:EB<]`!&G4?MR\C5.AV`"$(DG+CH9Z5IK&R,%D_SO,*S
M;)#(-VHK,RW*"DV9U`I?'#C!Q@O;'$K!B%#U2P9IOBLM<(*G#_TGF=Y@BI<Z
M_10RD!BL<G+]2A;3/YTPB8!>?Z<R'_S]%TOZY"DUR@<:<;4\!SYQ#K[?F'KY
M=I(4?'%Y!@8=4NBW'Y1?+\[N?D*"Z?Z#4]!KJ"VD];N/GU5US,U8Y1X\!&+S
MKWAEHS(CAN&L-'0%!-^L\#XY^4W<-V!;=^W4JD?@8]Q8ST>J^%?\=_-,YI[1
M5)0`.>-2<).&0E$B!2]QX+YSYRD!41CL\H\Q0.@15G$?G0E'!$JYH1^4?Y_?
MW%V<GGSV7WION:ZU7+M1;>D&^P2.1DHU^;.CS-WGJ@Q_-YE*X_#NZII5O_D?
M?+RZN[OZDJE,5'64>1(E*)33J\]7-]\K_YO=7>>0]26*M2],K)VGQ9K8)(K0
MQBKFYTK.`:X-5GR"!;;G`?:Y+8A,YLBU7BO7RCW5'I=KO>KDVL>KF[/SFX"C
M.5,IZNJ;XEB&/O]!D4/R]9CDZPDE7Q0_#0N^@0R"#^TU43BL2MEV?7)V=G'Y
M8X`B%<VX*EF#"[Q,H?-VV;U",^:-L;O8T)&(W8>2L'MO7]B]7Q*[;V7@9"XN
M0%IHS)1CD06+9`+'I,?'T@5B]H+.R_*^U@51*'P4-TBI8CE&<\D-UG"&95%Y
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M:`ZW]4YMO5-;[]36.[7U3FV]4UOOU-8[M?5.;;V39+*E\7JGR"SSTHN7CMF2
M07G4*]][LL3YK&#^Z:P<B@W:>A<OD5(S:Z1^OT7KD>49?*'%"N^4.9GI2\UP
M_O7NL/_N6.T-^],>6*(A4DH!^;@!-`RC:.B%:.BM1\-H/!UTJ\""3YGU8F*4
M21`\R"[&PG@*+OUNT,(XDQ9R,3`9[`P&)IDT<!IZD&?DW@TAR!(1?;"'=X<Y
MIIFDL2EB5!`;%4J-?_ZOPT/E__[ZY=^#__=__S-;>=]^,X?3^=_CIX??7LRO
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M;V\.#Y.J-!R4>K5`+!+3H6B\(08.ECVU'->A6/RH.61^K;W@N')Y!GSWL](.
M7QU2R@PAX9O9N-3A@7)[=W7ZR^''D]OS,^7TZLOU^>7MR=W%U26UC42S4B.F
M4UV#4B>UHT@X#=1;+C4[&.9-(W"']TA4=%ZJ3W<*^89_$SKJ$T<%:\^:/7?B
M,SP[.-*4K-S(C%.-,KEHNN<:C#==Z][K-C'<$U;=IBB4(V+X2C\P:\6R'=N*
M*L*BR-OSBK`8*@J6OB>#Y_5$_M<'\>NM3!MG=@.H&ROUK'3W:)-XL7_L1#+$
M=H1?DE<LC1S:1(9#RVV24/;E5$+\+,E<]Y:*:9E$+'CJJ#N,21U1W>$NJ)3,
MRM6]4RG#5J44DTYC&:13?2NEVL?D:A0Y%<I4AB-K%8I`H90C?XOG&T5@V*2,
M/:=/3^NF)<JV][9/3PP5;Z)/SZ0K@V#<U3X],7K8D3X]`G9OHS(^N\O>IV>B
M2L+N.]FG1\3NI3<4:9[=,UN[[1V[#V1G]TQ#K-7NU;![9H.;M\ON;8#,9W=Q
M@$PB=I>BV_`^:??,`OXZPA>;--,*0Q6Q'[V>G3.!JZ4+7VS!.KKPQ1:LO@M?
M;+EZNO`)SK#:IGB",ZQQP>J[\(G.L+0N?(7/L'3#9-T9UK@@/<-!W6<XJ/T,
MR](VA<^PQ@7I&0[K/L-A66>XE0(OO?U/HGCFM1<3TM<[3_)XL$Z;]VI%;,W%
M+$R>5^DD$B2K,X'7$D-U9O!09.-5Y_(VNE.!<;FC.TU9M3NZ3Z$YO:-[%=CQ
M.[I3@0.QHSM->2X[ND^AR[2C>Q7X:CNZ4X&3N*,[37FG.[I/H5N\HWL5^.,[
MNE-!(&!'=YJ*0.SH/H6ACWH#'Z4W>DLTV]O]P$=>X*K.P,<-<8AFSQX5S9PK
M<_)$#&N%I<MU13]D;%`:)70Y^KA)@HO</F[ODQNMEAZF#>$@V;XMBH+A8)#>
MK%244&I[I1A>9&_=)@D+2=&Z31)<Y+9NVR-QDH6"_G2\Y^*DXFYM.R).F@["
M2((+*DZRXC1[)$ZR4*!VNI.)S(10M309M-*D@#1I.E0D"2ZH-,F*)NV1-,E"
M`4B3D2HS(50M38;52I.MXG*QQ@9M0M+F<;EIHC=88W&Y'XE);,V@83EMOM1-
MW7$Q0^F)Q"-S:73M]HR%*+%7'IO;K+Q%PD[I,6REHG=)^JX;887IJQG]-TZ/
M:D@@K-\9#K?6@47[>S"R$A;(2-Y^/8;+3>*#Y1/FVQ-KTM3DOPFQ5GX]QHZ+
MM3R$J9WAI-^*M0W$6K$X92O6*HU5[J!8*[]$:<?%6A["QIW>8-B*M0W$6K&`
M:2O6*@V:[J!8*ZUJ;U_$6A[">IVQVFO%V@9BK5CD]E6$N57T-C&`HLVJW#AZ
M*TM6Y9WE:L;:V1W)2&XSL5PI[MLF3<5R^Z`5YI9W;P@%GKSHJB@5<T,L27Z#
M.<G-UAQTNM.M_8'URK&?H1PEO=:<;!:AW=LLB4E3X=DW+:G*S_+<14F5A26U
M,YUT6TF5D%0%@Z[[+JGJC[B^:4E5?@+I+DJJ+"Q-.OW^UE='.RNI"L91]UU2
MU1]$?=.2JOSDU%V45%E8ZG?&XU92)255P=!HO7'1V.RG=21<)(>UVNN'+`C6
M',%4V'!7%MA$O7EE@2W=QE<6R,0=?V6!3M0<6!;81'V$98$MW7)8%LC$W8EE
M@4[4R%@6V$0]CV6!+=T>61;(Q)V498%.U'19%MA$_9EE@2W=RED6R,1=G^NU
M1M7L$J'VGK[0/7VO*TN5U<5RI<U<Q3*5>\W19ZP)DFYX+IDK)G$5PW(<945L
MO+Y?PE/.HV:WU_917A#<V[>AFUR$I<NPVN"-$%&IZJLHGKI'756`D_V-X`#"
M-BNQVMMHLR^T*G4N=U%H9;J\K="*":U,/+5"*TMH%2V@VGNA56F$8A>%5F;<
MI!5:,:&5B2<06OU6:(F$5M'RJ+T76I6&N791:&4&WUJA%1-:F7@"H=5KA99(
M:!4M?BHUJ,H^TX#*\&/\U[W]G?_GUI''S`CC9*"*(\2OCBQF1Q)-Q7TD\#^;
M$&4)2SPZ"C'G9*[<DI5+EO?$5OK=CH*SU#O*,U%L,K-L_%Z;SW6L"BI0,*1H
MCJ+!+QW/<!5KH6BS&3%P<!T\_T0<.K\./J:O4:P5_M11=!/>99ID1M_TK+N/
M%%)XB_Y@LM?#;RS/5A:6O<18YZ-.%K`DF7G8;PJ^7>@S8A\EXIZ1DUW5=*I9
MO7BJ.]8[P-3",@SK&7%+*5AQO.52L_6_X8513,-I`+IT]P7Q2%%LZN9:6DB,
M&5R+5@Y"$K47EV?GEU1B?`M%3[?[.MDL%"E]'KL'L0/D:_.O_`^!'G&T^@RP
M)?AFA;2>_$;$HZGKEWYWFZ'9)0^?S[P1PR.B!Q3(27I^]QFZYE63TLL_S\24
MVK/L3)JJ]KE9Q78)F-A(B48QA$:'CR`0JTCK)G\V<^)BKC#T-U/J]=HHZP2C
M9UC;)5NPY"W>GCG*!QUUI>4YFCEW#D(*BDG""&&5>[M6M.+=/QAAS7N53,C,
MM`:XL!EIDYU'U4H;*FWZ&TN;IOA[/2MODG90B62<2B<9:SZC7PDZ]F1^J)P\
M@>?P0)3S;\2>Z;P;0<;I"8^R0-Y#$V>LJ@7.^-H&ER:ZF_U4,O4+WV:43';R
M9*MDJ)(9O"DELQ]+YJK2S3X6">N:->]XCS7O+JX4MR8*&P_KS`HI38KN9$^)
ME]N(Q0Q"*8\NGJV=<70W9*GI)D9X3V%?MC9S/<U0[HB]S/5=Y-A@9J!`43[\
M1C3;.4A8*_MDX%9J^(ENNM;&KS-K%QB6A=IZJTOR3`"$=::5+B@J'JUTP71%
M:*7+B<L\:SC#T@O]UIUAC0NFJRSK.,/R!PFL.\/2B^?6G6&-"Z8K%^LXP]*Z
MIF\EX$?Y`O[U,[B&.UX=IN;Q8`F7_86MWRO/=5S-Q"MK17.5GS73T^P7164W
M]S$[N)D:L`9[>D?HO?+6K;+W-X_B(K<O:U.=\2NM)\U!1FX%UV34&8PG)6;H
MR=Z(/(J934JU9*"@)B5+A9TVWIQD*;^/ZMN3*#GE58.2DW[?GD@I5DA5'1?Y
M`1]Y^:CR,JHW)U2RFGGNH[F2&3"<'/7V7+04*W>JU]DN?>"U7[Y1K8/=J'N=
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M6=SJ.O9:^>#0@N*"8V%3>5$E:H1^>+UN>`6#)/?@>GB4(Y/K=,03Q<'ISMZI
MO.;]O3I^2V,B94%8_IC(VO$E^]61:%YD#&-J;]CI3WLIM#1L&TMZW;3A-$D9
MDA\:E6Q5SI)\>V*K@D&1;U`69=/$:].K]U,4-7WU+7MILWA$Y-X+(VFNE:40
M2MD.[^2HVXJD#452`R71[+,:1ZEEE%B_VM/.]*SIGOP_='KIO5P9U@LARBV=
MMW7MV;-'S2'*M:&9%!^Z_[B@!W$4;W4-*DOD_=>`M%^)HLVME4M3`Y0\A"D?
M8O\\P`%QZG0Z/E+^V],,?:'#*PC_O:,LM1>%&&3F*JZE/&I/L`PH0MO5X%<K
M8J-.Q"$2U@(GGNFVXF@&]DC#,7./Q)CCKU;^<@Z;_\.GS<VLY=(R^0@USYP3
M-C0M!MR1<F$J/WLF"=FFUU75#GT!_>6C9<`O'47SW$<+A[+1_>OFS";X$IV-
MY3,]&IK!V7@,!O@?L9\(S:%0=,?Q-'-&LJ!0[E^48;?;`?^X0W^@P;9<S<#W
MJ?13])R3;Q8&A8X4G"@78&2%8R@0C^S7`(E"_L+>PX"VR?`?'*W*0@/,+C7[
M3^(J3YKA^?CVY\\!%E=DQHYNKKG$.5)N-0.`R=K0W+/I/+N"0^IHM@G\T<-)
M@H[N()4!!!/8>&],OQQ..L.QZN,`M@Z+:'S`"-LD//^^>]17Z>/P5P].$9Y=
MX5S")V*\`,C\QT\@6>F4.T3UPG,].X*QK!T]$WBJ/QIV1N-!!NK%63)"N?#/
M[SSG\$'35M^?Z<[,L!R`X6IQ&AG)>$,,'+MX:CFN0P'_B%,;K[67)7"$<T>^
MN1\-.)OC@/W_Z;\Q?#KZOA/;ULP'@K_^^))ZX<FS9L\O*1%?+4Z"@9$,8R<A
MZ7NF[MZ0Q;_>L8-XA^?E`BSTLUFO^_LGVUJJ/VLF<M&=U>\";^&?O_L"@\H+
M'[.(6)0,7R@BWRESH+&E9CC_>G=Q^>G=\9!&C$)45;BQXY)1N"GBU-]/G*M%
MOPM4A:2T%;K4;MGX2F-)@*;[]0O<)Q<(=H2<2^D>!`3;*Q/Y(;Z`,4D26[TH
MF?61S+;$6^_=<?=H,DR@K)(=':?8%+^\`,U`YF=46L*#NC5G.,_<A[..DDK#
M#:6I21<$<`0]V\%<U][[T;WWPKWWMA,_$]`X%>Q]'5<Z66QYQ0;NTK8VSH7)
MUO<G9/!)"GY1(:7#$%^>,X?'*Z88RDU]=0,!5-Y6M]&#=2.Z-/*DB.Z]'407
MU#.^7?;)LBD\=2A-L.C`H"M?9R;W(D!;U/+;_@`#2S".G$$64[\[IL&5IJ<\
M=_TQ\65/><Y/C@CGU6<.BQ#$GOS&Z*\,K-45-JUJ[%T$>6MGJ]:<UEWW?+LH
M*G*&J$9S29+)&?6-<LI/$JEUFI`Z7C,Z>M<&7-T]VH0H7UCXXQS#'[$321W/
MVA2>1@YMS7BR>E`9B[A4G?PDY?RIJ-19.V#UC:J48:M2N$H9MBJEF'1:,_ES
MUU3*)0;4"VL4.17*FC'IK4)I3*&4(W\WR%</8<B<_590.;5N6A*A7*=*4Z[<
MG$[M,YWJ9YL6'T->KV"<K)DF6X]@3%<75%=9T)"\Z_ORKO2AH<VS>QN5\=E=
M')61B-U52=B]MR_L7OI\V>;9O;[Z2]G9?2`[N^>,4F^U>Q7L7ENJ>GWLW@;(
M?'87!\@D8O=,0ZS5[M6P^[`D=M\J?)$I:W)OE&,_>CT[9P+'>W"4[NYD+\@:
M8=2X(.U&478)>/9RO,-#^=W-UIUAZ3;LNC.L<4%ZAF47NZX]P[SFB]6<8>F&
MR;HSK''!=%>8.LYP4/L9EJ5M"I]AC0O2,QS6?8;#LLYP*P6>B=XU5D_1,M77
M7DP4Z)RSR5ULZ;USU$D>#]9I\UZMB*VY6(%$OF$V)7&^K\L$KK)UTAHS>"BR
M\:IS>1O=J<"XW-&=IJS:'=VGT)S>T;T*[/@=W:G`@=C1G:8\EQW=I]!EVM&]
M"GRU'=VIP$G<T9VFO-,=W6>Y#4CEWJO`']_1G0H"`3NZTU0$8D?W*0Q]U!OX
M2+2\?3W>$@W9=S_PD1>XJC/P<4,<HMFS1]H$94Z>B&&ML%2TKNB'E.,N(H0N
MQXA927"1.V*VYG$7TX9PD#=M9S@8I#<K%264VW\NBA?9F_-*PD+[/CTG)4XD
MF9[3I#C)0D%_.MYS<=)T@]VW(4Z:#L)(@HM4;]T]%2=9*%`[W<E$9D*H6II4
MW!MW1Z1)TZ$B27!!I4E6-&F/I$D6"D":C%29":%J:3*L5IIL%9?+Z(S=)B05
MC<M-LR>@^>#4$Y?[D9C$U@P:EM/F2]W4'1<SE)Y(/#*71M>.S_"*$/M;&:TM
M";;>T&CM!,::T7]CP?RN.,+ZG>%P:QWXNOD4ZEN83Q'%Y6LF:^_!`*^46).F
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MJ0J&1NN-B\9F/ZTCX2(YK-5>/V1!L.8(IL*&N[+`)NK-*PMLZ3:^LD`F[O@K
M"W2BYL"RP";J(RP+;.F6P[)`)NY.+`MTHD;&LL`FZGDL"VSI]LBR0";NI"P+
M=**FR[+`)NK/+`MLZ5;.LD`F[OI<KS6J9I<(M??TA>[I>UU9JJPNEBMMYBJ6
MJ=QKCCYC39!TPW/)7#&)JQB6XR@K8N/U_1*><AXUN[VVC_*"X-Z^#=WD(BQ=
MAM4&;X2(2E5?1?'4/>JJ`ISL;P0'$+99B=7>1IM]H56I<[F+0BO3Y6V%5DQH
M9>*I%5I90JMH`=7>"ZU*(Q2[*+0RXR:MT(H)K4P\@=#JMT)+)+2*ED?MO="J
M-,RUBT(K,_C6"JV8T,K$$PBM7BNT1$*K:/%3J4%5]ID&5(8?__,[SSE\T+35
M]V>Z,S,LQ[/)U>(68VL?L5CF-%(K<V+;FOE`L"6Y\_$E?.9:>\'/3IXU>WY'
MOKD?#6OVY[$/QS_]!4X,^%QSR5S\]G-6B*-XIN[>D,6_WGG._)TRLTP77DD_
MF/4&OW^RK:7ZLV?@'/0[J]^])2O\\W>_=_J).3\+.Z?S=WXARWMBOU/F9*8O
M-</YU[O#_KOCX6``7!<BH!A\QZ5O:AC=5"_<5&^;3?6G8RDV->*;TLP23DKM
M3B9;[:KT;8VCVWKM6:G=D2K'MB:9?,5[G\&N3F*=S_*)<#C<<F/E;VV:R5U;
M;4T=3OJ2;*W?S>2QK;8V[@V&LFQ-S>2SK;;6&^-%EQ1;ZV6Q6A+F07>Z]7&4
M?AY93)1BCRD*:CF`'F2Q1Q+H2;^_-4^7#?0PB_!3,G8\?B70VFJE?7^+==%9
M#[,KV2OS(U[(HF)CU[&7Q#W7;%,W'YQK8I_2ZUBZ:&QC\!6]HG6V88#>NV,,
MT/[SN_*!/&YV^X58:7>W7X@IV?;[.[C]0NS-MM^K<ON^T+B=/9*Y9V2Z?'3Q
MJQ7^Z9S,0,_J[LL=^HZ!GU?T>(^I9X\_33OW%Y=GYY?4Q_X6.NO=[NNB&4(G
MO,^S7<!1M^?$YE_Y'\Z(83B`4,";X)N5-I^GOHF'.X3I2OVN[_AGYN:MB7K,
MP),@=@G8$&20P<KW^'$85Z`!@ON,V,Q649O2X,_&+`MNGF5GGE>US\TZ')6`
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M$7JO?-2![/.`HKC(G6/0U"2I2ONOY"`CM^/!9-09C"<E5K3(/K@GBIE-6AO(
M0$%-2I8*.].].<E2_MR!MR=1<MH1#$HNDGM[(J58XX'JN,@/^,C+1Y6W'7AS
M0B6K^?T^FBN9`</)46_/14NQ]@#U.MNQ6\4RSL`O=Z[6P6[4O4[@K#'W^D=;
M`UTQ3_C1S7C2#79+B!"S')ZT)+B0PI-.XJ(9U33.]Z3'H\ZX/ZQ6-TG5!B**
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MUPBC$A`F^[W)-.7KQES=?K\SF$Y2*"F]K%+<PK_[%EKX1W&YV8"W.&56[2%+
MPJ%2>,B2X**]M^7R)^_>=BS8<"M_\N1/T5EMNWI55L<@>WGV*HM;7<=>JW:K
MBXH+CH5-Y465J!'ZX?6ZX14,7M^#Z^%1CDRNTQ%/%`??DI5+QV8H_:ZP/CA)
M7OMT=?R6QJK+@K#\L>JUXTOVJR/1?/48QM3>L-.?]E)H:=@VEO2Z:</IZS(D
M/S0JV:J<O?[VQ%8%@]7?H"S*IHG7IE?OIRAJ^NI;]M)F\4CUO1=&TEPK2R&4
MLAW>R5&W%4D;BJ0&2J+99^G1PZ^?0I488+MV?G'6^&*^2,1!OO2H9QP,]Q*.
M]5)_/W&N%GWUC,Q$L_HFH\$X/L"V=``%PPA+7,/OE<Q[ZOKIY7020:&Y9SD(
MHM/.!KU*<),'=Q;&[M>O?+_QRD&7WDB37NS1VTL,!^PEY\,%&#N^GOPV[I\E
MT%0OL"5S&2VB=RY,(!K=FO]H6XZSAL\*C_0<C\;]8:D<)P`V/1YV^[GIPE5>
MS7;%IRT.-D%5>;LX3F$01?V%XWAD?N;90(/L'6S\5E0/!"4N99',H-^+#U3=
M')34=,77(M)_<Q,4T1N52!$;;60+OEJS_">6;>8!/D[,.<U#HV\(P"F+B/K]
MP;1<3;\6](V)[K4+UBF5QC4BLEZ2W-3$[#(+*HOPU-ZP/^U5;6-*:U_F8&=S
M];:[]F7.>%XP+QNV+>.XPH5M\@AKZT_DPIQ92W)IN5O.'=[ZEC?S-G<R[(I#
M5:^^Q<V\M<4WTQ$/'T8'H2M^>O7E^N;\I_/+VXM_GRN?KVYOJ9>=GF<3\<[#
M"USZ3OL[_\\J\)25HEL=HF*DHQCH5BPL6W$?B;*BDMY1;+*R;*!*Y5ES@)+@
M>6I*.I9!C!?%6BB69RLF<>FOCY0[^.DL^ZWNHTT(36L'RB;*$G;UZ"C$G,,K
MTY?K=,WW:N]HJBQUPP!^H3]]/P"$^I]T`$)G13#6`0"5"T"/`3`Z4N/KJ\.C
M4<[Z-E&>\3^FI<P>40XXBFXJY"]/=U\``,UE7Y-O,\/#=1?`D#$T4F@UPPB1
MST_C2%P#(*324$:M$Q!IE7T%J+(%/_L,P%T2]VIQIWV+:9N$DO&=<\_(LP*'
M[XX/U=Z47DF'T!99.^4,O1;@8F8K`CQ0>S(`W(]BN!<"W$L!/%*W@[=4<(?)
M:$TFN.IP5`9^SW1G93F:\:-M>2LP7)'50)?"QPB7;H*K>@5,Q>Q:_!3X#@Q>
M>92FJ%UK'1IS'-&89Q>WI_"+B\NOYV?*U?7YS<G=Q=6E;&HS*U>L!FSA'SI3
MI,Z2S(CGZC/-H$KBSM(-XMHORD?/`4WC.!0G>H`U(?X:P-ZD=NQ=F0J(K9>0
MS'I#U+9=T+G/3'<#XD#GH;H&#B9H9,R([6HX49[,'DW+L!Y>V%4<4Y6H.V>I
M$W#]$[CG)P"?*#?7X;IXF6*#MC^U;%"S5!0H'VZN%?[Y04?1%,>[=_2YCA-!
M`(Q3,-QU$][_$]$,][&C@&`Y4KZ"]<"M"[#/'7P0_Z$]@*F!]C[=UX.GT4ZH
M6-4'MH.I+[VE\D`CN2O;6N@NZGB\?,9IS0!(",?_T4"2_4"-KWO8QYPBA:X"
M/YQ[,Y=N[,IV'RWE#`#07$20/G.4#_3#`XH-_$;_4_FLW>-6+5O'HZ+@?V!?
M'2@?6&#YFH'S(P/X!=!P;[F/N-[SHSY[9,:+-@-S!DL4[U^4?P,\\*1R#8[.
M4O//@!H]>-!H2:G,,!,N`(80.DZ`/<N%-X%]-1T,.IBFYAMM"]UV@!#)$S%]
M/+XH+SCU[D@Y7RR8\:5\T6R`#@AIW,&E08#_X9DS>JK/.FQ`"ZA)<QP"6`/0
MHUA&LICTU#&@VO%F,R`8RZ;DJ)DOB&'-5$Z6,\L`K,$YFY1>@!0B%/*!?D_I
MQ@2V"`B`FI&._H"'=T_<9P+[\!QZ+.R-\'8XRR=]3A2NGM!4#$\8%EFMC)?P
MG,,3/5)^)<JC!B:B39YTRW/@,9O,+'M.*<W0M7O=X&][KT8L69L8&F4SBU'K
MTO(`4FJ>,J`"48#H"ER`N8=Q!I_@A0=Z!!A2/I%[FP[203790>1I]KWN4MI3
M;,^@#`YK@9&LS><Z1R:#PF$T9CV3.=*-#@;Z$Z+Q+W"!]86.&W/H&^=_>(Z+
MN;GL>P;7R>VI,AF"3`FD\RT<$9C?^,@Y/AB*X@[%)%"+@=(DX-P`TAA5H*7B
M(.KTU/8X9P!8"RH?\*W`K&AR4.Z'LR&V0_<,N]%F,QMG3VJ4B\]`;#&O@\T<
MZJ6L_`;TPB@K;;TZO<`\M_527(\XI4B0$9-.L0*;+O"A?$<6^,/!W!YZW*@Q
MX!08<_.1H',40N`%NL`6-%*/AQ,:B4C5:'8J']!%.V!>6];BX"4O-5NGO,@7
M=BAIZ;%W:*YKZ_<>O>A'1HRZBT#8(,J9H"^LX*ASB<+&,N9,W?GR#75*EMI%
MLK4,PWH&E8%*]A'$""S@''R_*26RG:2H\>+R[/SRCF>`^&D>W>[K4F2$Z1L#
M;@V"S@():/.O.#&#&6'@Y/,9G+C@FQ4*HN0WHJA5JMQC,/*31C+'7Q9,._/'
MO[TR?:BNY+`21MIG'&.`4);N=E9A=>QFQ>LE;'FCA*0H*C"WR\<$"`2D99,_
M&_6"DB4H]0VLSB^%J7=F<C]G9G*]6*EGI3L:VOS"(IKG&-&,G4B&*(_PBPR#
MKON9B9QU'EHL$EQUB9>44[:C4H=/V:ZI/T%]*F78JA2N4H:M2BDFG3)Y8#=5
MRB7>D176*'(JE$PN;Q5*PPJE'/F[055^"$/FA/O63=ON4/M<ITK3E*TYG=IG
M.M6OJ8WKU,QFXONK4T<R".AT+X?J^C@T)'?[OMS-C%&]7;'31H=\L2..#N6)
MG9K9?2P)N_?VA=TS;9VWR^[U=;N2G=T'LK/[1!)VWQOM7EMC@/K8O0W4^>PN
M#M1)Q.Y32=A];[3[L"1VWRJ,DBEKUB"M:$^1U\97"K0YW,3]+;_1X6#]'#RO
MWI!OT4S66!#8JYC)I.P/%F&#O1^:%\6%C$/SI@WA(F^.0'V=>=]P.YXH,E\S
M2&`/^A6FY%'3`P4DP47N0($]E$?5H6(OY9'<@P4DX<%TR\(]ET>B\KX]E4?5
MH6(OY5&Q;H6M/)H?51A6?'/R:-C*(U\>58>*O91'P^KET7:QR\.N\*"WY>;$
M_*O=#UT.<XZOSFC_*2V:B]?,8?%?K+@Z*+^.1R]39%=3V++!67OIL.5A1JE;
M)4)OZY$MDJ",13<3*(MB;/OI!Z4-:TF@JM'@9PZF#AOJ0]Y_"Q,,!8%/'Y7K
M5&D3]ILDW,GBGJU`VS@\V@JTHM'3'$RIO4D:)ZU0RXV>MD*M8/"T%6H;QUA;
MH58T!-M:::6%7UN!5C#ZV@JTC8.TK4`K&L/-P=2'40HCK4C+C>!N(](.BN!8
M%+AEG_FCK_!?%7<ZRZB/>74`,Z=1"VT1K3G8_`[CE;:N&<J]YN@SFG`YUPT/
M^Y315M`K0IL0+BU3H?W\L=VT9]"F=[D=R+;LN(T/BGO018\GN]?T:_ON)B8G
M?.;M"W6"4RE^#(*X5^9G"][JL1?Y'?*=C\0D"]UUKC5]GML].=H^N=O%AKX_
M>R:VCHSV(^Z^.YX.!K%>Q*^`)[$S0(U--(><$?;_+TS:Y_@$6P.2>62=W'UD
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M=H]KN\<U+=#:[G$[TCWNG]]MV;4JUO2*A0@OS',_0(BMOS`\>$VC@V$7L-Q6
M79&.8[13%^]\%>_4U7]W#&X`;=2UV=+'/F)*!'F8;"Z6!?+A:$N(*<!!ZSAR
M[PHZPFW40*R*_H!9D>I7QZASBVSO\8\/DP/E].J2\M_'S^?*Y=7=^:UR=Z7<
MG'\^N3L_`QD!WYS?4JJ_%];G1M@BV;6O*H2-:T?8A:F<K&S=P-:%:D=Y)@K-
MJR=S13==2]&46S+S;-9.[]JS9X^:0Y23!YN0)3RH?$A_=J`\Z^ZC,B.VJ^DF
MO`;(V?504F@&_.N).*YE.^$O;>>@`Y_S=H>PXL(SYXJV6.B&KF$S1_JZ7\@3
MO.ST2+D#)@$X'RU%=VB;1F`;W88M*]9"L3Q;^6AI]AS_<:;;9,;6HI_!,G@]
MH2FPWR=XL[(RM!G;!CSMK138[_O!T5!9ZH8!X.+-QBTQ=?@-10*`<FH!_+:K
M8Z^]2PLO/.8>`=3U5.4#_?<!``@P"3"ULJTG'5M'^NTEP_WCPBO_%^_5"`3:
M`_S^@<)J`XKT%::&+RV/@<P@T%SZ.AVD$3;#1"$`>#S"]SL>"`Q\NRN$J9.$
MXU&;TX^L%1Y7#"S`+S;IX\?XOG_4W11(S7Q10+`1D)LNT-L7[47I\=:9(15=
MT94Y%OE/;8*"+,`[I4O:T-/!]U,2L)8K>#TS7B<]=?R#$W3^=%$0XO**C2#"
M+WK##MI9_!5X'`1>_@*8IY_#$Y%]("FRQHZX,#"&X](S!QHE[!P9E!\8:3B(
MD%OZYH/-&H%6)5*FM8L4/+J9YCPJP'Y$?T*2QW:K`B+USP]1J(#QHYG8(!*Y
M6Y\]\G:M%/'LQP[2\XR>X:9<TJ%-8T'-VM8WJEP-/.^COO^.CF(2^G2PR,QR
M7.=(`?E(*15T=XI=R#=BSW2'4*;1;25!Q0CWPC.,#J6B9Q+B(\8^L"C%EOMH
M6][#8VJK^&^;+$&6(L;PIZ&3M@$&CI03!YF`(M5_K[\#_]^)'0@$Q!,)9`*3
M%;C#%+N[CUPJ<<ZDV+?N#?V!2G1D8`(_"YDH+9Q2W%,_[XS51G@G%'L.5SOW
M+XKCW3LN2'/@'B!=^(]_9)KC$#<I":,*%;4<Y370C?>:^2?*,SPMAZ-?HV:B
M;<$I!KB/B%_.LK#HO6634`C"`?>Z_PA)$;LM:Z;I+3O*2GNAW6C_`HL5GH:?
M`B=0&@=9J\<4R5JU1@S0X9Q-XL1(>?-GSR3<=`EE\3,VB=:6K%,ST!J@T)L1
M+H`X^%09P'<CT184LEC@LD#LX'6\A$^H5&&I4?R`,($S4BPSU&@]]0?ET7I&
MK<+`>K2,.;)/1-SA#U\`LK\\L%(`#020YILBX3-1M7E/'G23R@#$!D"Z@*W@
MHB%X3)_"?^%W1`,1RA;^/]K*<D`E,K6>9*P&^*K?!%\A\=*^X320@F?/K8H(
MOKFI!#X3'@5*L0['\X/^A*AGA$$%F`?XG05*/WK0RK/E&<"UM(7UC#&/]4SU
M`?DV(PXEA.G1=/J/E`'##\ISD=DI^T;MF"/E/#S5.*7,-'P_:TB-U#'GS:GA
M$=AU"`H"`A`_ZJL(\(JA+W47Q<PSF/JP=T"3J\^(CX]`JC#%_`Q:!Y^`UT8X
MA9EU(U69:R\.Q]J<&#JUK3BL[+4RB/;Z7=,3>NSIQO&=E*)$:0G_!/<'30#J
M_J#`GX.7?V@3@ZK0F?5$P%X*I'A`"4?*UY7%#"9K!NK#)MR.``(!B<0DS)PL
M-#0#$K_-D594\U-3Q.<>7W9%H6?"%I0(TU#4V;+LB/P&*XE!*8-M/*[?W2[J
ME/D(!2<8#AO-M@?=<5G`#:`"$F#*PE0^6?92N3T$S<2>`0!PP`'@'O2<!EIX
M-#T:I2U&[OU0`C!>\"<1"KJC)J=P1:1/D"V&AG9)R/R6F="4O6E4529-2&II
M4-W\K.F,L(`RUI$6VL`TID!EM+^VR06JFPTTVM_TM0Q!S&X*C9`<7'"I!O]^
M\3UX7S9:V/3_&8SG-"TW0,K-N'E<]UCL6%#"@&B;SZE\"I3+@C`3B3H%3+X=
M`NX.0:T!5N&!>T!EZ/+,-4J#'ZF'8;&W!G2VT+_%7UZE4\]8T;5<]%C#)9DR
MI19P`#3J=3+G+I%A`<Q`+?@1XR:;`$2D0X-;7)*S\2,>9REP#7%L`O5U,=3"
MC&%@`UB:BXJ%!NL\:89'XI+92GC'%'_,YXSR#YB/[,4@CO_V:9QY@RB/XB"!
M<K']!U8<]6KW\(5HMD(EB^^.`O*6,7".E#//]E_/)JBL&9S229\%:JNXJS[N
MTV-$5*TT?7X()/2GCL<(_P/7Q?#CE;AJ>-#WFA'UHOU(0"JZ$`]N"8[(C]E%
MT`'.@F[A\7[::EQ,)]PM^;8BIH,O!]5.4<?V0>77/*#PB'^3#F6,!Q0_N+K/
M^>][Z@0_[$2@-E[0:UJS+J<1S5?;8E1L.!U'%'[IAT"_[T]'`F#CDK5^L3JI
M/P*0;R;.--NF&DH@"`0HGDPX"3":UVE8%/B#BE;VV_>#SG1(GQ(ZXQ$Y$SHE
M'<"HXR1EQ@+?U1UW\5U`9OSUPTBH*]O;IY!1;XS,$P8Q]:50NH$(Z@TB;PMC
MP+KK)/RDDY1(,3-D`V(M8!]7@/@-_.7(,"?QC=QQ0$3\LC&,:^,O+E"&P]\7
M.`?)9(&/7\'\OV87%M?^?86:>UTZ^/W$N5KTNR<K&RVPW]D=!L7S%[JUY(2C
MP9!F'OC7D%O"E+A'I>N=>.ZC9>M_D_E75*W)WURPV-(ICP;G;6J8V%3\IR>4
MG,2[4V.[VQRLX\BF?#N6A4>%/\[=Q2BQB_C[Q/#WNU'X"T"0)#)ZBB:8Q1Y^
M&]Y3W*"$O_5M7PXT8ZHDW&-V=\S!QKMC?P>GE.UND>O2X%]<?GIWW!N&T!<`
M)22C*"\E?T3),_'["%>L@.F2>YAD[N':%PI99-0%*NI&1X`5!NFX,HZ8QDFI
M?*I/G,(UMV=I'@AL_Y*X5XL+;G2>XF5)+N5/,[&_5CRI?;Z5XJ`<EPG[H,M@
M_Z*]^*/B^)_K80^8=VO8XZ3F&V]`7>26VH?7Q,96>-H#R2?_C;1"[]UQ]ZB7
M2?!Y4*SCWZUW,%#I#G@>4)$-=$?;;B`'_B_HS.KNRQF:Y7$`_9&".`\1:3P'
MU&.\)3CL#@^[O2P8HPNM0VKTV1O,(H)-V6`FO`8^M5<<OLB:48GW,0@[7_E1
MYQ.,"T?NRG-/?`.`(V<_H&<_G4ZY\%L/Q7'2<M%GY)KZ=R>.8\UH&@K:/((W
MA73S&6/H&A]BZ>N#,$"RW3%<C]2S4(:7"U8\4X_I<:J";WB<C,S!M[VA4<2D
M]9?:8KX!,6`Y?+T)W^J=U9OR/Y,2<S0=Q:W15\$5L84"":SI\POS%]V<!YYP
MGO`?1+,/HVESOU^S&SOVKNN+7W!!H>TP[L=50`H``93^5^?,24?6.__&KW1/
MH@YZ#NR]+-"3\,4GM19=.C66]?409^<HQB'NJ9,M08[#'/WN:N$[;6@$7MMD
MB2G&KT4OS4OMQQ&\=M5D2FJ"J*_9_?H-NPJZ!JFK$^>47O7DT[+O1/D4G"M&
M`<V3R43H%ZZ%8HT._00F)[.U2P5W,!U.<LST<%4!O\4?_6KR(!B9^T=3+J3=
M<3<'4L'R:S`:/1P/%[Q:G/_E@78.'W'R=>THB_4*&.B]0=+,W1RZ#&G"J:P`
M=7?C9U!,QL5?+Z`+ZMGR&U$&,R)"PF3K23RIHLY4Z^F!<GMW=?K+3U>?S\YO
M;ED6@W+^WU\O[G[+SJ]N()K;8#XZ_J'3^"[F)3%^="WE!+AB9K`H)M9:V"N+
MW5Y2O.@!WD08;`"!C>2G1W*\GL.\+DQGPQQS'2Q??D.B1Q&(V`T28FCN"94\
M^%P8.-:"D$@\7QA^JW:&71K*9@'TE6;SF/M[<"Y4O/YA[SE2KFU,$0\N3_CQ
M=C9>%"/1:L$U:8YM?/?!RN%%P!/+'=24I?:'A;Z:GR/O1*0:N[LWB>#NOO'K
ME_IOM2_,R!4`NW=)(2S`+9826"#LV"5M<*Z1,@3XF*>,80X'NIN$G[:S,G1V
MTXF9,I&$KY!0*(DGT]C-%X42.+U^!B&"]R\V8=FZ-,]:/5Q8]J':I41,_^YU
M_0R(!YOFG@#Q,/#"'VOVB[\!%Q.]P)?"1(MG8CP%EWOT]2%VU&EP,V6!LL6K
M8+P)?'XDF!D1V3J]S*3;]2^ER3<-/G\&A`8LPC;EKXMWK;2[%*8,T+NK\"4T
M_2Q(/2-SQ@TAI]&[(G8U7!"O?KX>SQ1E=\(SO)$/,[`82`BC0W-2&6L%J$P"
M$:X6%RR8`X&IO1$A@#>JP>T]2T%8*]P8Q&#<6%&P*372="MV_W?OYU`PG,]8
MPRZVBR!C)D64S2>(3NN_=DTK:FKY*=>&9CH%E'$C:*H_C_;$I;2)6=(@]):$
MN+R,(R8@]9C2SI&?9D1K@;S`)WO=[EAAEC9:1/`-9EO@,:0T^E+[IB^Q#'@=
MUVE/FF[0E'36GPZ%(##O--"U&3_L\"P1W"-/$PD*+3"%=[CF]YE<OHJD`6K/
M(#X<!A4\%PJ`;$PP81/'*8J"7,2JTRF\;KDRK!="%$[=?OJA$+]K\0J?$?M)
M+,+H;3N^%1#M6U*\_HYE5,'+U"3^@A=J&5D0C9LD4QE\".0KA=_?*<$%7B$I
MU03*)/`:-BIJC=6OKL+4U0^Y/SOHQ-B:I\I'<UUIS1,8V)SJ1WDFR0=>1,AJ
MQS3;UKC'&%1D3OSW#'/?\RO_+2_+Q6Q*O^AK9>N\FJY[I$Y"]T+Y("8POX`V
M46_&WQ'-S6$"2OP66OS'S!),&5:"FAI,I*-5*PR(H,RLPRMW_,KAH(S.@A/F
MVXMAIGLTS))8'USK@9FG#!NL5A,3,[^:.FZ05HH&;XIA:$@QA,^Q[?F89?5&
M^A*;4C"[BV.8:AP\/_)MI;,:(9K(J2_H09A8&N%H876$7Q4YY_HECI[8DE@\
M=$\B%8AX,*S$RL1J$[NCZ(OLO'%:"$,-\VAR+<V+C:E*GO.(:>0<Q@R\ZCQ+
M2/&P^"!95AAPO`]_AY6T8="-5[+0<AK^=2=5.1#_%NM4M!>_<)*FHODK\FS;
M9*5/`)`;16*ZVB>WV"?VDFTJ?9`YQ1Y)#)>P>;H>33#GI3E:<.1SXN@/IL;]
M#W0'5QAZGWF&9H?"2E@I%&Q\YML'N%:0@8\G3AXLA,P(+@V+%`4A)U&(Z:N`
M:K0_(^BC!.FM`B\$6"%(+=64D7HXAXWQ5[.DVN:5?/UQAZ^!T81^=%#0D*MQ
M.H$,]2,V&Q6/!&[M[?EIK#PB4CQ"OV9DZOONA22`J+@X(+\/D7_QM[-\]1EF
M<O/<WS@-5&M=Q8;J5;-,B&R^7_S[AA\,HBT\Z8,M"W!.O`?/<95!5&'XI*`G
MRJ^W+J6A^^`YVM1[,0/-'&N_(-Y:6$X3_`I!HT_Y!E(V8NCB($"CXHF1J@MZ
MFM\M(QO=>/`[=3"(:`-6">>B?*8*THQ`P)N)H%#TNXXD"C,I=;)^(ZR4@ZK/
M%-B^F"@.?AQ>OVH#0WL^<(\8S*VW7*I(S9.?WQW(&C`;J$;]DY!5WLMY`RG+
M<]!0"@M[J,J/*#=:\_R!DAO%%U([J%2:]NH<[)ATF(<U,TP%QG";R[QB-,<5
M`3<=8B]9:2^^)D\4?&90KZ$#E<WIS^?:4GN@O0%$Q4KJ4?<?U%2F8>/`?(O7
MH@-A82!2"S/T^7Y8<"!M@=-JR:0OT0%39K5")><&<845,36#776,`!()JO.F
MW68:2?C''SA,'$$\!95Y;;VC25!1$?1I$7MN0?TWB"1ANQ1!X18@*'0*(Z5A
MQ6JD7-$NP!<;A2`SAS1J:VB^;=&T'3GMUA^@%0:+>F\F6#3MUA]?N_"-Z*#'
MCT]RB:B1$PK#L"_6NJB1*"H4LRP2X:%N3Q!43A8XT0A-3PEB1)E!BV%O&(GK
MI,+;V>&<!!L/^Q&>^R`FJ8,@ZB/X,AGUX3S>:_RR:=IM)#PY"])6&>%04F/W
M#'[Y9QZUQ>F4!O\3Q!JS"ZBIZ$0;_%P%_D)OT!&0_K:^H^M3P&U8B<U\R2V]
MFE`MC#C%;&MZ.B79GH5M*Y(.P411(S2=A@G3B>:4A.PI-(L\TPXRHV,K/!*#
M-X\*`%EC,4W3%E,#'-E,,X,BYM*P&^D[%S67!")O&W.I?Z0&YM(&"7-A8F/A
M?,540FFDDH^13U@OMBZ[?TQ3+S&EWTRF]-,20%Z,%LO`S%GN.!.P:\V^LEG!
MSK\Q,>J:V/3'L;S0:RR!V!!,5B^D"L'+6E20+?H*'$X8<)-,'&Z(PCS87H?&
M'$A+0J.8B-E&,4-EH\+/`2\]Y`FXT<SF5/'J[[<SD(7@@)_,7!#)&96@Z[@M
M&]"J]SKL;K'7:YK#1N;"W?9>M]OX5O&X:5\7%+7$=*B"/K%IIA=*S(\OX2.\
MNN8$LR/\I/&3H$G'AMPU5!,U5_UN%I]-4VQ6(=BE8VA3O/1XTGPF-H:E8R,+
M!WZ_>9I_<F&"1H[_XFH1(>$;GBCRR;(OPKR3W*WVXUO]G;XGN@?,@<FH88\5
M4[\"QCRE>ZJM=-<GD<AO/WG8/:GH+@?)2I0-=JGF*)ABT(GD&YC^@!Y\1QQ7
M%S1-$Y`(E.-H?O@^=W/#+"X62+=D>3L^EK5O5G$8+1?>!.IT<>ZIH3EP"CP,
M=67?H/L5O"?PZTXU;%ST\<6_&.,/KBNF'(X2E/RJS4_8WH>14W\=]$GK3?2V
M<QZNNT8W)OA2@`!FAX`'MJP*"=1D42=KMK\&X*0<CU;Y^[QQM=BD5<APG*3U
MH$RXV+ZP,"M=EU4,L$3](9?8?F8('`C?OX^5>03YZXAWDK6O%&6"J\4E[D8`
M)("/G5Q$3?E'>&?Y%^ML%?]?]'E8"?-]BM`C[\<AV@TC,7\S90`4+U@/2[RO
MS/,P]2BX;\^S&$?=E$P5%-`E2^K7K)CL0'/NAUJPW\+5XG-PDW3&+Y)R(4S;
M;D$%=B%.Z#.GQ%??ZX")XS:YQ"F-GER#Y8QWR37`/0HZ_^1!<AR'.61RILB0
M9N+&R8DY]T_KDM0@B7J36!>CC2%,25AF63I<21=NYE+*;M1>4JSF0).R^8)'
M@.3HA1CKZ<"X_9(\TZ_6&0&C7FK$$!^05$P3]C)MP%[*XB\$K]"5H3*K4%1A
M%)KGK]L%Y9IA;YCP6"@D.6V!MM/2HT'F*12#%JEIV!^5H:5?)V2'&4.VA,(J
M"^W=4,G5)63+@7NZD9`MD7Y&`OHQ-Z6?[O"5]/-:H5K*-OKJQD+UG]]]N[<-
M]O?_!U!+`P04````"`#'16Q#F8OL:]<'``#=2@``%0`<`&%P<&$M,C`Q,S`Y
M,S!?8V%L+GAM;%54"0`#)C&"4B8Q@E)U>`L``00E#@``!#D!``#M7%MSXC84
M?N],_X-+7]KIL(:P;);,)C,$LDEVDT"Y-$D[G8ZP#Z"-;3F2S.W75S*0<+'!
M,=::I-V7!2/K._J^HZ.C8SF??LIFM7-P@"(.IM89:[CR"[=_U;):A=ANT\#:
MI</%KP;'`Q#7G`%0\5W\WN?</=+UX7#XSA!-F8$I,.)1`YB\H&6S)YK\]^,/
MGR1(A8*$.-):'F@W9*#E#[1<[JA8.BKFM':KHAWD\H7I3>(."SL/'<1`&]F6
MPXXS"V"C#K7>$=K3#W*Y@CYOF)FV/!K)"TOMAP6_=;Y4*NG^KT]-&0YJ*+K-
MZW?75TVC#S;*8H=QY!@2@.$CYE^\(@;BF#@1[-)"6\AOV7FSK+R4S1]D"_EW
M(V9F3J;,:=HG2BQH0%?S33_B8Q>.,PS;KB4M\J_U*72/,\AU459RF"L5<K*/
MG^65?X1BC%C8E-R?(DN.I-D'X!E-=MQN7"Z-0=S21]1&4D!=-M!#[]=/%%AX
MZ0A@:'+QV08GEI&K7>A*J*P@UO]LD6$<"Y_NU><31-AF(,OP+-^KKH0E2S;"
MB(-C@CFW4O885[8G-@2F18PE'$NZ-:%S&`MUP#K.>"S;0\C]I\P8<%;Q*/65
M621L9HKOWUW$.KZ3S^[3)9$Z6)S-K_C49G/YF:__'`RP0,Z+394,EQV?Z+-'
M#P^0)7ID95Y!E(ZQT_L#61ZH&$(TX*>ILZQ[F2Z/$5%C;J/XN";Z<C29M="9
M9]M^;UDL)L#\_BXE]A8E.7DQ?X2:0(\S^8PV!-SK<_E1C"V69'4*+L+FV<@%
MAX$`K_$^4.4^%P567YPS>ZE7)/)F:AVLJ+5;.%`7!Q8\*3W.@\@.IG5U$L3F
MM4Z)*U*L<5T$;2ZDE!/0E2O9#2B:`1OPE@>R7SIL)BK<V^/)LC"C;HACJ(M(
MP4#[.AE":)FQ7UAC/Q;W5QAUL(4Y!I5+00#*+@Y3-@SBB56SCL:H8X'*O"D8
M*>TL(URUI6@:0E.2N87`H!Z8W\>-PL%2SR,B*Q+&5D(IQ'PW)4L)6(A^0SC,
M':`!EMRSU!$-U2E\>Q:]0_UDCY6(P4]HP(T9O9J<&`]]8HE>F5Q8^5C%7`E`
MV6G;1VR;.'ZGZG9XJQCIKLSA.BWMY]:(23IK+9LFEJ8BJRXV(I=.!;F8(TM)
M@`V!2C]7C29&*%5AT366(`W@"#M@GB'JB!T[$U'=LST_=E2ABPVL9/&+@)IR
MY(VF413VE.6X8B_S?<+O5LP]2B$WDK(HW8:\)229?"TC"VH5$C/\DK*^4E,^
M45YI7JV]QPU>-5<^CQ(3;U;14E)F6@>)/WL;P$#(+XNF51B`1?Q"Q*QC-8%V
M$V#*,394ON40NY&RL`0EECS3!YR6@"J;-G8PX]*^`2@4:!MDNN$GDD);64NX
MHCR-'E>$L<_"6!%7A(&>L'%FK(@S*H2*@!K;[YYH?@91&LD68%(.`=&U7*HF
M!O$5OE6)Z64<*#`^A9CY\@UQR!Q;49T]$JX?%?SC$G_=7O_Q_N^_[@S7&]T[
MQ9(Y.1ST[L=.N^H-SP]IZ?#KP;=V:\RLPX$QR5E?^,=VY:INWO]I%8K.7:=6
MJ5Z.SUN/@[L*O;U_/*O_B=_7:JW:M[R+\YY7K*/KK[W)M\E#X^*W@XN[^X;G
MT4=VV]=[[!Y?Y`?Y%D:3RMA\L"^NQX-NH3`^);W6M\=*[Z[?S+509UAKEKS^
MJ.Z.\]7ZA_&$5ZJWK5*S6[XO/XP.'XM?'HNXWQYTN_IG?'I[<<Y+^5.X_G+?
MSI=;AC$I5YT)0[_W*M=6_;8S''*7?/A:O.(?SX;G[WO'QW]KE69C=H+DU;EQ
M-!?;D+J]V*E%AVI#S#)`^EOMP`$O:[!=N=#(DL#R5<7,F(*"^8PIS*YU6VA4
MYISBCL=E1:]%&N`2ZJ_&X@8U6[WDC'MUVN^D1*(UF7DUH0ZT*791<(H8-F3^
MBRV//V^ZDM1]&V3<@+-]>@G$%3#?@'12N#!CTBYP1/2(EP6V4.8W9U(IU`N>
M3L+M4'D6$UEV4Z=D@(4EI^,VDX6(IU2R+$^N^H461>MB5/3X*\M_<75_H::+
M,V2%KB2?)%?!I6#@*1MB7VS+U6+B?U6ARR:XM$/7;AIM)#+ILSOST"H"#K%E
M,JY,L!"DUZU5&'U)/W->=():MPH=[J=NGL/K%&SLV2H4VP[ZVL-A!%IG2KY/
M(D2*T$M!.$L5IO]?.BM'?!1E@%M`7[N*$6B=J5A4IN+*L:#O)N0J;KJU<P4Z
MKA$[D_*#DLKZ_Z6)_?6-A.L6A\\.E-VA<+'NM+,W#JK0!4HA^,V#[Q,?(EF2
M\M.0I$-&-/9G/O!QS0<2W6A?.@-@J6VT@]#C#U$LI?(A-&N1LO'H80JA[QBH
M&.(+T/=T0['!%Y;>W'@!S>N[]^Q.CTF"S/Z,'>08:;EP$/H.+DR)`6#Z*\@E
M8YY\\[/673@`JL1SMX+N[=*\0?N5EXVVT9KLVY#/<`L'P>7F3;5^JW![&FIB
MZ+9&9-)UID6P6T0IDN>9@!I8T0FVC7AO:<:MDQE2>]I9-G\NUUP_U9[#*7DP
MMQWT+0D80FN2=:?@".W7+EG;$3@BC189!1[(/#FXI"G3#^43=2?;WDXPWDVB
MD%)7[,@=_`</ZD`Q,5>W7RH<Y$7X*6]FXW"U\G@N\F9XRRG@-S3\P*W3EM,G
M;VCX@1$D[`%3Z&F%3T]_=LEO]2]02P,$%`````@`QT5L0^N\]-0_(```O.(!
M`!4`'`!A<'!A+3(P,3,P.3,P7V1E9BYX;6Q55`D``R8Q@E(F,8)2=7@+``$$
M)0X```0Y`0``[5U;<]LXLGX_5><_>+,OY]261[8SF8Q3DZV2)3OC&<=2^3*9
M[-;6%$Q"$F8H4N%%MO+K#P"2$DGQ`H!H0<Q17F++(KKY?8T&T&@T?OK;\?'1
M!^QB'X78/GI:'9'!_X3S_STZ/AIX\\6]18ZNW9#^U0K)$M//W"7VZ>_T[[,P
M7+SK]9Z?G[^SZ%<#B_@X\"+?P@'[X.CX^)]'[-]__]=/3,C`QTS$NZ.'"!_=
M>LNCT[.CDY-W;\[?O3DY>GP8')V=G+Z.'Z)/.,3]ZPD%^.AE[KC!^U<982]/
MOO.=YT][9R<GKWOI%U_%WWSWPC[(??_Y-?_VZ?GY>8__=?W5@)1]D39[VOO]
MX\V]-<-S=$S<($2NQ00$Y%W`/[SQ+!02SQ70ZZCR&^RWX_1KQ^RCX].SX]>G
MW[T$]EI%^AT[7(O)-O"F%__Q%0?LZ.@GWW/P'9X<\7=\%ZX6^/VK@,P7#E.=
M?S;S\>3]*[18H&,&]LGYZQ,F[._LDS\HM8'G$)N1=($<]LKW,XS#5T>LX<>[
MZ]S+TD=FR)\CQG2/?:%7^7SOGT?Z-;QVJ6!\']*?Y]A54K+8!-=3NZ(#%,RN
M'.]91</UL[VT)[77[=8+\>E%%!`7!P%R*54!";S)F/9="@*W:E%519K2K/D9
M@^3R2T26R*$R`AE5MY[5K-OK*T3\WY`3X8\8!9'/K4I*PXH6>IIZ.!/Q_2T.
M;[P@&&/_GFJ`9=3;>E8S@&_N0\_ZBUH1M7PZH&`WD#;'JB;T]6TFY0?6MH]G
MM'DZ*#)(9'0L>5JO>F^')+`\-R1NA.W1@@WM%`,I':N:T*OHC\ET@CPYF/T>
MA-X==ICG&R/Z*992N;DQO<J?<U.;>8Z-_8"YE7`EHV[9XU1!'=KU+<N+&'?3
M,1U)+/KJ%RO^D[""-2U`.J,'1+F3(KVB!9U*5K@4>5WK&]+$?4WGE=>XOB%-
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MMA,4//%73A[N,>?4PTX8I)]P=W5\<IK$PO]>(R5C7NI*)W-`0(7SD\(<H7T_
MKS,U@%25Q!;$C"5YADU,17@)O6H@/)\./>]?G=#O<C-^QZ8"U,XN'?XMVA7P
M-`ZZIW^G4V)LOW\5^E'N+17YN+>PBWSB]5\(K!WE!"4#@79R2MUJ+5DY>RPE
M*H_0-E]%/E092<0\NL$"6V1"L#U,!C(`5BJ%Y=Y`+SG;(W0M,V66F2.H&K!F
MDO12],?)SDF"9BB=\,%0Q`!+2#JMZTEJ//6#`(=!_RD(V58Z!#4%"6"#36'&
MI3[L%"'1#WZ\&1OY/ENIU!!0M8U;^B28H3?C6OX.#-.Z-Q49'M2,FFVHTA5@
M85^U'PZ0[Z^(.^5;F1"V+B:X]T^P84-7'Q!$,*'PK(9")0+'/EX@8B=A8JK(
M*)QA/S:@Q)H@Z!,1"SGHZV)/"+Z$N]>5W+483P`Y*F-CS^DH!_Y[[=/BL<_"
M_>%J3)?./`)&>^Z":7>+@;I+C;Q.,%./6$+4&^U$9;KCK>=:<)VE7)#!F8(8
M+17X)'S\H'FI$@N"\U7[CW>*0`+P6\T`WQ#T1!S"]C=H']O>1H!<?0C+-CNN
MYVTPRXTX>-K#+=G)>U8-A;5*V>,&NX6L11:7,J5H-.*OYIWBE*=@C%8L_`8Y
MLRJ7U('52A5&"2,_ZEZ>4'FT`3MC!;"T5`CKPE*D!JJ$G7,]_25-<,]MKR<&
MD=]C+^6J.F->O,']#6TI@)-&O>J&D[:S`<!>4]E=]I2A.G12*@#"O[N=C-5/
MO_9@,E`PR/P>5YN9EUH8TYO//9<+AHM8%F7L_6)E&Y6T?V@/0_9MF[\_<L:(
MV-?N`"U(B!R04;Y"5"><5B5.*3/5049ESW7'<L]<;%\BWR7N-*`3C6@>\:%L
M2%&R"(@'$Y"ZO[,`&>A2YJJCE)K&F]V,,]WH1V7HI$341B%AXC(FXC%=6&XV
MXY:25A.J3#+H>OD4NDQ6(EQN7?&`L7)?/B37'9+K#LEUA^2Z0W+=(;GND%RW
MS5-R0LF=)ID8H'EVU<*Z$">N@:J1'\7U8X#I6[`LIR%>8L?C^_Z)=)BE8YW`
M+JP::P$32`53[$5Q%2B'RNW;<XH,LPMV*AJ0JR:1>Q\D:\2L,?M+D\?;B:?K
MPJ*Q!!F!1+!V),0+O;@.#"`-&3'[[\9*P1')]%+C@A>IPT$82TNXO_5<+U4#
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M"/!R"/6`AGIJ-W+E>T3?_C,*0GYO!`OMT0F&11R<1#<>//H#,X['@&4GMNTP
MNF3M[<)3+Z+-6\&'./PA#K\5A]=?OV2(%SX=H;DR+'-ASN1^3>K_ZK>`.G$=
M"!_6HB6PH:TV^TSB6\6;<``FGN62.D!,%4;-V]2*I]0RS(\F0_P4\NX=N>'8
MQW,2S2'H:1;:";<H@)W(/K7""F&&W"D.LD-S7![/M95+;<@UN=^S&UE\P#:'
MZ<#I8]J9ASC^_]I-JJL-\03[/BZOL@8T8U'19/]#[*H0BVQ*ZR*]4&)D-_P6
MA7;"I0I@)U);0B=SA0HD.R.O*'=O7:X<>B*[SZK1&;9F'?O>DMC8OEA5KEZ!
M0C>BTCLP"Y7!4F1_NFT4]-I=XD!7%+2NL6Y%06MA$2J?H%8J%*V2R%'?^A(1
M'U=6PH3H:1+2.]#39+!L+JN@V7>6V-<.?6>9]`XP*H.E4'V&EK[SBKC(M33Y
MSKK&NN4[:V$1+L&@4F;9PMB.W7<01.R>HM$D4Y8(Q&4V"NW$XD``NY0X@(,!
M6>F9:G@L[`/-65%<![Q@+5HI2_H#+EFQG^(;;R]?L&\1H-.$M?(ZUZFV$4N9
M`@B39`7SWAO?F1NDTD$R39N%=HZT"NS2G7B`,$FY'^8[%\&C2\5>TP]<=F*8
M53@JW=!@LUOP#ME*MX[YV'8\I,:B_TA`Q6RX9/:UPY5%F?0.\"V#9<JHOJA,
MJD7Y[3YC[!//+H8`(3B5DK__^Q=R<*:T:KYXYW#GU8[OO&H,X>SL;`>KYGUZ
M$07TY8(`N38[BQ)XDS$=0^@;Q-D'+;)R2,!>,/+Q`]7M@G[Y+\@R1G7BU'<6
M."2C'"1L0"53ETR(Q<)T\1X5I7GL.<2B#G@M'N(M6^EC-DHC8`_97M4.>>$[
M`G?:V<X*/J)%[ZIP.H`=K$&B]FE%B;WL[K7*A!O<A15CNWE0*L54]%303KO*
MZRM$?#YR?J33'ZKP?--AU*QLW>`&!-#^4BNOS1J\K&'0+E(OT.0\6X33;*]H
M@&X_1XWO"[4<6HP:Q1/GD/9?*4OY"%NQ15"CKQ9F=AK51&%=@0$I4]^YG;_A
MX<SM!&C%A>VFB_.-HG5[R;U%`R\(`X[*$Y.8;L;O9HFBI)'Z*D98\$56,&CW
M:JN2X5B]'N/*'<MHRY'`X+7S+OT#>Q,?S]C!W&5\3K!U;^YP-"&'1GRRBJ$$
MN[YIDFDTPB89%&@&<`_'M;?EI^;:](3MUG@)F6#A!<CYX'O1`GP@DU&AU<B5
M:9`R[D2L:DZY`CN*&+36R>2*2=%Z"B-52T[V,N+P8_&>R]#+7W&IW&&3TV$Q
M#*#]LEQ2B^Z7:Q"V5U6(,CW1JR4O?ZZV`JM]G)B=E]P^I5Z.J=@4D[#;^T!S
M$ML4,BIM>4==0%RXT0-!(FS7WTY7B>G>#0S;FTP7*_[3JDTH>KM5R-Y2(TTU
M:>`6A7RA"EO2O$2*X=&@F;A<TDX)2D#5O9+=TH)^B:GN8D>Z27*GB!-%L[G:
ME!*9-X1Z29OZR1V-.[7R.D5</7+-%:K4Y@S&LD&D\CXZ0J%DAH?NBXAN\7-&
MK.^Y]$<KWGS>F4N5UJ%3!,LCW%PXROB>+*_$VBH]H=M;L_?6#-N10R<[?<JK
MS8I9DR6^QU;D\ZSDRQ<6)<)V?"9HOHC"I'3.3O=T`;0T&CV7V0N&8&COEFLU
MV\B;'GK83=:WFUQ^M*3/SI)-8Y]^L=K:M>P_(]_>V>ZR#A5-1^SAMIJU$`A8
M5SQU6N5Z9@_`)4=@5KRC[V@84=;*8`!/OSWI8$GHLMY]V+;5,(Y\\[NWO.2"
M2.78NKY:49-"H5GSYQX4=UR5<=RS+(C,?3<+VK.H^LAQ5ND<U(L]PW-\`IT=
M1+(V.[$NVXF-[[E0+W3:;L)[`WE5C3;=6M3FU;8R`+L>1Z^&D.&2RAMV=!LA
MS-I.U[T^AKKJQ:J\`:@+@B#5-7_-$(A?R%51AF1;,.U"DXG>HCF&N_*H429@
M&$KHXJ,=]-MFP\ER`+8D;1(-<YV2F`'`FT#=S4I[9@-BUS2I9PG%"]J/N9F_
M]FR@G!"CL691M[>5^9/'"2C_(2E?!<=&7H#I#3<%+@H(05V452CXMM$.CIHF
MD09C;2I$-2+8F,9@8N;=G[,=W3V<8R>*F8S@0R[]--$F<I_A3D-&?.AX*D:2
MDPL=6L:#&O<\JK8\0"-!&K12[?M-`7RA[2#XX$];Y8S$??09F\R6BP1C.H(]
MJE=N>'.\J;'%OLQ4!XK5U(F#FUDK1%LT]<'M6_PJH`9;*E=(A0N3U`N$FP((
MA4@$S%V`,N!;HFNEPH0VFDDS&];0R1O,U=&IZ#L<8/IRK.[3$"^QX_'+(Y(Y
M$]SZ2T2LV2U8(4>4)5$(2:`N^`&[V$<.NYK3GE.<V+8PF]V#\R@FV&@02II(
M03!%ES]R&1#K.Y,2:>L]_H(?K<ATJ'G<Y/D_K?/91IR`(KA]A_\=5]3&3A0!
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M[4H:F(K(F$+S!>NM&`):`VC4]!,FTQGU&_TEG61-<7I-S-@G%DRX=D>J&YH@
M[8'MU3.J?2F3>X.M'9GM-WB2?H,[S."FGP\\EP,8(><!^_,S,/O<\6N8B7ZT
M,M5=$PVSJ=VVUWW@&>G7;GPGRP>?%;#<0Y]9IN;_,_]8RI3`A!C(KBJW:$K5
MW;LQ6J/Z1M9L8%:HD]?FL@8MLA/9I7#8'D8^*[+`E8DOA]O9=8L*6G1LF%2`
M.:&\^LYG,]YH?>MG9QV2W!MTS-!V3&]BI-478!N9BEUY_@23D-_PX=J7+PN2
MG'U,7VH?)V;-2G];PV-[#A/CJ[O$>S_-;^]<)N@+?6,>%);\Q*:KKSS?:50^
MWD.G&@0,5#MSGMS+GR=7J68E?&)=*F0OU:!TT)6+&'C!'%LX"HG%TP4>/.+@
MT%]=)-=C2NDKW)C!;J1"TGKC2ARMQ@"Y`E4SUFVOW<L@)',48M8]^8)_['L3
M$GZ($%N$X>*UTE5<";=F:J>C'5/B8(FE6NS3[;2)ZY<MS,^!$6]^:_^VUIY4
MVE7J!N*"2E+S6RN?R:C?33Y]6]+6/4(:M_8)\O+D9JX<V$J'K^"N\`A8MG-C
M1GL;ZURS5`1`>Y)Z04I94GHCT)L<90-YY35V4H*BS+EX#4`64\4EH#23[:V"
MIF`VMX)KQ^%HPD*+R+4P+\A6EO5;Y<.K'C9Q!+*VEVU<<N7[:LZOX-+&D6_-
MZ$JO^@!_!;*E#QJ<PC?B6OZF4$>_Z6IW26>88P?%Y9SA,M4K))F+I=4QT01/
M<[*KZFD0.KRZV$ZS!?N6%<TC7N-Q2,&Q",AI;0&IQOQ0R]FC#+#Z#_DDZ^Y<
M;0#N,NG/UR[]@XLM]@:?2#@KFMJI8-1"L7%3"V,=JP%U1`7ZK:H?]2R,[2`^
MO)]3#\:95HLSYU$U]=5:+`7SI25G%QF)]XB=YWVDJ`6\UNX\J87;=^VD'$M`
MISYB<P_Y9@W.3'3T3!4@H5(JLKJD\]31I.@4H'MGC623V5X`7;4.X\8<"E62
M!RA@!S[9?^R:NB6U.5;X.AQ0"UO1@?XWY$0@6WEB@COOBP7Q;4P_V)\[)3;Q
M9Z55?F/#\I%GT?:49Z#-0N2BS2)M@2T8JH/,DKSD@LM"\+0.*JM=,C1?.-X*
MXS@][=G%?C`C"^I<W<O[T7BSBF6W7-(/H4JQJ*AAK!RNBMEGW9X2YGJW3<54
M8?_#U681EKV;BA\UA5I:=!)QWK-@`QTB$U4`IJR+#-\FR[OLF&V8"C#<1^54
M2$._3/+I^?E;B3"W2#MFZ[G(^K'U\"P$D?XMLM9Y:/%QT]&D;]L<9^3$:>;]
M*)QY/OD*E,(/J*[)F*'"Y&XG#,(>W6RC=2>L[6!CE6R!Q:J5SXJNG2]+D<W%
M],9T.@X43`/4UG"PM:VY`5&H.\(N=/:J<I"'.;NKJ$J'#485?+`#CX?3N/M_
M&A=Z4`0XF5N[Q6!V)K:D@+&`$\_F1H"C)82NIC>K]F!NMLV?T*G+G6YZ_,!>
MT<<S%D59\O,'ROL=*7R;<,KZLLK=7)&]+4Y]N!F%,UYX;8/-YH0&SV1\0"\0
M;R,D=R\N%JXD-]N5Q&`4"H3OP[W`6OK&-W\S<"KIAJ`GXO"[2I@+7)]"&KDW
MGCNETTHN.BT3%%Q@E_(8!F-$0&(/;=0Q?3>\XMW"6IB`O#K`QW0,'>+X_VN7
MNXN^9=&&[8S.$-8@+MRPMVU)O03(^W<]^X^9=#[V>Q!ZR0WV8^0SI=LG9XB*
MD$_3D&^Y5<*&J#BYU`VY5@TD<2CSETOGD`3/3&)'YJ:X%536QI8,\RD92H:=
M=8';N,%D7GQ$?WK^`_UB,)KD;_6#R[AHE&GZTN`JH\T2U`P<V!RD231,WH08
M:V:OQ-%!'.CUO,G]("S--%RQ-:;G\EQ3(,]8+W`/3F*W]I,-D(+M7!?$`::G
ME0HR<[);RHYS24CE:`$E$Y8)`\HEJR+'K!O4PX]H1ICRO/#:I4O`B$>B`6>&
M!2F0H]2.YX=%_*`.[.9E;5\2#<=81I;A2Q*K[;6:E2Q2`I-!K=S`^+M:=LQ/
M_=0)$O)U:@%ESYV&V)\SR6S6">7J2N4`TK)#7U<.H4@-=3V4P7F["DFFU[]U
M-EM'#+2S*Y<'X^KJJ#'KZ=JQH]_3);4`*0S(&="&B#OMS[VHO,Y*92'-RL<-
M;F6(!L?68=DZ%'1WBF^F9)`RVJI5A-1B-]@EGL_'+[CZ0=M"C-XL6#\0YL(P
MV^@`'1Y+<I>NW5^):X^O?V4R`0LZ54LSZ)?$>:E#"V:^F\FVAJ-E6XC1?E(;
M#,Q5&M@&!Z`.\=@GKD46R)$>ALN?-)E,T!!ZR!1E*7UGH*J2AW)7^K>T6Q>\
MTCF=Y:^P.:CTZ%()1<GYR9YP=H)DLX:/8^A)59"%4N186.O9<JDF"I/G\G8Z
MSYL06/J#,''9RIS;CU^%+8SO6#)9G*DN1)1(.YTG2@@L@2-.6B+0F;<I:%(8
M_"`"TG7".SLX*N`,5HDL6PJ-Z;-='QED$=8LU6CI5BWTBD#;7(%,0P^^=NG2
MDKX#-2;,-Y+MY-0LFH*<,I20;O:0($`OKL=:X,HQ+8Q_1"'/F!I2!>`9SDG[
MQKQR'LG&Z[7TTW?'COM12_*+:TUH)K."O[EN6HEPPO"YYNEO?);%HBNB=0VA
M_B1DA]+2D5YH]BO03'?'36&@TNB`[A@0U9A8.#ZUW0\"CVI!-6<ABA*M-F[]
MALQ)F!Y=RKV]:`1!L]3.NF`H%E*#T;6#E$2W>.27K\;N\)0$;."WKSS_#@=H
M.\JE9!MM99@^_JXCAM@2Y91[@.+YB-CQ-DPZZ8/9K]J2TFE6Z]!+N:H)/BD>
M\8PE7+ZP.@H\&'WY8CF1'6_I4YV_<L\!P9^P["Y'K>2!3JFN#5\ID9V5$Z<=
M\/.KD1N.?3PGT1R"Y6:AWT2G%<`V);8F5-5J=X[K/D8KMI.4?X%!Y/NB\7ZI
M!CL^I98#+^6OKBB^ED7N%;)PO+4+OZ[-R.HNF<TPIMQIO](^+_+11;$?P';:
M_>$I+!/Z3?A4`6Q37FOB3GHW>M(24G$:S.8K.SC2(Z3%MS!74@$_-83:\%2K
M*7(R.)2.I7HGQ`5)WT"(L0K#-/=ACRI+G?.,M9GG4,V"V-"R14P4\VNJ6]W"
MK3&I1J0MM<ED?>MRA4F:V@%T5-7%2"1HR.7T-(+2_GKREJ?L[RWL(I]XX*?K
M<X+,%Q\1--?28_1YS(!RN%,ACVZPP!:9$#I]`3MC52W,^(4NM9::HZ<:L%U3
M!'/:JI:DO3A*KTP1S,4JZQ@+J^$*>:XT+V`_3L\K.+@"3N9NM*@L![W1T+59
M77+8<_8@>AH^HU_:%_34ZJXC!^JT*X2V0-X;RIC,'K0U8D]PE0CNHZ>`V`3Y
MJ_C6XOBB8JBY<:6PO:A)H#)%KH:O\;B"&E\;,<P\1I,':E<!XKO7@`-#LU3#
M;K[1CG.L"8`(>*]:HW0@ARQ&HN$J57IY%)QG'PKW&8\QU);J`ZCG<JC5=ZC5
M=ZC5UV)-R[IZ=H;+9JR`13!JQ!D]Y@^YMM^ZQZP*;["JPH?"#28+-Q3#B'TK
MC)`#V,G*Y)BM_].X*U`6;LWC!%)C*14U]KT%:TVBGD;%HV:]F`C,M2^NN<)2
M6K\C=[2<8GDJ5[BDZG&#U4O$5_#9.B:5.``5,RD1>=8.^K-O!?HS<9/7,.SN
MXC+K.G%FDVHD\Q"$\`,O<35&_LB/3^[^AIR('43B6@!35RG6<*I;>PZK`86[
M*GQ+9_8JL44M'%*LJ`%RL%9:!]/)K(I,RV/='!:"V5QKNB^U;]L<<.3LPFU#
MJFOR`*BJ&4&R!U<J1]<EO?MM:@<#*V5*_]W=2<GA]([$AQG.2Q]-,@/K'0ZP
MO^2'8=.J,D+3^S;M&ST]HY+7V@K,YNH\&M8(`[0@8>JU,FI<16'DXW)FM4\_
M!97H$OTMH!8HT]-Z\SAGBDPTMJF-;I:TT)O(C?*[R+4<P`+5?-0ZMX,"ZET^
M(3:XA"/_CDQGX5J?=0WT`7(<;%^LDN\%R1=!=I_;JM31Q4EK)IK+`>FSD,L7
M[%LDP&.?6'C]Q]V;19,>W0PJ*2$N4&FH==7%=-@93>HKU^JOO%@CN:/]7117
M@8)`*MM*\0IA2=5D&3-C["<6E=J9G9F+B.TV2;78K5"A"F0"Q7SD:<MY@<R"
M,'4'#UY:.#G6-OV-?Y]J_$AA%F)3BZ".]4R-"`M4!U+JMIO*82,WT9398JJ<
M$+5-;70H8"*&B4C]'H6N.)FP6EY+S,JGCB8WA&IKLYV#(9JCJ6#1M,9&.C6!
M$<1%H.R.CIUDNH)>L)*V+@J=E=)F<KZ%+BTR10!IKIZCPL%F4A,O<)D_S(>O
M^JZ=]LU;+'CE@7RS'9Q@J(`G4$:GS45701*A@*^R7B>O8_,(,0P%"N6T7[`5
M9JC@!?*WY'65NEH,14K;J"<#Q/&_8>03=QJ7EHUGFK?XF?\)Z,B'D.2.TBF*
M:W/UFS9[KWR)`+9I&K?>K6&O#)Z4@^9LMYU5(1IZ5GROMVM?NB$O=#7QZ#=X
M:%YVA+4Q^2-M,-/.%C[;!A)@Z[NIMZ1O36+;H#\43:*Q=7D;9DW&KQT7-6;.
MD&4UME>TM%43TVQ13IC-5L.A._\[JQ4[OJ'/,GAK!M;YLCCGWUY_&BR3D90^
MNR*!A9S/&/F7KEU_%XDHVI4M&QI%9=&O1J8Y&U+1PVSETXZB,`B1:V_=<:CN
M;VIE=(0:$;0TYRYNQ(ZC)X=85XZ':K9]Y#C)-MD!OU2"@_Z\/2:H3S6R>>E<
M!VGH`/GFC,069:$N(-"8QZ8.\1`'ED\6]0DMTDAG6^W"U*8<#H'L,E6/3T7Y
MR+FF4_*77_%*FY,O-&MF7:3HUHN0B%S%I@I_/,;?X06KY.Q.V>&'2,,:I+;U
M3CB>>GP:\[$4^?C-<R(W1/[JBCAT":V+B&*S7>H.6Y"(W'NF"#\7,:!SW*GG
M:_-%^48[-<,LX"%RFYDB\I^PX_SJ>L_N/4:!YV*;Q^1J3I_+<5#5?*?8J,1(
M>XY05K\X5JIM55S>;#<<4@4D0O=VJ1.P68!?T4\T!@B+#7=B7*Y$1?>-7-O"
M8MI!2,@VW85E0@TPPM=E5<7O?^HQ44\HP!R(_P-02P,$%`````@`QT5L0ZO?
MW,.@/P``2S4#`!4`'`!A<'!A+3(P,3,P.3,P7VQA8BYX;6Q55`D``R8Q@E(F
M,8)2=7@+``$$)0X```0Y`0``[7UK<^2VL>CW6W7_`XY/56JW[L@KV<=)UGE4
MS4I:1[&\TM5JL_9QG4I10XS$F$..28Y6XU]_\.`#Y.!-`J"VD@]962*Z&]V-
M1J/1Z/[S?QP=@>]@!HNH@C&XVX/D]$6U>0F.P&F^V;Y?)>`BJ]!?5U7R"-'O
MLD=8H/]&?W^HJNVWKUY]^O3IRQ7ZM%PE!2SS7;&")?X%.#KZ*\#_^[__Y\\8
MR6D!,8IOP>T.@G?Y(SCY"AP??_O-ZV^_.08?;D_!5\<G7]-!:$2:9+_<124$
M3YLT*__R!8/LZ:Y(O\R+^U=?'1]__:KY\`OZY;=/^!>][S]]3;X^>?WZ]2OR
MU_;3,N%]B,">O/KQA\OWJP>XB8Z2K*RB;(41E,FW)?GE9;Z*JB3/-.@"PB_P
M?QTUGQWA7QV=?'7T]<F73V7\Q5\IYP#X<Y&G\`:N`2']VVJ_A7_YHDPVVQ13
M1'[W4,`UGY*T*%[A\:\R>(^9C[&\QEA.?H^Q_&?]ZUM8E/`RNH/I%P!__N'F
M0CBSUSV`S,A77DFVHO:`T!3_XA(1U",5/E4PBV'<$(M!2"1-,!"]:@%CT/FJ
M!S3%*I,7#4R"^2]?[,JC^RC:_O-]A>C;P*RZ6K]-,J1N291>YV6"E6QY5U9X
M_7%Y1TA91^4=H:<&]PHOI5<PK<KF-T?X-T?')[5Z_:<17L2P9E*8ZMZTFB5O
MQ"LJ.VM&_#.]2\D:1H.S>R2O[.C#^R_^V@X%^1JT@T$S&OS<C/^?/U,2_LI(
M"__WLNB++"I6#97H1\7,ZB]>K7)D*[;546^2ZR+?V`F[RBUX\\I>$9=E":O2
MI<H-,+SZ*YA6NRK&F&E,4:!,]"-&4<*H"E\<K%)P9O/JD%ZG:_:0A&,A1[FK
M\+EP]I@UA5K+*MINHW^>[HH"K5K9TL+?D05S_/KK8[)<)".GML?"%2.F0;!J
MZF]!1#[^-I"=53,=BUDQN5=#JITL(3D1O&4T8#%_5WM^_#X>LVF=1N7#,HOQ
M/^>_[I+'*$4XRF5U&A7%/LGN_Q&E.[[K.7(OTT/L1Y6,:!*M7S0(1%D,5O@'
MV`T/:ZN-Y,N:<'U>F!KV!L-U`;=1$I\_;6%60H3KJGJ`!=7O6ME=*)X.VOZ"
M<JYW&B0)M*X>"2`=6A(-S/%HL.I9NU8+0RBA@:19%=1E"^L'6WCL#G6-IU43
M.R!Y%:5JEUVN1;<8B$AA0OJ8$N7@JX&M)<JWL*CVUX@K%=(S;/"V^+3X#CHR
M01)\OH\@,F*$5H<.(=8&-M\O0`:KX,<^'5GVC8QB^O9JQ9BK=XAP=V:&C\AG
M[(E+@4![R+<@S;/[(W1\VLS#WDAEQ>J+>*:C0T?N=J#IS[UZVXYTOYF%W/N<
M/]Q@QDKV,HGNDC2I$E@BX_*^RE>_/.1I#(L2&YIJ[S)<J(W;@;NK#"7J$B=0
M(68XV858`+^+MGGY)T#A!'5\3:7/ZI\1@R8/!<N,O0EEO#B,MNSF<^_@2Y#'
M%NX&&QUB<5E$2WG#@X1,.80HXJ9I-V(.P5.)((81/=%<_8=1!93(8JDLV^<6
M4!TO@U&AU>5JE>^RJKR.]M%="EV&&?B8_`9/^42([@CKC\&6?AW:"Y2*JN<5
MBF=I&P=%((L=C!D5=*LJ`F2>8YY"0L0:@[]O(YU!_3JER`8J(YFI<?"2FBV:
M3)8@%7R75[!1QQN8XF2=ZZ@0JI'(`3`!.+FW&>>K'8ZYD,RPL?,5*-!%MDIW
M<9+=`W2"[X*=R/_,VG,\V.8%)J%<@%5]SP$>\44'.JSBU!@\\BY*<4X;*!\@
MK$",\.._1.!3D505S,`6:4I20E#EV+BA/V2(X`5(,B3Z*$WW(,;@UC@1,,\@
MV,,(_5"`.[C/$2T8`PY((4X@W*O]*H4@69-H"2P6X--#LGI`M&7H>[045@]H
MAFA1K!&`")1;N$K6"?KO:(.-%*8+HT!_W.0%HABB:5*W^P625;(BY*SRS2;/
M0(G]TI<+$%4U#23QIYXS]5>_#'.59:WPW29OJCV>;*$5<5QOK(-!U*W=5[$6
M%A02^A4!1<*T6+!Q4I*]+*BW[%.LQ\/8NFTDQ^'^+-R8/<?OM/?E_MT1<QR8
MSXE=LC=+-F7;;%2?$3YY3,]O0,\XA,<)^T`R[MNP*1-FT1V-P)Q'K]H\&">6
M@N`X_]Q%,FX7."7>$L'@+C5JB,/G3=X0N2CLQGB-@2V]2"2];";>K,;$=N*8
MY(Y'Z764Q!?9:;1-T#[HY,0N0.4]59E/A^BXWGX-<`[/49*A4PL9$-J6*$37
M.[E+IFSO(MS`*DHR&)]'188.>>5RA0Z_.^*SGL%ULDJ<N`H:6+U>(JGI$0>"
MF@]!3+\,;(#T!<HJER8#QFQ6AQNA'R<TS)'ED`[ID:44.3ZA#918:G(G9Z19
M4EU3ALA0<'"%87+RY=(D5:IT<+4]6R73E;;)1?:H6Y"+;)5O8/M.S^6I683*
MMT<EH$,<OT9?@^ZIY@QN6S6%QRJ1;-(C4BV;D'F=+.[T&:8868A$*B$UHO3+
M]G:AN4K[-K0Q4DJOEX`IG:]7'U9*"B_8PN$];QD_;QG8Y#!U3G$)$='XY=$9
M?(1I3E*Q:RQNCD4RA)Y/1!)2!(NY&4.<C;@;%?Q$I"'&_F%(-?<QYR!:I"5%
MP)?Q)LD2K*NX)HM#O5*A]!G24]`B4*UZ%-&LJ#<N;'A>4YBL=NDP8$0P\,`:
M>G$Z0IR-#HB0'H;R@]UN7CN<ULXVZE#30J->[V5>NM4-!DT81Z@C0.E]INBC
MT(]^Q.+AZL1@=F.V)%(9#)85!5DKV[L\:]>,HZ>'6GA];DXZ!`E/Q'1H8UX&
M#Q##'(3UQ=H_%6MR8<0VU6GO6T3S:9XAN#L$NE;O/'-BFS2P3E_'2+6/J8D2
M/3M"0P`6.5BU@YI]#HV:22!&1\:',1DE.\;9.Q;%&4X](UA@W"%!.GZUOHV>
MEE55)'>["B=SW>8WD"1EHAT9#7`3AIZ.N#`AQ`DHEP<=7^#-^B55_)A!,E_5
MGT##Q"MD+)_MXR,(AUM7LH\@R#U>CP2!7J)O^@YD"(WC"H/5FL.96+[N>Q.5
MR0K'1I)T5\$8P<40KV'Q_B$JH-%+/TU03B0O??FG1YA`'\A@&@2CPTF2,]80
M@-8G*#&(0&F%%@)L,YP->.+EO&=(%"\$KB6I&:0>^A';F%BYVFM#&`>D$`+"
MN/DB8OR^4K2FT^Y``%XD&3C+TS0J&/U^&73;&JTW9D<'&3]MXVI-SE2SI`8(
M7"BX"J7W"BL*@A2.DTHQ@VBFIEA9_=/APHB8R4>8W#\@.,M'I,[W\-UN<P>+
MJS5!=;6K<'E[_*30@_Y94N(U#&Q'H^AY"!Y5@EV)7(0JQ\\4M^AK<*?A/Q#E
MIN-?!C^7CE,A5M='L'=<%FE;.QU7`WV;YI^<IM=(\?D.L,B(T2FF3\K"DE&S
M*=^M(T]![7P^"VQ+UC3`L.?0WK$L<;<4BP(VNL!\IF@942:K*[PF"D3<S.Y2
M-6I!!$O@LI)C]W[7A#,^[J2,J>*^Q=816.BL+W^"._;K@AR$W'@B.H@>/I/P
MH54Y(B*Q9?RO75EA(U[BD#2F+DEA'9BXS=$/6*8?D*]UD8TUQ5/A\EMX;"*J
MA<_A6NBT)$,-OW->T6_QSZ1Z//%YD0NKLO7>+<;$:M0:E"F9[[%LVH1D<]N^
M3*<T<W@L\%PT:&AEQ^D0KXV:A[M<;MW--E:I<8<;/C(YYRO<484!S^`6K>6$
MH,0YJ1L,_;=>[:LIS],R='Z#[Q)*!/LF.X)F(C-C@D;1-83(:I]JZK:1\";H
M"6/<<Q1FI3,U$F#RJT%\(F0%9HYPB]"8A`^;SX/JC5Q@O;B+>*[6I289M;M:
MG\&[ZJPN`G9=P$VRV[A0'#52[Z4L5!2)O'AF'*F@AD9RRJ@%J6JA*]E>?0LM
M/MB&]TAMPI)UMVCKLBRVKE)M!M)SY6HCXD31/@IDX,?3]H]X^^-7N?8?.;*2
M;1<_,F>5SV+8QM1QPX`&DIQ+NHMWL8YRHY%#7T"T/9Y!^N]%5C<,.X-K6!20
MWSC,4?*+#273!4:%G<6GY-QD+>A"G2U':,O@(&G+O9$9]`.T@UKD?C1[B-1K
MHJ@V6>9EYV>BE`*9RO6/-_E1>86'\`<5S+WIVA"O][*F.E29EJR?CZX)Q*I4
M-QX#1FSE=7CVNL@?DQC&;_;"0*T+Q3/`'N#-M3YUDI0_Y0U!:$MHK@&#FU(3
M'MFUHF<OO2^R1UA.E:XB`Q8V745"F6:Z2M)`F&>ZBH8<^5D/*LZ$25=14*63
MKL(5V/S255P)KI^N8M9%.-K7]X_+U:^[I(#"UK(N-C$#[!-N8OJWF_KTB<Z9
MB*B'"!\P\S5NLL+I0!QZ$S/7@%XG8C,.V=X!"/9*SKKPZ&OQL,_'U^)0I^MK
M\<QI:#4UUP`-7TO$H_&^UMLDB[+51+Z6#%A87TM"F::OM6X@S-/7TI`C?\M6
M<2:,KZ6@2L?7X@IL?KZ6*\&-\;6*?`5A3#VZLMSACFQ7:Z;+@Q,72XG4]T6V
MDB)AS)Z.HVI81BGI8<=V@FN[A"4U6/37L@I?Y4-;\#W/2HM-]A%3%C[3E`Q?
MJ+O6PR$ZO^DX$DJT-&\UZ%O76<2PL5(-@8KTB\<&6U>=A?LQ*HH(ET2%Q2IQ
M5&-2BB^D;1L2HZ5<G^@@`.M1@8L-Z@A3I%3<^4]CKXC]NR+=/LL&OI,'S&JD
M(36,2Y'>[HE'-OU29ZAK4@&+%$[,CFFTKMN%Z3/M#UD,BPOTBPS7Y<7=);C)
MCS@2XMSRC:(MW/X[AFPM1<>-@%MO$'F&9?U`'^,A?SS?;--\#W&/"KPDFH`=
MP"CFLY]/H7IJY])2!A,']3@',(]!/1[V^03U.-2I@GK;&@2XVW//[H&MOKD2
M:,3U1&RRU52,`RT$_`^.9S^BLR?.7(%%DL?#5`,7NFJ$WW]E6A/R).J:U)^"
M%W']\4M`6C"6M%4$^0%V"((^B;!1B5YS3U.>N7`TMP3=^RHJ*G/Y+M'2*XH]
M6F5M=U)A_)`GO@6X@_=)EI'B8VM`:0D>J]&:J[Y`N4R:?(52WIUGTLM,;0)/
MS*0(<>KLH?P^3^&=V(=_\3.5-"]W!;R%3]4;]/$O+BL2R=!Y?D$IID3T@K(=
M`?`00,;,X,&!@2A[[R@5#+!U2W#1K/)J?8T$AM2U>:;Y/KG/DG6RPO?O-,<6
M*?!UGB8KY`:U!+A0N5'TA&A#-X9@25%?DNW!`B66DP$+.KB@`0Q^[E0]?'/$
M*52+70*C.6UM=@6FW:'E56!TH.@RZRNG1G9+CY66_,","WW1:R95C2U>5(YZ
M`AWCF'U_ZL9#[OT=@C9IQFK(>`BSLIO&FJ!641&[1CQ=>!LE!7%I.]A.+:(4
MG^\;%!DQ`CW$0P`9PRC>;&RACC19-5,RP/ZZA`?:J?&3(YP^%*:R>%)Z#+5+
M8-?FHF)24Z;FPYAGI<,"VBYMEQ"7UQ*1(BH$*M5\#M#WM*@T__0\AX+I,E,E
MG?:4&N342(F1A3CT"JDQT"6>:9J#+DEMDGSB$\3U2'I>>T%Z`U/\ON04IR`2
M?*2H4_-@PD_HSXJB4-%!&V+5`41<SYP!"VJX@`!>4(6NZVTUP.=0>'):[>)'
M(ZT9;ANPU$;]AD7MU#:/)2E(*8F11#M:-'Q_==:+1JYG5JM&PG+[<Q7&6,`'
MA#1YA+0HZ+N\<AQ74N%TD!:C#"@I:!+%D=AAH.D/>DGZ@^+Q`MT-$D#2E'0O
M;J3#E3$V^[#H+&G54F[S,DJ_*_+=UKD_8T*"?P?&@#J)\6VK&W=@2/2S`00H
MI+G$G2PU8VA537DW0I$9D&B9I#O<>8A/@J?8_6B:_$>XQI(LUG]6QQ>@A0P$
M2V.A<PD0:%U,HFB#A3*>ZV,")DVA50K7J;7G8_)=]9M'A+#@]UW54\:YA-KD
M0NN7^A;.U]K>]D"Z-:,"5&$.9WQB='5G+J$UA?C$RC/5F8<\R'C(TQ@Q'%^'
M5GOLU+IMXB?%Z#EQ0TZ-K'Q\/>AW$=HR_@3HV/J<,P_/44^T_7Y^2F98!W#Y
ML#V9+GWDWK,WM$FST\6YIG`8JX-:3QVD<!SFR[FTC!)L/@J9J,F0U\[MYUG.
MPP:J!=CK>B"?^9@RIE%%@IK=\<&%`G&P!''.#ND0/4@B'^)`.!.,F8US)A9:
M[W4<?[+V+EF=Q3M0QCW]?Q^IY2K,071*CS95OG@W?$%MU1[\7/\[I]W13`4X
M*>`Z;++7T,L$;;HQVG8]N6]2?$&T44:10`?;(3V?3*I\(51/1[:LPBDY,>)L
M&NR-C=%K&M\'AC$/9^R>QP0Y(%B_@C%\[V);5N$3`[S(,_3C"I+K:&_;M3$-
M89Q!0RJ%;]<_]32V!VC6F[FMJO1+,%@P<83E73W`>)<BKW:),,9)NL-52M[#
MU:X@=1[.G_#5"(QI6;/-=E?5G>*\9GPZH#)`ML7TLQ#9_AH1\8,95*##!1ID
MM*X/@PX/XN:HXK8RHN469-]PIKJ]/<:-T*9(^>,7$EKB,G'WU&*\V1_D4"T_
M147L+05P"A*#W,E/.0.M_$`V!["7*\BBPD6'.,F"@."3+]'0>8,3*JLHCW`J
M48VYU^_,!9\:MJA>74UI3\3F:?^TILK_=<EHFC5V1]&J6]3UZVKX"]!@D"VR
ML)O@6'WC;WJC>&\11B<%Q&G.)<XGQ;LJ/RE'MF@$30`LP'IO!V!.HT#+^UFY
MQ,D3Y43.9M\8*?RV`+TE$ZW:5%SMJK**LIA$'BI<Y#%*T_U9[2?6:Z2NW8LS
M,9G:T/@JTZR-Q63(/)Y^)B5<H.P,>+#MX(/VX),W=KPN"$T3@8>EQ\.4P'.B
M1NU:F)3SOFH+3$XYKY+>5$H3/C_Q^6C0L?7!EW_Z?A=MX%F^B9+,29J&"J??
M)%H5.:*D#7X$:`'P2/`S'1L^>*HKX%X:APY';#5NNLB/J\[<$U/HNW+,M.1[
MCX5^1@%049MQ!Q*ROZH82<)EDL&+"FZ<Y&--1ML<=A1SLLUV'O/UAA$!@BEP
MDN'$*JC>RRQE,:V7I4W$<H,O+F>XP&K"O-88FH1DR<HZ:I=6V4(/'/"?5'TF
M7!P,+VV"^^081&*>!Y'0\R?\H^`9C2"*HP?)=XA&BRK9TP3>Y54]/%Q<Q4AJ
M[9%7GQ=>(R+:9/'"'2H9S22,X5A@]@$(&E1^CTP,N4N\Q!\C'.ZB#W*$7K<R
M*2GR"XAV$&A&\4(.(38K+8&RFY":"RYOCK7NL=U'&L82%R[(,)+R$;?)QCD<
M,PHM3*2,)K?+9B(9D?NHPBY"[C24,`%5/M\0CB=7M+`T%I-B+?'"!J$6U&2Z
MUEM)TS#?-D^CODW/[FM'J[WJ.=:[S18/]Y9MI"!$=-_<#`"P'O%MF#<4FF+H
M[O+D,_43?=2@A'M?>\ATYLQR'.P":UH9'(]ZQ9Z2OT-!C]$:H9/XG!YFW]Z?
M'ED:48T5NP/!050CV)6ID;A[\31]OIC[5^H3^<5FB_3]*L-O6%>D/%VZ0\2\
M@Q43N4/C-GE&"!P?5C/&.+TIC//5;M-T:W+.,DN=!@G!`]!O[C`FDO(24UP@
M@Q6`S?4,LF(8`L)'NT!_.=NHD:VVZ467K`0SG["A#?F\W?E"H3=I7A[J#'B1
M9.`L3].HH'\DOWTYTW#Q_/3(/)HYH(-F;YW!*DI2LU14%0R_'KR"&@UC2,>!
M>F"HXZ*)>#AJ)9Z\1\]>@QS5_41?&*%+#+D2RBA7W_KH7R=L,EF=[W:;.UCT
M5WW@6):0R*G-BE:KY\FG(0MYA>W#[DRM)@E;2?DYC\7T$2;W#VC?7CZB4_X]
M/'^"Q2HIX761K-S<S'@BW87'ZGOQR28H6)+-$%"/`<T@0$;-R8$-I,R.%K92
M5B/O?>[45-X94WD#\54P^OUIGI%M?A>EM[#8?.5LY7N>AH/WD/I&P.]<=0U"
M"P`P$``&$;BL4C@M/S`)`21G7[YXI`W[CKR#NLBNB5Y_5^3EO*Z))61ZS\V8
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MFZQ_Y=[^F5H%W_<\XP5JO/=K%P8TRH(R`NBOD+$Q;8HBDFE71#)FBTCF+:"Y
M5XP4YND8<\E3VTHKXKB)F=HRY+\`_]P%>CR\]M`W)Z=YN8$KN*N2590B0W:;
M)RFLBOV;79EDL#0S)=K`O->DU:5,8$1ZP\E^VP``#82`CZ=,9=CJF1%7?+S(
M-*:*9RTTA"4P$Y^GY(XM/8W3!^P*763G995LT!D8NSSD'NVZR-=)]=TN(A<>
ML-2S#=K0_"F:+DDBJT#&`^1OPP8"]L/!?4$>"A`@X+Z%$G9#,I9FIVM&;+)\
M:]4U0>!5(Q'HU,$@;ZHSQ*SNCW%8,<2["HAXW$J:.RM+@>*ZN2>-.4)&&+\)
M*?/U-1)#\X"LSB?G5/P0R-L4IL<7`X:DB?J&X2[8)^"HVZCP]O6F:0C*0@,O
M:G@O>04W_"N7I;Q;W;-AH+77JX_LDE\G8[2"7GJM=&%+W+1J>AF^EL58Z5NH
MZ^5AG0J_H<L;3$<&X^8-WG*UVFUV*;[5.(/K9)4(/>EF9%?0]`4S&-2C@\<6
MU1/D!0!UV6+U/)$I('\&[RJ<#H"MUD6&_I#!%5:/CTGU<%TDCPCA=1K1_H@G
MFL=L2^!^'S3:DBD\@W=-"S`\T``$%QGH0`(,$]1`00<UW+.[L;K`'/I&,#2`
MX4'G@Q6$<4EKF_9H%UF<9DA35KDO\L#5]B3SX1D8Y?3MCN4LV/<1+D'V(4NJ
M\FI=/ZS&&4;++&ZZ6;R#>K$["[#>HWCF-`IL2:MF&!+`H,#5&A!@^`<*KNZ?
MA@""!B)`(-D+MI=A?6Y[56AMBB5+;6_"673$?J$)7JV'%LO%E;4FYB!=I_5H
M4^DR,9G-<.J'#S9!H>J&MJ9J51`95@6[`NQZIU'Y@%L(H7_.?]TAFE*<.;:L
M3M$2VB-'\Q]1NB/'UZ]X3@X:10Y3Y`=F_`)$%6A```(C;+J>UC1YTC/@S^2W
MS<KZ16-<+/Y=1.?!Q-AI31JG%:W$5>>T?L).Z[9>K]L&[)>!0\9S<%R'%2;\
MZ('=MLC5`+R0+[)UFG^B%KJ,:*7='?$VT`]--2'B;>"UW_9JPT6'T`=)8]-7
M>5F508M4!?,X++SEQN"<;[9IOH>0YMY_RI`!?TBV2,NR\_=7U_A?=P70M7%[
M2LDPI4N4>58/;UH,-P"PJY&!%QC&RP7]CX-[CQ";E:D*L/N5$:OLCG0XF/@-
MO[*6U1V)#BPOQ?=-*)+%FK\!1U35CMX<%E.67(0$"2T;2+(73M;ED6VI8S4.
M\\L.77A>BP4:$#:%TO&N-6:H>/*[#!-^^7^T0DLD7:V7<9S@(5%*G],M=]5#
M7B2_.7J'Z9!<;Z%X#Y-Q5?U^`2ANTO>RQ4Z_+T&'_WF6*M+7Z4G2UC7%&*("
M64/:LUC3G\%*#K%^Q8LV5/S1F;I.NER=+%*;6D;72(\?HOK]2N^P?@V1AKL)
MVCND-M@C,B?3<;>$&]1UL<"\?SNV`#4!X?=@ITH]23DP/2G:>]>RPA.]*$9+
M"%(6-Y6]+$D)LBCM:)75XP84'*#P``6XJ/?`!1A$S[H5AN&&WQ?'J9%V*10%
M:R>/3SW"XBZ?50TI;@EQ#8LM[[^WJ$N/(T6CY."KID8%1]:"G:NK]EE5KQIQ
MU3&5N_D8)2F.-Y*7'I%#W\X%K4%2.%S-QN?9K,%-'C$1[.&].H?*[.*<QA6?
M?<G)J^J!-$S9%O`!$94\PNYI\#M87:UOHR<7:U,+K_?`APY5HFZ'>"CHC07-
MJW(\_.6"I/:AQ8!@!-5Z$Y&S&JS-G!'!@\LDNDO2I$KH&\#VX=]5=IEG]\C%
M(ZNFJ65<OH$97"=5>1TE3F)Y8\CQ5\AB`FH%2LU`I":[A8E[6&&H1PW8MK`W
M\@H;R`"##IM$-H%"L6M@+(O']#Y'JZV`:'<X@_3?BXRLR.5J5:#C#T.9BY6@
MC]R[T=8F35R_A8S#-Z[TIY?X0$,->@T%,&!"GU6,]8!58#-FC;#D/T3_RHM;
M]&%YM<8I>>_A"AW0,61WN5!*G'Z>Z^J2(]!',@R0<=A=("^1NJ'S2'?2E2ZK
M>EKLL$W[QXF^U1Y[)WF&/&>'^79<1#Z;R7,I$*71D6]!^_$\M$<JK%YFG'"J
M(RP321#.RJH@";KOH@VW(,0TVB+$Y24Y3D6%J*8$>?O8?H\.+F@$I[Q$F.U/
M)3Y6?Z03'^.+86\/.28;C`";-'<:),#D=R?C$R$Z-.!C`?Z:;%T+LI/-P^[(
MI=;S\\43MGJMC1/@_L@\4L#_75;Y#22OP:^C@FR#-IFX9E#]YN0:T29+E/PC
M..H]U27`0)6#&ARHX<E+E@1)F;22>B]QTIR+8_)W=;%=&F?RFD/VGM-K3.+4
M2GO)+6`R:\4]4`0KY;T<E__;XF,2F3YD,2R&+[XN,G3BB-+3-"^3[%Y;=PW!
M>G^W;DZC1'/9)#I`0'$>^M;00`TNM+;:R;VGJA;\L_(%FDP$>G7+1:6EESIP
M_!=04!,E>F7>)*G4?<T%BA?N`82!W+JGB)KLL%*D_NF&&MH2H;G!06AZ7:BE
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M:8LJW$@8,R9&VM?WBPP)"QW_D(K#]Q4Y`-*4].C>20,A`^P!2OCH4Z=K-1L8
MV$PBNTG!@`Y.T,"KN2J(#:>26;97B'TT/T05OIW<GR$,[O6SARWP%L[2HJM]
MS1B`!\U(U7A2%*O6P<PGNV5D(=_@C$^DN<6P&*MKQ6(1![=Y`L*L%`X0`,3H
M%57P#=E(\GK*.&205;B`)J.MDBAM:\PLUQ5.Z6S<3ZUH@088SSV\U!0)M*H;
MR!08(D.9<T?(R*:^R-K`@"8S1EP1)2M(GYDLRS)'B-`.C&NK<1!W&_-ELDFJ
M)C>R=Q^@&X*?&*O?0M63TR^.WN,W5A01Z##1ZG]<=>^P@0[=XO#B*O1%JANM
M8R\`'$C(LK-)_6Z71/%NX'U28H\W?IL7-Q#7]AM6-;1:4F-Q>'T#-07%PJ+O
M]*TY#0EW<`$"#"AD7OGWPXO=N423)U(>IK3F>+9;/S?$B?,7V?=)%C?'/B>A
MJT,L8:HT']`ABDZA#X^2[`A_VI[\0R?FB675"SSQYVC_@JT!<_Z$7]61\J_G
M3ZMT%R?9_7*3(U7\K5>$==I7$9JX0Y0=T"5.^"RB#BC5XQ=U%+2%`5@@0<_\
MIBK0?Q!AP"7_`6R6!)HV3YJU[K+JNH";9+<1/?-G![;/")JQX$4]^F6@TXWV
M]'@BT^1)@!:P_:WO.MKCE+Q^OM/IKBCJ6_\3GCO2*\".!4>]BZM=5591%O=2
M;4+6ZU;.D.-(F+)GNMN'M]$*(K79N2DT(,3EWUZ(2-&-J^$1@`Z9TU7KH?S$
M@;/!I*=3H@]91"T/C!N#XUZ;>$B#.*=*LG15C!G:;D@S"]I*)"W6.Q%+[%U;
M8<9`4Q."OH_J/G%RL6]!10AWUYQ,JX24KJA)_;:.`1C8F;)7%ZTT%3D?K8_X
MC0->NP,#[\'%:6V`*<!5&)\2U4&L_AHI)/T^[`8MEQOOB,69[=1A>&7;%;M$
M;]X!B_KE49<IOR,)RP<M=D!29\JO*+R@W56"I<H?3^\+JUOLZ"5?<[M$-LGH
M.4U&%\CVR\\R&SV$K#3SF;D]A/$G`$%)$[0*JQQ4#[B149LWBK9JVABK2PE/
M,O09I/LWN1JK?R[I+4"</"8Q@G6WIR.1W+-5LD5K."+GBH!B=Y@K'D+L>K?5
MW!7:W5M2H1"Q/^0I7JB?\EV*Q-<"3_<@_T0T@>K&9AME^]]%V[S\4PGR+K32
MZY3U9=!K'&=7_\=.CH\Z&^_T%ZR"?1G?@6_I'7@TN`/O=`)K1'T'ONUT*67N
MP%?,'5^&48;5B&=Z"1ZFO=X$MY;\;HO4/M!]HNANBW%UM(+>%G/Z+LHTZ=\7
MQ*V.V%6D15H8(8W]D)5;N$K6R`EP5XU#C,QS>STA(:)RKO7W./S6CN#6=`E3
MB54EQ%XI5>G<W94V%A9A)O^'RX0LLQC7%W=;4\@)G5[K$;F8@;P`%ADW(W5W
MJ&K3U!57,'K,I0IMR4J*\F.H5^M;1$X9D0W"X:I18_6[!I3TB"QYW=VW[HY"
M:G/AJL+=<(Z>!U%R;3GW5%:/+S8*V(:O7A/P]*Q84@MA57M)!<>33Z!+CZQ8
MS>NF%64]FAZ.FSN.^955TA1A+VJIPQ[KZEYBX)?&E9)T8/FMY*5!T23:=3F?
M^D<&`M74LLN#&D>6.RC3U\E'1T,9N@"79Q)R%#G>=,>4-0H,L4]J2)/=(%73
MMWW^RC8+BXJK@KZM)6EHU[`@J!PKEQ!MB'0"#;JTM`T-!GG1O,>F67T(`-5"
M53>DP.JHT@.!6DKY-:[Y7,^L8FM+U\$V38;W&D[>UAK3$*93D"&5LD9SW`T;
M@UO4O>4(1%F=EH`]YBRTY:"YG"D?+9]\-77Y+[+;!]AO^=/KXW@#2U@\DO!J
M4ZU#RZT<`]_S<]X1I*HZ/"!KBR\`#QI3#7J.@@8T">LWP,-=^DZ@'*V+.I:[
MT[BMI]$VJ9H&X0RJM[MJ5T"^9D_N;V@2X3^)VYA&+4^D!M4]=61TG((+J^JC
MU43@CABP<*JP9F]9T?:D:+UU@2S7`4XE?O\Z;4*>9N1S:,7KGKC(R#.PYA,#
MU54*4314BVMC-/@TC4JT"7R,\/U`=57<X"ZB+=JV6\MIE*8P?K.OOROK#YWD
MGH\E*8C_/9)HD3''4+&VU]_C4R49T%L)79\@"A[GL#4(VA'!6UA-I&D]@S\!
MT^V3$+C8>WUWVS_Z7R\J.D+$\"SH-%\7@];3W3?,4C@(P>`([<NPN\88;5*N
M"1TN6]V"#!K47L.BAMU@C!FG3.O0:@;1^WM?(_)D;9;9SL@X-MAH,@].N%.H
ME7S;<Z<YLZR4L*?=3*)#H^:W>9,$3PEJ_HM\CXCZD"5ZU?<G0>2_B,X49(M2
M;?K6E@&^Z.SN;0[:MQ44PZ+[!1V(5P!&,R?+/+ENM>MB,H'8]4SI<G>OLIH4
MO#P;[%I+007#;ZTU!37"3L?-*'"5`69<J[H!%4]32*U.Z;#`,DY]OE[C5-Y'
MB,OO7JTODU]W28QO>LZB372O67M,"<2C1ZI%D,CB-<-(T65PM0;=2%`/#99K
M:"2NSASI<,(Z^6KXVNP4_1;7;\ZB*MUKJ8X<@N>;"BDQPL+RPTY*=!2HAX5,
M>]$23_>:4#G[,3T,:"YJ60>_W'<OD.$+5`Q.3)&P+!P=T@9)![T*6(\J=.4G
M'0'WZ\8IV!$@BL$V41B<9H0OB/J-)88GO7F)2#(]KHB4[!AA$%JIHZUH5R39
M/7VF1IWB=_`3^9,3TZ").5RJAY(V68)'<VM"A]>E@Q?MV0S!H%\$CQF;*<!!
M'H<>DT8\0\/0R*',B0YVT$,DPW7H96&L^ORNR&D+I3X'\CEX*---T/]#^)%I
M&;R=9ICUDK6W1&6;]<*^=\?O5[N,@*2&'K#6P8S27@(]FC<.FO+T`$VX*9'0
MR3YJ`\Y5#NX@@`U`LF0_42Q?ACV\>@XXAZA_,57T3UK#AIIE&E(]:5W.BHG$
M'G_Y#6,4V+2AL+7,9QUQ/79PY%`JC$9H3V`#T/Z<E"#+08'O^;#XFS5/=H<V
M0E\7T(%/%21%52*=RBIHBX%/*T@O8O'G)<UW9RIKX#>*#_@@*BR^PM^6`ALA
M!['7,!4Q=")[/-5YBPPHS@U$>O$+A%LB75KXHJ#Q<B)J$LE"O*R2;)?O2J06
ML`V.8G<B`C$LD_N,:$65;"#XE*0I=CEV:=5X*$6M,UF45GNL!VD73HT_VW#J
ML?\J>,K0G:+B$A)-(R5B(#;1'M<U(38`R8J[^'-D=Q(T!FR;76?;9&6(FWP_
M^QCH@>-HF#'=UDK!1;RZ-*8?(/9@G600*5!.K:L].9A-7YCUW!7;(;5<F:2X
MG^G(P"_C-<7:SV=6LV)\N)TVYKB^^!X_='&G8Q)L/M5+3(8\OHZW*])YY04:
M])*\ACI4K(`Q=8D4.1%UT?1':!,^1".R'Y99?`8?89IO,:*ZPX8[M=)!Z[E,
MDP9)`EUK1@+D'`-F;-..91X:9R!I5O5TV6+]6+1VM]WI6A^!B^"03*UZV`4*
MU)SS#[>\,)L>5R2L4AQ.:ESE_'J/W"^?$F=U\7LX?.Y=0^2R6O;-=^!G_&58
M@R$2S+`"_<'<1ET=U@?4IG"<*XW@(_*I%EP*%"4!YZ`64A'U[_)$$QRC(+N[
M,HF3J-@S[ZV<*8D0F>\2DB)"1/K2?K\`O:=X0P4*HT$J&?:T2#IU^Q(5C4ZN
MJEV4NG,^N'@"%2!E:5#6'J4?<UV2H&5'>0+C51P]F.R(:B:U':.%)7!4/,]P
M?I/SO8F+T&_I0QDI\CJ>W;<'1B?LOB43(W?_$LY]3+SP(EOE&]CBN,0?XX*?
MCG1*AF[ZNS&92DDH$=<$02-`.P0T8PX5*U![':4H^SUVY`R8H"J8RYCS$(E?
M[3G`KU%/@[>)!:Z6(8L>\R9HJQ/O89;D!2G>[M#'.4#B5R<.\(N<&_)=W:5U
M)CHA%%!O)^).T%8G+O/LOH+%!I_=2=EH1UL.%X]GUY='@^A9&?KT"'];-\_&
MG\_BN"23%ZLEPKF.J^/'EB/'Y<4=VA$).L\614R)-$&;'8*OR+/9A'0U1'F0
MARUA@*WMZ6K5.S(Z?02^@_T][`)-H?T-N-8ED&YPA=+KXGXP+?MP_S`-P^'5
M-1^37TO")T+[P>%,O!2YT/H/BX3SM;49W\$,%E&ZS.)EO$FR.IOM$3J_I-9#
M[%>?M&@2J%<]EEQ3]T>+;ZI#V20CH;,*J,\@ZSTLJY(X27<8:I?<<_ZT2G<Q
MC/&+.KQQ[NK,TO5Y5&1)=E\VI97?[/D`G.V(#LGU>5_F<!ZBG9H9T,M,"W\)
MYT$'>PZ`8]Z/?6Q*N^0Z/IGTD`0XC[#XY:%W^N6\SAX\$1V<.`ZF:&NCSS?;
M--]#6@&\ZX.)F'7^_NKZ+"EQA^\=$M.;/?ZE*]MK0X9/FVI!GTCS:DAUQ+6%
M14_!+S"XE[0!UCQB]B,4A-5:6P:.,'C]%M$N,Z8&6'P?I@])D&5.=5_.Y5@M
M%M0P@XHS2\N:3YW&'2J&H$S/8(B_9E5]Q"+9MA^%O466<+=KWGXX(>^%+@]I
MX+T/DG'U&;#5[J5._;@<>9Y1>HH`(@]U2=Y:\_Q&86\.X7`?^[:"!N'].1D`
MZA&`#@GN'FK*@ZD+()VW[T)T<G+X51ZTY?",!6%5.HC[0@\MOZ\,UJ9DN+>U
M*:9!.^2+A\QC;:KE(7Q<.9BW[[4I)X=?ZTM;#L]8$"/69OT26!QI$:U*WD"?
MW79Y!(@68_/<611`\2]Y"=L[F8MFZ+>:KX@,:<$38:CJ>;'ZV#S)@E:^J;.5
MKXM\FY<P-EA8@J%^`I,2"E1/6)JO9V);Y1+H2A2)Y^J_,KR8&-Y:ZW+Z):Q_
M?GP_-@X.TS(?;,2NK1>$&';R^O4?#):?#AR?VYP&/7JAVZX6%8[<XM'S\$8-
M!-?5=-%DBM^-4I,JWEJVD]5G)2S;K19YQMDJV4:I<="'/]+GF?(0O?@X2;^5
M!!="'%_$G&=/+H)I!C@]\BD1'!R5'']V+)\TAG,R+H9S$F"]"6@PB>&<S$81
M%/*0A0Y.PJY""3G:,1R^')ZQ(.S7YCM87:U[U?@-5J9PL+\+0Q$)@F6)/L=]
M7@9]%<+'=%1B:/5`.E_O-XLR:GBK49/]SY3_@:I,RT@Z$0@A7[<5PL$*#0EK
M!R?A_HG]!?!9S>)E%I]G55+M+[)U7FSH$]P[G"V\TNLJJ`7(F].B0XTHQ:(>
M2O+"Z6#`C`8_-^,#[Z`FDNN2!W3YXC%NJE%WF+>6%<,^N]K+)U[C9R.[#O`$
M-@+DOSLY\*R\6PT8U&TEE*"?+S+TAPR7ALZSCTGU,/3.3T3BMX47=B';4GT@
M_''L]!HZUZC\S1.P:ES(_K<NJI^?^(S!=/W):-TOW,JA;S70EMYL%\A7%`G)
M'%+84*DIM9SH@1WK_)WCW[0M*=J,^>4:'3ZIQ2B181`)4STRW,:IINU`5+J,
M\+H-DC(CRUWUD!?);S#^D,6P&!KI?@:@\/!I#"GDTC.G]O#(:LDZCSGWO=<&
MG9[=8%><>F8B:6H,#9J;KR;O\'"HRPU_`NHG&'$U2+C3J8<&W=K4Y!WN9;K<
M\">@J5I2<1W*"6#_NPF8F.,^<^-,6]KQ],$(2,BU[;G]GU>#K&H;Q#]T2`8%
MS":>MF&2?\>4+N@DCY=EF2._&9U/<0R!XT=W';"Z2",3D2">FL1OG191X!N7
MJ:?#\WM=2,9G#*BV,,02W9"6>;`@`<D;6$:'42M=51H)-NAF/I)V3D!P`A9[
MW,)IG=[+O"2A%/P*E?9,A/'5%M*&BN4MWK!NX5/U)I6T]36'%'(S-Z>6%_BW
M8IW7VN;O(-K2RH?K(G],8AB_V7]`GL9%]C;)HFR%'S;B>"BI4R-+<<`@0`,#
MW.W!"PP&)-E+T$("':C0=2_T)\T*U99E7N79/\V_15X+36L4/H+OEXU8`#RD
MSN(,7&]/-!6>3.33]MK1AM1ZBJB_WE8.94YL;_;=)W5+.U):LKD:7,9Q@H=$
M:7TD:$-IPK<M^+NC.PRP7WR5P8H7)?M=TQJ0H%X`BAQGR73HZ?<EZ`@(W#'%
M'6=Y*N5<D&%+R5QDV/,H*WS51<KPQYU/JFTL&B``0UG0Y@1(MUI`815&?\)J
MDZ)FE]^6)*L'&.](*R"NFC*%Q,IZ/]KKN6D-9-(M26!8%DV!*XI@T6SM>_`S
M00(P%D#0A.ZR-)I/7-,P$?=]6X`F%>4,-BDIUP7<1DE\!M>P0.>0NC[H,HNO
MJ@=8H&,LK(2.7P,-O&C@O<2=9FN0;355G%!'H`$*+GA)*CLN\/1@##^]5K@;
MEJ*,RF2%>YGB8I1BOZ(9A@TZM04+0(;2'J]T<&A?7C$WGMBTV!%^;2Y7*^S"
MELBWP+;#<!DVHT$]/+`SKYR>WOKB\L1S.XUW4;4KD.WO3O'"HS'Y$N^DW;=H
MBYS+YG@X$>YQ5S!=BP<X,4S^21.0F;N,.A5R5Y45,BM,1L%A)<<2KKZ\SQ]?
M(3BTB"/Z85B[41.'K^6M1X[H43K-0V?;."V:4QDS.I0)-A,GUBD#;OAUIVW/
M>K63]S8OUC#!ZZ3$.?9/VZ1>*L@C(!<"#H_NK1/.$$%?,71D$+^,$!*V:ZYK
M-D]ZCC>3;<`HWX<LVN1%A2,+),IL$NYCQH)F</"&V]*IJ<_J0GZ,V[(0Y")*
M+[(8/GT/]Y/M4@.PGIP9(0&*K8A^#,C7`'T>1%>40AGL-9P9^FURCG8YG/J/
M]'%7H`V.V@VZ[[&Q@C;5P\=VT2";S>9@S"6NM;?DM>=6!JH]J51L2M^1I*]F
M!_H(D_L'=')=/B(7_1[V<L6D:54*52IU=8F2TRG2`C0D@9JF5MT`H2ITU,"C
M`*Q\DJGE;UPM"%O/)<(:D_NT-)K@5-8'YV?!'>`5=;EIO@'XHT"Q$B'/F^WL
M<":^HU3,L>TZ*JX*>A7RCRC=P2::)MJ[^J=8-!KD17-C1`!T8<;0UD%CEKQ5
MK<T<OYN-(%_A(GN$935%BD<+:?XI'IQ)&Z1X"%DVAY2=.CXW@3Q;2/.7)V?2
M!O(4LLQO\`D;C(<\C6%1TMY5.-6/AL:V:3)\DG,B/!PP<'X7;?/R3Z!NA87A
M-7>V!.0"=$`!@1K\5LZ4"T+GWYB3OKMQ)]%=DA)E.]T5!10':Y@OD<#HMZ'7
MX2'U/$&(YNB9U8?W1_0:=K4JT/F0(=+P;JV^SJ9@``,G^"K2GK'>=9N47;Y]
MS[&!7.:&075@<AU[84AY_D?E:=CN(G1O)''/MJGU/>H<$:$-ZKRQYLN@8;H#
MNGF"$TS.JUM%;!?6FP(^(!J21]@EY).R:K?1DY#GQ,#W!@,Z&KS`XU\N0%U4
M#@$)>XFO,TVNB+39\XSM/$W%]6[1*=IGFBTMXJ)C`\V*RKO&)?=9LDY6$:*.
M)ACABX,\35;(V5%GS':C03<<-.,%"3]AE$)KHEQ)&[#(\T[**V!!7\S5B?CT
M*-A](NX(.;P=9X"Q;R3J8S4#,;239LX#]36Z/B<]7YZUV=<C.[(;Y<*SN$"'
M##38`!8(8/`113G(H)5FR(>R"I,SE&M!'(G-JU-9[V'E;;Y<H;500-R2!RT2
MTMB:U%=%O]UN)$&=!@*H<E##``V0!6EA@NP.2=]J(`7>,_2GS).Z*<.L+BJ;
M^K;T-O0\B\^BJA6Y_84E'ZS'!!TN`:H"QO1C<(Y3]-'GP1)TI$)I;C3%,_29
MH,-6"VQJKUZM>466^!T7Z&BZ`[2EWI'Y/^C%$/9(H#=-[BHV8)!G[P_?ZR`S
M@O_!IN0Q2K&YH?HT#&@*KZ;Q71BVN>0'!LRB64V<0'!@LVPR;^YEM3'??*[(
MOB?Z`WZ"@!Q/;!QN\-'R?145E?`B[,"-;\83@P@(!/)8M9A3JJM@DFH_7<H=
MK]X1?=^FN-6B'\WF0JM',X_9G$E9YA'7,-XFY2I*?X)1,9FG(H3L\YF+B`B!
MPU)_#NCW``\X=%K\)V"IA-1X+M+9CO)B*4AJB=^BWY7C]4,,VHM]D)*@\F=K
M_:@W8C(DY(,GI92&KBU_PIZ])')POE,':N^&@=I>'<E>^>RZ_H'#X'K7V!,C
MQP[U((>04C"#.+L3S@H#[@[EZ#>2UQ35J%_S*AR'MMA(_3G/A0B3<\&;!3_!
M0CQ?KXX:W_G'CZ72O-QI1$:%)R;0`>%??,SGK,29KOY!2<@KWW=7N'A!>;4>
M7,KLZ?\KY4A&D_!V.WY!;Z[VX.?ZW[E(46^F/!&:\"AXBMKH[#1%7MH\TM)L
M,](^EV0TY:OBT"EJ6J_)#9+7GF,.Q"@AN<B7F$!K/-_5'F1DFV>O+ZNJ2.YV
M%;DWK7+\="B\UW\P+ZZX!;/WO,<T=W!7Z_9U;-M.5'E-B<O`D8<#_1ZV03T!
MV81DEY!B!EA&]-H'>6>P7!7)ENU8.\%#21:JMT`-#[ORU23S;9B%J9+&P1/*
MX>P\K\G:);U&<&'=ZAA9]'&):*TSST(EF[=5BEI`']^*+1+/?P2;_>Z7;Z.D
M(`]&N_.E6NYX4/V$EADFRCL,LV%*)\:3G`8GO%Y(ME2(BG[JO-Y7BI*)GDCJ
MK^K7:%"DFP6Y]9R6D]S[41?"\JQMR`..TN^*?+=%SCW.C$,FBM]#P"!LU\`%
M%#`NX%R#!BQLIESA0AG0"ZA'HW@D4)P)^,YHBO'EWRWZ;KK[/@+-A^(.D:HN
M]?`WP3/36%X/;^W:2?C=_VG+89S,H;^HVS&]I2H)W@9:L+*Y\1:CFA>^4\VZ
M2[/3:)M436%_IG/[VQT.SK#]V]6E4&I836'/!AI8YP6@\-JS=]B@A_'\N=<I
M=DQ\5BT\!KW\T)1(O28O_3N:IAT-<J)&!/TSC<4JF#IIF%5+@"%2-]1A_]G$
MV^7![V"1:.;&"(MS%V&!0EA>99<Y\O!V1=.#KRJB%3H4D)Y]N-!X(JS&R("D
MJZP%"M#BQ6"/&KB@!;P`#6B`80?.71C!%?Z6/9+)OG.,3<Y..*M8>1@*E4>L
M>\"1S=FW8>-6ZS&0B+S@T2PS4;3GK'>=)&68]ROQB'3$P43V]U%:CO4BNT76
MH(Q63<B=*]*H[CQ$7>,#MX:"PA?0#+#0CZH-YLT5JS'??%I)QJ3CR+GV?2Z[
M.3;/&:M]\*B1:CJ*74W"`O\UXT1ECM_!3^1/PLO=[D(75WTGX]N$#@H"US?Y
M1+\(7]1*;[)"BZG)IE'%X3_"-/T^RS]E[V%4YAE:M1AR^_W8(O$B\/Z[F`@H
MD5>-QX..?L&C0#.,ZE81\*&'EN#ZA>1EDY_/\C_?;--\#VG=PS;O&\EEE#UH
MH-;9(%UN/@8<WJ<R9X:QO5#QU>]Y%I^9+K+ODRQNLLK%J3Q)?)1D1_C;MF-G
M<*-^2#\_<X<_RW&=/&C>_0W<XBXAV3VNTSS%*RLI='_USF5D*+I[U$_RVD&`
MC@JF++HR&_3[$$\];,]=IJ*.;E%?>4DB217?\`^:);,5A28,6.6]\GT:E>75
M^F.$H\C557&#$VU[^;7M'\OZK\+]EL#"I]IZ`*Z$3T8L!NG3S#=E^U'8W=:&
M#]Q[(&M^/H_.<(.K!+]-W,6=VY_SU8_;=NWS:-)N_<!36?+V!FZB!!?2:L+O
MNRB]A<7FJ_`%CUO2`$,;P,2%#NWYEX90MT,HA=\C#7=+:)=G6RCN-$I3W,-A
M@MV6L9A=13\*'VNV9.L-=6P:R2/MG=B4[?Z?3=:UBFFY0)*<A]18W9.Y5\:Y
M*=K8#&?[-*N>'85Z2*F8-T_"NMRR25RD1ZX;>)\@UQWIQ;MH,T$"(Q>JMR<P
M/.SRDW/W+<`?!P]K\N71/R9SYA<NH4[73>;VPN;XN:',LWA&BF0XL?LY@Z)K
M=I76PF=%\&>CCCX<SGUP#C`TC__(TUU61<7^;9+"8K)0XQ"L]][!`P+D-K+]
M&-"O9Q!5%,BE;R=YDYQ5.JJJ66C;Z==U;0'M?K&<WL-&?7#F&<:85`Y6,0X'
MFN#W"$B++<I+1P9VP2D1//&PQ`=HS#KLY(*3P]2%G,0];F@6W8RZ5ZCF*/"P
M-/CBN7_G)^;5<9%GZ$=:0+DTJMV$,W38Q]P]2+.MXF0Z>YY0[3CH/41!+ZSK
M%EC8P:0M#G"_T0V^F?PMDJ5"MN7N:@`+@$$L0`L$L%#"^MJZ<^4')TSXU-N.
M#+WPZ]T=4HNW:1ZUN09C/7`6I*]WE@>8Y6XW_1"0+\/5YA!*H.]K#V<U1MS$
M73]%)[C[O-A/)?`^4/_Y=SW\<L&33T'S;;#7MA)A]&5_.+4)RBCCRLQ.BBAW
M@/UE]@@HT*R@3"IL']1/#EQ`^4`^_/+)_;GZ=JZ-&T=Q^S[-Y;F04=<FC>9+
M8?JT8#^!]*G4*V?6Z]%"':FZ@^><ZIHIY\<3D2Y70I7+86,5-S!%!CXF5!U$
M*M25COKE<7IAJ!HRE>*"%X425T0*70;'@D/<&/843+?(K.VRIQ$:4CP#WYF*
M-]QU5-X1GM4#Z:X+TZIL?C/<?@48/.?<L[@%>V[[45UX*?1K0YY`^@GO!Y.R
MN>DX`'>99/`"_2AQNR;0@@Z+]S2M`Q+4"H$_!>3;\,63Q(+B:D=_ENVF7T\#
M_?679BKH5^B_L-TE:_-_`5!+`P04````"`#'16Q#E&?RB/4?``".Y@$`%0`<
M`&%P<&$M,C`Q,S`Y,S!?<')E+GAM;%54"0`#)C&"4B8Q@E)U>`L``00E#@``
M!#D!``#M7>ESVSBR__ZJ]G_P9K^\5Z\\/G(ZE4R5+-F))XZE]9%CM[:F:!*2
MD%"@PD.V\M<OP,,B*1XX"2+C^3*.+:$;OVXT&HU&]YN_[^[NO`,(^%8(G)W;
M]0X<_F^X^+^=W9VAMUA>V7#G#(7XKW8(5P#_#JV`C_^-_SX/P^7KO;V[N[O?
M;/S1P(8^"+S(MT%`?K&SN_O[#OGO;__SAA`9^H"0>+US'8&="V^U<W"XL[__
M^OG1Z^?[.S?7PYW#_8.GR9?P-UR(OM]:`=BY7[@H>/LD1^S^UG=_\_S9WN'^
M_M.][(-/DD^^OB>_*'S^[FG\Z8.CHZ.]^*\/'PU@U0?QL`=[7SZ>7]ESL+!V
M(0I""]F$0`!?!_$OSSW;"J&'*/C:J?T$^==N]K%=\JO=@\/=IP>_W0?.D]\3
MY'9VWOB>"R[!="=F_76X7H*W3P*X6+J$H_AW<Q],WSZQEDMKEV"X?_1TGXSQ
M#_*;/['$`L^%#L'^V'+)3*[F`(1/=LC`-Y=GA3G@K\PM?V$1`>Z1#^S5?G_O
M=P4<GB%,&%R%^.<%0%Q,EH?84P+ET`KFIZYWQ\/APW?WL@4BSMN%%X*#XRB`
M"`2!A;"H`AAXTPE>DAB$6%EI6:492C+GAP22DQ\17%DNIA&PL+KU7<F\/3VU
MH/_)<B/P$5A!Y,=:Q<1AS0A[O\MC\MD%",^]()@`_PIS`%C8V_JN9`"?7X6>
M_1UK$=9\O$\`%#"K8]T0\M8VH?*"C.V#.1X>[W4$$A8>*[XME[V7(QC8'@HA
MBH`S7I(=&V/`Q&/=$'(9?95Z"?#6!>3?0>A=`I=8OHF%?PN86&X?3"[S1[&J
MS3W7`7Y`S$JX9F&WZNN801G<#6S;BXCL9A.\D]AXZL?K^"=J!AM&4&F,KBTL
M.R:AUXP@D\D:D\+.:_-`DF3?L'C9.6X>2!+'XR@D?K.#E6V):6)JENNN'>A&
MY"#A+6.2=Y;O6W@OQ)^S-\L<D64><T,[*SG$I'FTL4;<EC7BY)[\")@F1C&2
M`J[',6`C$%K091-$XQB2-"MQ\%UL'J:^MW!RNNP5=9F6:?H!91J@%A<[14ZB
MTYZ-*'>_K#%_'.RWC"1-SZN=-0Z&ZP>1RFN-N>9@N&4DJ5RW^FT<_%./*74F
M%2X=!^\-H\@Y;XT\.R('RP%R3K"(P_49FGJ8#9:S5N,8F?E>YFS*.>:HP"NX
MQ]NO`YR,6S(L;X1I`PNFZGIV@9!+0G">G]%QK5O@OGT2!;LSRUK^^1#^&4]/
M(<)#8H=@X@60\#RX#4(2SRP"FK(8A^BF5G`;Q^G2X?8(T'O`#8/L-S'TN_L'
M:;CN'TQT4R#Y)Y7N;@K9+VYW_)QB_0!G^,=`*;<;*GL%G<EKZL`O3L#R[8PG
M_..6FA9#M>DG]I;X+(+"77L.W0<-)SX#G^*%7KUL/1_;B;=/#G[;%U>7*QL@
MRX?>X!ZJE4.!T(9MG6(H+)5*P(OHR,`]'?`&!4M@PRD$SLA;6!`IP;Z6V,;-
MTRR"*O4K2*(>KU0:^XDT^C"9=GW*F;R4_<.4?3YU&@0!"`.5FU:)0D^0WMHZ
M\FB70<DIR@YF>@I\'SCG"9"U3,4<A=@=`_$GF1?\,/+);)H$5'>35/E-K1:S
M>A8$\YII:H$\XY;<^6`GM73U,PB'EN^O(9K%MRTJU@H=X?QJ[^T:HL0PMR,R
MRMG-1,QK^B8^6%K02<-=F-=Q.`=^HHBI5JJ0,0W9WNRNC2*F`C"W2W$+6&!G
M4RC(*I'U7F;5TGG*86:]T'+/<VN0=Q&2*&BXGN"3>1P8P+9B269Q`12MO@9Z
MALBP&;-4I,_$+"J?-',&X,)#MKJU5TVH'X?"1MG5()0*[;F0T`3,I#K[:()0
M,@Q2*;P0MX9<HCB'UBUT(0DUXU6]'=%5>4JCIJW;-2GJ:UZ*]/#).EPPV\ET
MW\USRG&PJ_JZUE7&JKBY<U\E%-+DPV<1DSR68&*M23A&I0=93<F(\UT=2JGL
M7FHXT&&6_`@3VZB46MG5$--M(:GE5P=6*L)7G1W9RA>OJ4X5;U\K95F?2TT_
M8)\CDFS(I(([ZMZ+[&;-U2ZVWLJO"9\L],6SS17<3<[[NR[=RV:'LA>>2TEO
MB[<O7?B2?*%J;['P4,R@NJATF88!1[IM7++EIB/4/'"<^([><B<6=,[0T%I"
MO(*5^"4UI`PQE+5(9>(3"21SR>Z2Y%$AX)Q8/H)H%F#'*5I$\?X[`E-H0R4&
MDX)JG_T6%O`RR7($H06O"*H>8W2Q]YFR&*OPR:3%$5^6X+6T11ITA,;,.*^W
M(Y=)EB,(77T9]&:OG,R9);BK3/(LO]#E=JU*`ZETC^M(B=S%/.9S]C^?LT7%
MZ%,X19%_3.)L@OPQB?,QB;//29SI8QLT2U-QE.9SUA/KC3HU.D(-8.F]=[K$
M@.')DJRY$5@!UXMS.E(NU9PQFPCV9#6U'"\;(9.07,@ER:3BD8NY&C@+B"#1
M+_)46*$LVTCV8ZMM%&8K:C)2"249V$X,JQD'RPIL)&85BHDK\:^36BL*!98C
M8X+5K(1'0MH@YRD;[YT@"!->4AVZ\)"7,:DH$92*K@%6DPX_??F%&QT[Q;,;
M)N_#,5OY$D.J`BJ-5$U8J33@R4I:E"#=Z@(`6`''TVOK?A"&/KR-0G(\NO8N
MP=+SXVTC?@JN7@E$F-,>*.)1%R%IR$GCXE,JS*+:C;M(P!#AEE#A3](2?+E!
M:K_8Y,!%ZA\!IU1+BRF?E7*HG@N(%A#^["P9T87VK01S7)I*6NQ1Q_9<QXP1
M1R(!K`62PL0-;W9+G^ENB445FM!&T@`/O!4U@<PC.>?ASP#.YIB5P0KKWPQ<
M1(M;X(^G,;>YXG8=B)N3$Q-\=5Z0920V:;QN?R@W+5I'9CS-AE)Z?=%([_&^
M_=>^;Z=1ML=+]WY<DCY>NC]>NO?QTOW!<!#?_B&4/B`=3#A>=-(.UANMJ?2!
MZ#&1^/3V,;:D.+8D^%*"34`#YUL4A''O"A*.M#UD0Q>DP91K#_]`E.PF(`F>
MHJM.%JU^;*65DI4&)_^EN^!;^<<KAC[ID[HK!I8L@:-$LQ"8D:.G8$1T!#!5
M&R88(V>P(.S]3"L:RU>5)G)&1#4;\9)3=8C/KT^#;N4&0`J<^FI*1DBO#B4I
MF0&<KR)S&C2>CL!M&-N3"(43'RQ@M%`APW:BAEAB"O3X4P/X_;CAW$(S$.2]
MBJ2T)W*XR]ZP#=ECKXP5'/Y;>'G.EP^PT1B!Y/]G*"WZ.$J9J2S^J,C3XN&D
M)^&)-I^*"V2.%("B`W4MHP+!-O>ETD#=:$.9J"%6G`(]:7D#4B5<*A[4F9#+
M='ML[=GP$RD'(RLT1F("$]];00<XQ^O:Z("BN!DM=2/\;18T928("`2SS]`*
M!+*"V4V#&13,;L1$X.I>DFG&FT0:XQO8/R+H@]K:P"K6+`-U(]8L"YH\54ND
MAJ]J#$R%PG9HKJNH&R%Z%C2EE4`1,]=I!R@YYKII,(/,=2,F(@5.))EKW[,!
M<)*=)0@BTHUN/,W5*E-BI5N)&G)6HD`O$[%(R$M8LKFBG20LIUJF97)&V-M&
MO#(I:GE]DN?L<]+4^>0>^#94].RWD9Z!*W,;LTR<(@6%A449&XBD;720\:8D
MQ;F=J(%"K4$ODZQ(Q6&)&VE\QQ7<(,S4&?X%(M4#2+&SRJLOXM,K7]!"O!EG
MR,4DD66::'GZ4N/_5_B3'9ZFJJ@;H10L:&9B[S[XE7%;W:IN`GSH.>78K0KI
M,]$WX4*+#=!,`7BB:$4%D"C]QV:/X@*O:_9XR%$89ADK#^;&#\4J%E"Q^N>^
M9H'_(B(G.&9"YXB6)4(_04Y!Y-V]<R,M-PZ.HP#C$`06<LC;O<";3G)D>)^]
MD5P=UPLB'UQCQH[QA[^K?/761([_ZC_&8US`@SAY<(;@%-HD9)[<96-UF'@N
MM/%^_T!>Q2R%^-$=Y:30B/SZ$\->9GOE;M?C8<GB\"[`&ONE<`VV4!2XN:\>
MN4*ANIM6%7&MJ1IT\F[?X2I1E=U0L-LE]?34@GZ\7W_$'CF>V2)=6'S:^##:
M!BJEZZJ1GLBYL&I@I4NIF:#>DQ^-5/.KIP4\<S>@9Z4"/[P;4+ELB,HE4DN+
M^]1<'E'INJ@GIMMI:Q-B4YT8)?M']^OA>7PWL/VRA/M4L3$8\>7NPXAIT\.A
M%X1!#.`MH9GE['1S>N+BB/^`14WX.$]8Z5H494E[>$..>A4>QHE*2?*C^&[7
M_PLR91_,\:SA*GE`+D'?#8Z*%/!(WLL2G-0>PMIH:@XC,P8WVB$T><=\6?UL
M6FS9;(\7%QD+EEY@N>]\+UHJWR)96!#:$W,#8N5P(U)7K9J!CF(@PCSI/=MQ
MZD]I#Q24BMDQE%?E3MVA5VS2+;"ZTZ>]"6)*%W$U)8&U6AA0[1*L(:7?WVP4
M7['`0@U:1ON'1Q6])@6*/6P-1FATV[J\0%&D<$7ER!VM%WKBFE]8TLB[N6EM
M+:KF;CG;EWO'Z_BG-7?8?GM(E:NJ@1IO9L>%%<9'<+6=12JH:-]BVD572,ZK
MP$GN<8HWD:`TCU2CNT@9:*-LF(AI\>0O]"=%[.<0VV<'6^B.]KQ&>H:)N!D[
M>57[^#P;;2E`3,D^Q@B;,:V'I_&>#+%?@+L<>[Z'\(]VDDW0F4%GYL$P56#'
MF+\TG_Y0:?FR/2[SS)^:8O:=^Y4]!T[D8M=M@*7OD`82<`6N@!WY\5N*DWL2
M=0-.\J9RL8S"M#A<IY?U"KC4?'G!<LFO0D;F'E,;\@,V*_DQ34!FFD#U$[L!
M>9,[2[:)X_769?3@SO*=SM(&9+"H_\)$70Z!%!'*-AH"NU7U?/)/BM/W@.O8
M*'2T.W%SI34>*E_S9,A)6ARA-Y?Q4K:G7_Y.GJ8:?-.:KJE,Q#&L[D10@2MT
M'A!-37_)-<);XL6'YVFY[CISD[W$RMPE%43(BSM[<ZN.R*UZTN:'8U?*$9YL
M"(]2PJEY2TN7$+&5K_.9*FM)(R80@9-V#E'6S4XNAR*NBB`#YRK;Z$GC3=,A
M6O;"4W/8EMC>3Y"5XW7U`*J:!*ID5V_F@!(+6.C`H%+295T4R3%)5ME'0#K2
M*LLE*1#1'+'K8`UNI9P402YU2.1MW)S81762*Q+0?Q72K=Q*\$I:<J5RAALV
MU(FQC:160]RQ4%OA%^K^V3RI"VL!U/64;:7YU[*Z[2+(78?KC@_TWALYKVN/
MJ\,)'BS(!7</W=V4,;VW#[*/JQ*U*!,<?WQJJY1C=\&IV(V[+<>_T^9+W)&G
MZNO/K*432UB);B09,2.!&RCUX2)1YH2.4VVTZT@KC1%)X$J+A\BT-%CNK!@T
M54K,)PGA;PKGD0\3-A3%;)K(Z:X7*=N&;#<?KH&Y*$@N,5YBN/!42=6G$5@!
MUXM[O:3ZJ.[T1D-6M_]*H>%Y25$A68Z1<,GL'4#`MUS2D-A90`2)T2#.BW*I
MT1'6O!P9Q48)IJ1`20USZ@[0S03U.O6,DFK!KA3C^$7W`QG>6#D:1,!Z\_?=
MW9U_?_[XZ=E__OW%7D;W7]'S(^?GR]7LZQK=C**[=R_]HY<?#K_=7*\#]^7*
M_KGO_A&^NAF>3YRO_W*?/D=?;L?#T=GZW?6/U9>A__GKCY/)O^"S\?AZ_.U@
M"0^BZ/G$^OAA]O/;S^^7[___\/V7KY=1Y/\(/L_W9L%7^/Y@=7`-K9_#M?-]
M\?[C>C5]^G1][,VNO_T8SK[,K_8Q)'?CJZ-H?C]9K@]&DQ?KG^%P]/GZZ&HZ
M^#KX?O_RQ_,_?CR'\YO5=+IW"H\_OW\7'AT<@X]_?+TY&%S_TXLN_CB__?3#
M^_C^V8WW_/UD<G1V<7@]_78R_+K\Y][@[=O_[`RO+G=WV6/7#QT.4Z/Q<(.W
M3W7(:?BZWNLD:9X_T>`FD#2_Q1NX\=]!3;.&E&$EL1DZRMIO*>2J`BON_+EV
M+J=F-![3SA9+K+9C1)X<VG&^DQOA25R`,!<;2GMTQ>42A2,=S!1U'XFDJHMD
M8?`_%,P'ZG3%Z9([UQ$(+>CF<\,XU;LP'&=HKGH,WA,IM^ZDB36Y[)N+2-GU
MOW0F-4>C&O5`B@-:+Q[^W7^[6X)VG?L,X&R.#=!@A=V=&<@ZATU\:*L)$G?$
MNC871*^.-HN3WS&IT%P1W=VZPMF>["WS9"\!.5GCWP\]%&,=6>XU\!>'RO2X
MXVGHBC#RJG374N;WE*K;V'1NE]_%*;9G*.G#]<XGE5I[:(.KV/PKV=M*,?$7
M=A!OC<@?N*N<4>]\`HGL:SIIJM!2F4*55X%"(`F:-"<%SBCRR4N$I)M<W*2T
ML\;`'%R8M"=S8)SJQ7,&O3A*]`*!&0F5R?$719;!0YMK8\T;VPQ,TLB.99MJ
M\PLICZ`[]PY//7\*8!BW]4'.R?T2ID]/L\GWT5=L9_H7VI'%!9AJZ$MQ>]M/
M%>V=[54ZH5_)%*N5?*KWKPPK3Y'D>+CX`$B`=W*%`;QB80#F>F@T)0>8[C^8
M!F3>XX9>L``VB$)HQ\E)UQYT0>BOC]/6O$RL4@^F:WWQ"(<L-GJ4I&48L$EQ
M3E;[&3H)0KC`NPE9U7%X8^)[4QB^BRQRI`0@H!,C]6A:+I.XA4@/DK1$@%XU
MU$YWD[]H#REZ@"H>6M2L%-8Q57*]E=(@B?-SO0\9&'2/+')F*9<2;IF$D^L]
MLO4<H0;WTE?T9)!R+@6";WG*\LJ<,ZX+$(ZG)"9F(1O$I=FJTM'KE+_NRWK$
M4:U&L3;7SE)FDU]JT">1;\_Q.:*^Z$4-X)5?U.4$UL-=/3^I%?B8]UQ\SEIA
M9V7B6DDI:G6O+FHH:0KSU$NI#9FMM'-.FU[U6*+5JF\>//0)LNU);;W?-VL;
MXG*+I%2GN"3#(N!D69\#VXX645PA=`2FT(9*7&$*JGUW);;\T^*CMG94M6QY
MI9(G\5Z,?SY#^`\(V&1^GV$X+]NB`\IX">?@6LR+H*CYD93H8_+NP9X-@!,D
M-1H*TU"S$=>3T[0;2UKFC4#*:ZS#Z-7FF+JRR'NZ&P3#("X"O4B+-`^0DQ52
MQ#XYG<_+/JPNCUA0NCP`RFNG([ZDLP/6>%HV/JI7=P-E`[PRZJ7>!+#$!";.
MFG)60-[2D_^1GI8KK,"D7&HXQ.JZQK[()\N-E%QQTA$VV^!3@LN1K=2?+KPU
M75CRT?;'/BPB4?MF@-FB]31C,<=JV@=F#\[3CJ?]R:Z\MAG4LMXJDL'7L6RQ
M=+TU`$D&Y1W"EF0.EWAK0B=7X\EF6J3_+_ZEJHI#/&QH._\Q+,7\-L`%M5#Y
MJ`+%+*Y+QCXX.GK)$+FF&4=W`2$!129"HH)*3UX#W0S)_]55MJ&F;;@:L&-=
M?77:;XO$M%57E_KI*#,S>;4\G@X<!Y*O6&Z2\#^(PKGGPY^*7E(H9+>GNU;C
M`4:I^/0WDA.=G1$J^:B(U:+2'E?G?FS\X*60).1"G'$"?%M1X$XAMSH#OZ(Z
MJ4A^NFX#J![=U;K,:IY]<[)BJE;Q(J_[3N'Q-7??7W.KWH/[\;(;#W?KB5<K
ME.5QK#"NY!@6I]M;"O=F%;QJO8;K@;NX+3QI=S7=W]2\(%CX8([A@*OX!8G4
M2QH#'T5DHX[#>5R]<(/.YI5-G(1\;=VKF`T571/>';`!*36:VHNFWI(6TB_?
MUCNC=`ZM6^C&'8"(:7UX>S9&YQZ:8;\W)IV5R@J.`0)3&`83"RJ)L8BPH[<*
MND!W<"FRT![#P_;%!W@7'X'D_V<HMD$#V_8Q)+FYJ=`;>N+:C;B@DC#`+/7!
M2+?6_56Y1W3HI??X$\LGLY-AY\%MF'NJH-*<5U/BRT*AA88M'X5M5*[,%%H2
M[#DJ["/KSU9I5+[LAI!1UG+R47(M5=>JDDVV:&B["N%:3GF#O`V74,+(&<+6
MVW*'6#$@FB7-%AGR1!J^KG?GJU$J@F33E#5URO@U7IC2@-_'MZ8?K6^>?XT_
M&(RGQ0;/ZM)K6FEJ;C'1)$-ZW,3>I&YN1M*>5"27.ER3,(.'XFQ*1=M%,T%]
M23_"FT<+DA+:-.?N-%4VIR\3T=V0A49#BRWEMV`J]2[D2Q@LDE>8'5A)2&\[
M+589U(`EH>MG_-`381\[BN\7%#JU)2I:KVVDN+9EV&H?[-,^<H3(ADO+9?9L
MJ[^IW:FM5JOD.6+E5+4'ZHI<7UB+R@H3*I9$CI;F8&VCX-J!DM)1F@1UL4@7
MA`QQVE29I4HZ.G-RA.U2-7*Y1`7^+&F`H.?'3*GSEK:):/:6FC2QX*UNHR.E
MP7-Z[W^&/D#D3,X^$`H*ZPO54].ZF]!*H0DMD2IR=7RHVQUJ*!FR&NIPJBGO
M8XJ1Y0S5Y])Q.(K_/A:WX1#=UD6)E/(V'3^MBR>X>0UP@S`39>:*`6+J:R'&
M84UPB2I%S@.AK`"O0%2]DD^.('OU.,9*DPHD6:\2V$H2%LY#R1P#\L*>X)KD
M:5*)CV8<8\5'!9*L%P(2SO^YN9:8/5#A\M$3-W/[Y0!9>^6A?(DDPO=VM5\E
MQ[!VJOV_V&G4`1I<Y54<DF`+SA`>%,\5:R:(H_=.^@S.FBEYZ<-`W8"3%(,]
M:`9:5I<Q"1KQT0KC&^<1YE&]!A2H_4KVOP@C1X\NE3<`>>8NR;,<K)%^^7"M
M6MQYPK_66J^%5U;+*B852)+&;7P4?"BI,IB&Y*E(YI90N?`4PQBZ>=,`E$KN
MJ/,%C&<#;9"\VAP$@8?9Q+,B\9P*MC=;RCE<P#![/%!`AC:6(IFJF;9=`?I9
M&*;K_,8TW24^CEZ"&0R(/^*<>OXE"*SM:"&7VHC2,")WHB8&*XANIA8:2XU;
MT$ENF#)?5<U5W!85<Z7>!%TF4`EE1#@?9R6<G-R3-]CQS<#)O>U&3I)PC>?V
M,\98A9"I:1L;\V-'.=,'&35"^#0BST^2+1P_3HM0./'!`D8+%:K03M3\Y4\!
M;"9]"2$_WGO6>'H3:TWN!HMS'$:^3WL1PS2@H0<"-M`RT0H']"0<[$\M&R2Y
MA^K/\CE:ALJY'<-,ML*!.3EQFQMD):8&.)F%42_G*J+FVVP*8#/A2XC:R;VU
MRPKE)-GSFX]TD.).Q87Q7AT/\IFVB/>C%_7XT^VJ<E>7Z]^7*)D>Q:T#,!.M
M>/2O^[(*1_$#I[GGXBD$B=IN"BGPEZ<L#$CHJ"RFT$*1IX=O(S)L=13:QI'.
MWI8."[!X7JB/H//E&(U29:EOK:*3\EKCX37;E0V0Y4-/^5O7`B%M$7/*A5'Y
MJ+4(E9SJ%`]CVF%DN0H?:531T?V0OU$)"R*H1$GD16LVXL3WEEX`'(:7>S5?
M[<L3X3HLZV:LJ]5\6;8W*%@"&TXA/J8H>Z)13\RXM5"!EXS&&G&U4I7O]XH$
MM!ZV.3:#$CP2*AK$/.2KR9*RVPHW@@9RFDU8I>IME3"O@ZJX&W1<:7S#.G((
M4VJ?(2OA4Z^/W"Y[);*1XTM'MP%TH.6ODS:]26=>5?YT+3&=D2D>M[H>M7)1
M!M:2#(77)1C'`[:Z#'5?UUM^I$W)TAH-M7/7\QZN@J-#,6D<FBR-PWY4),LQ
M3:SA>'J-S6A@Q2D\"K>M=JJ:`S4T4F7!<*L^V6.!,FW1F\:29$)5-AYKDCW6
M)#-$!BPUR?J[MJFO$$I5',37=Q>-&9O(:;R%9+BSJ5GU"CMUBLIU8OEC/WFZ
M]LER(Y(5'W.K6+ZU9/MYEJ,5=#V:^GMC5M[%)>JY=&'YA;N29V/,//0T2-JH
M#NQ`RVM-J2;X]]A1NK>ZUD$W:3W%+1X[2?\U%+!6[81SZAF[-61=>*[GH,A;
MH9WP)1:*OXK?@&4%(*C">2+C]S'J4*D40B#**J`AZA`/K24,,W.8X_0T"B,?
M5`M=NGM,R80QFB&`LZPB&MS>42[:65#II*,TUO5-]%-U[+B5OG$*P8:NQ((;
M?&;"M0)LRCY;9'\+Q_XEZ;?\P/=#DXZAY;K`.5ZGGPO2#RH)6(NR9.()2U@,
MLBIVR%2C0K?NAS]VKSMM?!@8B.."6UIM$.%2;ME>.)XV%]F47\ZM@;*)=H,6
M5(G%/!AS<XL]TB?`3_4RTU8GYT#1I>PRC6A0\)41*HF%.)@D6C`SN6-Q9F^N
MO:Q,;#*A[%_QY_&D;A"D>\$MA9!)BUH.LM+J>3!IQ::2T!BE\R!*G+%.)?"V
M,4R))+5B(;/$!MO:G4Y);9\5(-4=Q]-SB.?BD*N=D;6P9I3%DUH',<>?:L=#
M8CT,P6R[(0:?%.-$5NBNN1+NBB,8<[!N`4):60M6\6P\K^3(3\QO,2HX0$ZV
MZ"\`9?UX]F$-<G%X0)-8VD*D`U"0QG34%Y]NHF>2.T,'H,3B%>+GTI+#K;RX
M^!8](^7;"*#,<A/\62))['44^1#-DBJ9B0M]`>[B/RG*O*6B;*+,:4&55Y%"
M)!,D/B`INRU/1C=H%Z[")DO8$0X0=5LY9.3929],Y)R@,"YU,_7P)^++%7:M
M:1JNNG!(71\9FH%8S]@.@'\FHR656XFE)<\5ZC4[`/9O,V^UA[^9*#7^H:S+
MM:/J.2"PB(`H<STH6T4=V-'.F"$O#L51+HRF)9C!`VX1`Y%GZ62TM%;1*0QL
MR_T*+/\$.<T='&C1K1U9V_[*@W8]/EO=K3EMQU82]S@*@]!"SE;_.GY+TDC#
M*'G08%9Z=\0MF4ETZT+[U/6LAFLP-D'DAS3&XE2@(=+"DPPYP#PX<=%,UY*@
MY<7A-,4[>:`MX9#+1&(/D!3&&X'`]N&R.66(&=[\J.:X(]6@Y#)]>-V1U!CA
MD7W+/<.N\OT'L)9FLTO#ZCK0"%CI,C"YI!A^7SO=D2_!DA1>13/R%B9JB!<P
MHEX]ND$FI1FE7,X)GX5)AO_DN1&&P%^?0A<?-V6A7Q[6/)W?`B:?Z<&U52;C
MQL,-L>,Y\WQI)J8XJ(%^8`F5?`J&F$W_#%SW`_+NT!6P`@\!)PZ@-3P^9P.^
M;G@#15"+5#[O0?2\GT0SI1U-JX<UR=C4`)-/9.`R-MFXF_/N*?Z-!/M>-[!!
M&VLM-OF<!,X#9W'L1*I*D,\/;8X'WP!//MV@.=S]9H^,>6L%(/[G?P%02P,$
M%`````@`QT5L0^/@A\^%#```AVL``!$`'`!A<'!A+3(P,3,P.3,P+GAS9%54
M"0`#)C&"4B8Q@E)U>`L``00E#@``!#D!``#M76U3V[@6_GYG[G_0S9?;G=TT
M+Y32,(69D$";+I`,A*7LSLZ.8BN)6ELVEAP(O_X>R7;B&/DE)$.]=]-/(!\=
M/><\TM'1&_WXGVH5?2*,>%@0$XWFB';>"/LG5$4=QW:O#8IZ3,!70]`9@3(V
M(Q[\#M^G0KB'M=K#P\-;`T2Y03W"'=\S")<%J%H]1O+?O__U43;2\8ALXA`-
M?8(NG1EJ-%&]?KC?.MROHYMA!S7KC;V@$M1XY(?<F!(;HT?;8OSP<>19]*@2
M:U.6O'6\2:U9K^_5*.,",X-40GGFVWII4W@U,7=)#22(1XT*$MB;$'&);<)=
M;)"5:MAUI]BSL32H)@'66WOUJ(U'OB+[L!?!:=2^7IQ?*_@+/`XK`,EAU06L
MH!X`P,41^;PJ%2UQC3$?J3:B+ZI*M=ZH[C469EB4?==9TFBU6C7U-1)])KE*
M@OP\PAQ((!:Q"1-GCF=WR1C[ECBJW/O8HF-*S$J,4U,L],5U[=>"CY5CU8$0
MDAT",^8(+*C#HM*PW'4I&SO'41F42B2'$9PK,D;*C$/I@J,*I[9KR9ZBRJ8>
M&1]5I)^KD3O_LO#H+6",1+!G>(Y%LGU4<SW'A;%!P<E+1P0*GM5>]9O\7(,V
MB76^A%RI'6_-'M<CKVX/M,FA"RB^$F9MCRB3C%_=,&B3,JHQ:UM&&=AZ=:.@
M3<.WM&2MFB6EAV`(DC_<7/72@Y/2"Q,&=RQJRM!_@BT9HJ^GA(@*HF9@]U^I
M(DN/1HTO77\,41;FH&OH7RK2J/F*F81QF,5"+4BIX>A-Q_<\*3.`R.J8Z(9A
MWZ30VD\?:TFUL;X9->J#RCX[5C\G.W6H(!3)KKO:;Y(U<QI.\).HO:"HML+1
M\Y&V`7L]!L5DX?`4`I-2&I^LD-A,)7%1RI$S1GU79BA0!^C<\?<2_CJ83\\L
MYR&%N,5GG0M7*-LK2)G4B*3*'65K4';I"-(X\3EEA'/,(")RRIWQ(.:%&(-%
MI',)?0<D=BDW+(?['H%?I%8DPVND&8%JI'1+8N/:-73NR%PALRG'P>F]3V?8
MDD,CP=ZSS[ET[6OIDH%4C;B8KMU8RZ=G[PQ3[S=L^>2"8.E06T-2BI#>KA6R
MWFO)DB%4JD1*)XHKU7*V8RW!VKM+(LX=SB&CNX;/),'7L\^Y@^I`RY.,C*`*
M25TR>T1*VXZB(A3M7PO'^`Z3!N06CNU"AJ";O-*D\O+&#UJ^]E5J`@JK2B.*
MJ]S-5'F,O9?N\L@4/$9G1/;Y!%D:@3R>6EJ>WH?;BPM=:H3MQE41E@ZD.QTF
M*/.AL<6R*$%5FE0.7XVZEJ\H.D8*8\NQ'6E%2/L0;IS3D47D[UPX5\22ZZX!
M5ILV"?KRY?.(;&B)_!"LUR+5JI`CX:!0.PK5[S+'?$Y;:J:9.I9)/"ZS;C%/
ML*B3.-89M,)<4\M<*YK:0G7_18%"'5,[HA9$M0W#\674F@P<BQK0M4_FZJ<X
M5QE"^2F^/+1:Y6NI#D7Z?I$G:X%*]"8JU.^%[-C+3O6'&`)7,EZF"!5@3[_Y
MH4_\T9M`[XZX#18`6OZR9?-CIGY/)&LYD,/ECLQ"6:>6S&S9?#+U>R89.>AN
M7&YQ=[E+!*96DM."E?*R4OTV2[&M9O0F;$5'\_\;Q^K*S!^W%[^]^_./KX;K
M/]ZQ_9;Y=#";W,W93==_^'3@M0Y^;7Z[&<ZY=3`SGNK6%_'AIG,^,.]^M_;V
MV==1O]/MS3\-[V=?.][MW?WIX'?ZKM\?]K\U7-KP_?T!OOAU\O3MZ?O5YY^;
MG[_>7?F^=\]OI[4)OZ.?&[/&D.*GSMS\;G^^F,_&>WOS$V<R_';?F7R=7M=A
MR#WTKUO^]''@SAO=P?OYD^AT;X>MZW'[KOW]\>!^_\O]/IW>S,;CVAD]N?W\
M2;0:)^3BR]U-HSW$/]^=GTYH]_'BP^2F??#AR^FTCW_C@[UW]T^S6L.9'!W]
MB3K75^$MHHUZ?=\7\G:0"1F9"_T-`@BVK+E)+5]>:G)<%40>L.=A)F0'-Y8K
M)"872"JZQ`;$=O1E'V\W]#M<:8E)-#3@<PP=BL%#$3X4`OP%11#5F(N!1`KE
M;F+<(,O11]$<X9P>H=]+RTYR_D$A<P,BE?]&25I.'^6/)#GZ"PAG$]G4;[(5
M(W(A-'HN%&+8<5V,Z[X;&WSI+&O$<G/8IG[[[444!^VC\.LN*K_L*$,?D-/E
M<H:P?I-.?ZZ1&85WY!5=:^H9S!'.H?'9WEW^4G/'95$N@[N`X%H^]AS;C#G4
M6=T4B%%:O$[^WEY3O[=7B%V0":"@-Q+,3TC"07$\R-F=@6WW#$P_P`M7RQGJ
M^BW"H@=B.>-^1W7>T9B>W`S!O"L[3?TV8=HY63:!._X6_'4=PY<WT=K,/(50
M)^8]-G9`0L((V,N4R$V-Z\]6/Y$^!`I1H!'%5/YS-G4_UE9>,ZG2H&SEY5-0
M#L74=AU/(*9]NI;V/BYX5G?N&$I?1A7Y6S6J5Y5%U4:SNM=X^\C-Q<.0-6%(
MPX.G*>O!B.J]"$;V([@4(`I$O.8$8U=5K!%+\(6NZE+7`M&:GGG^)+&(<Y*U
MI&M:TC6-]YL#B3]$7`^,PRXS\!1`I'T&6+2[1!5DX_O/W1`^2U2M'E7"9T%M
MSHG@[1$7\I5K!07/M-2#TT,HHVS2$\26([6"<"AU5!&>+Q]8*2E7O2L:JGJF
M[X6ADE'+DIEJ),M]J$R%+[]^\AS?C1JAH#[^*D,+*WQ?EFK%.<4C:E&9JY3.
M%!VV='L2Z=X`SV73JSE?J'C50MMA,,5[<YV-8VQQK9%!@!/1IU'P=.RH8GC$
MI&(#T]<Q(Q[&5KTA3\(,F!>[<O.>F(EK#N5ANB#.1!!(,!\^0>)GL-8*%V5L
MTI8OS\O6KXLBK1VGF]LVO_E<J$O_0UC2P,+2H-!9`L\-'?A!-G/#Y:.Z4GMC
M6X:DAX0I9A/"X[6#X,C,<H:]]?"FVQWO9CV()[RL7:`PTJP!L:+DC#((Q'\'
M<[.09ID;["_),2*U9-R9&9)'<6+!DC8R//AC$H<B*E]KPMO<^A<`S_)#[+QZ
ML#RN[H:GU<'I![\-CZIA""5GUO)TBZU9DI&TZD^0PY._\KBB&,P,.Q>A,ZRS
M<$[]QQN7@2TUEF<ZI&?#$DCTV?,LZA1[#!J2F134@PPW?.X6!@*(`FZ88[UR
M$-BN/5GQ8=G2RDEL&?NZ'F!JGR@22,MCYEIHTU<T'8?;Q"#0G($MZ!M#!Y)%
MX<VC"X#E,;@PTLRD1N6"/78*3=JP].-GC@>-PMK(<\94?/*QG`V(O$2[\5IV
M:?*V%[.%C4CG?;GEVW5L3%DBF3%5X2L'L6>8,B:DXK=@PS/-5^Z^ICB<0DW/
M\$=J+GC1!=X`^E:\<`XB$@?_\0/Y):"+[$]UR4CT./<EIAZ##XP84MDM%=.!
M1V<P4@86-E3MQM]CKVH]DU*=!''!(,14,\4UMDA_?,.HX/UQ..G+&1,B:I0+
M7Y)M;.6EAC^3C#9QSPN,R9H1\B^"EC*`%(&<'OWS-90L7A0%F[FCN<[]A5*2
MOA[X;/J+ZBI91U@?=FZ7X&U?3!V//A'SAIG$2P;6GCR`QE8'4A,PN<03QPN,
MR8J,`]\SIC#B@F645EN)G5$$?9;U:NH%;)ZZ#!'T.@Z:KF0G5LODY(A09:^=
M,A=`F3D`3@@C8VI`E^@_,*@[I6Y[+.1V0*0JL;MAR$[TND86P)@9ZZA!@K\U
MV>;<`340+&0"I5$[".S#$W).;1KDHLF`L\IZ9-TKNV3[5F6NFI=[0_R*3"@'
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M/XZRZX[#!2^/1:G8,K?&,EX<E>>^0"&4:DBI1SW!DX:`Q?\!4$L!`AX#%```
M``@`QT5L0RY&,E6#8@``WNX$`!$`&````````0```*2!`````&%P<&$M,C`Q
M,S`Y,S`N>&UL550%``,F,8)2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MQT5L0YF+[&O7!P``W4H``!4`&````````0```*2!SF(``&%P<&$M,C`Q,S`Y
M,S!?8V%L+GAM;%54!0`#)C&"4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`,=%;$/KO/34/R```+SB`0`5`!@```````$```"D@?1J``!A<'!A+3(P,3,P
M.3,P7V1E9BYX;6Q55`4``R8Q@E)U>`L``00E#@``!#D!``!02P$"'@,4````
M"`#'16Q#J]_<PZ`_``!+-0,`%0`8```````!````I(&"BP``87!P82TR,#$S
M,#DS,%]L86(N>&UL550%``,F,8)2=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`QT5L0Y1G\HCU'P``CN8!`!4`&````````0```*2!<<L``&%P<&$M,C`Q
M,S`Y,S!?<')E+GAM;%54!0`#)C&"4G5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`,=%;$/CX(?/A0P``(=K```1`!@```````$```"D@;7K``!A<'!A+3(P
M,3,P.3,P+GAS9%54!0`#)C&"4G5X"P`!!"4.```$.0$``%!+!08`````!@`&
+`!H"``"%^```````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>130</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Balance Sheets (Current Period Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Disclosure - Note 1 - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note1BusinessandBasisofPresentation</Role>
      <ShortName>Note 1 - Business and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 2 - Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note2CashEquivalents</Role>
      <ShortName>Note 2 - Cash Equivalents</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 3 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note3FairValueMeasurements</Role>
      <ShortName>Note 3 - Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 4 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note4NetLossPerShare</Role>
      <ShortName>Note 4 - Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 5 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note5StockBasedCompensation</Role>
      <ShortName>Note 5 - Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 6 - Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note6ComprehensiveLoss</Role>
      <ShortName>Note 6 - Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 7 - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note7DiscontinuedOperations</Role>
      <ShortName>Note 7 - Discontinued Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 8 - Convertible Notes to Related Parties</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.appharma.com/role/Note8ConvertibleNotestoRelatedParties</Role>
      <ShortName>Note 8 - Convertible Notes to Related Parties</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 9 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note9StockholdersEquity</Role>
      <ShortName>Note 9 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 4 - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note4NetLossPerShareTables</Role>
      <ShortName>Note 4 - Net Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 5 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note5StockBasedCompensationTables</Role>
      <ShortName>Note 5 - Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 7 - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note7DiscontinuedOperationsTables</Role>
      <ShortName>Note 7 - Discontinued Operations (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 1 - Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note1BusinessandBasisofPresentationDetails</Role>
      <ShortName>Note 1 - Business and Basis of Presentation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 4 - Net Loss Per Share (Details) - Outstanding potentially dilutive options, warrants and convertible notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.appharma.com/role/OutstandingpotentiallydilutiveoptionswarrantsandconvertiblenotesTable</Role>
      <ShortName>Note 4 - Net Loss Per Share (Details) - Outstanding potentially dilutive options, warrants and convertible notes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 5 - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note5StockBasedCompensationDetails</Role>
      <ShortName>Note 5 - Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/StockbasedCompensationExpenseTable</Role>
      <ShortName>Note 5 - Stock-Based Compensation (Details) - Stock-based Compensation Expense</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 5 - Stock-Based Compensation (Details) - Stock-based Option Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/StockbasedOptionDetailsTable</Role>
      <ShortName>Note 5 - Stock-Based Compensation (Details) - Stock-based Option Details</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 6 - Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note6ComprehensiveLossDetails</Role>
      <ShortName>Note 6 - Comprehensive Loss (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 7 - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note7DiscontinuedOperationsDetails</Role>
      <ShortName>Note 7 - Discontinued Operations (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 7 - Discontinued Operations (Details) - Income (loss) from discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/IncomelossfromdiscontinuedoperationsTable</Role>
      <ShortName>Note 7 - Discontinued Operations (Details) - Income (loss) from discontinued operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 8 - Convertible Notes to Related Parties (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.appharma.com/role/Note8ConvertibleNotestoRelatedPartiesDetails</Role>
      <ShortName>Note 8 - Convertible Notes to Related Parties (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 9 - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.appharma.com/role/Note9StockholdersEquityDetails</Role>
      <ShortName>Note 9 - Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element appa_ConvertibleNotesPayableRelatedPartiesCurrent had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromConvertibleDebt had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '017 - Disclosure - Note 1 - Business and Basis of Presentation (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '025 - Disclosure - Note 8 - Convertible Notes to Related Parties (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '026 - Disclosure - Note 9 - Stockholders' Equity (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Condensed Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Condensed Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>appa-20130930.xml</File>
    <File>appa-20130930.xsd</File>
    <File>appa-20130930_cal.xml</File>
    <File>appa-20130930_def.xml</File>
    <File>appa-20130930_lab.xml</File>
    <File>appa-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 5,885<span></span></td>
        <td class="nump">$ 3,626<span></span></td>
        <td class="nump">$ 23,188<span></span></td>
        <td class="nump">$ 10,022<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">6,779<span></span></td>
        <td class="nump">2,428<span></span></td>
        <td class="nump">17,438<span></span></td>
        <td class="nump">5,181<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">12,664<span></span></td>
        <td class="nump">6,054<span></span></td>
        <td class="nump">40,626<span></span></td>
        <td class="nump">15,203<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(12,664)<span></span></td>
        <td class="num">(6,054)<span></span></td>
        <td class="num">(40,626)<span></span></td>
        <td class="num">(15,203)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
        <td class="num">(209)<span></span></td>
        <td class="num">(195)<span></span></td>
        <td class="num">(614)<span></span></td>
        <td class="num">(402)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
        <td class="num">(12,873)<span></span></td>
        <td class="num">(6,249)<span></span></td>
        <td class="num">(41,240)<span></span></td>
        <td class="num">(15,605)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">128<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(6)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (12,873)<span></span></td>
        <td class="num">$ (6,121)<span></span></td>
        <td class="num">$ (41,240)<span></span></td>
        <td class="num">$ (15,611)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Loss from continuing operations (in Dollars per share)</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.07)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss (in Dollars per share)</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.07)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute basic and diluted net loss per share (in Shares)</a></td>
        <td class="nump">307,496<span></span></td>
        <td class="nump">274,488<span></span></td>
        <td class="nump">306,096<span></span></td>
        <td class="nump">225,063<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4613673-111683<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of nonoperating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeExpenseNonoperatingNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA795"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">A.P. Pharma, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA798">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company&#8217;s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&#8217;s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed
      phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA800">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the APF530 NDA in the first quarter of 2014.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA802">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.</font>
    </p><br/><p id="PARA1249" style="text-align: left; line-height: 1.25; margin: 0pt;">
      <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">In November 2013, we initiated a program to expand our pipeline of sustained release products, including a new program targeting the relief of post-surgical pain.&#160; We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents.&#160; Currently there are no approved 5-HT3 receptor antagonists for the treatment of delayed HEC.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA803">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. The name change is part of our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming approval of APF530.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA805"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&#160;GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2013 or for any other period. The condensed balance sheet as of December&#160;31, 2012 has been derived from the audited
      financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March&#160;1, 2013 (2012 10-K).</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA807"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Liquidity</b></font></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA809">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $224.8 million as of September 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were
      comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of September 30, 2013, we had cash and cash equivalents of $22.6 million.</font></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA811">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We believe that our current working capital is sufficient to fund planned operations into 2014. However, we will require additional capital to fund our development and operating activities. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.</font></font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA814"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Critical Accounting Policies and Estimates</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA815">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA817"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Recent Accounting Pronouncements</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA819">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA793">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(1)&#160;BUSINESS AND BASIS OF PRESENTATION</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA795">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">A.P. Pharma, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA798">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company&#8217;s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&#8217;s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed
      phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA800">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the APF530 NDA in the first quarter of 2014.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA802">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.</font>
    </p><br/><p id="PARA1249" style="text-align: left; line-height: 1.25; margin: 0pt;">
      <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">In November 2013, we initiated a program to expand our pipeline of sustained release products, including a new program targeting the relief of post-surgical pain.&#160; We also announced we will pursue a post-approval expansion of APF530 with the goal of demonstrating the utility in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents.&#160; Currently there are no approved 5-HT3 receptor antagonists for the treatment of delayed HEC.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA803">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In September 2013, our stockholders approved an amendment to our certificate of incorporation to change our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. The name change is part of our recent corporate restructuring and rebranding of the Company. We believe the name change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming approval of APF530.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA805">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&#160;GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2013 or for any other period. The condensed balance sheet as of December&#160;31, 2012 has been derived from the audited
      financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March&#160;1, 2013 (2012 10-K).</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA807">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Liquidity</b></font></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA809">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $224.8 million as of September 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were
      comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of September 30, 2013, we had cash and cash equivalents of $22.6 million.</font></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA811">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We believe that our current working capital is sufficient to fund planned operations into 2014. However, we will require additional capital to fund our development and operating activities. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.</font></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA814">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Critical Accounting Policies and Estimates</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA815">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA817">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Recent Accounting Pronouncements</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA819">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (Current Period Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 22,597<span></span></td>
        <td class="nump">$ 53,506<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">763<span></span></td>
        <td class="nump">584<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">23,360<span></span></td>
        <td class="nump">54,090<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">2,857<span></span></td>
        <td class="nump">1,752<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
        <td class="nump">153<span></span></td>
        <td class="nump">130<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">26,370<span></span></td>
        <td class="nump">55,972<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,250<span></span></td>
        <td class="nump">1,912<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">2,360<span></span></td>
        <td class="nump">1,750<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Convertible notes payable to related parties, net of discount</a></td>
        <td class="nump">888<span></span></td>
        <td class="nump">492<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">5,498<span></span></td>
        <td class="nump">4,154<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
        <td class="nump">3,110<span></span></td>
        <td class="nump">3,024<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">242,589<span></span></td>
        <td class="nump">232,381<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(224,827)<span></span></td>
        <td class="num">(183,587)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">20,872<span></span></td>
        <td class="nump">51,818<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 26,370<span></span></td>
        <td class="nump">$ 55,972<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_ConvertibleNotesPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Comprehensive Loss (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
        <td class="num">$ (12.9)<span></span></td>
        <td class="num">$ (6.1)<span></span></td>
        <td class="num">$ (41.2)<span></span></td>
        <td class="num">$ (15.6)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669619-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 9 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA883">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(9) STOCKHOLDERS' EQUITY</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA885">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>Amendments to Articles of Incorporation</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA887">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In June 2011, we amended our certificate of incorporation to increase the number of shares of authorized common stock to 1,500,000,000, par value $0.01 per share. Prior to the amendment, the number of shares of authorized common stock was 100,000,000, par value $0.01 per share. The certificate of amendment was approved by a majority of our stockholders on June&#160;29, 2011.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA889">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In September 2013, our stockholders approved a proposal to authorize our Board to effect a reverse stock split of all outstanding shares of our common stock at any ratio at its discretion, from 1-for-10 to 1-for-20 and to grant the Board discretionary authority, within twelve months from September 19, 2013, to determine whether to effect the split and the exact whole number ratio within the range at which the split will be effected. The number of issued and outstanding shares of our common stock would be reduced in accordance with the ratio selected by the Board. The number of shares of common stock that are authorized for issuance under our certificate of incorporation would also be reduced proportionately based on the exchange ratio of the reverse stock split.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA891">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>Stock Plans</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA893">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">At our annual meeting of stockholders in June 2011, our stockholders approved an amendment to our 2007 Equity Incentive Plan to increase the maximum number of shares of common stock available for grant by 90,000,000 shares of common stock, resulting in an aggregate of 95,000,000 shares of common stock authorized for issuance pursuant to awards granted under our 2007 Equity Incentive Plan. The stockholders also approved an amendment to our 1997 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance under the plan by 500,000, for a total of 1,000,000 shares reserved as of September 30, 2013.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA895">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>2011 Private Placement</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA897">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In June 2011, we entered into a Securities Purchase Agreement with certain purchasers (Securities Purchase Agreement), pursuant to which we agreed to sell 160,000,006 shares of our common stock (Shares) and warrants to purchase 80,000,005 shares of our common stock (Warrants) with an exercise price of $0.18 per share (2011 Private Placement), for an aggregate price of $24.0 million. The 2011 Private Placement closed on July 1, 2011. For each share purchased, the investors received one Warrant to purchase 0.5 shares of common stock (together with a Share, a Unit), at a purchase price of $0.15 per Unit. The Warrants were immediately exercisable and expire on the fifth anniversary of the closing date of July 1, 2011. The Warrants may be exercised for cash only or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the
      Warrants, by surrender of such Warrant, or a portion of such Warrant, by way of cashless exercise. There is no right to exercise the Warrants to the extent that after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the Warrants can amend or waive the foregoing limitation by written notice to the Company, with such waiver taking effect only upon the expiration of a 61-day notice period.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA899">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Under the terms of the Securities Purchase Agreement, on July 29, 2011, the Company filed a registration statement with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants (the Warrant Shares, and collectively</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">with the Shares, the Registrable Securities). The registration statement was declared effective on August 4, 2011. The Company is obligated to maintain the effectiveness of the registration statement with respect to an investor&#8217;s Registrable Securities until the investor is able to sell the Registrable Securities without limitation or restriction under Rule 144. There is currently only one investor who is an affiliate of the Company and is therefore not able to sell the
      Registrable Securities without limitation under Rule 144, and that investor has agreed to waive their right to require the Company to maintain the effectiveness of the registration statement until they provide notice otherwise. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions)</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">during the period the Company is obligated to maintain the registration statement, the Company may be obligated to pay to the holders of the Registrable Securities liquidated damages in an amount equal to 1.0% per month of such holder's pro rata interest in the total purchase price of the Private Placement, capped at a total penalty of 6.0%.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA901">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company received total proceeds of $22.8 million from the 2011 Private Placement, which was net of issuance costs of approximately $1.2 million. During the nine months ended September 30, 2013, the Company received $0.6 million for an exercise of a Warrant.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA903">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b><i>2012 Private Placement</i></b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA905">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In July 2012, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell 102,000,000 shares of its common stock (2012 Shares) at a purchase price of $0.525 per share of common stock, for an aggregate price of approximately $53.6 million (2012 Private Placement). The 2012 Private Placement closed on July 30, 2012.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA907">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In connection with entering into the securities purchase agreement, the Company also entered into a registration rights agreement. On August 24, 2012, the Company filed a registration statement with the SEC to register the 2012 Shares for resale. The registration statement was declared effective on September 6, 2012. If the Company fails to keep the registration statements continuously effective for a designated time (with limited exceptions), the Company may be obligated to pay to each holder of the 2012 Shares an amount equal to 1.5% per month of the aggregate purchase price of the unregistered 2012 Shares held by such holder, capped at a total penalty of 9.0%.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA909">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company received total proceeds of $50.5 million from the 2012 Private Placement, which was net of issuance costs of approximately $3.1 million.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1205.finRow.2">
        <td style="WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.2.amt.D3" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1176">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1178">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.2.amt.D5" colspan="6">
          <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"></font>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1177">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended</font></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1179">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">September 30,</font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.2.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.3">
        <td style="TEXT-ALIGN: center; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1180">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1181">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1182">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.lead.D5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.3.amt.D5" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1183">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.3.trail.D5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.4">
        <td style="WIDTH: 52%">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B2">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B3">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B4">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.lead.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.symb.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.amt.B5">
          &#160;
        </td>
        <td id="TBL1205.finRow.4.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1184">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Operating expenses:</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.lead.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.symb.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.amt.B5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1205.finRow.5.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1185">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Research and development</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.2">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.2">
          544
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.3">
          397
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.4">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.4">
          1,088
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.lead.5">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.symb.5">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.amt.5">
          1,061
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.6.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.7">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1190">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">General and administrative</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.2">
          3,551
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.3">
          1,583
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.4">
          7,245
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.symb.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.amt.5">
          2,712
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.7.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1195">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Total stock-based compensation expense</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.2">
          4,095
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.3">
          1,980
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.4">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.4">
          8,333
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.symb.5">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.amt.5">
          3,773
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.8.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.9">
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.lead.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.symb.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.amt.B5">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff" id="TBL1205.finRow.9.trail.B5">
          &#160;
        </td>
      </tr>
      <tr id="TBL1205.finRow.10">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1200">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Impact on basic and diluted net loss per common share</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.2">
          0.01
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.3">
          0.01
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.4">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.4">
          0.03
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.4" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.lead.5">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.symb.5">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.amt.5">
          0.02
        </td>
        <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1205.finRow.10.trail.5" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1230.finRow.4">
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1206">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Shares (in thousands)</b></font></b>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D3" colspan="2">
          <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b></b></font></b>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1209">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted- Average Exercise</b></font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1211">
            <b>Price</b>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D3">
          <b>&#160;</b>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.lead.D4">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.4.amt.D4" colspan="2">
          <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b></b></font></b></font></b></font></b>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1207">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-</b></font></font></font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1208">
            <b><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Average</font></font></b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1210">
            <b>Remaining Contractual Term</b>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1212">
            (Years)
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.4.trail.D4">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1230.finRow.5">
        <td>
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B2">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B3">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.lead.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.symb.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.amt.B4">
          &#160;
        </td>
        <td id="TBL1230.finRow.5.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1213">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Outstanding at January 1, 2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.2">
          86,478
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.3">
          0.42
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.amt.4">
          8.2
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.7">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1217">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Granted</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.amt.2">
          76,735
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.amt.3">
          0.40
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.7.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.7.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1220">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Exercised</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.amt.2">
          (4,323
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.trail.2" nowrap="nowrap">
          )
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.amt.3">
          0.26
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.amt.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.8.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.9">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1223">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expired and forfeited</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.amt.2">
          (33,498
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.trail.2" nowrap="nowrap">
          )
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.amt.3">
          0.47
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.9.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.lead.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.amt.B4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: right; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1230.finRow.9.trail.B4">
          &#160;
        </td>
      </tr>
      <tr id="TBL1230.finRow.10">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1226">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Outstanding at September 30, 2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.2">
          125,392
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.3">
          0.40
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.lead.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.amt.4">
          8.0
        </td>
        <td style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1230.finRow.10.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 8 - Convertible Notes to Related Parties<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA865">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(8) CONVERTIBLE NOTES TO RELATED PARTIES</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA867">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In April 2011, we entered into a Securities Purchase Agreement (Purchase Agreement) with certain institutional investors (Purchasers), including a fund affiliated with Kevin C. Tang, who is the Chairman of our Board of Directors (Board), for a private placement of up to $4.5 million in Senior Secured Convertible Notes due 2021 (Notes). The Purchase Agreement provided for the Purchasers to purchase $1.5 million aggregate principal amount of Notes at the initial closing. Pursuant to the Purchase Agreement, the Purchasers had the option to purchase an additional $3.0 million aggregate principal amount of Notes at any time until May 2, 2013 (Purchase Option). The Notes are convertible into shares of the Company&#8217;s common stock at a rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes (Conversion Shares).</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA869">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The cash received from the initial closing of the Note financing, which resulted in the issuance of $1.5 million aggregate principal amount of Notes, was approximately $1.3 million, net of issuance costs. In May 2012, the Purchasers exercised their Purchase Option in full, and we received $3.0 million of cash through the issuance of the remaining $3.0&#160;million aggregate principal amount of Notes. As a result of the exercise of the Purchase Option, the Purchasers have purchased the full amount of Notes that the Company was obligated to sell under the Purchase Agreement.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA871">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Notes are secured by substantially all of the assets of the Company, including placing our bank accounts under a control agreement. The Notes initially bore interest at 20%&#160;per annum, payable quarterly in cash or in additional principal amount of Notes at the election of the Purchasers. In June 2011, the Notes were amended to reduce the interest rate to 6%&#160;per annum effective July&#160;1, 2011. The Notes mature on May 2, 2021; however, the holders of the Notes may require prepayment of the Notes at any time beginning on or after May&#160;2, 2012, at each holder's option.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA873">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of the Company's outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to the Company, which will not be effective until 61 days after delivery of the notice.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA875">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">As of September 30, 2013, the Company was in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require the Company to redeem all or a portion of their Notes.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA877">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to the Purchase Agreement, the Company filed a registration statement on Form S-1, registering for resale 69.6&#160;million shares underlying the Notes. The registration statement was declared effective on July&#160;29, 2011. The Purchasers have agreed to waive their right to require the Company to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA879">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Notes contain an embedded conversion feature that was in-the-money on both issuance dates. Based on an effective fixed conversion rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates, and the Company began amortizing the resultant debt discount over the respective 10-year or remaining term of the Notes. During the three months ended September 30, 2013, accrued interest of approximately $73,000 was paid-in-kind and rolled into the principal balance of the Notes, which resulted in an additional full debt discount for the respective periods. For the three and nine months ended September 30, 2013, interest expense relating to the stated rate of the Notes was approximately $74,000 and
      $218,000, respectively. Interest expense relating to the amortization of debt discount for the three and nine months ended September 30, 2013 was approximately $134,000 and $396,000, respectively.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA881">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">As of September 30, 2013, the carrying value of the Notes was approximately $888,000, which is comprised of the $4,958,000 principal amount of the Notes outstanding, less debt discount of $4,070,000. If the $5.0 million principal amount of Notes is converted, the Company would issue 124.0 million shares of its common stock. Accrued interest on the principal balance was $74,000 at September 30, 2013.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA825">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>(3) FAIR VALUE MEASUREMENTS</b></font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA827">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The three-tier fair value hierarchy utilized prioritizes the inputs used in measuring fair value as follows: Level 1) observable inputs such as quoted prices in active markets; Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3) unobservable inputs in which there is little or no market data, which require us to develop our own assumptions. The hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. We measured our available-for-sale securities at fair value on a recurring basis. We used quoted prices in active markets (Level l) to measure the fair value of our cash equivalents on our Condensed Balance Sheets as of December&#160;31, 2012. Cash equivalents consisted of highly rated money market funds with maturities of ninety days or less. Due to
      the high ratings and short-term nature of these funds, we considered the inputs used to value all cash equivalents as Level 1 inputs.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Net Loss Per Share (Details) - Outstanding potentially dilutive options, warrants and convertible notes<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity Option [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">125,392<span></span></td>
        <td class="nump">67,940<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">79,377<span></span></td>
        <td class="nump">84,377<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Debt Securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">123,957<span></span></td>
        <td class="nump">116,790<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Net Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1175.finRow.1">
        <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.1.lead.D3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1163">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Nine Months Ended September 30,</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.1.trail.D3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.2">
        <td style="TEXT-ALIGN: center; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.lead.D2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1164">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2013</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.trail.D2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.lead.D3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1165">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2012</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1175.finRow.2.trail.D3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.3">
        <td style="WIDTH: 70%">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.lead.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.symb.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.amt.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.trail.B2">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.lead.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.symb.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.amt.B3">
          &#160;
        </td>
        <td id="TBL1175.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1166">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Options outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.amt.2">
          125,392
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.amt.3">
          67,940
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1169">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Warrants outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.amt.2">
          79,377
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.amt.3">
          84,377
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr id="TBL1175.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id="PARA1172">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Common stock underlying convertible notes outstanding</font>
          </p>
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.lead.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.amt.2">
          123,957
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.lead.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.amt.3">
          116,790
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1175.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock-Based Compensation (Details) - Stock-based Option Details (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_StockBasedOptionDetailsAbstract', window );"><strong>Stock-based Option Details [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares</a></td>
        <td class="nump">125,392<span></span></td>
        <td class="nump">86,478<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in Dollars per share)</a></td>
        <td class="nump">$ 0.40<span></span></td>
        <td class="nump">$ 0.42<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years<span></span></td>
        <td class="text">8 years 73 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">76,735<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in Dollars per share)</a></td>
        <td class="nump">$ 0.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(4,323)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in Dollars per share)</a></td>
        <td class="nump">$ 0.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired and forfeited</a></td>
        <td class="num">(33,498)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired and forfeited (in Dollars per share)</a></td>
        <td class="nump">$ 0.47<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_StockBasedOptionDetailsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_StockBasedOptionDetailsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1LAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock-Based Compensation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Employee Stock Purchase Plan 1997 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Employee Stock Purchase Plan 1997 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Employee Stock Purchase Plan 1997 [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_Note5StockBasedCompensationDetailsLineItems', window );"><strong>Note 5 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
        <td class="nump">90,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
        <td class="nump">95,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80,027<span></span></td>
        <td class="nump">58,571<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.31<span></span></td>
        <td class="nump">$ 0.21<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">365,674<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_Note5StockBasedCompensationDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_Note5StockBasedCompensationDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase price of common stock expressed as a percentage of its fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">AP PHARMA INC /DE/<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">313,616,369<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000818033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock-Based Compensation (Details) - Stock-based Compensation Expense (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 4,095<span></span></td>
        <td class="nump">$ 1,980<span></span></td>
        <td class="nump">$ 8,333<span></span></td>
        <td class="nump">$ 3,773<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare', window );">Impact on basic and diluted net loss per common share (in Dollars per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.03<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">544<span></span></td>
        <td class="nump">397<span></span></td>
        <td class="nump">1,088<span></span></td>
        <td class="nump">1,061<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 3,551<span></span></td>
        <td class="nump">$ 1,583<span></span></td>
        <td class="nump">$ 7,245<span></span></td>
        <td class="nump">$ 2,712<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock-based compensation expense impact on basic and diluted net earnings per common share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>appa_StockBasedCompensationExpenseImpactOnBasicAndDilutedNetEarningsPerCommonShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>appa_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
